



Universidad del
Rosario



**Interacciones parásito-hospedero-microbioma en infecciones causadas por
protozoos y helmintos**

Sergio Andrés Castañeda Garzón

**Documento de tesis presentado como requisito para optar al título de Doctor
en Ciencias Biomédicas y Biológicas**

**Doctorado en Ciencias Biomédicas y Biológicas
Universidad Del Rosario
Bogotá, D.C.
2024**



Universidad del
Rosario



**Interacciones parásito-hospedero-microbioma en infecciones causadas por
protozoos y helmintos**

Sergio Andrés Castañeda Garzón

Director:

Juan David Ramírez González, Ph.D.

Profesor Titular

Facultad de Ciencias Naturales

Universidad del Rosario

**Documento de tesis presentado como requisito para optar al título de Doctor
en Ciencias Biomédicas y Biológicas**

Doctorado en Ciencias Biomédicas y Biológicas

Universidad Del Rosario

Bogotá, D.C.

2024

AGRADECIMIENTOS

El camino recorrido durante esta doctorado ha sido un camino lleno de retos, de objetivos conseguidos, de pruebas, de aprendizaje, de adaptación y de absoluto crecimiento. Tengo la fortuna de decir que, a pesar de los momentos complejos, esta ha sido una experiencia muy feliz y enriquecedora en muchos aspectos. En este camino he tenido la oportunidad de conocer y compartir con personas increíbles, seres humanos invaluable con quienes estoy profundamente agradecido y de quienes he tenido la oportunidad de aprender innumerables e inestimables cosas, desde lo académico, profesional y fundamentalmente, desde lo personal y humano. A todas estas personas que han hecho parte de este proceso, mil y mil gracias por todo su apoyo en este lindo proceso.

*Todo esto ha sido posible gracias al apoyo y enseñanzas brindadas por mi familia. A mi madre, **Sandra Garzón** y mi Padre, **Juan Carlos Castañeda**, agradezco y debo todo lo que soy y he podido conseguir. Su empeño, su perseverancia, su resiliencia, su amor y por supuesto su ejemplo, además de ser admirables, han sido mi guía durante toda mi vida y por supuesto, han sido una de mis motivaciones más grandes. He aprendido de ellos que, con trabajo duro, humildad, dedicación y perseverancia podemos alcanzar cada una de esas metas que nos proponemos. Simplemente nada sería posible sin ellos. Los amo y los admiro profundamente y solo espero que la vida me alcance para demostrarles siempre lo mucho que agradezco cada cosa que hacen por mí. Jamás podré encontrar palabras suficientes para expresarles todo lo que significan para mí. A mi hermana, **Paula Castañeda**, gracias por siempre apoyar mis ideas locas, por estar cuando lo he necesitado de manera incondicional y por ser un excelente ejemplo para mi hija. Hemos estado siempre en las buenas y en las malas y sin duda, así seguirá siendo siempre. Que gran ejemplo de trabajo duro y esfuerzo admirable ha sido para mí y el resto de la familia. Gracias, por tanto. A mi esposa, **Sandra Urrego**, gracias por estar ahí en los momentos agradables y también en los más difíciles, por apoyarme, acompañarme y escucharme y por compartir conmigo tantas aventuras inolvidables en este tiempo. Por su paciencia, amor y comprensión cuando el tiempo ha sido restrictivo y las jornadas de trabajo han sido extensas y por seguirme y mantenerme en pie en este plan, en este camino. Gracias por su ejemplo, de disciplina y esfuerzo y por ser el mejor modelo que seguir para mi hija. Y las palabras jamás serán suficientes para darle las gracias a mi hija, **Salomé Castañeda**, la razón de todas las cosas bellas de mi universo. Gracias, hija por darme la fuerza y la motivación para todo, para querer ser mejor cada día, mejor padre, mejor ser humano, mejor científico. Indudablemente cada paso que doy, lo doy pensando ella, en su felicidad, en su crecimiento y en su tranquilidad. Sin lugar a duda, cada abrazo, cada sonrisa, cada palabra, cada aventura, cada chiste, cada momento que me ha brindado y que hemos compartido, ha sido esencial en este proceso. Espero ser cada día un mejor ejemplo. Gracias por ser el amor de mi vida y mi motor para conseguir cada objetivo. A mi familia entera, millones de gracias, los adoro infinitamente, estaremos en las buenas y no tan buenas, siempre unidos.*

*Quisiera agradecer al **Centro de Investigaciones en Microbiología y Biotecnología de la Universidad del Rosario, CIMBIUR**, por ser mi hogar durante todo este tiempo. A todos sus integrantes gracias por aportar de diferentes maneras en mi crecimiento personal y académico. A esas personas que hicieron de este proceso, un proceso único, enriquecedor, feliz y lleno de momentos inolvidables, les debo demasiado. Dentro de estas personas, quisiera agradecerle a la **Dra. Marina Muñoz** por su acompañamiento durante el doctorado. Sin duda sus enseñanzas, su orientación y su apoyo fueron esenciales en este proceso y estaré siempre muy agradecido por cada momento compartido, por su amistad y por su acompañamiento. A la **Dra. Lissa Cruz**, una de las científicas más brillantes que he conocido, pero más que nada, un ser humano excepcional que desde el principio de este camino académico me brindó su bonita energía, su apoyo incondicional y sus excepcionales y originales cuestionamientos científicos que, sin duda, me permitieron verla como un ejemplo y como un modelo a seguir, gracias infinitas. Gracias por su amistad y por cada momento compartido. A la **Dra. Luz Helena Patiño**, por creer y confiar en mí y en mi trabajo desde el primer momento. Por brindarme no solo su apoyo y su amistad, sino también, oportunidades para crecer, para aprender y ser mejor cada día. Su humanidad, sencillez, inteligencia y sabiduría es ejemplar y estoy profundamente agradecido por cada palabra, por cada momento en que me tendió su mano y en que me ayudó a seguir luchando y perseverando en momentos complejos y por cada enseñanza y conocimiento compartido, gracias y más gracias. A **Nathalia Ballesteros** y **David Martínez**, personas brillantes, seres humanos únicos, mis amigos más maravillosos que gracias a este proceso tuve la fortuna de conocer. Ustedes simplemente hicieron de este camino un camino lleno de momentos únicos e inolvidables. Su apoyo, sus palabras, su ejemplo y más que nada, su absoluta incondicionalidad, han sido y son fundamentales en lo académico y en lo personal. Gracias por estar siempre, en las buenas y malas y por hacer de este proceso un proceso maravilloso y feliz. Gracias por esta invaluable y perenne amistad.*

*Y todo este camino recorrido ha sido gracias a las puertas abiertas por mi mentor y director, el **Prof. Juan David Ramírez**, a quien quiero dar mis más sinceros y absolutos agradecimientos por cada una de las oportunidades brindadas, gracias a las cuales he podido aprender y crecer en lo académico y profesional. Gracias por creer en mí y en mi trabajo, por permitirme desarrollar mis habilidades en este campo y por mostrarme que con dedicación, pasión y esfuerzo se pueden cumplir los objetivos propuestos. Su apoyo ha sido trascendental en cada uno de los momentos de este proceso, no solo en lo académico sino también en lo personal. Gracias por ser un ejemplo y un referente, un mentor y director excepcional. Nunca encontraré palabras suficientes para agradecerle por todo. He sido muy afortunado al contar con su acompañamiento y nada de esto habría sido posible sin sus enseñanzas, su confianza, su orientación y su incansable apoyo. Ha sido un inmenso honor aprender de usted y compartir este camino.*

*Quisiera también agradecer a increíbles científicos y seres humanos que tuve la fortuna de conocer durante mi pasantía doctoral. Al **Dr. Rune Stensvold**, por abrirme las puertas del **Statens Serum Institut (Dinamarca)**, por su hospitalidad y por el constante apoyo en proyectos colaborativos y en proyectos académicos futuros. Al **Dr. Antonio Marcilla**, la **Dra. Alba Cortés**,*

al Dr. Christian Sánchez y a todo el gran grupo del Laboratorio de Parasitología de la Universitat de Valencia, quienes además de brindarme un entorno académico y de aprendizaje excepcional del más alto nivel, me hicieron sentir en casa y en familia. Su profesionalismo, apoyo, hospitalidad y amabilidad hicieron de esta experiencia una inigualable. Ha sido un inmenso honor.

Así mismo, extendiendo mis agradecimientos al Dr. Luis Reinel Vásquez, a la Dra. Claudia Patricia Acosta y a todo el equipo de trabajo del Centro de Estudios en Microbiología y Parasitología y del Grupo de Investigación en Genética Humana de la Universidad del Cauca, por permitirnos diseñar y ejecutar colaboraciones esenciales en este proceso doctoral, por el apoyo humano y científico y por permitirme participar en actividades académicas de socialización donde dimos a conocer este interesante proyecto.

Quiero expresar mi sincero agradecimiento a los jurados de mi tesis doctoral por su tiempo y dedicación en la lectura y evaluación de este documento de investigación. Es para mí un honor contar con la opinión de expertos en las áreas de mi estudio, agradezco sus importantes aportes a los resultados obtenidos y sus valiosas consideraciones sobre los análisis realizados.

Agradezco a la Universidad del Rosario por su gestión y apoyo durante mi formación doctoral, a la Vicerrectoría de Investigaciones de la UR y a la Dirección del programa de Doctorado en Ciencias Biomédicas y Biológicas por su constante colaboración y gentil orientación en cada paso de este proceso.

Gracias al Ministerio de Ciencia, Tecnología e Innovación de Colombia por la financiación de mi formación doctoral a través las Becas de Excelencia Doctoral del Bicentenario, dentro de la convocatoria del Fondo de Ciencia, Tecnología e Innovación del Sistema General de Regalías (Departamento del Cauca) y a COLFUTURO por ejercer como entidad cooperante de la Universidad del Rosario para esta convocatoria.

TABLA DE CONTENIDO

Contenidos

1. LISTA DE PUBLICACIONES	8
2. LISTA DE ABREVIATURAS.....	9
3. RESUMEN	10
4. MARCO TEÓRICO.....	14
4.1. Parasitosis por protozoos	14
4.2. Parasitosis por Helmintos.....	16
4.3. Importancia de las infecciones causadas por <i>Ascaris</i>	16
4.4. Infecciones sistémicas por el protozoo <i>Trypanosoma cruzi</i>	17
4.5. Microbioma intestinal.....	18
4.6. Aproximaciones metodológicas para el estudio del microbioma: metagenómica y metabarcoding.....	18
4.7. Interacciones Protozoos Intestinales-Hospedero-Microbiota.....	20
4.8. Interacciones Protozoo-Hospedero-Microbioma: <i>Trypanosoma cruzi</i>	21
4.9. Interacciones Helmintos-Hospedero-Microbioma.....	23
4.10. Interacciones <i>Ascaris</i> -Hospedero-Microbioma	26
4.11. Selección de Modelos Biológicos para el Estudio de las Interacciones Parásito-Hospedero-Microbioma	27
4.12. Relevancia del estudio de las interacciones parásito-hospedero-microbioma en infecciones causadas por protozoos y helmintos	28
5. OBJETIVOS	30
5.1. Objetivo general	30
5.2. Objetivos específicos	30
6. INTRODUCCIÓN A LOS CAPITULOS.....	31
6.1. Capítulo 1.....	31
6.2. Capítulo 2.....	34
6.3. Capítulo 3.....	36
7. CONCLUSIONES.....	38
8. PERSPECTIVAS.....	44
9. PRODUCTOS DE LA TESIS.....	47

9.1. Artículos científicos:	47
9.2. Capítulo de libro:	48
9.3. Presentaciones En Eventos Científicos:	48
9.4. Cursos:	48
9.5. Pasantía Internacional	49
9.6. Beca	51
10. REFERENCIAS	52
ANEXOS	66

1. LISTA DE PUBLICACIONES

Esta tesis se estructura en siete artículos científicos generados durante la formación doctoral. Todos los artículos publicados y sometidos a publicación se encuentran anexos a este documento:

Artículo 1: Castañeda, S, Acosta, Claudia Patricia, Vasquez-A, Luis Reinel, Patiño, Luz H, Mejía, Rojelio, Ramírez JD. Molecular detection of intestinal parasites in a rural community of Colombia: A one health approach to explore potential environmental–zoonotic transmission. *Zoonoses Public Health* [Internet]. 2024 [cited 2024 Oct 23];71(6):723–735. <https://doi.org/10.1111/zph.13138>.

Artículo 2: Castañeda S, Stensvold CR, Andersen LOBB, Acosta, Claudia Patricia, Vasquez-A, Luis Reinel, Ramírez JD. Impact of *Blastocystis* Colonization and Burden on Gut Microbiota Composition in a Non-Westernized Rural Population from Colombia. *Sometido a PLOS Neglected Tropical Diseases (Q1)*.

Artículo 3: Castañeda S, Muñoz M, Hotez PJ, Bottazzi ME, Paniz-Mondolfi AE, Jones KM, Mejia R, Poveda C, Ramírez JD. Microbiome Alterations Driven by *Trypanosoma cruzi* Infection in Two Disjunctive Murine Models. *Microbiology Spectrum* [Internet]. 2023 [cited 2023 Jun 16];11(3). <https://doi.org/10.1128/spectrum.00199-23>

Artículo 4: Castañeda S, R,Poveda Charlie Suarez-Reyes, Yifan Wu, Noah Haugen, Patiño, Luz H, Weatherhead JE, Ramírez JD. Microbiota Dynamics During *Ascaris* Larval Migration: Implications for Host Microbial Communities. *Sometido a Microbial Pathogenesis (Q1)*.

Artículo 5: Castañeda S, Adeniyi-Ipadeola G, Wu Y, Suarez-Reyes C, Jain A, Ramírez JD, Weatherhead JE. Characterizing Excretory-Secretory Products Proteome Across Larval Development Stages in *Ascaris suum*. *Sometido a Microbes and Infection (Q1)* <https://doi.org/10.1101/2024.07.03.601870>.

Artículo 6: Castañeda S, Paniz-Mondolfi A, Ramírez JD. 2024. Detangling the Crosstalk Between *Ascaris*, *Trichuris*, and Gut Microbiota: What’s Next? *Frontiers in Cellular and Infection Microbiology* [Internet]. 2022. <https://doi.org/10.3389/fcimb.2022.852900>.

Artículo 7: Ramírez JD, Castañeda S, Weatherhead JE, R,Poveda. 2024. Parasite-Microbiota Interactions: A Pathway to Innovative Interventions for Chagas Disease, Leishmaniasis, and Ascariasis. *Sometido a Future Microbiology (Q1)*.

2. LISTA DE ABREVIATURAS

AGCC: Ácidos grasos de cadena corta

BALB/c: Cepa de ratón de laboratorio BALB/c

BLAST: Herramienta básica de alineamiento de secuencias locales

C57BL/6: Cepa de ratón de laboratorio C57BL/6

DADA2: *Divisive Amplicon Denoising Algorithm 2*

LC-MS/MS: Cromatografía líquida-espectrometría de masas en tándem

MAGs: Genomas ensamblados de metagenomas

NGS: Secuenciación de nueva generación

PCR: Reacción en cadena de la polimerasa

ES: Productos de excreción-secreción

qPCR: Reacción en cadena de la polimerasa cuantitativa

.

3. RESUMEN

El microbioma intestinal cumple un rol esencial en diversas actividades metabólicas, fisiológicas e inmunológicas en el hospedero, las cuales, en equilibrio, promueven un adecuado funcionamiento y salud intestinal, ofreciendo adicionalmente, una barrera de protección frente a la colonización e infección por agentes patógenos virales, bacterianos y eucariotas. Dentro de estos organismos, diferentes parásitos, protozoos y helmintos, tienen una importante interacción con este microbioma y se ha propuesto que esta interacción puede tener una gran relevancia con aspectos asociados a la dinámica de la infección, progresión, persistencia, heterogeneidad clínica, entre otros. Una amplia variedad de parásitos pueden ser agentes etiológicos de diversas infecciones y enfermedades tanto a nivel intestinal como sistémico y es claro que a diferencia de los principales patógenos bacterianos y virales, no existen vacunas disponibles para prevenir estas infecciones y por ello su manejo se fundamenta en aspectos de prevención y tratamiento.

Actualmente se conoce que las infecciones parasitarias tienen una interacción con el microbioma intestinal del hospedero influyendo en aspectos de salud y enfermedad, establecimiento, progresión y persistencia de la infección e incluso se ha considerado que estos cambios pueden predisponer al hospedero a diferentes enfermedades intestinales, cardiovasculares, cáncer, obesidad y algunos desórdenes del sistema nervioso central. Diversos estudios han revelado hallazgos de gran interés relacionados con, como el microbioma intestinal puede verse alterado por la presencia de parásitos, tanto protozoos como helmintos, los cuales principalmente han sido desarrollados bajo enfoques descriptivos en seres humanos y de manera complementaria, implementando modelos animales para comprender estos cambios. Sin embargo, estos estudios han usado principalmente la estrategia de metabarcoding (usando marcador 16S rRNA), las cuales brindan información asociada a la composición y estructura de la microbiota, pero que no permiten obtener información referente a predicciones funcionales que brinden un panorama general de cómo los cambios en el microbioma también pueden verse reflejados en cambios en la abundancia de ciertos genes y vías metabólicas claves en estas interacciones. Es por lo anterior, que se requieren estudios como el presente, enfocados en determinar las interacciones parásito-hospedero-microbioma a partir de la integración de una aproximación descriptiva en seres humanos y otro experimental en modelos animales utilizando complementariamente aproximaciones basadas en metabarcoding y metagenómica que permitan un visión más completa de los aspectos vinculados a esta interacción. Los cambios en la estructura y composición del microbioma intestinal en respuesta a infecciones y colonizaciones por protozoos y helmintos, tanto en seres humanos como en modelos animales facilita la correlación de estos hallazgos con distintas variables de interés que pueden representar factores de riesgo asociados a la infección, permitiendo así un mejor entendimiento de los procesos fisiopatológicos y epidemiológicos relacionados con estas infecciones. Esto adquiere mayor relevancia en países en vía de desarrollo donde la prevalencia de infecciones parasitarias es mayor y donde información relevante en el campo de la biología del parásito y de la fisiopatología de la infección y enfermedad, puede brindar un insumo esencial para el desarrollo de nuevas estrategias de manejo, prevención, profilaxis, tratamiento y

diagnóstico en el marco de las políticas de salud pública dirigidas a la mitigación de este tipo de eventos. Teniendo en cuenta lo anterior, el presente estudio tuvo como objetivo, evaluar cambios en los perfiles de microbioma en humanos y modelos animales infectados por protozoos y helmintos y sus potenciales implicaciones en las interacciones parásito-hospedero-microbioma. Como objetivos específicos, los cuales son abordados en cada uno de los capítulos que serán descritos a continuación, se establecieron, (1) Determinar la frecuencia de protozoos intestinales (*Blastocystis*, *Giardia*, *Cryptosporidium*, complejo *Entamoeba histolytica/dispar/moshkovskii*) y helmintos (*Ascaris lumbricoides*, *Trichuris trichiura*, *Uncinarias*) en una población rural del departamento del Cauca, Colombia, mediante la aplicación de técnicas moleculares (PCR - qPCR) y convencionales (microscopía). (2) Describir los cambios en la microbiota intestinal en una población rural del departamento del Cauca, Colombia con presencia de *Blastocystis* a partir de un enfoque de metabarcoding usando simultáneamente los marcadores 16S y 18S rRNA. (3) Caracterizar los cambios en el microbioma intestinal del hospedero asociados a la infección por el protozoo *Trypanosoma cruzi* en un modelo animal a partir de un enfoque metagenómico. (4) Evaluar los cambios en la microbiota del hospedero y del helminto asociados a la infección por *Ascaris suum* en un modelo animal a partir de un enfoque de metabarcoding. (5) Identificar el proteoma de los productos de excreción-secreción (ES) de diferentes etapas larvales de *Ascaris suum* (L3-huevo, L3-pulmón, L3-tráquea) a partir de un enfoque proteómico.

En el *primer capítulo*, en relación con el primer objetivo, se encontraron altas frecuencias de protozoos y helmintos intestinales en muestras de humanos, animales y agua, siendo *Blastocystis* el protozoo más frecuente. La detección en animales domésticos sugiere la posibilidad de transmisión zoonótica. Se identificaron múltiples especies de protozoos y helmintos conocidas por presentar frecuencias relevantes en humanos y animales, tales como *Blastocystis*, *Giardia*, *Cryptosporidium*, *Entamoeba histolytica*, *Ancylostoma duodenale*, *Taenia solium*, y por primera vez en Colombia, se reportó la presencia de *Ancylostoma ceylanicum*. Lo anterior resalta la importancia de utilizar técnicas moleculares para la detección de estos en comunidades rurales. Los resultados indican una alta frecuencia de protozoos y helmintos intestinales y subrayan la necesidad de implementar medidas de salud pública para prevenir su transmisión, especialmente en áreas con riesgo de transmisión zoonótica y ambiental.

Respecto al segundo objetivo de este *primer capítulo*, teniendo en cuenta que se identificó que *Blastocystis* fue el protozoo más prevalente, se describieron los cambios en la microbiota intestinal de los hospederos humanos colonizados por este eucariota. Se observó que la presencia de *Blastocystis* se relacionó con una mayor diversidad de la microbiota, tanto bacteriana como eucariota. Además, se identificaron taxones diferencialmente abundantes relacionados no solo con la presencia del protozoo, sino también con su carga. Se identificó que géneros tales como *Bacteroides*, *Prevotella*, *Oscillibacter*, *Faecalibacterium* y *Alistipes* fueron diferencialmente abundantes en los individuos positivos para *Blastocystis*, encontrando adicionalmente, una relación entre la carga de *Blastocystis* y la abundancia de géneros como *Alistipes* y *Lachnospira*.

En el *segundo capítulo*, en relación con el objetivo 3, se caracterizó el efecto de la infección por *Trypanosoma cruzi* en el microbioma intestinal de un modelo murino utilizando dos cepas distintas de ratón, mediante un enfoque metagenómico. Los resultados mostraron cambios significativos en el microbioma intestinal de ambos modelos tras la infección, siendo estos cambios más pronunciados en el modelo BALB/c. Se identificaron bacterias cuya abundancia se vio alterada, incluyendo miembros de los géneros *Lactobacillus*, *Bacteroides* y *Alistipes*, entre otros. Además, los análisis de predicción funcional y ensamblaje de genomas permitieron determinar el impacto de la infección en diversos procesos metabólicos, tales como la síntesis de ácidos grasos de cadena corta, aminoácidos y procesos energéticos. Este estudio demuestra que la infección por *T. cruzi* puede alterar significativamente el microbioma intestinal, con efectos dependientes del modelo de hospedero, lo que sugiere una compleja interacción entre el parásito, el hospedero y el microbioma. Estos hallazgos podrían tener implicaciones para el desarrollo de nuevas estrategias profilácticas e incluso terapéuticas contra la enfermedad de Chagas, basadas en la modulación del microbioma.

En el *tercer capítulo*, para el cumplimiento del objetivo 4, se evaluó la microbiota asociada con diferentes etapas de desarrollo de *Ascaris* y su impacto en la microbiota del hospedero durante la migración larval en un modelo murino. Se evaluaron muestras de heces, intestino, hígado y pulmones en los días 4, 8 y 14 post-infección. El análisis de la diversidad bacteriana mediante secuenciación del 16S rRNA identificó 8,040 variantes de secuencias de amplicones (ASVs), siendo la microbiota asociada a *Ascaris* la más diversa y distinta en comparación con la del hospedero. Se encontraron géneros específicos en *Ascaris*, como *Bradyrhizobium*, *Achromobacter* y *Pseudomonas*, lo que sugiere un posible intercambio de bacterias con el hospedero durante la migración larval. Estos hallazgos proporcionan una base para investigar las dinámicas ecológicas y funcionales de las interacciones helminto-microbiota, con potenciales aplicaciones terapéuticas.

Complementariamente, para el desarrollo de objetivo 5, se realizó la identificación del proteoma de los productos excretores-secretorios (EPS) de *Ascaris suum* durante sus diferentes etapas de desarrollo larval. Los EPS son fundamentales para la interacción del parásito con su hospedero y representan posibles blancos para el desarrollo de nuevas estrategias de control. Se identificaron un total de 1,738 proteínas en los EPS de *A. suum*, observándose variaciones en la composición proteica a lo largo del desarrollo larval. Las proteínas identificadas participan en diversas funciones biológicas, incluyendo metabolismo, señalización celular, inmunomodulación y protección contra el sistema inmunitario del hospedero. Este análisis proporciona una visión global del proteoma de los EPS de *A. suum* durante su desarrollo larval y podría contribuir a una mejor comprensión de la biología del parásito y de su interacción con el hospedero y su microbiota, así como al desarrollo de nuevas estrategias de control y tratamiento.

En conclusión, los resultados presentados en esta tesis doctoral subrayan la complejidad y relevancia de las interacciones entre parásitos, microbioma y huésped en diferentes escenarios biológicos y geográficos. Se evidenció una alta frecuencia de protozoos y helmintos intestinales, principalmente *Blastocystis*, ligada a condiciones deficientes de saneamiento y calidad del agua. La colonización por *Blastocystis* se asoció con una mayor diversidad bacteriana intestinal y la

presencia de taxones beneficiosos para el hospedero, lo que sugiere posibles efectos protectores en la salud intestinal. Las diferencias en la composición del microbioma entre individuos con diferentes cargas de *Blastocystis* y aquellos no colonizados subrayan una relación dosis-dependiente que, en conjunto con factores ambientales y dietéticos, puede influir en la regulación del microbioma, abriendo la posibilidad de usar *Blastocystis* como un marcador de salud intestinal en poblaciones rurales no-occidentalizadas. Los modelos murinos infectados con *Trypanosoma cruzi* evidenciaron alteraciones significativas en el microbioma y respuestas inmunológicas específicas, destacando el papel de ciertas bacterias como en la respuesta inflamatoria del hospedero y en cambios funcionales en diversas vías metabólicas como la síntesis de ácidos grasos, vitaminas y nucleótidos esenciales para el hospedero. Asimismo, el análisis de la microbiota del helminto y del hospedero durante el ciclo migratorio de *Ascaris* sugirió una potencial transferencia de bacterias desde el huésped al parásito, lo que podría influir en la supervivencia y patogenicidad del nemátodo. Estos hallazgos no solo enfatizan la necesidad de estudios longitudinales para comprender mejor las interacciones entre parásitos, microbioma y huésped, sino que también plantean nuevas perspectivas en la modulación microbiana como estrategia terapéutica para mejorar la salud de poblaciones vulnerables.

Finalmente, de manera complementaria, este proyecto doctoral buscó contribuir con las diferentes estrategias establecidas por el gobierno nacional y territorial en el marco de los lineamientos estratégicos de políticas públicas, así como también aquellas relacionadas con ciencia, tecnología e innovación. Como se ha especificado para Colombia en el *Plan Nacional de Desarrollo*, una de las metas es el fortalecimiento de las IES públicas, motivo por el que el trabajo conjunto y colaborativo llevado a cabo en el presente proyecto representa un aporte fundamental para el alcance y cumplimiento de esta meta. A nivel departamental el *Plan Estratégico de Ciencia, Tecnología e Innovación para el Departamento del Cauca (PEDCTi)* en el marco la propuesta “Visión Cauca 2020”, constituye el referente sobre el cual se estructura el desarrollo de la ciencia, la tecnología y la innovación para beneficio de la sociedad en el departamento del Cauca y en general en el país. Con base en lo anterior, es claro como la contribución desde el punto de vista de la generación del conocimiento y del fortalecimiento de la educación en IES en el departamento, representa un aspecto clave en el cual el presente proyecto aporta en el avance de la innovación y desarrollo tecnológico del Cauca y en la adecuación de la sociedad a los cambios que conlleva el desarrollo científico.

Palabras clave: Microbioma, metagenómica, interacción parásito-hospedero, protozoos, helmintos, *Ascaris*, *Trypanosoma cruzi*.

4. MARCO TEÓRICO

4.1. Parasitosis por protozoos

De acuerdo con la Organización Mundial de la Salud (OMS), 1.500 millones de personas, es decir, el 24% de la población mundial presentan infecciones transmitidas por parásitos intestinales [1,2]. Estas parasitosis generalmente se encuentran asociadas a factores como la contaminación fecal del suelo, los alimentos, insuficiencia de agua potable, ausencia de saneamiento ambiental y condiciones socioeconómicas deficientes, siendo los países en vía de desarrollo los lugares en los que se reportan las mayores tasas de infección por parásitos [2,3]. Los protozoarios *Blastocystis*, *Giardia duodenalis*, *Cryptosporidium* y el complejo *Entamoeba histolytica/dispar/moshkovskii*, se caracterizan por causar importantes episodios de diarrea en niños [2,4]. El modo de transmisión de estos protozoos es a través de la vía fecal-oral después del contacto directo o indirecto con las formas infectivas [2,5,6].

Blastocystis es un género de protozoos entéricos cosmopolitas. Su prevalencia puede superar el 5% en países industrializados y alcanza hasta el 100% en países en desarrollo, como en el caso de Colombia [7,8]. Los principales síntomas clínicos relacionados con *Blastocystis* son náuseas, anorexia, flatulencia y diarrea aguda o crónica [9,10]. Así mismo, se ha establecido una asociación de *Blastocystis* con el síndrome de colon irritable y manifestaciones extra-intestinales como la urticaria [11]. Sin embargo, su rol patogénico aún es controversial ya que ha sido encontrado tanto en individuos sintomáticos como en portadores asintomáticos incluso, resultando beneficioso para el hospedero [12–17]. *Blastocystis* presenta una amplia diversidad genética, la cual ha conllevado a la subdivisión en múltiples subtipos (STs). En la actualidad se conocen al menos 40 STs [18–22]. Los ST1 al 8 infectan humanos y animales, el ST9 infecta solo humanos y los ST10 al 17 solo se han aislado en animales [10,19,22]; sin embargo, se ha demostrado que los humanos pueden estar infectados por uno o más STs de los cuales se encuentran en huéspedes no humanos, lo que establece su potencial zoonótico [22–25].

Giardia duodenalis (también conocido como *Giardia lamblia* o *Giardia intestinalis*) [26,27] afecta aproximadamente 280 millones de personas alrededor del mundo. En Colombia se presenta una prevalencia de *Giardia*, que oscila entre 15.4 y 61% [1,8,28]. La sintomatología producida por la infección de éste parásito es muy variable; algunos pacientes pueden presentar diarrea aguda o crónica, dolor abdominal, náuseas, vómito, deshidratación, pérdida de peso o ser asintomáticos [26,29]. Marcadores moleculares como el glutamato deshidrogenasa (*gdh*), factor de elongación alfa ($\text{ef}\alpha$), triosa fosfato isomerasa (*tpi*), SSU rRNA y beta giardina (*bg*) [30–32], clasifican a *Giardia* en ocho ensamblajes distintos, identificados de la A-H. Los ensamblajes A y B a su vez han sido clasificados como AI, AII, AIII, BIII y BIV e infectan principalmente a humanos [33,34].

Con relación a las especies del género *Cryptosporidium*, según datos recientes del Global Enteric Multicenter Study (GEMS) sobre la carga y la etiología de la diarrea infantil en los países en

desarrollo, estos parásitos son hoy en día una de las principales causas de diarrea moderada a grave en niños menores de 2 años [35]. Al igual que *Giardia*, esta infección fue incluida por la OMS como una enfermedad desatendida [36]. En algunas personas causa diarrea secretora y síndrome de malabsorción que puede estar acompañada de dolor abdominal, vomito, fiebre leve, malestar general, fatiga, náuseas y pérdida de apetito [6,37]. Actualmente se han identificado al menos 30 especies y 70 genotipos, de las cuales 20 han sido reportadas en humanos, siendo principalmente *Cryptosporidium hominis* y *Cryptosporidium parvum* las responsables de la mayoría de las infecciones [38,39]. Existen 10 subtipos para *C. hominis* (Ia-Ik) y 16 subtipos (IIa-IIp) para *C. parvum* [8,40]. En Colombia, se ha estimado que *Cryptosporidium* presenta una prevalencia nacional del 0.5% por microscopía, sin embargo, estudios con aproximaciones de epidemiología molecular en regiones específicas del país, como el realizado por Villamizar y cols en 2019 [38], y evidencia obtenida a partir de revisiones sistemáticas como la desarrollada por Galvan y cols en 2018 [41], han mostrado a partir de identificación por qPCR principalmente, una prevalencia entre 7,3% y 9.8%, y han permitido la caracterización de genotipos tales como *C. parvum* subtipo Iia y *C. hominis* subtipo IbA9G3R2. [1,8,38,41,42]. Adicionalmente, se ha destacado su importancia en agua y animales, donde se estima una prevalencia de 38,9% y 20,4% respectivamente, siendo esto esencial a tener en cuenta en la dinámica de transmisión [41]. Sin embargo, un aspecto relevante en la caracterización molecular y genotipificación de este protozoo está relacionado con el uso de diferentes marcadores e incluso de perfiles de MLST (Multilocus sequence typing) que puede permitir una estimación variable de la diversidad genética [40,41,43].

El género *Entamoeba* comprende varias especies, de las cuales seis pueden habitar en el intestino grueso del hombre: *E. histolytica*, *E. dispar*, *E. moshkovskii*, *E. polecki*, *E. coli* y *E. hartmannii* [44]. *Entamoeba histolytica* es considerada como patógena, causante de la amebiasis humana afectando al 10% de la población mundial y puede alcanzar hasta el 50% en zonas de centro y Sudamérica, África y Asia. En el mundo, cerca de 500 millones de infecciones se le atribuyen a *E. dispar* y para *E. moshkovskii* se ha estimado una prevalencia entre 2.2% y 61.8% [45–47]. En Colombia, la identificación molecular por qPCR ha permitido estimar una prevalencia de *E. histolytica* cercana al 1% y así mismo, otros estudios epidemiológicos han descrito especies como *E. moshkovskii* principalmente en poblaciones rurales [8,38,46–48].

Una de las grandes dificultades que se presenta en el diagnóstico de estos parásitos intestinales es la relativa y limitada especificidad y sensibilidad de la microscopía, además de la inestabilidad de algunos parásitos protozoarios que tienden a deteriorarse rápidamente fuera del huésped. Así mismo, estas determinaciones dependen de la experticia del operador y del tipo de parásito [49]; por tal motivo, es una necesidad inmediata la implementación de técnicas moleculares como la PCR y qPCR que permitan diagnosticar especies y subpoblaciones circulantes de estos parásitos en poblaciones vulnerables, con el fin de obtener mediciones precisas de la prevalencia e intensidad de las infecciones en las zonas endémicas [15,49].

4.2. Parasitosis por Helmintos

La OMS estima que la infección por helmintos afecta aproximadamente a 1500 millones de personas, principalmente en zonas tropicales y subtropicales. En América Latina se calcula que 46 millones de niños en edad escolar están en riesgo de contraer infecciones por helmintos [50].

Dentro del grupo de las helmintiasis, existe un subgrupo que se caracteriza por que su transmisión se da a través el contacto con suelo contaminado con huevos larvados o las larvas de los helmintos (geohelmintiasis). Las especies de helmintos transmitidos por el suelo que infectan al ser humano y que representan un gran interés en salud pública son *Ascaris lumbricoides*, *Trichuris trichiura* y las uncinarias (*Necator americanus* y *Ancylostoma duodenale*) [1,2,51]

Ascaris lumbricoides es un nemátodo que se encuentra principalmente en zonas tropicales y templadas del mundo [2,15]. En Colombia la prevalencia estimada de infección por este parásito varía de acuerdo con la población. Estudios realizados en Cauca, Cali y Turbaco determinaron prevalencias de 32%, 8.3% y 16.7% respectivamente [52,53]. La encuesta Nacional de Parasitismo encontró que la prevalencia de este parásito fue del 11.3% [1]. Morfológicamente, los huevos de diferentes tipos de helmintos son muy similares lo cual dificulta su identificación por microscopia [54].

En el caso de *Trichuris trichiura*, se estima que infecta a unos 450 millones de personas, en su mayoría niños en edad escolar [2,55,56]. Aunque muchos casos muestran solo síntomas leves o incluso son asintomáticos, la tricuriasis aún tiene importantes consecuencias para la salud (Knopp et al., 2012). De acuerdo a la Encuesta Nacional de Parasitismo, *T. trichiura*, fue el helminto más prevalente (18.4%) [1].

Las uncinarias de importancia médica que parasitan el ser humano y causan morbilidad son: *Necator americanus* y *Ancylostoma spp.* [1,2]. Los pacientes con uncinariosis suelen ser asintomáticos; sin embargo, se ha descrito que la infección crónica causada por estos parásitos puede generar anemia [58], diarrea, dolor abdominal de tipo cólico, náuseas, y eosinofilia [59]. En Colombia se estima que la prevalencia de uncinariosis es aproximadamente del 6% [1].

4.3. Importancia de las infecciones causadas por *Ascaris*

Las infecciones por *Ascaris* son una de las más frecuentes en el mundo y es considerada también como una Enfermedad Tropical Desatendida [2,50,55,60]. La prevalencia de las infecciones por helmintos supera el 10% en países en vía de desarrollo y un gran porcentaje de estas, está dado por las infecciones por *Ascaris lumbricoides*, principalmente en ciertas regiones de África y Sur América [2,55,56,60]. Se ha relacionado principalmente con desnutrición, retraso en el desarrollo por infecciones persistentes y se estima que causa cerca de 60,000 muertes anuales en población infantil principalmente [2,55,56,61,62]. Así mismo, este helminto es de gran relevancia desde la perspectiva del control y prevención. Entre otras cosas, factores como la gran resistencia de los

huevos de este parásito en el suelo húmedo, incluso por varios años, las reinfecciones pese al manejo terapéutico con antihelmínticos y la no disponibilidad de vacunas, se asocian con una alta dispersión de *Ascaris* no sólo en hospederos humanos sino también en otro tipo de hospederos [63–65]. Adicionalmente, además de la afectación generada en la salud humana por *A. lumbricoides*, existe una alta prevalencia en cerdos de la especie *Ascaris suum*, que ocasiona un proceso infeccioso muy similar al dado en el humano, generando grandes pérdidas económicas en el sector porcícola [66–71]. Lo anterior, adquiere aún mayor relevancia cuando se considera que diferentes estudios han encontrado a partir de análisis genómicos, mitocondriales y del genoma completo, que *A. suum* y *A. lumbricoides* pueden formar un complejo genético que es capaz de entrecruzarse, lo cual puede asociarse a un gran potencial de transmisión zoonótica y con ello, se destaca la necesidad de un mejor manejo de estas infecciones en porcinos bajo un enfoque de One Health para controlar de esta forma la propagación de la ascariasis humana [2,69,72,73].

4.4. Infecciones sistémicas por el protozoo *Trypanosoma cruzi*

El protozoo flagelado *T. cruzi* es el agente causal de la enfermedad de Chagas, enfermedad que afecta aproximadamente 6.3 millones de personas en el mundo [74–77]. En Colombia se estima que alrededor de 130,000 personas se encuentran infectadas con el parásito, con una incidencia de 7.69 por cada 100,000 habitantes [77,78]. Además, este parásito se encuentra asociado a diferentes manifestaciones clínicas y escenarios eco-epidemiológicos zoonóticos y enzooticos, hallándose desde el sur de Estados Unidos hasta Argentina y Chile [76,77,79,80].

T. cruzi posee un complejo ciclo de vida; se han descrito cuatro etapas morfológicas y funcionales bien diferenciadas: tripomastigotes procíclicos, tripomastigotes metacíclicos, amastigotes y epimastigotes. El ciclo de vida transcurre entre hospederos mamíferos, humanos y reservorios selváticos, donde se pueden encontrar las formas amastigotes y tripomastigotes, y entre vectores de la familia Reduviidae, quienes transmiten el parásito, en formas epimastigotes y tripomastigotes metacíclicos infectivos [76,81]. En el hospedero mamífero, se generan dos fases importantes, la primera corresponde a la infección de las células mononucleares de sangre periférica por parte de los tripomastigotes metacíclicos provenientes del vector, y la segunda, corresponde a la infección de células específicas (cardíacas, enterocitos, adipocitos, tejido nervioso), por tripomastigotes procíclicos liberados a partir de las células mononucleares, que pueden provocar importantes afectaciones a nivel intestinal y cardíaco [74,75,77,82,83].

La enfermedad de Chagas se caracteriza por dos fases, una aguda y una crónica. Se considera fase aguda a la etapa en la que aparecen o no los síntomas y en la que además, el paciente presenta tripomastigotes circulantes en sangre periférica [76,77]. En la enfermedad de Chagas, independientemente del mecanismo de transmisión, los síntomas aparentes se presentan entre los 8 y 10 días después de la invasión parasitaria o entre 20 a 40 días cuando la transmisión es por transfusión de sangre infectada. Se puede presentar fiebre prolongada, malestar general, astenia, irritabilidad, cefalea, convulsiones, hepatoesplenomegalia, edema subcutáneo local o

generalizado, miocarditis severa o se puede llegar a producir la muerte por insuficiencia cardíaca [76]. Posterior a la fase aguda, hasta un 30% de los pacientes manifiestan síntomas entre 10 a 30 años post-infección, principalmente de compromiso cardíaco, como arritmias, trastornos de la conducción AV, taquicardia, fenómenos embólicos, cardiopatía dilatada. Adicionalmente, se pueden presentar manifestaciones digestivas como megaesófago, megacolon o una combinación de las anteriores (cardiodigestivas) y en algunos casos se puede presentar encefalitis, siendo más común en pacientes inmunosuprimidos [78]. Uno de los aspectos más relevantes con la prevalencia de esta enfermedad, es que se estima que más del 90% de los individuos infectados con el parásito no son diagnosticados y que sólo el 1% reciben el tratamiento etiológico específico (con benznidazole o nifurtimox) [77].

4.5. Microbioma intestinal

El microbioma del intestino humano se refiere a un complejo sistema de múltiples microorganismos, sus productos génicos y funciones fisiológicas correspondientes, que pueden ser encontrados en el tracto gastrointestinal [84]. Dentro de esta denominación se incluyen bacterias, arqueas, virus y organismos eucariotas, que mantienen una interacción constante entre ellas y con el hospedero [85]. Se ha descrito que alrededor de 100 millones de células microbianas habitan el intestino humano, las cuales en conjunto son las encargadas de suplir diversos procesos biológicos del ser humano [86]. El desequilibrio de la microbiota intestinal ha sido asociado con diversas enfermedades, como la obesidad, la malnutrición, alergia o intolerancia a cierto tipo de alimentos, las enfermedades inflamatorias intestinales y el desarrollo de cáncer de colon, enfermedades cardiovasculares, infección por *Clostridioides difficile*, entre otras [87–92]. La diversidad y composición de la microbiota son altamente dinámicas, y depende de variables tales como el estado físico del huésped, genotipo y fenotipo inmune, así como también de factores ambientales como la dieta, el uso de antibióticos y el estilo de vida [93]. Se ha descrito que las especies pertenecientes a la familia Firmicutes y Bacteroidetes son las más comunes, abarcando más del 70-75% del total de especies. Los siguientes phyla más comunes son Actinobacteria, Proteobacteria y Verrucomicrobia. Los géneros más predominantes son *Bacteroides*, *Clostridium*, *Faecalibacterium*, *Eubacterium*, *Ruminococcus*, *Peptidococcus*, *Peptidostreptococcus* y *Bifidobacterium* [84,85,94,95].

4.6. Aproximaciones metodológicas para el estudio del microbioma: metagenómica y metabarcoding

La metagenómica y el metabarcoding constituyen enfoques metodológicos esenciales en el análisis de comunidades microbianas y eucarióticas en diversos ambientes naturales y clínicos [96–99]. Ambos métodos son ampliamente utilizados en la microbiología ambiental y médica para explorar

la diversidad biológica, aunque presentan diferencias significativas en cuanto a su teoría subyacente, alcance de la información obtenida y aplicaciones [96–99].

La metagenómica, particularmente en su modalidad de secuenciación shotgun, se refiere a la secuenciación aleatoria del ADN extraído directamente de una muestra ambiental [97,99]. Esta metodología permite la caracterización exhaustiva del contenido genético total presente en la comunidad microbiana, sin la necesidad de aislamiento y cultivo de los organismos. La secuenciación aleatoria de fragmentos genómicos facilita la identificación de los distintos taxones presentes, además de ofrecer información sobre los genes funcionales y las rutas metabólicas potencialmente activas en el ecosistema. Por lo tanto, la metagenómica, a partir de un robusto esquema de análisis bioinformático, no solo permite describir la composición taxonómica, sino también explorar la capacidad funcional y adaptativa de la microbiota y reconstruir genomas completos a partir de datos metagenómicos (MAGs) [97,99–101]. La relevancia de la metagenómica reside en su capacidad para descifrar la complejidad de los microbiomas de ambientes complejos como el intestino humano, el suelo o los ecosistemas acuáticos. Este enfoque es crucial para estudiar aspectos como la resistencia a los antimicrobianos, la interacción huésped-microbioma y la funcionalidad metabólica de comunidades microbianas, aportando una perspectiva integral que combina taxonomía con función biológica. La metagenómica ha ampliado significativamente el conocimiento sobre la ecología microbiana y la diversidad genética [97,99].

Por otro lado, el metabarcoding o metataxonómica es una técnica de secuenciación dirigida que utiliza genes marcadores filogenéticos para la identificación taxonómica de microorganismos en una muestra [97,102]. En microbiología, los genes del ARN ribosomal 16S y 18S son comúnmente utilizados para bacterias y arqueas, y para eucariotas, respectivamente, debido a la conservación de sus regiones de bajo y alto grado de variabilidad [97,103]. La amplificación por PCR de estas regiones permite su secuenciación masiva, proporcionando una caracterización taxonómica precisa de la comunidad. Sin embargo, al centrarse en secuencias genéticas específicas, el metabarcoding no proporciona información sobre el contenido funcional del genoma de los organismos detectados ni permite el ensamblaje de genomas de estos microorganismos [97,103]. La importancia del metabarcoding radica en su capacidad para realizar estudios de manera eficiente y costo-efectiva, con una menor necesidad de datos de secuenciación en comparación con la metagenómica. Se utiliza en estudios ecológicos para caracterizar la composición de comunidades microbianas y eucarióticas en distintos ambientes, siendo útil para la identificación de especies y la evaluación de biodiversidad. No obstante, su limitación principal es la falta de información sobre funciones biológicas y rutas metabólicas [97,103].

Las diferencias clave entre la metagenómica y el metabarcoding se encuentran en la naturaleza de los datos obtenidos y el alcance de su análisis. Mientras que la metagenómica proporciona una descripción holística de la comunidad microbiana al incluir tanto la identificación taxonómica como el análisis funcional a nivel genómico, el metabarcoding se limita a la identificación de organismos mediante genes marcadores sin aportar detalles sobre su capacidad funcional. La metagenómica implica un mayor coste y complejidad técnica debido a la necesidad de análisis

bioinformáticos más avanzados y a una mayor profundidad de secuenciación, en contraste con el metabarcoding, que es más accesible y ampliamente utilizado para estudios específicos de biodiversidad taxonómica. La integración de ambos enfoques permite obtener una comprensión más completa de la ecología y función de los microbiomas en diferentes contextos ambientales y clínicos [97,102,104,105].

4.7. Interacciones Protozoos Intestinales-Hospedero-Microbiota

Diferentes protozoos han sido usados como organismos modelo para estudiar las interacciones fprotozoo-hospedero-microbioma a partir de aproximaciones descriptivas en seres humanos, experimentales *in vitro* y con el uso de modelos animales [106].

En el caso de *Blastocystis*, existe evidencia obtenida a partir de estudios descriptivos en seres humanos, de que la presencia de este protozoo puede estar relacionada con una composición de microbiota “normal” o “saludable”, favoreciendo un ambiente anaerobio y anti-inflamatorio, donde se destaca una mayor abundancia de taxones del género *Faecalibacterium*, importantes en el mantenimiento de la salud intestinal [16,17,107,108]. Sin embargo, estudios realizados con subtipos como el ST7, permitieron evidenciar *in vitro*, que este subtipo conduce a un desequilibrio de la microbiota intestinal que podría favorecer la aparición de síntomas clínicos y que puede estar asociado a la fisiopatología de la infección [109].

Para el caso de *Giardia*, se ha planteado la hipótesis de que en humanos la infección por este protozoo desencadena alteraciones permanentes de los microorganismos comensales, generando un desequilibrio en la microbiota intestinal y promoviendo la invasividad bacteriana en la mucosa intestinal [110–112]. Incluso se ha evaluado el potencial *in vitro* de ciertos taxones bacterianos para impedir el establecimiento de la infección en el caso de *Giardia*, donde se encontró que el uso de *Lactobacillus johnsonii* inhibe la adhesión de este protozoo a las células, evitando el progreso de la infección, fortaleciendo de esta manera el hecho de que el restablecimiento de la microbiota saludable a partir del uso de probióticos puede jugar un papel clave en nuevos esquemas de profilaxis y tratamiento [113].

Respecto a *Entamoeba histolytica* se ha evidenciado que el impacto que puede generar a nivel de la microbiota intestinal por acción enzimática y de adhesión puede provocar cambios en ciertos grupos bacterianos que han sido incluso considerados como marcadores de infección y de predicción del desarrollo clínico de la enfermedad. En relación con esto Morton y cols en 2015 propusieron que la presencia de *Entamoeba* se correlacionaba significativamente con la composición y diversidad del microbioma y que la colonización por este protozoo se podía predecir con un 79 % de precisión en función de la composición de la microbiota intestinal de un individuo [114]. Así mismo, Gilchrist y cols en 2016 plantearon que una alta carga de parásitos junto con el aumento de la abundancia de *Prevotella copri* se asociaron clínicamente con enfermedad diarreica, representando importantes predictores del desarrollo clínico del proceso

infeccioso [115]. Estudios como estos, recalcan la importancia de enfocar investigaciones en este contexto que puedan complementar parámetros profilácticos y diagnósticos en infecciones causadas por protozoos.

Se han efectuado también análisis en relación con *Cryptosporidium*, donde se ha mostrado que puede provocar un desequilibrio en la microbiota, principalmente a partir de la alteración de bacterias como *Escherichia coli*, *Bacillus spp.* y *Clostridium spp.*, disminuyendo concomitantemente las concentraciones fecales de indol, lo cual puede estar relacionado con la acción de este metabolito sobre los tejidos del huésped para mejorar la respuesta innata aumentando la integridad epitelial y/o estimulando las vías antiinflamatoria. Estos datos indican que algunas bacterias, pueden influir en la capacidad de *Cryptosporidium* para establecer una infección y así mismo que los niveles de indol preexistentes en el intestino junto con la carga parasitaria y el estado inmunitario del hospedero pueden ser factores importantes que determinan el resultado de la exposición a *Cryptosporidium* [116,117].

Es claro como los estudios que han buscado evaluar interacciones protozoo-hospedero-microbiota han destacado la contribución del microbioma intestinal a la variación clínica en las infecciones por protozoos parasitarios. Así mismo, los hallazgos han facilitado la comprensión parcial de estas interacciones y de ciertos mecanismos involucrados, entre los que pueden nombrarse: (I) alteración de la virulencia del parásito mediados por comunidades bacterianas específicas; (II) inducción de cambios y alteraciones que provocan un desequilibrio en la composición de la microbiota intestinal; (III) modulación de la inmunidad del huésped al protozoo parásito [118]. Lo anterior ofrece un marco de trabajo muy interesante ya que el impacto de la infección parasitaria a nivel de la microbiota intestinal puede generar firmas únicas que puede ser esenciales en el campo diagnóstico y que a su vez pueden suministrar información clave en el diseño de nuevas estrategias en el contexto clínico y de salud pública.

4.8. Interacciones Protozoo-Hospedero-Microbioma: *Trypanosoma cruzi*

En el caso de *T. cruzi* se han efectuado diferentes estudios que han permitido identificar que la composición de la microbiota intestinal puede influir en fisiopatología de las infección parasitarias modificando el equilibrio entre el huésped y sus comensales, interrumpiendo la homeostasis del ecosistema presente, además de beneficiarse del metabolismo de nutrientes y sustratos para la obtención de energía necesaria para el cumplimiento de procesos fisiológicos parasitarios involucrados en su ciclo de vida y supervivencia [119–123]. Así mismo, como en el caso de otros protozoos, se ha demostrado en modelos murinos que el mantenimiento de la homeostasis de los microorganismos comensales es fundamental en la respuesta inmune mediada en buena parte por las células dendríticas, de manera tal que la pérdida del equilibrio de estas comunidades puede influir en la susceptibilidad del hospedero a la infección [123–129].

Se han implementado aproximaciones descriptivas en seres humanos y ciertos ensayos experimentales a nivel de modelos murinos en relación con las infecciones por *Trypanosoma cruzi* y su interacción con la microbiota del hospedero. Robello y cols en 2019 encontraron que la presencia de *T. cruzi* generaba alteraciones en la microbiota intestinal en niños y que estos cambios desaparecían con el tratamiento antiparasitario, sugiriendo que el efecto de la infección sobre la microbiota intestinal podría ser más importante que el efecto del tratamiento y de cómo el restablecimiento de la microbiota estaba asociado a la resolución de la infección [130]. Estudios en modelos murinos como el realizado por McCall y cols en 2018, que incluyó estudios a nivel de microbiota y metaboloma, indicaron que la infección por este protozoo efectivamente modula el microbioma intestinal provocando cambios funcionales en el entorno químico del intestino que podrían estar afectando a las respuestas inflamatorias del huésped, lo que al final puede tener un impacto en la fisiopatología de la enfermedad de Chagas, particularmente en formas crónicas digestivas [131]. En este sentido se han evaluado los cambios en la microbiota en formas cónicas tanto indeterminadas, cardíacas y digestivas y se ha observado que la infección por *T. cruzi* da como resultado un cambio en el microbioma intestinal, provocando un desequilibrio caracterizado por menores abundancias de microorganismos asociados con la salud como *Akkermansia* y *Lactobacillus*, importantes en la producción ácidos grasos de cadena corta y en el mantenimiento del pH intestinal [132]. Un estudio de gran relevancia en este campo fue el realizado por Hossain y cols en 2020 en un modelo murino, donde se evaluaron aspectos relacionados con la microbiota y metaboloma a partir del uso de cepas bioluminiscentes de *T. cruzi* que además facilitaron establecer un mapeo espacial de la infección y de cómo esto se relacionaba con los cambios provocados por la presencia del parásito [123]. Allí se logró determinar que, tanto en formas agudas como crónicas, *T. cruzi* tiene un importante tránsito gastrointestinal y que afecta en términos de carga parasitaria, de microbiota y de metaboloma de manera diferencial ciertas porciones anatómicas, revelando aspectos fundamentales en la transición de formas agudas a crónicas y relacionadas con la persistencia del protozoo. Adicionalmente, se pudo observar que el esófago, el colón y el intestino grueso son regiones donde además de encontrar altas cargas parasitarias, fueron también donde se generaron mayores cambios en la composición de la microbiota y el metaboloma, lo cual resalta la importancia de estos cambios asociados a la fisiopatología de la enfermedad de Chagas, principalmente asociada a megaesófago y megacolon [123]. Se encontró que el tropismo por estas regiones puede estar vinculado con las manifestaciones crónicas de esta enfermedad y que esta persistencia se encuentra fuertemente relacionada con los cambios permanentes generados a nivel de la microbiota del hospedero en estas regiones anatómicas específicas, donde adicionalmente se encontraron alteraciones funcionales asociadas a la disminución de aminoácidos aromáticos como el triptófano (precursor de la quinurenina) y la tirosina [123]. Con base en lo anterior, los autores sugieren que los cambios en la composición de la microbiota, en conjunto con la disminución de estos metabolitos durante la infección aguda, puede responder al hecho de que los metabolitos de quinurenina tienen efectos antiparasitarios directos y contribuyen al control de la infección aguda por *T. cruzi* lo cual puede estar favoreciendo el establecimiento de la infección en esta fase inicial. Sin embargo, en la

infección crónica no se observó dicha disminución de estos aminoácidos, lo cual puede relacionarse con el hecho de que además de lo anterior, la quinurenina tiene la capacidad de activar células T reguladoras, motivo por el que en formas crónicas, esta modificación puede contribuir a la persistencia del parásito a partir de la inmunomodulación [123].

4.9. Interacciones Helmintos-Hospedero-Microbioma

Las interacciones entre los helmintos y la microbiota intestinal del hospedero puede dilucidar aspectos claves en la biología y fisiopatología de estos parásitos, razón por la cual se han buscado comprender los mecanismos que están involucrados en esta relación (Figura 1). La mayoría de estudios han estado dirigidos a la comprensión de las interacciones entre los helmintos y el sistema inmunológico del hospedero ya que se ha evidenciado la gran capacidad inmunomoduladora e inmunoreguladora que tienen estos parásitos y que les permiten infectar, diseminarse y persistir en el huésped infectado [133–139]. Sin embargo, se ha observado cómo las infecciones por helmintos ocasionan cambios en la composición de la microbiota intestinal lo cual juega un papel clave en la biología del parásito y en la dinámica de la infección [139–143]. Los cambios en la abundancia relativa de ciertos taxones bacterianos y los cambios diversidad de la microbiota intestinal frente a la presencia de helmintos, se han vinculado con efectos en el ciclo de vida del parásito, con cambios metabólicos que promueven la infección y diseminación y con alteraciones en la respuesta inmune del hospedero que pueden estar relacionados con la persistencia de este tipo de infecciones [64,66,112,144–158]. La comprensión de los mecanismos a partir de los cuales la presencia de estos parásitos influye en los cambios en la microbiota intestinal del hospedero son objeto de gran interés, ya que abren un camino muy relevante en la búsqueda nuevas estrategias de control y de alternativas terapéuticas.




Figura 1. Modelo de influencia recíproca de interacciones huésped-parásito-microbiota. **Fuente:** Adaptado de Cortés *et al* 2018.

Los estudios de la microbiota en relación con la presencia de helmintos han mostrado resultados heterogéneos, principalmente en los estudios descriptivos realizados en humanos, esto debido a que el contexto geográfico, las condiciones socioeconómicas y de higiene, la alimentación, entre otros factores, pueden influir en la composición de la microbiota y en la respuesta a la infección [139,159,160]. Por lo anterior, se ha optado por complementar estos hallazgos a partir de la utilización de modelos animales, principalmente cerdos y ratones, que permitan reflejar las infecciones en seres humanos y de esta manera poder tener un mayor control del proceso infeccioso y de aquellas variables que influyen en la composición de la microbiota intestinal del huésped [129,152,161–164].

Los estudios realizados en torno a las interacciones *Ascaris*-Microbiota-Hospedero han sido también desarrollados a partir de diseños descriptivos en poblaciones humanas y con base en modelos animales. Una particularidad en el caso de *Ascaris* es que, durante su ciclo de vida, posterior a la infección dada por la ingestión de huevos que eclosionan dentro de las 3 horas siguientes a la ingesta, las larvas (L3) tienen la capacidad de invadir el tejido mucoso de tracto gastrointestinal donde pueden realizar posteriormente una migración hacia tejidos hepáticos y pulmonares [165,166]. En el pulmón, la infección desencadena una inflamación caracterizada por la infiltración de eosinófilos generando un complejo de síntomas denominado síndrome de Loeffler en pacientes humanos [166]. Estas características en la migración de ciertos estadios del parásito se han vinculado con posibles mecanismos de alteración de la composición y estructura de la microbiota intestinal ya que, por ejemplo, se puede promover la translocación de bacterias sobre las barreras en el intestino y, poco después, también a nivel de la mucosa pulmonar [167].

En un estudio realizado en población ecuatoriana por Cooper y cols, los autores presentan la hipótesis de que la infección por *Ascaris lumbricoides* genera un impacto a nivel de la microbiota intestinal del hospedero [155]. Allí se plantea que la infección única por *Ascaris lumbricoides* o en coinfección con otros helmintos, puede generar un perfil de microbiota alterado caracterizado por abundancias relativas más bajas de ciertos taxones, predominantemente de la clase Clostridia y más altas de bacterias del género *Streptococcus*. Así mismo, sugieren que la presencia de este helminto se relaciona con una menor diversidad en la microbiota del huésped [155]. Lo anterior fue explorado y corroborado en un modelo animal porcino donde se utilizó el helminto *Ascaris suum* [168]. En dicho estudio, se demostró que la infección redujo significativamente la diversidad de la microbiota intestinal de los cerdos y que este efecto fue independiente de la carga del parásito. Así mismo, se logró determinar una abundancia relativa diferencial asociada a la infección de al menos 49 géneros bacterianos, dentro de los que se destacan *Prevotella* y *Faecalibacterium* [168]. Adicionalmente, se observó la presencia de cambios en el perfil metabólico de los cerdos infectados por el helminto, observando una disminución en el metabolismo de carbohidratos y de aminoácidos [161]. Como en otros casos, existen resultados heterogéneos entre algunos estudios. Así por ejemplo, a pesar de que Wang y cols [168] identificaron una mayor diversidad en la microbiota intestinal de los porcinos infectados por *Ascaris suum*, un estudio previamente realizado por Williams y cols, determinó que la infección por *Ascaris* modifica la microbiota intestinal del huésped, pero en este caso sugiriendo un aumento en la diversidad de esta con la concomitante reducción en la abundancia relativa de los géneros *Lactobacillus*, *Ruminococcus* and *Catenibacterium* [70].

Lo anterior resalta la importancia de realizar tanto estudios en poblaciones con condiciones específicas a partir de diseños epidemiológicos robustos y como aquellos basados en modelos animales en los cuales se puedan controlar la mayor cantidad de variables asociadas a la infección y que puedan impactar en cambios en la microbiota intestinal del hospedero y así mismo, la necesidad de establecer protocolos experimentales y de análisis bioinformáticos reproducibles que permitan validar los resultados obtenidos en estas investigaciones.

Uno de los aspectos que también ha sido considerado en las interacciones *Ascaris*-microbiota-hospedero, es el hecho de como la infección por este parásito puede generar una susceptibilidad a la infección por otros agentes patógenos, principalmente de tipo bacteriano. En modelos porcinos se ha evidenciado como la infección por *Ascaris suum* [168] y por *Trichuris suis* [146] se relacionan con una mayor abundancia relativa del género *Campylobacter*, lo cual sugiere que las infecciones por estos helmintos pueden aumentar el riesgo de infecciones secundarias causadas por bacterias, razón por la que este representa un campo de estudio fundamental en el aspecto clínico y de salud pública [168].

4.10. Interacciones *Ascaris*-Hospedero-Microbioma

Se han propuesto diversos mecanismos potencialmente involucrados en la interacción de *Ascaris* con la microbiota del hospedero [143,169]. En las infecciones por *Ascaris* se han identificado productos secretados por este helminto que promueven la modulación de la respuesta inmune y que pueden estar relacionados con las interacciones indirectas con la microbiota intestinal del hospedero. Se han identificado productos E/S, vesículas extracelulares y otros metabolitos que pueden interactuar de maneras diferentes con la microbiota del huésped y que pueden jugar un papel clave en la biología del parásito y en la fisiopatología de la infección [71]. Se ha destacado además, la relevancia que puede tener la microbiota propia del helminto en esta interacción, siendo uno de los campos hasta ahora menos estudiado [157,170,171]. Se ha confirmado en este sentido que la presencia del helminto *Ascaris suum* tiene la capacidad de inducir en el hospedero la producción de péptidos antimicrobianos de tipo ASABF (*Ascaris suum* antibacterial factor) [66,172] y de péptidos microbianos de la familia de la cecropinas (P1 a P4) que han demostrado tener un efecto bactericida contra una amplia gama de microbios, tales como bacterias grampositivas (*Staphylococcus aureus*, *Bacillus subtilis* y *Micrococcus luteus*) y gramnegativas (*Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Serratia marcescens* y *Escherichia coli*) [173]. Lo anterior resalta la capacidad de *Ascaris* de producir metabolitos que pueden ejercer un efecto sobre la microbiota intestinal del hospedero, siendo en la actualidad esta producción de diferentes metabolitos, uno de los mecanismos más estudiados en esta y otras infecciones por helmintos.

Las características de la infección por *Ascaris* que incluyen la migración de los diferentes estadios del parásito, la modulación de la respuesta inmune y en este caso particular, los cambios que puede tener sobre la microbiota del huésped, en conjunto conforman una compleja red de mecanismos que le permiten al parásito establecer la infección y sobrevivir en el hospedero. Estudios en seres humanos y en modelos animales han permitido identificar como *Ascaris* tiene la capacidad de generar cambios en la estructura y composición de la microbiota del huésped por medio de la interacción directa o a partir de producción de metabolitos y diferentes productos de E/S, como los péptidos antimicrobianos, que pueden reestructurar las poblaciones bacterianas predominantes. Lo anterior, tiene un efecto negativo sobre bacterias anaerobias estrictas esenciales para el adecuado

funcionamiento intestinal como *Faecalibacterium* [168] y *Ruminococcus* [70], con el concomitante aumento de anaerobios facultativos como *Streptococcus* [155], lo cual en conjunto con la inmunomodulación generada por este helminto, le permite propiciar un ambiente metabólico adecuado para su supervivencia y reproducción. De esta manera, es evidente que las alteraciones y el efecto a nivel de la microbiota del hospedero tienen un papel fundamental en la biología y fisiopatología del parásito y abre un campo muy interesante de estudio en la búsqueda de alternativas terapéuticas de las infecciones por *Ascaris* a partir del restablecimiento de la microbiota normal del huésped. Así mismo, es importante destacar que la capacidad inmunomoduladora que presenta este helminto y el impacto sobre la microbiota del huésped puede generar una mayor susceptibilidad de sufrir infecciones o coinfecciones por otros agentes bacterianos que pueden ser potencialmente perjudiciales para el hospedero siendo esto de gran relevancia desde el punto de vista clínico y de salud pública.

4.11. Selección de Modelos Biológicos para el Estudio de las Interacciones Parásito-Hospedero-Microbioma

La elección de parásitos intestinales (particularmente *Blastocystis*), *Trypanosoma cruzi* y *Ascaris suum* como modelos biológicos para el estudio de las interacciones parásito-hospedero-microbioma se fundamenta en su relevancia epidemiológica, diversidad biológica y capacidad para modelar interacciones complejas [2,61,77]. El enfoque integrador que representan estos organismos abarca protozoos intestinales, sistémicos y helmintos, ofreciendo una visión comprensiva de cómo los parásitos pueden modular la composición y función del microbioma en diversos contextos de infección.

Blastocystis, un protozoo intestinal altamente prevalente en humanos, históricamente se ha asociado con alteraciones gastrointestinales. Sin embargo, estudios recientes sugieren que podría tener un papel beneficioso en la promoción de la salud intestinal y cardiometabólica del hospedador [9,16,174]. Este organismo modula de manera favorable la composición del microbioma intestinal, lo que lo convierte en un modelo ideal para explorar cómo las interacciones con la microbiota influyen en la fisiología y funciones metabólicas del hospedador [175]. La capacidad de *Blastocystis* para interactuar con bacterias comensales, patógenas y otros eucariotas, sugiere un papel complejo en la regulación de la homeostasis intestinal, la fermentación de fibra dietética y la producción de metabolitos clave [16,107,176]. Además, su alta prevalencia en diversas poblaciones lo sitúa como un indicador relevante en el estudio de la diversidad y funcionalidad del microbioma intestinal [8,20,38].

Por otro lado, *Trypanosoma cruzi*, el agente etiológico de la enfermedad de Chagas, presenta un ciclo de vida complejo que involucra múltiples tejidos del hospedador, incluyendo el tracto gastrointestinal, lo que le confiere la capacidad de provocar alteraciones sistémicas y localizadas tanto metabólicas como microbiológicas que van más allá de la respuesta inmune [77,123,177]. El

desarrollo y uso de modelos murinos ha proporcionado información clave sobre las alteraciones en la composición y función del microbioma asociadas con la infección, revelando cambios en la regulación del metabolismo de lípidos y carbohidratos [123,129]. Estos estudios no solo mejoran la comprensión de la patogénesis y fisiopatología de la enfermedad, sino que también ayudan a identificar potenciales estrategias profilácticas y terapéuticas. La manipulación del microbioma durante la infección por *T. cruzi* podría tener implicaciones significativas en la modulación de la respuesta del hospedador y en la mejora de la calidad de vida de los pacientes con Chagas [177].

En el caso de *Ascaris*, un helminto con una alta prevalencia en humanos, especialmente en zonas con condiciones socioeconómicas desfavorables, se convierte en un modelo crucial para investigar tanto la respuesta del hospedador como la interacción con la microbiota del propio parásito [2,164,178]. Las infecciones por *Ascaris* inducen cambios significativos en la microbiota intestinal, afectando la fermentación de carbohidratos y la producción de ácidos grasos de cadena corta, los cuales son esenciales en la regulación del metabolismo energético y la homeostasis intestinal [112,170,179]. Adicionalmente, la microbiota asociada al helminto podría desempeñar un papel relevante en la biología del parásito y en la modulación de la respuesta del hospedador, lo cual proporciona una perspectiva única sobre cómo los factores externos e internos contribuyen al resultado de la infección. Los modelos murinos han sido ampliamente utilizados para estudiar estas interacciones y entender la dinámica funcional del microbioma frente a infecciones prolongadas [143].

Estos tres modelos biológicos permiten explorar tanto características comunes como diferencias en las interacciones parásito-hospedero-microbioma. Aunque todos impactan la composición y función del microbioma, los mecanismos específicos de interacción varían según el parásito y el entorno fisiológico. La aplicación de estrategias metagenómicas, de metabarcoding y proteómica, permite identificar cambios taxonómicos y funcionales que pueden ser claves en la biología del parásito, el metabolismo del hospedador y la dinámica del microbioma [99,180,181]. La elección de estos modelos biológicos facilita el desarrollo de protocolos experimentales y bioinformáticos aplicables a otros protozoos y helmintos, lo cual fortalece el conocimiento sobre las dinámicas presentadas en estas interacciones, proporcionando información esencial para el desarrollo de alternativas profilácticas, diagnósticas y terapéuticas.

4.12. Relevancia del estudio de las interacciones parásito-hospedero-microbioma en infecciones causadas por protozoos y helmintos

Este estudio aborda una brecha esencial en el conocimiento de las interacciones tripartitas entre parásito, hospedero y microbioma intestinal en el contexto de infecciones causadas por protozoos y helmintos de alta relevancia epidemiológica, como *Blastocystis*, *Trypanosoma cruzi* y *Ascaris suum*. A pesar de la creciente evidencia sobre el impacto de estos parásitos en la composición y

funcionalidad del microbioma intestinal, la mayoría de los estudios actuales se han centrado en análisis descriptivos de comunidades bacterianas, relegando la investigación de otros componentes del microbioma como virus y eucariotas [97]. Esto ha dejado sin explorar perfiles funcionales críticos, que podrían revelar rutas metabólicas y genes esenciales para la adaptación y persistencia de estos parásitos en el hospedero [180–182]. Además, el enfoque predominante en protozoos de transmisión fecal-oral y exclusivamente intestinales ha dejado un vacío en el análisis de helmintos intestinales y protozoos con infecciones sistémicas y tránsito entérico, como *T. cruzi*. Este sesgo es notable, dado que estos parásitos pueden ejercer una influencia directa sobre la microbiota del hospedero y contribuir a cuadros clínicos graves y debilitantes, como la forma digestiva de la enfermedad de Chagas y el megacolon chagásico, cuyos mecanismos subyacentes aún no se comprenden completamente [122]. Asimismo, en organismos como los helmintos, cuya propia microbiota puede jugar un papel clave en la interacción con el hospedero durante su ciclo de vida y sus diferentes formas larvarias, los estudios siguen siendo escasos [157,183].

Ante este escenario, la presente tesis busca contribuir al conocimiento de estas interacciones a través de un enfoque innovador que integra técnicas de metagenómica, metabarcoding y proteómica, aplicadas tanto en modelos animales como en estudios descriptivos en poblaciones humanas. Este enfoque permitirá una caracterización taxonómica exhaustiva del microbioma modificado por estos parásitos, así como la identificación de cambios funcionales clave que se producen en distintas etapas de la infección. Al examinar los cambios en el microbioma del hospedero, del helminto y sus perfiles funcionales durante la infección, este estudio proporciona elementos fundamentales en la comprensión de cómo estas alteraciones pueden estar asociadas con la progresión y el desenlace clínico de las infecciones, suministrando una base para el desarrollo de biomarcadores específicos y posibles objetivos terapéuticos.

Mediante el uso de modelos animales bajo condiciones experimentales controladas y estudios en poblaciones humanas, este trabajo se posiciona como una contribución significativa para comprender el papel de las interacciones de protozoos y helmintos con el microbioma del hospedero y su impacto en la dinámica de establecimiento, persistencia y cronicidad de infecciones parasitarias. Este conocimiento resulta fundamental para la formulación de intervenciones diagnósticas, profilácticas y terapéuticas novedosas, con impacto directo en la salud pública y en el manejo clínico de estas infecciones de importancia global.

5. OBJETIVOS

5.1. Objetivo general

Evaluar los cambios en los perfiles de microbioma en humanos y modelos animales infectados por protozoos y helmintos, y sus potenciales implicaciones en las interacciones parásito-hospedero-microbioma.

5.2. Objetivos específicos

- 5.2.1. Determinar la frecuencia de protozoos intestinales (*Blastocystis*, *Giardia*, *Cryptosporidium*, complejo *Entamoeba histolytica/dispar/moshkovskii*) y helmintos (*Ascaris lumbricoides*, *Trichuris trichiura*, Uncinarias) en una población rural del departamento del Cauca, Colombia, mediante la aplicación de técnicas moleculares (PCR - qPCR) y convencionales (microscopía).
- 5.2.2. Describir los cambios en la microbiota intestinal en una población rural del departamento del Cauca, Colombia con presencia de *Blastocystis* a partir de un enfoque de metabarcoding usando simultáneamente los marcadores 16S y 18S rRNA.
- 5.2.3. Caracterizar los cambios en el microbioma intestinal del hospedero asociados a la infección por el protozoo *Trypanosoma cruzi* en un modelo animal a partir de un enfoque metagenómico.
- 5.2.4. Evaluar los cambios en el microbiota del hospedero y del helminto asociados a la infección por *Ascaris suum* en un modelo animal a partir de un enfoque de metabarcoding.
- 5.2.5. Identificar el proteoma de los productos de excreción-secreción (ES) de diferentes etapas larvales de *Ascaris suum* (L3-huevo, L3-pulmón, L3-tráquea) a partir de un enfoque proteómico.

6. INTRODUCCIÓN A LOS CAPITULOS

6.1. Capítulo 1

Objetivo 1: Determinar la frecuencia de protozoos intestinales (*Blastocystis*, *Giardia*, *Cryptosporidium*, complejo *Entamoeba histolytica/dispar/moshkovskii*) y helmintos (*Ascaris lumbricoides*, *Trichuris trichiura*, *Uncinarias*) en una población rural del departamento del Cauca, Colombia, mediante la aplicación de técnicas moleculares (PCR - qPCR) y convencionales (microscopía).

Objetivo 2: Describir los cambios en la microbiota intestinal en una población rural del departamento del Cauca, Colombia con presencia de *Blastocystis* a partir de un enfoque de metabarcoding usando simultáneamente los marcadores 16S y 18S rRNA.

Para cumplir el objetivo 1, el primer estudio se centró en evaluar la frecuencia y dinámica de transmisión de diversos protozoos y helmintos intestinales en una comunidad rural colombiana, adoptando un enfoque integral de "Una Salud". Mediante el análisis de 125 muestras fecales, provenientes de 99 individuos humanos, 24 perros domésticos y 2 fuentes de agua, se identificó una amplia gama de protozoos y helmintos intestinales.

Para la detección de estos organismos, se combinaron técnicas microscópicas tradicionales con métodos moleculares de alta sensibilidad, como la reacción en cadena de la polimerasa cuantitativa (qPCR). Además, se empleó la secuenciación de Oxford Nanopore para caracterizar los subtipos de *Blastocystis*, lo que permitió comprender mejor la diversidad genética de este protozoo y su potencial papel en la epidemiología de las infecciones. Los resultados revelaron una alta frecuencia de estos organismos en la comunidad estudiada. El más frecuente fue *Blastocystis*, con una frecuencia del 87%. Le siguieron *Giardia* (16%), *Ancylostoma duodenale* (22%), *Ancylostoma ceylanicum* (5.6%), *Entamoeba histolytica* (4.8%), *Cryptosporidium spp.* (9.6%) y *Taenia spp.* (0.8%). Es importante destacar que se observó una elevada frecuencia de coinfecciones, con el 43% de las muestras positivas para más de un tipo de parásito. La caracterización molecular de *Blastocystis* permitió identificar una diversidad de subtipos, siendo el ST2 el más frecuente. Este hallazgo sugiere la existencia de múltiples fuentes de colonización y la complejidad de las dinámicas de transmisión de este protozoo. Además, la detección de *Cryptosporidium spp.* en muestras de agua indica la importancia de las vías hídricas en la transmisión de estos protozoos.

Los resultados de este estudio subrayan la importancia de utilizar técnicas moleculares para una detección precisa y sensible de protozoos y helmintos intestinales, especialmente en comunidades con alta prevalencia. El enfoque de "Una Salud" permitió identificar la complejidad de las interacciones entre humanos, animales y el medio ambiente en la transmisión de estos organismos. Los hallazgos obtenidos tienen importantes implicaciones para la salud pública y resaltan la

necesidad de implementar programas de control y prevención más efectivos, dirigidos a mejorar las condiciones sanitarias y promover prácticas de higiene adecuadas.

Respecto al objetivo 2, teniendo en cuenta la alta frecuencia de *Blastocystis* identificada previamente, se buscó evaluar el impacto de la colonización por *Blastocystis* y su carga en la composición de la microbiota intestinal en una comunidad rural. La investigación se llevó a cabo en la comunidad de Las Guacas, Cauca, donde se recolectaron 88 muestras fecales de individuos. Para analizar la composición de la microbiota, se empleó secuenciación de los genes 16S y 18S del ARN ribosomal, lo que permitió caracterizar tanto la microbiota bacteriana como la eucariota.

Los resultados revelaron una clara asociación entre la presencia de *Blastocystis* y cambios significativos en la composición de la microbiota intestinal. Los individuos colonizados por *Blastocystis* presentaron perfiles de microbiota distintivos en comparación con aquellos que no lo estaban, lo cual se vio reflejado en el análisis de beta diversidad. A nivel bacteriano, se observó un aumento en la abundancia de géneros como *Bacteroides*, *Prevotella*, *Oscillibacter*, *Faecalibacterium* y *Alistipes* en los individuos positivos para *Blastocystis*. Además, se encontró una correlación entre la carga de *Blastocystis* y la abundancia de géneros como *Alistipes* y *Lachnospira*, mientras que géneros como *Akkermansia* se asociaron con una menor carga parasitaria. En cuanto a la microbiota eucariota, los resultados mostraron que la presencia de *Blastocystis* se relacionó con una mayor frecuencia de *Entamoeba coli*. Por el contrario, los individuos negativos para *Blastocystis* presentaron una mayor abundancia de hongos como *Candida albicans*. Estos hallazgos sugieren que *Blastocystis* puede influir en la composición no solo de la microbiota bacteriana, sino también de la eucariota, lo que podría tener implicaciones para la salud del hospedero. Para profundizar en el análisis, se emplearon modelos de aprendizaje automático, específicamente un modelo *random forest*. Estos modelos permitieron identificar a *Faecalibacterium* y *Bacteroides* como biomarcadores potenciales para predecir la colonización por *Blastocystis*. Estos resultados sugieren que la composición de la microbiota intestinal podría utilizarse como herramienta para diagnosticar y monitorear infecciones por *Blastocystis*.

En conclusión, este estudio proporciona evidencia de que la colonización por *Blastocystis* tiene un impacto significativo en la composición y estructura de la microbiota intestinal en una población rural colombiana. Estos hallazgos abren nuevas vías de investigación para comprender mejor el papel de *Blastocystis* en la salud humana y para desarrollar estrategias terapéuticas basadas en la modulación de la microbiota. Así mismo, propone estrategias metodológicas y analíticas que pueden ser implementadas en el estudio de otros protozoos intestinales.

Como productos de este capítulo se adjuntan los siguientes artículos científicos:

Artículo 1: Castañeda, S, Acosta, Claudia Patricia, Vasquez-A, Luis Reinel, Patiño, Luz H, Mejía, Rojelio, Ramírez JD. Molecular detection of intestinal parasites in a rural community of Colombia: A one health approach to explore potential environmental–zoonotic transmission. *Zoonoses Public Health* [Internet]. 2024 [cited 2024 Oct 23];71(6):723–735. <https://doi.org/10.1111/zph.13138>.

Artículo 2: Castañeda S, Stensvold CR, Andersen LOBB, Acosta, Claudia Patricia, Vasquez-A, Luis Reinel, Ramírez JD. Impact of *Blastocystis* Colonization and Burden on Gut Microbiota Composition in a Non-Westernized Rural Population from Colombia. *Sometido a PLOS Neglected Tropical Diseases (Q1)*.

ORIGINAL ARTICLE

Molecular detection of intestinal parasites in a rural community of Colombia: A one health approach to explore potential environmental–zoonotic transmission

Sergio Castañeda¹ | Claudia Patricia Acosta² | Luis Reinel Vasquez-A³ | Luz H. Patiño¹ |
Rojelio Mejía⁴ | Juan David Ramírez^{1,5}

¹Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia

²Grupo de investigación en Genética Humana, Departamento de Ciencias Fisiológicas, Facultad de Ciencias de la Salud, Universidad del Cauca, Popayán, Colombia

³Centro de Estudios en Microbiología y Parasitología, Facultad de Ciencias de la Salud, Universidad del Cauca, Popayán, Colombia

⁴Department of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston, Texas, USA

⁵Molecular Microbiology Laboratory, Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York city, New York, USA

Correspondence

Juan David Ramírez, Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia.
Email: juand.ramirez@urosario.edu.co; juan.ramirezgonzalez@mssm.edu

Funding information

Dirección de Investigación e Innovación from Universidad del Rosario

Abstract

Aims: Protozoan and helminth parasitic infections pose significant public health challenges, especially in developing countries with rural populations marked by suboptimal hygiene practices and socio-economic constraints. The parasites are the etiological agents of these infections and have a notably elevated global prevalence. Therefore, this study focuses on estimating the frequency and transmission dynamics of several parasitic species, including *Blastocystis*, *Giardia*, *Cryptosporidium* spp., *Entamoeba histolytica*, *Ascaris lumbricoides*, *Trichuris trichiura*, *Taenia* spp. and hookworms, within a rural community in southwest Colombia with a particular emphasis on the One Health framework, considering environmental and zoonotic transmission potentials.

Methods and Results: This study involved the analysis of 125 samples, encompassing human participants ($n=99$), their domestic pets (dogs) ($n=24$) and water sources ($n=2$). Parasite detection was carried out utilizing a combination of microscopy and molecular techniques. Furthermore, the characterization of *Blastocystis* subtypes (STs) was achieved through Oxford Nanopore sequencing of the rRNA-18S gene. The investigation also entailed the examination of potential associations between intestinal parasitism and various sociodemographic factors. Results revealed a high frequency of parasitic infections when employing molecular methods, with *Blastocystis* ($n=109/87\%$), *Giardia* ($n=20/16\%$), *Ancylostoma duodenale* ($n=28/22\%$), *Ancylostoma ceylanicum* ($n=7/5.6\%$), *E. histolytica* ($n=6/4.8\%$), *Cryptosporidium* spp. ($n=12/9.6\%$) and even *Taenia* ($n=1/0.8\%$) detected. *Cryptosporidium* spp. was also identified in water samples. Coinfections were prevalent, with 57% ($n=70$) of samples exhibiting single-parasite infections and 43% ($n=53$) showing various degrees of polyparasitism, emphasizing the complexity of transmission dynamics. *Blastocystis* subtyping, conducted via Oxford Nanopore sequencing, revealed a diversity of subtypes and coexistence patterns, with ST2 being the most prevalent.

Conclusions: This research underscores the importance of using molecular techniques for frequency estimation, particularly emphasizing the relevance of zoonotic transmission in parasitic infections. It highlights the significance of the One Health approach in comprehending the circulation of parasites among animals, humans and

environmental sources, thereby directly impacting public health and epidemiological surveillance.

KEYWORDS

intestinal parasites, One Health, qPCR, transmission dynamics

1 | INTRODUCTION

Parasitic infections attributed to protozoa and helminths exert a profound impact on public health, notably in developing countries, including rural populations, where they are intricately associated with suboptimal hygiene practices and socio-economic status (Cimino et al., 2015; Pullan et al., 2014; Sánchez et al., 2017; Villamizar et al., 2019). Prominent among these are *Giardia*, *Cryptosporidium* spp., *Entamoeba histolytica* and *Blastocystis*. Despite the potential for subclinical infections, these protozoa are frequently implicated in disease pathogenesis, with a particular emphasis on diarrheal illnesses, especially among paediatric populations (Galvan-Díaz et al., 2020; Sánchez et al., 2017; Sponseller et al., 2014; Wawrzyniak et al., 2013). Conversely, helminths encompass a diverse spectrum of parasitic organisms, such as *Ascaris lumbricoides*, *Trichuris trichiura* and hookworms (*Ancylostoma duodenale*, *Ancylostoma ceylanicum* and *Necator americanus*), spanning from asymptomatic infections to conditions characterized by diarrheal afflictions, malabsorption syndromes, malnutrition and stunted growth (Karo-Atar et al., 2023).

According to the World Health Organization (WHO), an estimated 3.5 billion individuals were afflicted by parasitic infections in previous years (Cooper et al., 2013; Specht & Keiser, 2022). These parasitic infections are commonly associated with factors such as faecal contamination of soil and food, limited access to clean water, inadequate environmental sanitation and impoverished socio-economic conditions. It has also been identified that there is a zoonotic potential involved in transmission dynamics (Lebov et al., 2017). Protozoa are renowned for their capacity to induce significant diarrheal episodes, particularly among children (Cimino et al., 2015; Villamizar et al., 2019).

Blastocystis is a globally distributed genus of enteric protozoa, with prevalences from 30% to 60% in developing countries. In Colombia, the reported prevalence stands at 52.1%, and molecular studies have even shown prevalences of 100% (Higuera et al., 2020). However, the pathogenic role of *Blastocystis* remains a topic of debate (Audebert et al., 2016; Castañeda et al., 2020; Stensvold & van der Giezen, 2018). Currently, 44 subtypes (STs) have been reported, based on nucleotide polymorphism within the small subunit of ribosomal RNA (rRNA-18S) (Higuera et al., 2023; Stensvold, 2013; Stensvold & Clark, 2016).

The most critical factor in transmission dynamics is associated with zoonotic transmission, underscoring its significance (García-Montoya et al., 2023; Higuera et al., 2020; Villamizar et al., 2019). *G. duodenalis* (*Giardia lamblia* or *G. intestinalis*) afflicts an estimated 280 million individuals worldwide (Zajackowski et al., 2021). In

Impacts

- Our study revealed a high frequency of intestinal parasites in a rural population (Las Guacas), with *Blastocystis* being the most common, followed by *A. duodenale*, *Giardia* and *Cryptosporidium* spp.
- The presence of parasites in both humans and dogs, including *A. ceylanicum*, highlights the potential for animal-to-human transmission. Suboptimal hygiene, water usage and sanitation practices create favourable conditions for zoonotic transmission and parasite persistence.
- Our findings underscore the urgency of improved water sanitation infrastructure and access to clean water. A One Health approach is crucial for designing effective prevention and control strategies that address the interconnectedness of human, animal and environmental health.

Colombia, the prevalence of *Giardia* infection fluctuates between 15.4% and 61%, depending on the detection method (microscopy or qPCR) (Sánchez et al., 2017; Villamizar et al., 2019).

Cryptosporidium infection has been classified by the WHO as a neglected disease (Savioli et al., 2006). To date, a minimum of 30 species and 70 genotypes have been identified, with 20 of them documented in humans, with *C. hominis* and *C. parvum* primarily responsible for the majority of infections (Chalmers & Katzer, 2013; Ryan et al., 2014). In Colombia, studies have reported prevalence rates ranging from 7.8% to 9.8% through qPCR (Galván-Díaz, 2018; Villamizar et al., 2019). Additionally, their presence in water and animal reservoirs, with prevalence rates of 38.9% and 20.4% respectively. The genus *Entamoeba* encompasses several species, six of which can inhabit the human large intestine: *E. histolytica*, *E. dispar*, *E. moshkovskii*, *E. polecki*, *E. coli*, and *E. hartmannii*. *E. histolytica* is considered pathogenic, causing human amebiasis, affecting up to 10% of the global population. In Colombia, molecular identification has allowed for an estimation of *E. histolytica* prevalence close to 1% (Higuera et al., 2020; Villamizar et al., 2019). Molecular studies have also identified other species within the complex, specifically *E. dispar* and *E. moshkovskii* (Higuera et al., 2020; Villamizar et al., 2019).

On the other hand, the WHO estimates that helminth infections affect approximately 1.5 billion people, primarily in tropical

and subtropical regions (Hotez et al., 2008; Silver et al., 2018). Soil-transmitted helminths include *A. lumbricoides*, *T. trichiura* and the hookworms (*N. americanus*, *A. duodenale* and *A. ceylanicum*) (Knopp et al., 2012; Papaïakovou et al., 2017; Silver et al., 2018). In Colombia, the estimated prevalence of *Ascaris* infection varies according to the population studied, reporting prevalence rates up to 32% (Papaïakovou et al., 2021; Saboyá et al., 2013) and the hookworm infection is approximately 6% (Ministerio de Salud y Protección Social, 2014).

One of the primary challenges in estimating the prevalence of these parasites lies in the inherent limitations associated with microscopy. As a result, efforts have been ongoing to adopt molecular techniques such as PCR and qPCR for identifying circulating species and subpopulations of these parasites, especially in rural communities (Higuera et al., 2020; Villamizar et al., 2019). Obtaining precise measurements of the prevalence and intensity of infection in regions endemic to these parasites is crucial. This consideration is particularly important due to the significant zoonotic potential and the dynamics of transmission involving various hosts, including animals, humans and environmental sources such as drinking water. Consequently, the objective of this study was to assess the presence of intestinal parasites by microscopy and to conduct molecular characterization of *Blastocystis*, *Giardia*, *Cryptosporidium* and *E. histolytica*, as well as helminths, namely *A. lumbricoides*, *T. solium*, *T. trichiura* and hookworms (*N. americanus*, *A. duodenale* and *A. ceylanicum*), in samples obtained from humans, their pets (dogs) and water sources within a rural community in Colombia.

2 | MATERIALS AND METHODS

2.1 | Ethical considerations, informed consent and necessary permissions

Informed written consent was obtained from every participant or their respective parent or caregiver. The study design and research protocols received approval from the Bioethics Committee of Universidad del Cauca, Colombia.

2.2 | Study population

A total of 125 samples, consisted of 99 samples from humans (including children and caregivers), 24 samples from pets (*Canis lupus familiaris*) and 2 water samples, were evaluated from a rural population in the Cauca department, Colombia, known as Las Guacas village, located in the municipality of Popayan in southwest Colombia (Figure 1a). Additionally, within the rural area, the sample collection was spatially divided into three defined subzones (identified as A, B and C) where households and the population are concentrated. These subzones represent areas of clustered housing within a village in a rural setting. Such clustering exhibits characteristics such as vehicular and pedestrian pathways, as well

as the provision of basic public, social and welfare services infrastructure (Figure 1a). Stool samples were collected from children aged 1 to 15, their caregivers and their pets (dogs). Additionally, water samples were collected from the La Carnicería Creek – the water source from which the residents of this population obtain their daily water supply.

2.3 | Sample size

A non-probabilistic convenience sampling approach was employed, and stool samples were collected from children and caregivers who agreed to participate in the study and provided a faecal sample. Samples were also obtained from dogs living with the children and caregivers.

2.4 | Sociodemographic variables

At the time of obtaining informed consent, we conducted a structured survey involving 123 sample elements to gather data on various variables, including sex, age, availability of utilities, water quality, water treatment, presence and number of pets (dogs), faecal disposal practices, handwashing practices, garbage storage/disposal methods and antibiotic consumption (Table S1).

2.5 | Stool sample collection


Stool samples were collected from both dogs and humans. Each stool sample was obtained using sterile gloves and deposited in a sterile container without transport media. The faecal samples were divided into two portions. The initial portion of each sample was preserved using SAF solution for the direct examination and microscopic identification of intestinal parasites. Another fraction of the sample was dedicated to molecular processing and transported under refrigeration at temperatures between 2 and 8°C. Upon arrival at the laboratory, it was then stored in ultra-freezers at -80°C for subsequent analysis.

2.6 | Water sample collection

Water samples were collected from La Carnicería Creek, the primary water source for the residents of this population. A composite water sample was obtained, with two samples collected due to accessibility challenges. Each sample was gathered at a depth of 30cm from the sampling point, with a volume of 500mL. These samples were then transported at a temperature of 4°C in a polystyrene cooler and processed on the same day of collection to ensure optimal DNA extraction results.

For the extraction process, two 200-mL vacuum filtrations were performed for each sample using 0.45 µm cellulose

(a)



(b)




FIGURE 1 (a) Geographical sampling area corresponding to the rural region of Cauca, Colombia. (b) Frequency of intestinal parasites detected in the samples analysed by molecular techniques (qPCR) and microscopy.

nitrate membranes, followed by a refiltration through 0.2 μ m membranes to capture smaller microorganisms. A standardized protocol was implemented for shotgun metagenomics. The

membranes were placed in sterile 50-mL Falcon tubes, and the biomass was recovered by scraping with molecular-grade water (15 mL) twice, with each membrane being pipetted for 15 min.

After centrifugation, the pellet underwent nucleic acid extraction using a DNeasy Power Soil kit (Qiagen), with the elution solution pre-warmed to 65°C for optimal results. All steps were conducted in a laminar flow cabinet. The extracted DNA was assessed for concentration and integrity using NanoDrop and electrophoresis respectively.

2.7 | Molecular analysis

DNA extraction from stool samples was carried out using the Norgen faecal DNA extraction kit, which included an initial disruption step. Following that, a qPCR multiplex assay was performed according to the prescribed protocol and with the specified primers for the detection of *A. lumbricoides*, *Cryptosporidium* spp. (*C. parvum*/*C. hominis*), *A. duodenale*, *A. ceylanicum*, *N. americanus*, *Strongyloides stercoralis*, *G. lamblia*, *E. histolytica* and *T. trichiura* as previously reported (Mejia et al., 2013); the primers used are shown in Table S2. For *T. solium*, primers and probes were used from a previous study and genomic DNA as a control and standard (O'Connell et al., 2020). For *Blastocystis*, we used the primers reported by Stensvold et al. (2012) (Table S2). Given that the *Cryptosporidium*-specific PCR Multiplex method only detects *C. parvum* and *C. hominis*, we implemented a specific conventional PCR assay for *Cryptosporidium* spp. (Burnet et al., 2013). The DNA concentrations of each parasite in the samples were calculated by comparing them to a standard curve generated from 10-fold dilutions as reported elsewhere (Mejia et al., 2013).

2.8 | Molecular characterization of *Blastocystis* subtypes (STs)

Molecular characterization of *Blastocystis* was conducted on PCR-positive samples. These samples underwent PCR to generate amplicons of the complete rRNA-18S gene, approximately 1800bp in length., using 1µM of primers SSU-F1 (5-AAC CTG GTT GAT CCT GCC AGT AGT AGT C-3) and SSU-R1 (5-TGA TCC TTC TGC AGG TTC ACC TAC G-3) forward and reverse respectively. The experimental protocol was performed as reported elsewhere (Maloney et al., 2020).

The Oxford Nanopore Technologies (ONT) MinION platform was employed for characterization, following the protocol established by Maloney et al. (2020) and Maloney and Santin (2021). The library preparation utilized the SQK-LSK109 and SQK-LSK110 ligation sequencing kits from ONT, following the manufacturer's instructions for PCR coding amplicons (PBAC12_9112_v110_revB_10Nov2020). For barcoding each sample, the EXP-PBC001 PCR Barcoding Kit from ONT, Oxford, UK, was employed in conjunction with ligation kits. Subsequent purification steps ensured the loading of 50 or 75 fmol of the library in 12µL into the flow cell. The sequencing runs were facilitated using MinKNOW v20.10.06 software (Maloney & Santin, 2021).

Base calling was performed using Guppy v4, followed by FASTQ read filtering to retain sequences with lengths ranging from 1600 to 2100 nucleotides. Adapters used for full-length sequencing PCR were trimmed. Off-target reads were filtered from the resulting FASTA files using the NCBI reference databases. Subtyping was accomplished through alignment, selecting the best match with full-length *Blastocystis* reference nucleotide sequences obtained from the reference database (<http://entamoeba.lshtm.ac.uk/blastorefs eqs.htm>, accessed on 03/02/2021), in addition to other accepted full-length ST sequences present in GenBank. This alignment process utilized the CENTRIFUGE algorithm.

2.9 | Statistical analysis

Descriptive statistics were employed to summarize qualitative variables in terms of frequencies and proportions. Quantitative variables were summarized using central tendency and dispersion measures. Since qPCR identified more positive samples for each parasite and microscopy did not detect any additional positives, analyses were based on qPCR. The possible existence of associations between categorical variables was evaluated using Pearson's Chi-squared tests and Fisher's exact test. Regarding quantitative variables, a normality test (Kolmogorov-Smirnov) was initially conducted, and based on the results, non-parametric tests were applied for group comparisons. Statistical analyses were carried out using the R software. All tests of significance were two-tailed, and p -values < 0.05 were considered statistically significant.

3 | RESULTS

3.1 | Sociodemographic characterization

The evaluated population consisted of 99 samples from humans, 24 samples from pets (*C. lupus familiaris*) and 2 water samples. Among the individuals assessed, the median age was 22 years (IQR: 33.5), with the majority falling within the age range of 20 to 40 years ($n=26$), followed by individuals aged 0 to 5 years ($n=21$) (Table 1). Among these individuals, 64% were women, and 36% were men. The average number of residents per household was four members. The majority of individuals surveyed (97%/ $n=119$) reported using septic tanks for excreta disposal, while the remaining few (3%/ $n=4$) reported using latrines.

As this is a rural community, the residents source their water from a stream, from which the water is transported. Regarding this, it was found that 42% did not carry out any type of treatment before consumption, while 58% used some method of treatment, such as boiling the water, filtering it or using chlorine compounds for treatment. Additionally, only 28% of the individuals considered the water they use to be of good quality, while the remaining individuals considered it to be of regular (57%) or even poor quality (15%) (Table 1).

TABLE 1 Characteristics of the population and statistical results of the variables that were herein analysed.

Group	Variable	Category	<i>Blastocystis</i>			<i>Giardia</i>			<i>Cryptosporidium</i> spp.	
			Pos	Neg	p value	Pos	Neg	p value	Pos	Neg
Individual human characteristics (n=99)	Sex	Female	57	6	0.842	7	56	0.431	1	62
		Male	33	3		6	30		3	33
	Age (Years)		21 (IQR: 32, 75)	40 (IQR: 41)	0.530	10 (IQR: 12)	24, 5 (IQR: 34, 5)	0.068	4, 5 (IQR: 16, 75)	22 (IQR: 33)
Household characteristics per survey (n=123)	Water quality	Treated	71	7	0.2683	11	67	0.393	8	70
		Non-treated	38	7		9	36		2	43
	Presence of Dogs	Yes	105	12	0.082	19	98	0.977	10	107
		No	4	2		1	5		0	6
Source of samples (n=125)	Source	Human	90	9	0.0002	13	86	0.129	4	95
		Animal	19	5		7	17		6	18
		Water	0	2		0	2		2	0

3.2 | Parasite infection and statistical analyses

Microscopic evaluation yielded 80 negative samples for all evaluated protozoa and helminths. Among the positive samples identified through microscopy, *Blastocystis* exhibited a frequency of 20.2% (n=25), *Endolimax nana* at 5.6% (n=7), *Giardia* at 4% (n=5) and *E. coli* at 9.6% (n=12). *Cryptosporidium* spp. could not be identified via microscopy (no staining was conducted) (Figure 1b). Additionally, one sample was found to contain hookworm eggs during microscopy examination (0.8%) (Table S3).

On the other hand, the frequency of different parasites by qPCR was notably higher. Thus, the frequency was for *Blastocystis* 87% (n=109), *A. duodenale* 22% (n=28), *A. ceylanicum* 5.6% (n=7), *Giardia* 16% (n=20), *E. histolytica* 4.8% (n=6) and *Cryptosporidium* spp. 9.6% (n=12), and even a specific case positive for *T. solium* 0.8% (n=1) was found (Figure 1b and Table S1). Specifically, among human hosts, the most frequently identified parasite was *Blastocystis* 90.1% (90/99), followed by *Giardia* 13.1% (13/99), *Ancylostoma* 9.1% (9/99), *E. histolytica* 6% (6/99), *Cryptosporidium* 4% (4/99) and *Taenia* 1% (1/99). Conversely, among dog hosts, the most common parasites identified were *Ancylostoma* 79% (19/24) and *Blastocystis* 79% (19/24), followed by *Giardia* 29% (7/24) and *Cryptosporidium* spp. 25% (6/24). In the case of water samples, only *Cryptosporidium* spp. was found in both samples (Tables 1 and S4).

Interestingly, this study is the first reported infection in Colombia with *Ancylostoma ceylanicum*, a zoonotic hookworm from wild animals including dogs, cats and rodents (Papaiakovou et al., 2017). *Cryptosporidium* was detected in both water samples analysed via qPCR. Furthermore, it is important to emphasize that all the samples that tested positive for *Cryptosporidium* were not identified by multiplex PCR, which is designed for the detection of *C. parvum* and *C. hominis*, but rather through qPCR targeting *Cryptosporidium* spp. This implies the possibility that these positive samples may correspond to other species.

The qPCR allowed the estimation of parasite DNA concentrations in fg/ μ L (Figure 2a). We did not find correlation between DNA concentrations of parasites evaluated. It was observed that the DNA concentrations of *Blastocystis* were higher in subzone B than in subzone A (Kruskal-Wallis, p-value=0.0010). A similar situation was observed with *Giardia* concentrations (Kruskal-Wallis, p-value=0.0065) (Figure 2b). Similarly, *Blastocystis* DNA concentrations were higher in human hosts than in animals (Kruskal-Wallis, p-value=0.0075). Conversely, higher DNA concentrations were observed in animal hosts for *A. duodenale* (Kruskal-Wallis, p-value=0.00009). Spearman correlations were conducted among the DNA concentration values of the different parasites; however, statistically significant results were not obtained.

Regarding the possible relationship between the different variables evaluated and the presence of protozoa and helminths (Table 1), no statistically significant association was found between the presence of different parasites and gender (Table 1). In the specific case of the host or sample origin, *Blastocystis* showed a higher frequency in humans than in animals (chi-square, p-value=0.0002), while *A. duodenale* showed a higher frequency in dogs (Chi-square, p-value <0.001). Despite the significant presence of parasites in dogs, no statistically significant relationship was found between owning pets (dogs) and the presence of any of the identified parasites. Statistically significant associations were not found with other evaluated variables (Table 1).

3.3 | Coinfections and polyparasitism

Among the 125 samples evaluated, qPCR results revealed that in 6% (n=8) of these samples, no identification of any parasite was made. Of the samples, 57% (n=71) exhibited a single parasite, 28% (n=35) showed coinfection with two parasites, 7% (n=9) had three parasites and two cases, accounting for 1.6% (n=2), exhibited coinfection with four different parasites (Figure 3a). The most frequent coinfection was *A. duodenale*-*Blastocystis* (n=17), followed by *Giardia*-*Blastocystis*

p value	<i>Entamoeba histolytica</i>		p value	<i>Ancylostoma</i> spp.		p value	<i>Taenia</i>		p value
	Pos	Neg		Pos	Neg		Pos	Neg	
0.101	2	61	0.111	6	57	0.842	1	62	0.447
	4	32		3	33		0	36	
0.364	33 (IQR: 52, 75)	22 (IQR: 33, 33)	0.572	26 (IQR: 29)	21 (IQR: 33, 75)	0.774	6 (IQR:0)	22 (IQR: 33, 75)	0.353
0.255	4	74	0.865	23	55	0.019	1	77	0.445
	2	43		5	40		0	45	
0.455	6	111	0.569	27	90	0.714	1	116	0.8201
	0	6		1	5		0	6	
<0.001	6	93	0.437	9	90	<0.001	1	98	0.876
	0	24		19	5		0	24	
	0	2		0	2		0	2	

($n=9$) (Figure 3b). Coinfections involving three parasites were mainly *A. duodenale*-*Giardia*-*Blastocystis* ($n=3$) and *E. histolytica*-*Giardia*-*Blastocystis* (Figure 3b). For the two cases of polyparasitism related to four parasites, coinfection was observed among *A. duodenale*-*Cryptosporidium*-*Giardia*-*Blastocystis* (Figure 3b).

3.4 | *Blastocystis* subtypes

Due to the high number of positive samples obtained for *Blastocystis*, we decided to perform subtype (ST) typing of this protozoan by complete sequencing of the rRNA-18S gene using the Oxford Nanopore platform. A total of 65.1% ($n=71$) of the samples could not be successfully typed and classified into any subtype. Among those that were successfully typed, we found unique STs and the coexistence of different STs (Figure 4). The most frequent unique subtype was ST2, accounting for 17.4% ($n=19$), followed by ST3 at 3.7% ($n=4$) and ST1 at 0.9% ($n=1$). We also identified the coexistence of STs, with the most frequent being ST2-ST3 at 6.4% ($n=7$), ST1-ST2 at 2.75% ($n=3$), ST1-ST3 at 1.83% ($n=2$), ST3-ST9 at 0.91% ($n=1$) and ST3-ST2-ST1 at 0.91% ($n=1$) (Figure 4).

4 | DISCUSSION

The rural population of Las Guacas Village, faces distinct socio-economic challenges, particularly in housing and limited access to education, healthcare, clean water and sanitation. Our study reveals water quality and sanitation issues, raising the risk of intestinal parasites (Tables 1 and S1). Most residents do not treat their water; 42% consume untreated water, posing potential risks of waterborne infections (Table 1). Inadequate excreta disposal practices can contaminate water and coexisting pets, contributing to complex transmission dynamics (Lebov et al., 2017). Parasite presence does

not significantly correlate with demographics, indicating widespread infections. Further validation across various regions is necessary.

The characteristics mentioned above are closely linked to the data on intestinal parasitism that we uncovered, and they align with previous studies conducted in the region (Higuera et al., 2020; Villamizar et al., 2019). In our current study, we analysed human samples from a population consisting mainly of individuals aged 0 to 5 years and those aged 20 to 40 years, representing young children and their caregivers respectively. This demographic characteristic holds significant implications for transmission dynamics through untreated water, contaminated food and oral-faecal transmission facilitated by caregivers, particularly impacting young children who are more susceptible to infection (Pullan et al., 2014; Villamizar et al., 2019).

Additionally, the significant presence of pets (dogs) within the community has indicated that they harbour a variety of parasites commonly found in both human and animal hosts. These parasites include *A. duodenale*, *A. ceylanicum*, *Giardia*, *Cryptosporidium* spp. and *Blastocystis*. Given the prevailing suboptimal hygiene practices and patterns of water usage, this context potentially fosters favourable conditions for zoonotic transmission (Lebov et al., 2017; Walker et al., 2023) enabling the cross-species spread of these parasites between humans and animals (Ryan & Cacciò, 2013).

In this context, the frequency of intestinal parasites found in the present study through qPCR analysis was notable, with *Blastocystis* exhibiting the highest frequency at 87% ($n=109$), *A. duodenale* at 22% ($n=28$), *A. ceylanicum* at 5.6% ($n=7$), *Giardia* at 16% ($n=20$), *E. histolytica* at 4.8% ($n=6$), *Cryptosporidium* spp. at 9.6% ($n=12$) and even a specific case positive for *T. solium* at 0.8% ($n=1$) (Figure 1). It is worth noting that these frequency rates for some parasites were higher than what has been previously identified in other populations (Galvan-Diaz et al., 2020; Higuera et al., 2020; Villamizar et al., 2019). It is evident from our findings that DNA concentrations in fg/uL indicate higher burdens of *A. duodenale*, *Blastocystis* and *Giardia* compared to *E. histolytica*, which was exclusively found in




FIGURE 2 (a) Violin plot of DNA concentrations of main parasites found by qPCR. The fg/μL values obtained for each case were normalized using log₁₀ to visually compare these concentrations. (b) DNA concentrations (fg/μL) of *Blastocystis* and *Giardia* between geographic subregions sampled (upper part). DNA concentrations (fg/μL) of *Blastocystis* and *Ancylostoma duodenale* between hosts (animal or human) (bottom). A Kruskal-Wallis non-parametric test was conducted to assess statistically significant differences in DNA concentrations of each parasite concerning the presented variables. The asterisk (*) denotes results with $p < 0.01$.




FIGURE 3 (a) Detection of polyparasitism by molecular tests (qPCR-PCR). (b) Number of parasites found in polyparasitism events. (b) Co-infections among the different protozoa and helminths studied.




FIGURE 4 *Blastocystis* variation between STs in animal and human hosts. In this study, the detection of mixed and unique infections from different *Blastocystis* subtypes was conducted. Bar plots were constructed by host to illustrate the percentage of each ST detected by the sample. All subtypes were assigned a colour to differentiate them from each other.

human hosts (Figure 2a). This observation underlines that in rural settings, zoonotic cycles can lead to a greater number of infected hosts and consequently result in persistent infections with higher parasite concentrations. Our comparisons of DNA concentrations between different subzones and host categories revealed significant variations (Figure 2b). *A. duodenale* displayed higher concentrations in animal hosts (dogs) than in humans, while *Blastocystis* exhibited

higher concentrations in humans than in animals (Figure 2b). These findings underscore the necessity of customizing treatment, prevention and diagnostic efforts for specific populations, focusing on the most affected hosts to effectively curb the transmission of these parasites (Wiśniewski et al., 2016). Additionally, this study is the first reported infection in Colombia with *A. ceylanicum*, a zoonotic hookworm from wild animals including dogs, cats and rodents

(Papaïakovou et al., 2017). These studies stress the need for research in rural areas where limited access to clean water, coupled with socio-economic conditions and poor hygiene, may increase infection and facilitate parasite spread (Higuera et al., 2020; Villamizar et al., 2019). Therefore, it is essential to bolster molecular detection strategies, such as qPCR, to obtain accurate data for informed decision-making (Table S3) (Papaïakovou et al., 2021; Villamizar et al., 2019).

The most frequently identified protozoan in humans was *Blastocystis*. The pathogenic potential of *Blastocystis* has long been a subject of debate, and its varied clinical presentations have been attributed to its extensive genetic diversity and its interactions with the host microbiota (Castañeda et al., 2020; Yason et al., 2019). However, the detection of *Blastocystis* in both humans and animals highlights its significant zoonotic potential, which may also involve other parasites known to cause illness through water and food contamination (Higuera et al., 2020; Rune et al., 2020; Villamizar et al., 2019). Considering this, we conducted subtype (ST) typing of *Blastocystis* in the positive samples. Although a substantial number of samples could not be successfully typed maybe due to the use of a longer PCR fragment that might have reduced sensitivity. The ones that were classified into STs revealed that, consistent with previous reports, the most prevalent was ST2, accounting for 17.4% ($n=19$) of cases, followed by ST3 at 3.7% ($n=4$) and ST1 at 0.9% ($n=1$) (Higuera et al., 2020; Villamizar et al., 2019). Previous molecular detection studies conducted in various populations in Colombia have identified sequence types (STs) that align with those identified in this study (Higuera et al., 2020; Villamizar et al., 2019). In the current analysis, the most prevalent was ST2. This observation is in line with the fact that approximately 90% of the isolates belonged to ST1-ST4, which are known to be responsible for the majority of human infections worldwide and are involved in zoonotic transmission cycles (Ramírez et al., 2017). The findings are notable as our study comprised mainly asymptomatic individuals without gastrointestinal symptoms, despite testing positive for *Blastocystis* and other protozoa. This aligns with the notion that ST2 is linked to asymptomatic individuals and is part of the healthy host microbiota (Castañeda et al., 2020; Stensvold & Clark, 2016; Stensvold et al., 2022).

An intriguing finding was the presence of co-infections with different STs, including ST2-ST3 at 6.4% ($n=7$), ST1-ST2 at 2.75% ($n=3$), ST1-ST3 at 1.83% ($n=2$), ST3-ST9 at 0.91% ($n=1$) and ST3-ST2-ST1 at 0.91% ($n=1$) (Figure 4). Previous studies have documented the occurrence of coinfections involving different sequence types (STs) in the Colombian population. These coinfections have primarily been associated with the presence of ST1 and ST3 (García-Montoya et al., 2023). This finding is relevant for understanding the interactions among protozoans, hosts and the host microbiome, and how these infections might influence the host's response (Castañeda et al., 2020; Gentekaki et al., 2017). Additional analyses are necessary to expand the typing of a greater number of samples.

A compelling discovery pertained to the identification of *Cryptosporidium*. Initially, the multiplex qPCR, which was used to detect *C. parvum* and *C. hominis*, yielded negative results for all

samples. However, upon conducting a complementary analysis employing PCR for *Cryptosporidium* spp., we identified 12 positive samples. This observation suggests that the species circulating in this region may align with those previously documented in our country, including *C. muris*, *C. andersoni*, *C. viatorum* and *C. ubiquitum* (Higuera et al., 2020). Further research is warranted to molecularly characterize these species and genotypes, thus confirming this potential correspondence. Significantly, *Cryptosporidium* spp. was the sole parasite identified in the water supply. Notably, it was detected in water from both of the filters previously described, implying that the water used and consumed by the community may potentially be contaminated by this protozoan. Furthermore, *Cryptosporidium* spp. was identified in both animal and human hosts. These findings underscore the need for a One Health approach to evaluate and address prevention measures for parasitic infections, emphasizing transmission dynamics across the environment, animals and humans and enhancing water sanitation for consumption.

Giardia was also detected in both animal and human samples, with a frequency (16%) similar to that reported in previous molecular studies (Higuera et al., 2020; Villamizar et al., 2019). Complementary investigations are essential to molecularly characterize *Giardia* assemblages and subassemblages, enabling a more comprehensive evaluation of the zoonotic potential of this protozoan (Ryan & Cacciò, 2013; Ryan et al., 2021; Wielinga et al., 2023). Conversely, positive cases of *E. histolytica* were exclusively identified in humans (4.8%). Indeed, considering that parasites such as *Giardia* and *E. histolytica* are transmitted through the oral-faecal route, it is of utmost importance to place the findings presented here in the context of programmes designed to promote the proper handling and management of food, water and waste (López et al., 2015).

In the case of helminths, *A. duodenale* was the most prevalent parasite among animal hosts, and notably, *A. ceylanicum*, a zoonotic hookworm typically associated with wild animals, was found for the first time in Colombia (Papaïakovou et al., 2017). The detection of this nematode in both animals and humans highlights the significance of this zoonotic infection in communities where transmission risk is heightened due to the presence of dogs, coupled with inadequate use of water and management of excreta (Walker et al., 2023). In Colombia, the molecular identification of helminths is limited, and reliance on microscopy has led to an underestimation of the potential circulation of this nematode (Quiroz et al., 2020). Consequently, one of the WHO's priorities has been to address the management of these nematodes through timely and appropriate chemotherapeutic treatments within the framework of One Health strategies (Lebov et al., 2017; Walker et al., 2023). Our study revealed a potentially higher burden of this nematode in dogs, as assessed by DNA concentration, compared to the human host. This indicates that dogs can potentially harbour higher parasitic burdens, thereby promoting transmission and facilitating zoonotic events (Figure 2b) (Walker et al., 2023). This is a critical step towards the development of novel strategies for controlling and preventing infections of this nature. In the case of *Ancylostoma* spp., vaccination strategies have been proposed for dogs, leading to significant reductions in infection rates

and parasite burdens (Walker et al., 2023; Wiśniewski et al., 2016). This is crucial in rural areas where freely roaming dogs contact contaminated water and excreta, facilitating transmission to other animals and humans. A comprehensive evaluation is necessary for detection and estimation of parasitic burdens in broader areas.

The frequency of coinfections and polyparasitism within this community was remarkable. Although no statistically significant relationships were identified between the evaluated variables and polyparasitism events, it is imperative to acknowledge that the simultaneous presence of multiple parasites in the same individual (or even in dogs where we found 1–4 parasites in the same host) can introduce complexities in understanding clinical presentations, diagnostics and even transmission dynamics (Donohue et al., 2019). The most frequently observed coinfections and co-occurrences, such as *A. duodenale*–*Blastocystis* and *Giardia*–*Blastocystis*, may hold implications for disease severity and clinical outcomes (Donohue et al., 2019). Moreover, comprehending the interactions between parasites, be it helminth–protozoa or protozoa–protozoa, in cases of intestinal polyparasitism, could potentially shed light on key aspects of parasite biology, infection, host disease pathophysiology and their interactions with the host's immune system and microbiota (Burgess et al., 2017; Donohue et al., 2019; Stensvold & van der Giezen, 2018). Hence, it is imperative to conduct studies rooted in community ecology to comprehensively grasp not only the interactions occurring at the host level but also to delve into the epidemiological and social aspects that underpin the complexities of polyparasitism.

The purpose of this research was to comprehensively analyse the molecular epidemiology of protozoa and helminths in a specific area, considering various potential sources of infection such as water, humans and dogs. By combining these samples, we aimed to compare results obtained from microscopy and molecular tests, identifying similarities and differences in parasite prevalence across different hosts and environmental sources. Additionally, we investigated coinfection events to understand potential cross-species transmission pathways. Our findings contribute significantly to the understanding of zoonotic transmission dynamics in this community and offer insights for future research and public health strategies. It is important to acknowledge certain limitations within our study. Firstly, the acquisition of a single stool sample rather than conducting serial coproscopic analyses may have limited our ability to detect low-burden parasites. Additionally, the availability of only two water samples restricts our examination of the environmental impact on transmission dynamics. Furthermore, there are limitations regarding the characterization of species, assemblages and genotypes for specific parasites. Moreover, the identification of *Blastocystis* subtypes (STs) through complete sequencing of the rRNA-18S gene was not feasible for a significant portion of the samples examined. Future research endeavours should prioritize molecular typing and the development of high-resolution methods for various parasites to overcome these limitations. This would involve analysing a greater number of samples involving human and several animal hosts using probabilistic calculations and including a larger number of environmental samples to confirm transmission dynamics. Addressing these

limitations will lead to a more comprehensive understanding of the complex dynamics involving the environment, animal hosts and human hosts.

In summary, this study provides crucial insights into the molecular epidemiology of intestinal protozoa and helminths in a rural Colombian community, emphasizing the need for integrated control measures, including improved water and sanitation practices, health education and targeted treatment strategies. The findings underscore the importance of a One Health approach to understanding and addressing zoonotic transmission dynamics in both human and animal populations.

AUTHOR CONTRIBUTIONS

SC, CP, JDR and LRV conceived the study. SC, LHP and RM developed the experiments and analysed the data. All authors read and approved the final version of the manuscript.

FUNDING INFORMATION

This study was funded by Dirección de Investigación e Innovación from Universidad del Rosario. We thank the Ministerio de Ciencia Tecnología e Innovación (Minciencias) of Colombia under the framework of the Sistema General de Regalías for providing the PhD scholarship of Sergio Castañeda.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest related to the research, authorship or publication of this article.

DATA AVAILABILITY STATEMENT

The data that supports the findings of this study are available in the supplementary material of this article.

DECLARATION OF GENERATIVE AI AND AI-ASSISTED TECHNOLOGIES IN THE WRITING PROCESS'

During the preparation of this work, the author(s) used ChatGPT in order to improve readability and language. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

REFERENCES

- Audebert, C., Even, G., Cian, A., Blastocystis Investigation Group, Loywick, A., Merlin, S., Viscogliosi, E., Chabé, M., El Safadi, D., Certad, G., Delhaes, L., Pereira, B., Nourrisson, C., Poirier, P., Wawrzyniak, I., Delbac, F., Morelle, C., Bastien, P., Lachaud, L., ... Rabodonirina, M. (2016). Colonization with the enteric protozoa *Blastocystis* is associated with increased diversity of human gut bacterial microbiota. *Scientific Reports*, 6, 1–11. <https://doi.org/10.1038/srep25255>
- Burgess, S. L., Gilchrist, C. A., Lynn, T. C., & Petri, W. A. (2017). Parasitic protozoa and interactions with the host intestinal microbiota. *Infection and Immunity*, 85(8), e00101–17. <https://doi.org/10.1128/IAI.00101-17/ASSET/C24B0107-0C23-410F-98E1-94E5CA4CD45C/ASSETS/GRAPHIC/ZII9990921110002.JPEG>
- Burnet, J. B., Ogorzaly, L., Tissier, A., Penny, C., & Cauchie, H. M. (2013). Novel quantitative TaqMan real-time PCR assays for detection of

- cryptosporidium at the genus level and genotyping of major human and cattle-infecting species. *Journal of Applied Microbiology*, 114(4), 1211–1222. <https://doi.org/10.1111/JAM.12103>
- Castañeda, S., Muñoz, M., Villamizar, X., Hernández, P. C., Vásquez, L. R., Tito, R. Y., & Ramírez, J. D. (2020). Microbiota characterization in Blastocystis-colonized and Blastocystis-free school-age children from Colombia. *Parasites & Vectors*, 13(1), 521. <https://doi.org/10.1186/s13071-020-04392-9>
- Chalmers, R. M., & Katzer, F. (2013). Looking for cryptosporidium: The application of advances in detection and diagnosis. *Trends in Parasitology*, 29(5), 237–251. <https://doi.org/10.1016/j.pt.2013.03.001>
- Cimino, R. O., Jeun, R., Juarez, M., Cajal, P. S., Vargas, P., Echazú, A., Bryan, P. E., Nasser, J., Krolewiecki, A., & Mejia, R. (2015). Identification of human intestinal parasites affecting an asymptomatic peri-urban Argentinian population using multi-parallel quantitative real-time polymerase chain reaction. *Parasites and Vectors*, 8(1), 1–7. <https://doi.org/10.1186/S13071-015-0994-Z/FIGURES/3>
- Cooper, P., Walker, A. W., Reyes, J., Chico, M., Salter, S. J., Vaca, M., & Parkhill, J. (2013). Patent human infections with the whipworm, *Trichuris trichiura*, are not associated with alterations in the Faecal microbiota. *PLoS One*, 8(10), e76573. <https://doi.org/10.1371/JOURNAL.PONE.0076573>
- Donohue, R. E., Cross, Z. K., & Michael, E. (2019). The extent, nature, and pathogenic consequences of helminth polyparasitism in humans: A meta-analysis. *PLoS Neglected Tropical Diseases*, 13(6), e0007455. <https://doi.org/10.1371/JOURNAL.PNTD.0007455>
- Galván-Díaz, A. L. (2018). Cryptosporidiosis in Colombia: A systematic review. *Current Tropical Medicine Reports*, 5(3), 144–153. <https://doi.org/10.1007/S40475-018-0149-3/TABLES/3>
- Galvan-Diaz, A. L., Bedoya-Urrego, K., Medina-Lozano, A., Uran-Velasquez, J., Alzate, J. F., & Garcia-Montoya, G. (2020). Common occurrence of *Cryptosporidium hominis* in children attending day-care centers in Medellín, Colombia. *Parasitology Research*, 119(9), 2935–2942. <https://doi.org/10.1007/S00436-020-06782-5/FIGURES/2>
- García-Montoya, G. M., Galvan-Diaz, A. L., & Alzate, J. F. (2023). Metataxomics reveals Blastocystis subtypes mixed infections in Colombian children. *Infection, Genetics and Evolution*, 113, 105478. <https://doi.org/10.1016/J.MEEGID.2023.105478>
- Gentekaki, E., Curtis, B. A., Stairs, C. W., Klimeš, V., Eliáš, M., Salas-Leiva, D. E., Herman, E. K., Eme, L., Arias, M. C., Henrissat, B., Hilliou, F., Klute, M. J., Suga, H., Malik, S. B., Pightling, A. W., Kolisko, M., Rachubinski, R. A., Schlacht, A., Soanes, D. M., ... Roger, A. J. (2017). Extreme genome diversity in the hyper-prevalent parasitic eukaryote Blastocystis. *PLoS Biology*, 15(9), e2003769. <https://doi.org/10.1371/journal.pbio.2003769>
- Higuera, A., Salas-Leiva, D. E., Curtis, B., Patiño, L. H., Zhao, D., Jerlström-Hultqvist, J., Dlutek, M., Muñoz, M., Roger, A. J., & Ramírez, J. D. (2023). Draft genomes of Blastocystis subtypes from human samples of Colombia. *Parasites and Vectors*, 16(1), 1–10. <https://doi.org/10.1186/S13071-022-05619-7/TABLES/2>
- Higuera, A., Villamizar, X., Herrera, G., Giraldo, J. C., Vasquez-A, L. R., Urbano, P., Villalobos, O., Tovar, C., & Ramírez, J. D. (2020). Molecular detection and genotyping of intestinal protozoa from different biogeographical regions of Colombia. *PeerJ*, 2020(3), e8554. <https://doi.org/10.7717/PEERJ.8554/SUPP-4>
- Hotez, P. J., Brindley, P. J., Bethony, J. M., King, C. H., Pearce, E. J., & Jacobson, J. (2008). Helminth infections: The great neglected tropical diseases. *Journal of Clinical Investigation*, 118(4), 1311–1321. <https://doi.org/10.1172/JCI34261>
- Karo-Atar, D., Gregorieff, A., & King, I. L. (2023). Dangerous liaisons: How helminths manipulate the intestinal epithelium. *Trends in Parasitology*, 39(6), 414–422. <https://doi.org/10.1016/j.pt.2023.03.012>
- Knopp, S., Steinmann, P., Keiser, J., & Utzinger, J. (2012). Nematode infections. Soil-transmitted helminths and Trichinella. *Infectious Disease Clinics of North America*, 26(2), 341–358. <https://doi.org/10.1016/j.idc.2012.02.006>
- Lebov, J., Grieger, K., Womack, D., Zaccaro, D., Whitehead, N., Kowalczyk, B., & MacDonald, P. D. M. (2017). A framework for one health research. *One Health*, 3, 44–50. <https://doi.org/10.1016/j.onehlt.2017.03.004>
- López, M. C., León, C. M., Fonseca, J., Reyes, P., Moncada, L., Olivera, M. J., & Ramírez, J. D. (2015). Molecular epidemiology of entamoeba: First description of *Entamoeba moshkovskii* in a rural area from central Colombia. *PLoS One*, 10(10), e0140302. <https://doi.org/10.1371/journal.pone.0140302>
- Maloney, J. G., Molokin, A., & Santin, M. (2020). Use of Oxford nanopore MinION to generate full-length sequences of the Blastocystis small subunit (SSU) rRNA gene. *Parasites and Vectors*, 13(1), 1–8. <https://doi.org/10.1186/S13071-020-04484-6/TABLES/3>
- Maloney, J. G., & Santin, M. (2021). Mind the gap: New full-length sequences of Blastocystis subtypes generated via Oxford Nanopore Minion sequencing allow for comparisons between full-length and partial sequences of the small subunit of the ribosomal RNA gene. *Microorganisms*, 9, 997. <https://doi.org/10.3390/MICROORGANISMS9050997>
- Mejia, R., Vicuña, Y., Broncano, N., Sandoval, C., Vaca, M., Chico, M., Cooper, P. J., & Nutman, T. B. (2013). A novel, multi-parallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. *American Journal of Tropical Medicine and Hygiene*, 88(6), 1041–1047. <https://doi.org/10.4269/ajtmh.12-0726>
- Ministerio de Salud y Protección Social, U. de A. (2014). Encuesta nacional de parasitismo intestinal en población escolar 2012–2014.
- O'Connell, E. M., Harrison, S., Dahlstrom, E., Nash, T., & Nutman, T. B. (2020). A novel, highly sensitive quantitative polymerase chain reaction assay for the diagnosis of subarachnoid and ventricular Neurocysticercosis and for assessing responses to treatment. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 70(9), 1875–1881. <https://doi.org/10.1093/CID/CIZ541>
- Papaïakovou, M., Littlewood, D. T. J., Gasser, R. B., & Anderson, R. M. (2021). How qPCR complements the WHO roadmap (2021–2030) for soil-transmitted helminths. *Trends in Parasitology*, 37, 698–708. <https://doi.org/10.1016/J.PT.2021.04.005>
- Papaïakovou, M., Pilotte, N., Grant, J. R., Traub, R. J., Llewellyn, S., McCarthy, J. S., Krolewiecki, A. J., Cimino, R., Mejia, R., & Williams, S. A. (2017). A novel, species-specific, real-time PCR assay for the detection of the emerging zoonotic parasite *Ancylostoma ceylanicum* in human stool. *PLoS Neglected Tropical Diseases*, 11(7), e0005734. <https://doi.org/10.1371/JOURNAL.PNTD.0005734>
- Pullan, R. L., Smith, J. L., Jasrasaria, R., & Brooker, S. J. (2014). Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. *Parasites and Vectors*, 7(1), 37. <https://doi.org/10.1186/1756-3305-7-37>
- Quiroz, D. J. G., Lopez, S. D. P. A., Arango, C. M., Acosta, J. E. O., Parias, L. D. B., Alzate, L. U., Castro, C. H., Lozano, A. P. M., Vergara, G. D. S., Giraldo, A. M., Trujillo-Trujillo, J., Bolaño, I. D. C. P., Segura, C. M. C., & Montoya, M. P. A. (2020). Prevalence of soil transmitted helminths in school-aged children, Colombia, 2012–2013. *PLoS Neglected Tropical Diseases*, 14(7), e0007613. <https://doi.org/10.1371/JOURNAL.PNTD.0007613>
- Ramírez, J. D., Flórez, C., Olivera, M., Bernal, M. C., & Giraldo, J. C. (2017). Blastocystis subtyping and its association with intestinal parasites in children from different geographical regions of Colombia. *PLoS One*, 12(2), 1–13. <https://doi.org/10.1371/journal.pone.0172586>
- Rune, C., Lebbad, M., Hansen, A., Beser, J., Belkessa, S., Brien, L. O., & Clark, C. G. (2020). Differentiation of Blastocystis and parasitic

- archamoebids encountered in untreated wastewater samples by amplicon-based next-generation sequencing. *Parasite Epidemiology and Control*, 9, e00131. <https://doi.org/10.1016/j.parepi.2019.e00131>
- Ryan, U., & Cacciò, S. M. (2013). Zoonotic potential of giardia. *International Journal for Parasitology*, 43(12–13), 943–956. <https://doi.org/10.1016/j.ijpara.2013.06.001>
- Ryan, U., Fayer, R., & Xiao, L. (2014). Cryptosporidium species in humans and animals: Current understanding and research needs. *Parasitology*, 141(13), 1667–1685. <https://doi.org/10.1017/S0031182014001085>
- Ryan, U. M., Feng, Y., Fayer, R., & Xiao, L. (2021). Taxonomy and molecular epidemiology of cryptosporidium and giardia – A 50 year perspective (1971–2021). *International Journal for Parasitology*, 51(13–14), 1099–1119. <https://doi.org/10.1016/j.ijpara.2021.08.007>
- Saboyá, M. I., Catalá, L., Nicholls, R. S., & Ault, S. K. (2013). Update on the mapping of prevalence and intensity of infection for soil-transmitted helminth infections in Latin America and the Caribbean: A call for action. *PLoS Neglected Tropical Diseases*, 7(9), e2419. <https://doi.org/10.1371/journal.pntd.0002419>
- Sánchez, A., Munoz, M., Gómez, N., Tabares, J., Segura, L., Salazar, Á., Restrepo, C., Ruiz, M., Reyes, P., Qian, Y., Xiao, L., López, M. C., & Ramírez, J. D. (2017). Molecular epidemiology of giardia, Blastocystis and cryptosporidium among indigenous children from the Colombian Amazon basin. *Frontiers in Microbiology*, 8, 1–14. <https://doi.org/10.3389/fmicb.2017.00248>
- Savioli, L., Smith, H., & Thompson, A. (2006). Giardia and Cryptosporidium join the “neglected diseases initiative”. *Trends in Parasitology*, 22(5), 203–208. <https://doi.org/10.1016/j.pt.2006.02.015>
- Silver, Z. A., Kaliappan, S. P., Samuel, P., Venugopal, S., Kang, G., Sarkar, R., & Ajampur, S. S. R. (2018). Geographical distribution of soil transmitted helminths. *PLoS Neglected Tropical Diseases*, 12(1), e0006153.
- Specht, S., & Keiser, J. (2022). Helminth infections: Enabling the World Health Organization road map. *International Journal for Parasitology*, 53, 411–414. <https://doi.org/10.1016/j.ijpara.2022.10.006>
- Sponseller, J. K., Griffiths, J. K., & Tzipori, S. (2014). The evolution of respiratory cryptosporidiosis: Evidence for transmission by inhalation. *Clinical Microbiology Reviews*, 27(3), 575–586. <https://doi.org/10.1128/CMR.00115-13>
- Stensvold, C. (2013). Blastocystis: Genetic diversity and molecular methods for diagnosis and epidemiology. *Tropical Parasitology*, 3(1), 26. <https://doi.org/10.4103/2229-5070.113896>
- Stensvold, C. R., Ahmed, U. N., Andersen, L. O. B., & Nielsen, H. V. (2012). Development and evaluation of a genus-specific, probe-based, internal-process-controlled real-time PCR assay for sensitive and specific detection of Blastocystis spp. *Journal of Clinical Microbiology*, 50(6), 1847–1851. <https://doi.org/10.1128/JCM.00007-12/ASSET/0F8D1284-11EC-4A44-B724-C34241B3CB2E/ASSETS/GRAPHIC/ZJM9990916480001.JPEG>
- Stensvold, C. R., & Clark, C. G. (2016). Current status of Blastocystis: A personal view. *Parasitology International*, 65(6), 763–771. <https://doi.org/10.1016/j.parint.2016.05.015>
- Stensvold, C. R., Sørland, B. A., Berg, R. P. K. D., Andersen, L. O., van der Giezen, M., Bowtell, J. L., El-Badry, A. A., Belkessa, S., Kurt, Ö., & Nielsen, H. V. (2022). Stool microbiota diversity analysis of Blastocystis-positive and Blastocystis-negative individuals. *Microorganisms*, 10, 326. <https://doi.org/10.3390/MICROORGANISMS10020326>
- Stensvold, C. R., & van der Giezen, M. (2018). Associations between gut microbiota and common luminal intestinal parasites. *Trends in Parasitology*, 34(5), 369–377. <https://doi.org/10.1016/j.pt.2018.02.004>
- Villamizar, X., Higuera, A., Herrera, G., Vasquez-A, L. R., Buitron, L., Muñoz, L. M., Gonzalez-C, F. E., Lopez, M. C., Giraldo, J. C., & Ramírez, J. D. (2019). Molecular and descriptive epidemiology of intestinal protozoan parasites of children and their pets in Cauca, Colombia: A cross-sectional study. *BMC Infectious Diseases*, 19(1), 1–11. <https://doi.org/10.1186/s12879-019-3810-0>
- Walker, M., Lambert, S., Neves, M. I., Worsley, A. D., Traub, R., & Colella, V. (2023). Modeling the effectiveness of one health interventions against the zoonotic hookworm *Ancylostoma ceylanicum*. *Frontiers in Medicine*, 10, 1092030. <https://doi.org/10.3389/FMED.2023.1092030/BIBTEX>
- Wawrzyniak, I., Poirier, P., Texier, C., Delbac, F., Viscogliosi, E., Dionigia, M., & Alaoui, H. E. (2013). Blastocystis, an unrecognized parasite: An overview of pathogenesis and diagnosis. *Therapeutic Advances in Infectious Disease*, 1(5), 167–178. <https://doi.org/10.1177/2049936113504754>
- Wielinga, C., Williams, A., Monis, P., & Thompson, R. C. A. (2023). Proposed taxonomic revision of *Giardia duodenalis*. *Infection, Genetics and Evolution*, 111, 105430. <https://doi.org/10.1016/J.MEEGID.2023.105430>
- Wiśniewski, M., Łapiński, M., Daniłowicz-Luebert, E., Jaros, S., Długosz, E., & Wędrychowicz, H. (2016). Vaccination with a cocktail of *Ancylostoma ceylanicum* recombinant antigens leads to worm burden reduction in hamsters. *Acta Parasitologica*, 61(3), 556–561. <https://doi.org/10.1515/AP-2016-0074/MACHINEREADEABLECITATION/RIS>
- Yason, J. A., Liang, Y. R., Png, C. W., Zhang, Y., & Tan, K. S. W. (2019). Interactions between a pathogenic Blastocystis subtype and gut microbiota: In vitro and in vivo studies. *Microbiome*, 7(1), 1–13. <https://doi.org/10.1186/s40168-019-0644-3>
- Zajaczkowski, P., Lee, R., Fletcher-Lartey, S. M., Alexander, K., Mahimbo, A., Stark, D., & Ellis, J. T. (2021). The controversies surrounding *Giardia intestinalis* assemblages A and B. *Current Research in Parasitology & Vector-Borne Diseases*, 1, 100055. <https://doi.org/10.1016/J.CRPVBD.2021.100055>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Castañeda, S., Acosta, C. P., Vasquez-A, L. R., Patiño, L. H., Mejía, R., & Ramírez, J. D. (2024). Molecular detection of intestinal parasites in a rural community of Colombia: A one health approach to explore potential environmental–zoonotic transmission. *Zoonoses and Public Health*, 00, 1–13. <https://doi.org/10.1111/zph.13138>

1 **Impact of *Blastocystis* Colonization and Burden on Gut Microbiota Composition in a**
2 **Non-Westernized Rural Population from Colombia**

3
4 Sergio Castañeda¹, Rune Stensvold², Lee O'Brien Andersen², Claudia Patricia Acosta³, Luis
5 Reinel Vasquez-A⁴, Juan David Ramírez^{1,5}

6
7 ¹Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de
8 Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia

9 ²Laboratory of Parasitology, Department of Bacteria, Parasites and Fungi, Statens Serum Institut,
10 Artillerivej 5, DK-2300 Copenhagen S, Denmark.

11 ³ Grupo de investigación en Genética Humana, Departamento de Ciencias Fisiológicas, Facultad
12 de Ciencias de la Salud, Universidad del Cauca

13 ⁴Centro de Estudios en Microbiología y Parasitología, Facultad de Ciencias de la Salud,
14 Universidad del Cauca, Popayán, Colombia

15 ⁵Molecular Microbiology Laboratory, Department of Pathology, Molecular and Cell-Based
16 Medicine, Icahn School of Medicine at Mount Sinai, New York city, NY, USA

17
18 **Abstract**

19 *Blastocystis*, a common intestinal protozoan in humans and animals, has long been debated
20 regarding its role in human health. Recent studies suggest a connection between *Blastocystis*
21 colonization, healthier lifestyles, and beneficial modulation of gut microbiota. Nevertheless,
22 studies concerning the relationship between *Blastocystis* colonization, its burden, and gut
23 microbiota composition—encompassing both bacterial and eukaryotic communities—in
24 individuals from rural populations are limited. Therefore, this study examines the impact of
25 *Blastocystis* colonization and its burden on gut microbiota composition in a rural community,
26 which provides a distinct microbial profile and higher protozoan prevalence. A total of 88 human
27 samples were collected from the rural population of Las Guacas village, located in the Cauca
28 department, southwest Colombia. We utilized 16S and 18S rDNA sequencing to analyze both
29 bacterial and eukaryotic microbiota, comparing *Blastocystis*-positive and -negative individuals, as
30 well as groups with varying *Blastocystis* burdens (low, medium, high), to identify distinct
31 microbiota profiles and differentially abundant taxa linked to each condition. The analysis revealed
32 significant differences between *Blastocystis*-positive and -negative individuals. In terms of

33 bacterial composition and structure, *Blastocystis*-positive individuals exhibited distinct microbiota
34 profiles, as shown by beta diversity analysis. Characteristic taxa included *Bacteroides*, *Prevotella*,
35 *Oscillibacter*, *Faecalibacterium*, and *Alistipes*. Higher *Blastocystis* burdens were associated with
36 an increased abundance of taxa like *Alistipes* and *Lachnospira*, while lower burdens correlated
37 with beneficial bacteria such as *Akkermansia*. Regarding eukaryotic composition, beta diversity
38 analysis revealed distinct profiles associated with *Blastocystis* colonization. Differentially
39 abundant taxa, including *Entamoeba coli*, were more prevalent in *Blastocystis*-positive
40 individuals, while *Blastocystis*-negative individuals exhibited a higher abundance of opportunistic
41 fungi, such as *Candida albicans*. Machine learning models, including random forest classifiers,
42 supported these findings, identifying specific microbial taxa like *Faecalibacterium* and
43 *Bacteroides* as predictors of *Blastocystis* colonization. These findings suggest that *Blastocystis*
44 may modulate gut microbiota, contributing to microbial balance providing new insights into the
45 ecological implications of *Blastocystis* in rural populations.

46

47 **Introduction**

48 *Blastocystis* is an ubiquitous intestinal protozoan, commonly detected in both humans and animals
49 worldwide [1,2]. Despite its frequent occurrence in human stool samples, its role in human health
50 has long been debated. Traditionally regarded as a pathogen, emerging evidence suggests a more
51 complex relationship, with studies indicating that *Blastocystis* may act as a commensal organism,
52 or even provide benefits to gut health [3–8]. Recent research has linked *Blastocystis* to
53 improvements in dietary habits, serving as a biomarker of healthier lifestyles, and positively
54 influencing individualized host responses to diet and disease susceptibility [7]. This protozoan's
55 association with the gut microbiota is particularly significant, as it seems to coincide with favorable
56 shifts in microbial diversity and composition, shaped by a range of host factors, including immune
57 status, lifestyle, and geographic location [5–9]. However, most studies on the impact of
58 *Blastocystis* on microbiota ecology have been conducted in Westernized populations, which
59 possess distinct socio-economic, demographic, dietary, and lifestyle conditions [3,8]. These factors
60 shape a characteristic microbiota profile that differs from non-Westernized populations,
61 particularly in rural areas [10,11]. Given these differences, rural populations may exhibit unique

62 microbiota profiles that could potentially alter the interaction dynamics between *Blastocystis* and
63 the host microbiota, highlighting the need for further investigation in these contexts.

64 Rural communities from non-westernized offer a unique and underexplored context for
65 investigating the intricate interactions between *Blastocystis* and the gut microbiota. It has been
66 observed that modern Westernized populations differ from traditional and agrarian populations in
67 terms of gut microbiota composition [11]. Non-Western individuals tend to harbor a more diverse
68 community of protists, which contributes to the overall diversity of the human gut. This distinction
69 underscores the importance of studying non-Westernized populations to better understand the full
70 spectrum of gut microbial diversity and the ecological roles of protists like *Blastocystis* [11].
71 Additionally, protozoan colonization, including that of *Blastocystis*, is more prevalent in these
72 settings, likely influenced by factors such as limited access to healthcare, clean water, and
73 consumption of diets rich in unprocessed foods [12–15]. Despite this, there remains a dearth of
74 comprehensive studies examining *Blastocystis* and its microbiota interactions in rural populations,
75 with most existing research focusing on specific subgroups, such as school-aged children, and
76 primarily analyzing bacterial components using 16S rRNA sequencing [5,16,17]. The role of
77 eukaryotic microorganisms, which may hold the key to understanding broader microbial
78 interactions, has largely been overlooked in these studies.

79 The ability of *Blastocystis* to alter the structure and composition of the gut microbiota has been
80 well documented [4–8]. However, a more nuanced approach is necessary, considering not only its
81 presence but also its burden and the potential dose-dependent effects on microbial ecosystems.
82 Studies on *Giardia* have shown that its presence induces changes in the host microbiota. Notably,
83 shifts in microbial diversity and the abundance of specific taxa are linked to varying levels of
84 *Giardia* burden [18–20]. For example, Mejia (2020) found that children with *Giardia* DNA
85 concentrations greater than 1 fg/ μ l exhibited significantly lower microbial diversity and a higher
86 abundance of *Prevotella* compared to uninfected children [18]. This suggests that the burden of
87 protozoa may be a critical factor influencing microbiota structure and composition. This is
88 particularly relevant in rural populations from non-Westernized regions, where the prevalence and
89 burden of protozoa like *Blastocystis* are significantly higher compared to urban populations.
90 Contributing factors include deficiencies in access to clean water, waste management, and sanitary
91 conditions, as well as challenges in accessing healthcare services [12,13,15,21]. Understanding the

92 impact of *Blastocystis* burden on both bacterial and eukaryotic components of the microbiota could
93 offer insights into how this protozoan shapes microbial communities and influences host health.

94 This study aims to address a key gap by investigating the relationship between *Blastocystis*
95 colonization, its burden, and gut microbiota composition—including both bacterial and eukaryotic
96 communities—in individuals from a non-Westernized rural community in Colombia, South
97 America. Specifically, we seek to determine whether *Blastocystis* colonization is associated with
98 shifts in microbial diversity and the presence of key taxa that could impact host health. By
99 integrating analyses of both bacterial and eukaryotic components.

100

101 **Methods**

102 **Ethical considerations, informed consent, and necessary permissions**

103 Informed written consent was obtained from every participant or their respective parent or
104 caregiver. The study design and research protocols received approval from the Bioethics
105 Committee of Universidad del Cauca, Colombia.

106 **Study Population**

107 A total of 88 human samples were evaluated from a rural population in the Cauca department,
108 Colombia, known as Las Guacas village, located in the municipality of Popayan in southwest
109 Colombia (Fig. S1) [15].

110 **Sample Size**

111 A non-probabilistic convenience sampling approach was employed, and stool samples were
112 collected from children and caregivers who agreed to participate in the study and provided a fecal
113 sample.

114 **Stool Sample Collection**

115 Each stool sample was obtained using sterile gloves, deposited in a sterile container, and
116 transported under refrigeration at temperatures between 2-8°C. Upon arrival at the laboratory, it
117 was then stored in ultra-freezers at -80°C for subsequent analysis. DNA extraction from stool

118 samples was carried out using the Norgen fecal DNA extraction kit, which included an initial
119 disruption step.

120 **Microbiome sequencing and analysis**

121 *Primer design*

122 The 16S rDNA gene was targeted for amplification, using a modified version of the published
123 universal prokaryotic primers 341F/806R, targeting the V3-V4 hyper-variable regions [22,23]. The
124 forward primer had three additional nucleotides attached in the 5' end
125 (ACTCCTAYGGGRBGCASCAG, 341F3) and the reverse primer had five additional nucleotides
126 attached in the 5' end (AGCGTGGACTACNNGGGTATCTAAT, 806R5). Changes were made due
127 to compliance with our standard PCR program (annealing temperature).

128 The 18S rDNA gene was selected as target gene to ensure an as broad spectrum of eukaryotic
129 species (parasites and fungi) to be amplified from as few primer sets as possible, when assuming
130 that the 18S rDNA sequence would be the most inter-species conserved gene [23]. 18S rDNA
131 sequences were aligned for each species or genus and a consensus sequence was generated. The
132 consensus sequences for each species were used for phylogenetic analysis in order to group the
133 parasites according to their 18S rDNA sequence similarity rather than taxonomy. The consensus
134 sequence from all species within each group was then aligned and primers were designed, to
135 amplify all species within each group. Additionally, a consensus sequence from human 18S rDNA
136 was aligned with each group, in order to design primers that would preferentially amplify non-
137 human 18S rDNA. Three different primer sets were chosen, G3F1/G3R1
138 (GCCAGCAGCCGCGGTAATTC / ACATTCTTGGCAAATGCTTTCGCAG), G4F3/G4R3
139 (CAGCCGCGGTAATTCAGCTC / GGTGGTGCCCTTCCGTCAAT) and G6F1/G6R1
140 (TGGAGGGCAAGTCTGGTGCC / ACGGTATCTGATCGTCTTCGATCCC). G3 and G6
141 primers are targeting the hyper-variable regions V3-V4 and G4 is targeting the hypervariable
142 region V3-V5 of the 18S rDNA gene. Each primer set was aligned using BLAST to the NCBI
143 database, using NCBI's Primer-Blast, with standard settings (excluding predicted Refseq
144 transcripts and uncultured / environmental samples).

145 *Library preparation and sequencing*

146 Purified genomic DNA from each sample was initially amplified using the 16S and three different
147 18S primers. For each primer, the rDNA was amplified using a short PCR setup; Initial
148 denaturation at 95°C for 3 min, 20 cycles of 95°C (16S: for 30 sec; 18S: for 1 min), 60°C for 1
149 min, and 72°C for 30 sec, and a final elongation at 72°C (16S: for 7 min; 18S: for 4 min). PCR
150 was performed in a 25µl volume, using the PrimeSTAR® HS DNA Polymerase premix (Takara
151 Bio, Shiga, Japan) with 0.4µM of each primer and 2µl template. This PCR is referred to as PCR1
152 or amplification PCR. The products from PCR1 were prepared for sequencing by a second PCR
153 (PCR2 or adaptor PCR) using the same PCR program. PCR2 attaches an adaptor A, an index i5,
154 and a forward sequencing primer site (FSP) in the 5' end of the amplicons and an adaptor B, an
155 index i7, and a reverse sequencing primer site (RSP) to the 3' end of the amplicons. Hence, four
156 different PCR amplicon products were generated for each sample. DNA was quantified using the
157 Quant-IT™ dsDNA High Sensitive Assay Kit (Thermo Fisher Scientific), and PCR2 products were
158 pooled in equimolar amounts between samples into the pooled amplicon library (PAL).
159 Undesirable DNA amplicons were removed from the PAL by Agencourt AMPure XP bead
160 purification in a two-step process. Firstly, DNA fragments below 300nt were removed by a 10µL
161 PAL to 24µL AMPure beads ratio, following the manufactures protocol and eluted in 40µL TE
162 buffer. Secondly, large DNA fragments above 1kbp were removed by 10µL AM1 to 16µL AMPure
163 beads ratio, as previously described. The resulting AMPure beads purified PAL was denoted bPAL.
164 The bPAL was diluted to its final concentration of 7.5pM DNA with a 0.001 N NaOH
165 concentration, used for sequencing on the Illumina MiSeq desktop sequencer (Illumina Inc., San
166 Diego, CA 29122, USA). The library was sequenced with the 500-cycle MiSeq Reagent Kit V2 in
167 a 2x250nt setup (Illumina Inc., San Diego, CA 29122, USA).

168

169 *Data analysis*

170 The data analysis was performed using BION, a semi-commercial software package that utilizes a
171 k-mer-based approach for species-level annotation [23]. BION can handle non-overlapping paired
172 end reads and custom reference databases. It accepts raw sequences and includes several
173 processing steps: de-multiplexing, primer extraction, sampling, sequence and quality-based
174 trimming and filtering, de-replication, clustering, chimera checking, reference data similarity
175 assessment, and taxonomic mapping and formatting.

176 Prokaryotic sequences were mapped against the RDP reference database (v11.04), while
177 eukaryotic sequences were mapped using the SILVA reference database (v128). For eukaryotes,
178 an in-house improved taxonomy definition was applied, aligning with prokaryotic taxonomy levels
179 (phylum, class, order, family, genus, species, and sequence levels) [8,23–25]. Taxonomy profiling
180 was conducted with an 85% k-mer similarity cut-off at the species level, corresponding to
181 approximately 98% sequence similarity. At the genus level, the cut-off was set at 60% k-mer
182 similarity, equivalent to around 95% sequence similarity. Query sequences with k-mer similarity
183 below 60% were excluded from further analysis. Mapped query sequences were clustered at 98%
184 k-mer similarity, providing a resolution higher than the basecalling error rate.

185 Microbial diversity analysis was performed using the R Phyloseq package [26]. This package was
186 employed for calculating diversity and abundance indices and generating the corresponding
187 graphs. Linear discriminant analysis (LDA) effect size (LEfSe) analysis and DESeq2, were
188 employed to identify taxa with differential abundance [27]. The threshold of the logarithmic LDA
189 score was 4.0 with a maximum kw value of 0.01 for LEfSe analysis. For DESeq2, a pCutoff of
190 0.05 and an FCcutoff of 1.0 were used.

191

192 ***Blastocystis* Positive and Negative Classification and Burden levels**

193 To assess *Blastocystis* colonization status (positive or negative) and categorize colonization
194 burden, we analyzed sequencing data generated using Illumina technology, which targeted the G3,
195 G4, and G6 regions of the 18S rDNA gene, following previously established protocols [8,25,28].
196 Colonization status was determined based on read counts obtained from the target regions. We
197 first evaluated the distribution of read counts across all samples to establish a threshold for
198 distinguishing *Blastocystis* presence from absence. An empirical cutoff of 100 reads was used to
199 classify samples as either *Blastocystis*-negative (≤ 100 reads) or *Blastocystis*-positive (> 100 reads),
200 based on an analysis of read count distribution and alignment with recommendations from the
201 literature. This cutoff was chosen to minimize false positives while maintaining sensitivity to
202 detect true colonization. For *Blastocystis*-positive samples, we categorized the burden into three
203 levels (low, medium, or high) using a modified quartile-based approach. Specifically, individuals
204 in the 0-25th percentile were classified into the "Low" burden group, those in the 25th-75th
205 percentile were assigned to the "Middle" burden group, and individuals with read counts exceeding

206 the 75th percentile were placed in the "High" burden group. This classification was applied to
207 ensure a statistically meaningful distribution across groups, allowing for comparisons that account
208 for variability in read counts. The corresponding read count ranges were defined as follows:
209 Negative (0-100 reads), Low (110-694 reads), Middle (694-6118 reads), and High (more than 6118
210 reads). To reduce skewness and improve the normality of the read count data, a natural logarithmic
211 transformation (ln) was applied to the positive read counts. This transformation helped to compress
212 the range of values and diminish the influence of extreme outliers, making the data more suitable
213 for parametric statistical analyses. The log-transformed burden levels were as follows: Negative
214 (0-4.61), Low (4.62-6.52), Middle (6.53-8.76), and High (8.77 and above). By employing this
215 classification framework and normalization procedure, we provided a robust statistical basis for
216 analyzing *Blastocystis* colonization and burden across the study population.

217

218 **Statistical analysis**

219 The quantitative variables were summarized in terms of medians and interquartile range, and the
220 qualitative variables were summarized in frequencies and proportions. The number of reads in
221 each sample was normalized using the average sequence depth. As indicators for the comparisons
222 between groups, relative abundance, and alpha diversity metrics, observed richness, Shannon, and
223 Fisher index, were used [29]. The alpha diversity indices were compared between groups using
224 the non-parametric Mann-Whitney-Wilcoxon and Kruskal Wallis test. To explore the differences
225 in the general composition of the microbial community between groups (beta diversity), the Bray-
226 Curtis taxonomic distances were calculated. Using the *Phyloseq* package, a principal coordinates
227 analysis diagram was produced, in which the Bray-Curtis dictations were used between the
228 samples to visualize the behavior of the groups. Permutational analysis of variance
229 (PERMANOVA) test for multivariate effect was done using the *adonis* function from the *vegan*
230 package [30], stratified by groups.. Statistical analyses were carried out using the R software [31].
231 For all continuous values, normality hypotheses were evaluated using the Kolmogorov-Smirnov
232 test. All tests of significance were two-tailed, and P -values < 0.05 were considered statistically
233 significant.

234

235 **Machine learning model**

236 We employed a machine learning-based classification approach to predict the variable of interest
237 from microbiota composition. Specifically, a random forest classifier, a supervised method
238 designed to optimize classification accuracy, was utilized [32,33]. The dataset was analyzed in R
239 using ggplot2, phyloseq, randomForest, and pROC packages. Samples were filtered to include
240 only those with *Blastocystis* groups status (Positive or Negative), and OTUs from the
241 *Blastocystidae* family were removed. Rare OTUs were pruned based on a relative abundance
242 threshold of 0.01%. The random forest model, consisting of 100 trees, was trained to classify
243 *Blastocystis* status, and the 20 most important OTUs were identified using the Mean Decrease in
244 Gini Index. Model performance was evaluated through a confusion matrix, precision, recall, F1
245 score, specificity, and ROC curve with AUC values. Visualization of OTU was performed using
246 ggplot2.

247

248 **Results**

249 **General microbiota profile**

250 The composition of intestinal microbiota among participants with and without *Blastocystis* was
251 evaluated using together 16S and 18S rDNA (Fig. 1-3, Fig. S2-S5). The general profile shows that
252 Firmicutes was the dominant Phyla, followed by Bacteroidetes, Proteobacteria, Actinobacteria,
253 and Ascomycota (Fig S1a). Within these phyla, the most abundant bacterial families' taxa were
254 Lachnospiraceae and Rimunococcaceae, and for eukaryotes, were Saccharomycetaceae and
255 Entamoebida (Fig S1 c, d).

256 **Bacterial Microbiota Composition**

257 *Alpha and beta diversity analyses revealed potential differences in bacterial composition between*
258 *Blastocystis-positive and Blastocystis-negative individuals.*

259 To evaluate changes in bacterial alpha diversity, we calculated observed richness, Pielou's
260 evenness, Shannon, and Simpson indices (Fig. 1a). While the overall composition of the intestinal
261 bacterial community did not differ significantly between groups, there was a trend toward higher
262 observed richness in the *Blastocystis*-positive group. No significant differences in diversity metrics

263 were observed in relation to varying levels of *Blastocystis* burden. However, beta diversity analysis
264 revealed significant distinctions (PERMANOVA: adonis2, $P = 0.0001$) between *Blastocystis*-
265 positive and -negative individuals, indicating the existence of two distinct microbiota profiles
266 based on *Blastocystis* presence. Notably, in *Blastocystis*-positive individuals, taxa such as
267 *Bacteroides uniformis*, *Oscillibacter* sp., and *Prevotella copri* were more abundant, while
268 *Eubacterium rectale* and *Blautia luti* were more prevalent in *Blastocystis*-negative individuals
269 (Fig. 1b).

270

271 *Microbiota Bacterial Composition: Relative Abundances and Differential Taxa*

272 To understand the global composition of the microbiota in relation to *Blastocystis* status, we
273 analyzed relative abundances and differential taxa. Both *Blastocystis*-positive and -negative groups
274 were predominantly characterized by the families Lachnospiraceae, Ruminococcaceae,
275 Clostridiaceae, Prevotellaceae, and Bacteroidaceae. However, the *Blastocystis*-positive group
276 exhibited a subtle shift, with a reduction in the relative abundance of Lachnospiraceae and an
277 increase in Ruminococcaceae and Bacteroidaceae, suggesting specific microbial alterations
278 associated with *Blastocystis* colonization (Fig. S3a). When examining relative abundances based
279 on *Blastocystis* burden levels, these patterns became more pronounced in the high-burden group,
280 where the abundance of Ruminococcaceae and Bacteroidaceae was notably higher compared to
281 other groups (Fig 3a).

282 We employed Linear Discriminant Analysis Effect Size (LEfSe) and DESeq2 to analyze the taxa
283 differentially abundant among the comparison groups. Our comparison between *Blastocystis*-
284 positive and -negative groups revealed that the *Blastocystis*-positive group exhibited higher
285 abundances of genera such as *Bacteroides*, *Faecalibacterium*, and *Alistipes*. In contrast, the
286 *Blastocystis*-negative group showed a greater prominence of genera like *Blautia*, *Staphylococcus*,
287 *Enterococcus*, and *Klebsiella* (Fig. 1 c, d, and Fig. S3b). Further analysis of *Blastocystis* burden
288 groups (high, medium, and low) identified distinct taxa associated with each burden level. High
289 burden levels were linked to genera such as *Alistipes*, *Lachnospira*, and *Arcanobacterium*; medium
290 burden levels were associated with *Acetivibrio* and *Peptoniphilus*; and low burden levels correlated
291 with *Bacteroides*, *Phascolarctobacterium*, *Paraprevotella*, and *Akkermansia* (Fig. 3c). These
292 findings suggest that specific alterations in the microbiota may be linked not only to the presence

293 of *Blastocystis* but also to the burden of *Blastocystis*. This implies that variations in *Blastocystis*
294 burden could have a relevant impact on the dynamics underlying changes in the composition and
295 structure of the host microbiota.

296 **Eukaryotic Microbiota Composition**

297 *Beta diversity analysis of the eukaryotic microbiota also showed potential differences between*
298 *Blastocystis-positive and -negative groups.*

299 Although alpha diversity indices did not show significant differences between *Blastocystis*-
300 positive and -negative groups, our analysis revealed that among *Blastocystis* burden groups, higher
301 burden levels were associated with reduced eukaryotic diversity compared to the *Blastocystis*-
302 negative group (Mann-Whitney-Wilcoxon test, $P < 0.05$) (Fig. 2a). This suggests that the presence
303 of *Blastocystis*, as an eukaryote, may diminish the abundance of other eukaryotic organisms,
304 particularly fungi, in the host microbiota. Beta diversity analysis further confirmed significant
305 differences in eukaryotic microbiota composition between *Blastocystis*-positive and -negative
306 individuals (PERMANOVA: adonis2, $P = 0.0001$), indicating distinct eukaryotic profiles
307 associated with *Blastocystis* presence. Specifically, *Entamoeba coli* was commonly found in
308 *Blastocystis*-positive individuals, whereas the fungi *Saccharomyces cerevisiae* and *Candida*
309 *albicans* were more characteristic of the *Blastocystis*-negative group (Fig. 2b).

310

311 *Eukaryotic Microbiota Composition: Relative Abundances and Differential Taxa*

312 In terms of eukaryotic microbiota, both groups were predominantly characterized by the families
313 Saccharomycetaceae, Blastocystidae, Entamoebida, Malasseziaceae, and Trichomycetes. In the
314 *Blastocystis*-positive group, we observed a notable reduction in the relative abundance of
315 Saccharomycetaceae and an increase in Entamoebida (Fig. S4a). Regarding *Blastocystis* burden
316 groups, we observed that higher *Blastocystis* burdens were associated with a reduction in the
317 relative abundance of other eukaryotes, particularly fungi from the families *Saccharomycetaceae*
318 and *Malasseziaceae*. Notably, the family *Entamoebida* consistently maintained a higher relative
319 abundance across all burden levels in *Blastocystis*-positive individuals (Fig. 3b).

320 To identify differentially abundant eukaryotic taxa for each group, we employed LEfSe and
321 DESeq2. In comparing *Blastocystis*-positive and -negative groups, we found that the *Blastocystis*-
322 positive group exhibited a differential abundance of genera such as *Barnettozyma*, *Entamoeba*, and
323 *Endolimax*, while the *Blastocystis*-negative group was characterized by higher abundances of
324 *Candida* and *Malassezia* (Fig. 2 c,d and Fig. S3b). Additionally, analysis of *Blastocystis* burden
325 groups revealed that high burden levels were associated with genera such as *Issatchenkia*,
326 *Pleurostomophora*, and *Citeromyces*, whereas low burden levels were associated with genera like
327 *Adelina* and *Cyniclomyces* (Fig. 3d).

328 **Microbiota composition as a predictor of *Blastocystis* presence**

329 The random forest classifier was trained to predict *Blastocystis* colonization status based on
330 microbiota composition (Fig. S6). The model achieved an out-of-bag (OOB) error rate of 23.86%,
331 indicating the proportion of samples misclassified during the internal validation process. The
332 confusion matrix reveals that the model correctly classified 41 of 49 negative samples (class error
333 = 16.3%) and 26 of 39 positive samples (class error = 33.3%). When evaluating the model on the
334 test data, it achieved a perfect accuracy of 1.0, with a 95% confidence interval of (0.9589, 1).
335 Additionally, the P-value for accuracy being greater than the No Information Rate (NIR) was
336 highly significant ($P < 2.2e-16$), indicating that the model's performance was far superior to
337 random chance. These results suggest that the random forest model was highly effective in
338 classifying *Blastocystis* colonization status based on microbiota composition, although there was
339 some degree of misclassification in the training process, particularly among positive samples.

340 The random forest model identified the top 20 taxa that were most important for classifying
341 *Blastocystis* colonization based on the Mean Decrease in Gini Index, which reflects each taxa
342 contribution to the accuracy of the model. A bar plot of the Mean Decrease in Gini values revealed
343 that taxa predictors varied significantly in their importance (Fig. S6). The taxa with the highest
344 Mean Decrease in Gini were the most influential in differentiating between positive and negative
345 *Blastocystis* colonization. This visualization highlights the specific taxa that play a key role in
346 driving the model's predictive performance, indicating potential microbial markers associated with
347 *Blastocystis* status.

348

349 Discussion

350 Our findings suggest that *Blastocystis* colonization is associated with significant shifts in both the
351 composition and structure of the gut microbiota, which may correlate with improvements in host
352 health observed in non-westernized rural populations in previous studies [7]. Piperni et al. (2024)
353 reported that the changes in the gut microbiome related to *Blastocystis* vary across different
354 geographical regions and lifestyles, highlighting a strong connection with healthier, plant-based
355 diets common in these populations [7]. Additionally, their study indicated that *Blastocystis* was
356 associated with improved cardiometabolic profiles, and its presence increased following a diet-
357 improvement intervention program [7]. These findings suggest that *Blastocystis* may have a
358 profound impact on the host—not only in terms of microbiome composition and structure but also
359 regarding metabolic and immunological processes that contribute to improved health conditions
360 [7]. These results are particularly relevant for non-westernized rural populations, such as the
361 Colombian cohort used in the present study, where environmental exposures, dietary practices, and
362 lifestyle factors differ significantly from those in urban settings [8,10,11]. Such differences may
363 profoundly influence microbiota diversity and parasite prevalence. In this context, we found that
364 the presence of *Blastocystis* was related to increased bacterial diversity, which aligns with previous
365 research [7,8]. This suggests that *Blastocystis* may play a role in promoting a more diverse and
366 stable microbial community. Greater microbial richness is often associated with improved health
367 outcomes, as a more diverse microbiota provides functional redundancy, enhancing the gut's
368 resilience to disruptions such as infections or dietary changes [34–36].

369 Beta diversity analysis revealed that the bacterial microbiota exhibited a distinct profile concerning
370 *Blastocystis* presence, suggesting that this protozoan may modulate both the structure and
371 composition of the gut microbiota (Fig. 1). The analysis also showed that among *Blastocystis*-
372 positive individuals, certain bacterial taxa, such as *Bacteroides uniformis*, *Oscillibacter* sp., and
373 *Prevotella copri*, were more prevalent, consistent with findings from previous studies. *B. uniformis*
374 is well-known for its role in carbohydrate metabolism and energy extraction from plant-based
375 diets, contributing to nutrient absorption and gut barrier integrity [37–39]. In this context, *B.*
376 *uniformis* has been shown to improve whole-body glucose disposal, increase butyrate production,
377 and restore the balance of intraepithelial lymphocytes and type-3 innate lymphoid cells in the
378 intestinal epithelium. These functions enhance both the metabolic and immunological properties

379 of the gut barrier, which is particularly beneficial in non-westernized rural populations with higher
380 fiber intake [37]. *Oscillibacter* has been associated with anti-inflammatory effects, which may
381 help protect against gut inflammation and promote overall well-being. In addition to these
382 properties, *Oscillibacter* has demonstrated potential benefits for lipid homeostasis and
383 cardiovascular function. By contributing to the regulation of lipid metabolism, it may play a key
384 role in maintaining metabolic balance, further supporting its protective effects on the host's overall
385 condition [8,40]. Furthermore, *Prevotella copri*, although associated with inflammation in certain
386 contexts, is a key indicator of diets rich in fiber and plant-based foods [11]. *P. copri* is also
387 recognized as an important SCFA-producing bacterium, which plays a crucial role in maintaining
388 proper metabolic functions in the gut and supporting energy processes in enterocytes [41,42]. The
389 increased abundance of SCFA-producing taxa in *Blastocystis*-positive individuals suggests that
390 *Blastocystis* may enhance these beneficial microbial functions, contributing to gut health.

391 These findings underscore the complex relationship between *Blastocystis* colonization, diet, and
392 gut bacterial microbiota, highlighting how the presence of *Blastocystis* may contribute to
393 microbiota diversity by promoting taxa linked to improved metabolic and immune functions. This
394 interaction could have positive health implications, particularly for individuals consuming fiber-
395 rich diets, as the promoted taxa may enhance nutrient absorption, immune responses, and gut
396 homeostasis. These effects are especially relevant in non-westernized rural populations, where diet
397 and lifestyle play a significant role in shaping microbiota composition [7,8,37,39,42–44].

398 Furthermore, *Blastocystis* burden levels appeared to be related to specific microbial taxa,
399 suggesting a potential dose-dependent relationship between *Blastocystis* burden and its impact on
400 the microbiota (Fig. 3). In examining *Blastocystis* burden groups (high, medium, and low), higher
401 *Blastocystis* burdens were related to taxa such as *Alistipes* and *Lachnospira*, both known for their
402 anti-inflammatory properties and role in maintaining gut homeostasis [45–47]. *Alistipes*, in
403 particular, has been linked to a reduced risk of inflammation and metabolic disorders, suggesting
404 that higher *Blastocystis* levels, along with other host conditions, may confer protective effects
405 against inflammatory processes [46]. In contrast, lower *Blastocystis* burdens were associated with
406 taxa such as *Akkermansia*, a bacterium recognized for maintaining the gut mucus layer and
407 improving metabolic health. These findings suggest that the interaction between *Blastocystis* and
408 the microbiota is complex and potentially modulated by the protozoan's abundance in the gut [48].

409 To accurately assess these relationships, it is essential to develop study designs and protocols based
410 on longitudinal cohorts. Such approaches would allow for a more dynamic evaluation of
411 *Blastocystis* colonization over time and its potential impact on gut microbiota composition.
412 Moreover, studies should not only focus on *Blastocystis* but also consider other common parasites
413 and luminal protozoa that may co-exist in individuals. These co-occurring organisms could interact
414 in agonistic or synergistic ways, influencing the observed microbiota changes. Investigating these
415 interactions would provide more precise assessments of *Blastocystis* burden and yield deeper
416 insights into the causal mechanisms and dynamics underlying its presence, as well as its broader
417 impact on the host's microbiota structure and composition.

418 We aimed to explore the eukaryotic microbiota concerning *Blastocystis* presence (Fig. 2). Our
419 findings revealed that *Blastocystis* colonization was associated with relevant changes in the
420 eukaryotic microbiota. In the *Blastocystis*-positive group, we observed an increased abundance of
421 *Entamoeba coli*, a commensal protozoan often considered benign [3]. This contrasts with
422 *Blastocystis*-negative individuals, who were more likely to harbor *Saccharomyces cerevisiae* and
423 *Candida albicans* (Fig. 2). There are a limited number of studies that involve the analysis of
424 eukaryotic microbiota; however, changes in fungal communities have been reported in conditions
425 such as irritable bowel syndrome (IBS), characterized by an enrichment of *Saccharomycetes* and
426 a decrease in alpha diversity, which is consistent with our findings [49]. Furthermore, while
427 *Candida albicans* is a normal component of the gut microbiota in healthy individuals, it has been
428 associated with mucosal diseases and can translocate into the bloodstream, potentially leading to
429 invasive, life-threatening infections, particularly in immunocompromised patients [50,51].
430 Additionally, *C. albicans* has been observed to contribute to the development of colitis in mouse
431 models and shows increased abundance in patients with Crohn's disease, although the pathogenic
432 mechanisms remain not fully understood [52]. These findings suggest a potentially beneficial and
433 complex interaction between *Blastocystis* and other eukaryotes; however, the level and type of
434 interaction among *Blastocystis*, other microbial eukaryotes (including fungi), and the host
435 microbiome remain unclear. Future studies should focus on exploring the eukaryotic component
436 of the gut microbiome as a whole, rather than targeting individual microbial species, to better
437 elucidate the role of eukaryotic microbiota within the gut ecosystem.

438 Further analysis regarding *Blastocystis* burdens groups revealed that the burden of *Blastocystis*
439 may be related to the abundance of specific eukaryotic taxa (Fig. 3). Higher *Blastocystis* burdens
440 were linked with genera such as *Issatchenkia*, *Pleurostomophora*, and *Citeromyces*. These genera,
441 likely stemming from the consumption of fermented foods and vegetables, may indicate a response
442 to or modulation by elevated *Blastocystis* levels [49,53,54]. These genera, while not extensively
443 studied, could contribute to the gut's eukaryotic diversity by promoting an anaerobic environment
444 and potentially interacting with other microbial components to maintain balance. However, their
445 impact on these interactions requires further analysis to determine whether these changes are
446 beneficial or detrimental to the host. The observed differences in eukaryotic taxa associated with
447 *Blastocystis* presence and burden underscore the protozoan's potential role in shaping the
448 eukaryotic microbiota [53,54]. Metagenomic and metabolomic approaches, particularly in
449 longitudinal prospective studies, are crucial for characterizing all microbiota components and
450 predicting functional changes. These methods allow for a comprehensive understanding of the
451 mechanisms and direction of changes mediated by *Blastocystis* presence and burden. By
452 integrating these approaches, it will be possible to establish causal links, identify metabolic
453 pathways affected by *Blastocystis*, and elucidate how these shifts impact host health, potentially
454 revealing key insights into the protozoan's role in modulating the gut ecosystem.

455 The random forest classifier's ability to predict *Blastocystis* colonization status based on
456 microbiota composition highlights its potential as a promising approach [55]. The model
457 demonstrates superior performance compared to random chance, validating its utility in
458 distinguishing between *Blastocystis*-positive and -negative individuals. The classifier's
459 performance, while showing some misclassification in training—particularly among positive
460 samples—suggests that the model effectively identifies key microbial indicators associated with
461 *Blastocystis* colonization. The model identified several taxa as critical for classifying *Blastocystis*
462 status (Fig. S3). Notably, and in line with the results presented earlier, *Faecalibacterium prausnitzii*
463 and *Bacteroides ovatus* were among the top taxa with high Mean Decrease in Gini values.
464 *Faecalibacterium prausnitzii* is well known for its anti-inflammatory properties and its critical role
465 in maintaining gut health, which may correspond with the observed microbiota stability in the
466 presence of *Blastocystis*. The prominence of these taxa suggests that *Blastocystis* colonization
467 could be linked to the promotion of beneficial microbial communities that contribute to gut
468 homeostasis.[56–58]. Similarly, *Bacteroides ovatus* is involved in the breakdown of complex

469 carbohydrates, contributing to a more balanced and diverse microbial environment. Likewise,
470 *Bacteroides thetaiotaomicron* and *Ruminococcus bromii*, both significant in the classifier, are
471 involved in complex carbohydrate digestion and the production of short-chain fatty acids, which
472 are crucial for gut health and homeostasis [5,8,56–61]. *Entamoeba coli*, another important taxon
473 discussed before, is a commensal eukaryote often found alongside *Blastocystis*. Its presence may
474 indicate a balanced eukaryotic community that can coexist with *Blastocystis* without causing
475 dysbiosis [3]. These findings suggest that the classifier could be a valuable tool for predicting
476 *Blastocystis* colonization by analyzing the relative abundances of specific taxa. For instance, a
477 high presence of *Faecalibacterium prausnitzii* or *Bacteroides ovatus* might indicate a higher
478 likelihood of *Blastocystis* colonization. This predictive capability could provide key insights into
479 microbial interactions in future research, potentially aiding in the development of targeted
480 interventions or treatments aimed at maintaining or improving gut health. By leveraging these
481 microbial signatures, we may better understand the functional dynamics of *Blastocystis* within the
482 gut ecosystem.

483 It is important to acknowledge the limitations of our study. First, the sample size was relatively
484 small, and we were unable to collect detailed information regarding key variables, such as diet.
485 The hypothetical role of *Blastocystis* suggested through our analysis necessitates further
486 investigation using longitudinal studies that incorporate metagenomic, metabolomic, and
487 immunological approaches, alongside comprehensive data on dietary habits, lifestyle factors, and
488 comorbidities. Such information is crucial for making accurate inferences about *Blastocystis*-host
489 interactions, particularly considering the co-occurrence of other eukaryotes that may influence the
490 observed changes [11,62]. Further research is needed to elucidate the mechanisms underlying the
491 interactions between *Blastocystis* and the host microbiota. While our study employed a
492 metabarcoding approach to characterize both bacterial and eukaryotic communities, this method
493 does not enable predictions of metabolic and functional changes that may elucidate the dynamics
494 involved in these interactions. Larger sample sizes and prospective longitudinal studies are
495 essential to determine the directionality and causality of these relationships. Although we
496 identified several relevant taxa, particularly within fungal communities, a deeper understanding of
497 the significance of these specific taxa in the microbiota is necessary to clarify their potential
498 positive impacts on host health. This comprehensive approach will enhance our ability to interpret
499 the role of *Blastocystis* and its possible effects on the gut ecosystem.

500 Our findings have significant implications for understanding the role of *Blastocystis* in gut health.
501 Rather than being a pathogen, *Blastocystis* may act as a commensal organism that supports a
502 diverse and functionally rich gut microbiota [5–8]. The presence of *Blastocystis* was related to taxa
503 that promote nutrient absorption, immune regulation, and protection against pathogens, all of
504 which are critical for maintaining overall health. In non-westernized rural populations, where diet
505 and environmental factors play a significant role in shaping the microbiota, *Blastocystis* may
506 enhance the gut's ability to adapt to these influences, contributing to a healthier microbiome [7].
507 The potential for *Blastocystis* to modulate the microbiota beneficially also opens the door to new
508 therapeutic approaches. By promoting the growth of beneficial bacteria and maintaining a balanced
509 eukaryotic community, *Blastocystis* may serve as a marker of gut health and could be used as a
510 target for microbiota-based therapies [7]. Future research should focus on exploring the
511 mechanisms by which *Blastocystis* interacts with the microbiota and the specific conditions under
512 which it exerts its beneficial effects.

513 In conclusion, our study suggests that *Blastocystis* colonization is linked with a more diverse and
514 functionally rich gut microbiota, challenging the traditional view of *Blastocystis* as a pathogen.
515 The presence of *Blastocystis* was linked to taxa that play critical roles in gut health, particularly in
516 non-westernized rural populations where diet and environmental exposures differ from urban
517 settings. By fostering a diverse microbial community and promoting beneficial taxa, *Blastocystis*
518 may act as a commensal organism that supports gut health and resilience. Further research is
519 needed to fully understand the role of *Blastocystis* in gut microbiota dynamics and its potential
520 implications for human health.

521

522 **Figure Legends**

523 **Figure 1.** Bacterial profile 16S rRNA. (a) Diversity metrics—observed richness, Pielou, Shannon,
524 and Simpson indices—compared between *Blastocystis*-positive and -negative groups. Statistical
525 analyses were performed using the Kruskal-Wallis (KW) test, followed by a post-hoc Mann-
526 Whitney-Wilcoxon (MWW) test for multiple comparisons. The plots show interquartile ranges
527 (IQR; boxes), medians (lines within the boxes), and the lowest and highest values within 1.5 times
528 the IQR from the first and third quartiles (whiskers). (b) Principal coordinates analysis (PCoA)
529 ordination of Bray-Curtis distances of microbial communities, comparing *Blastocystis*-positive

530 and -negative groups. Permutational analysis of variance (PERMANOVA) was performed using
531 the adonis function from the vegan package. *** p-values <0.001. (c) Boxplot of differentially
532 abundant taxa across *Blastocystis*-positive and -negative groups, evaluating distribution patterns.
533 The threshold for the logarithmic LDA score was 2.0, with a maximum Kruskal-Wallis
534 (KW)/Wilcoxon Test value of 0.01. (d) Volcano plots showing differentially abundant taxa
535 between *Blastocystis*-positive and -negative groups, based on DESeq2 analysis.

536 **Figure 2.** Eukaryotic profile 18S rRNA. (a) Diversity metrics—observed richness, Pielou,
537 Shannon, and Simpson indices—compared between *Blastocystis*-positive and -negative groups.
538 Statistical analyses were performed using the Kruskal-Wallis (KW) test, followed by a post-hoc
539 Mann-Whitney-Wilcoxon (MWW) test for multiple comparisons. The plots show interquartile
540 ranges (IQR; boxes), medians (lines within the boxes), and the lowest and highest values within
541 1.5 times the IQR from the first and third quartiles (whiskers). (b) Principal coordinates analysis
542 (PCoA) ordination of Bray-Curtis distances of microbial communities, comparing *Blastocystis*-
543 positive and -negative groups. Permutational analysis of variance (PERMANOVA) was performed
544 using the adonis function from the vegan package. *** p-values <0.001. (c) Boxplot of
545 differentially abundant taxa across *Blastocystis*-positive and -negative groups, evaluating
546 distribution patterns. The threshold for the logarithmic LDA score was 2.0, with a maximum
547 Kruskal-Wallis (KW)/Wilcoxon Test value of 0.01. (d) Volcano plots showing differentially
548 abundant taxa between *Blastocystis*-positive and -negative groups, based on DESeq2 analysis.

549 **Figure 3.** Microbiota profile across burden groups of *Blastocystis*-positive samples. Bar charts
550 display the relative abundance of the top taxa at the family level between burden groups of
551 *Blastocystis*-positive samples, based on (a) 16S rRNA data and (b) 18S rRNA data. Linear
552 discriminant analysis effect size (LEfSe) identifying taxa enriched in burden groups of
553 *Blastocystis*-positive samples, corresponding to (c) 16S rRNA data and (d) 18S rRNA data. The
554 threshold for the logarithmic LDA score was 2.0, with a maximum Kruskal-Wallis (KW)/Wilcoxon
555 Test value of 0.01.

556 **Figure S1.** Geographical sampling area corresponding to the rural region of Cauca, Colombia.

557 **Figure S2.** (a) Proportion of samples by total reads showing abundance by phylum. (b) Diversity
558 metrics—richness, Shannon, and Simpson indices—compared between *Blastocystis*-positive and
559 -negative groups. (c) Bar chart displaying the relative abundance of the top taxa at the family level

560 for individual samples in *Blastocystis*-positive and -negative groups. (d) Bar chart showing the
561 relative abundance of the top taxa at the family level aggregated by group.

562 **Figure S3.** (a) Bar chart showing the relative abundance of the top taxa at the family level between
563 *Blastocystis*-positive and -negative groups. (b) Linear discriminant analysis effect size (LEfSe)
564 identifying taxa enriched in *Blastocystis*-positive and -negative groups, with a bar plot showing
565 enriched taxa at the genus level.

566 **Figure S4.** (a) Bar chart showing the relative abundance of the top taxa at the family level between
567 *Blastocystis*-positive and -negative groups. (b) Linear discriminant analysis effect size (LEfSe)
568 identifying taxa enriched in *Blastocystis*-positive and -negative groups, with a bar plot showing
569 enriched taxa at the genus level.

570 **Figure S5.** Diversity metrics—observed richness, Pielou, Shannon, and Simpson indices—are
571 compared between burden groups of *Blastocystis*-positive samples, corresponding to (a) 16S rRNA
572 data and (b) 18S rRNA data. Statistical analyses were performed using the Kruskal-Wallis (KW)
573 test, followed by a post-hoc Mann-Whitney-Wilcoxon (MWW) test for multiple comparisons. The
574 plots show interquartile ranges (IQR; boxes), medians (lines within the boxes), and the lowest and
575 highest values within 1.5 times the IQR from the first and third quartiles (whiskers).

576 **Figure S6.** A random forest model was trained to classify *Blastocystis* colonization status. The
577 figure highlights the 20 most important taxa identified based on the Mean Decrease in Gini Index,
578 reflecting their contribution to the model's predictive accuracy.

579 **Table S1.** Summary of sequence results and classification in *Blastocystis*-positive and -negative
580 groups, as well as across different burden groups. The table provides an overview of total reads,
581 and classification accuracy for each group.

582 **Data availability**

583 The code for generating the figures and the analysis is available
584 at https://github.com/scastanedag/Blastocystis_burdens.git.

585

586 **Declaration of Competing Interest**

587 The authors declare that no competing interests exist.

588

589 **References**

590 1. Stensvold CR, Clark CG. Current status of Blastocystis: A personal view. *Parasitol Int.*
591 2016;65:763–71.

592 2. Wawrzyniak I, Poirier P, Texier C, Delbac F, Viscogliosi E, Dionigia M, et al. Blastocystis, an
593 unrecognized parasite: An overview of pathogenesis and diagnosis. *Ther Adv Infect Dis.*
594 2013;1:167–78.

595 3. Stensvold CR, van der Giezen M. Associations between Gut Microbiota and Common
596 Luminal Intestinal Parasites. *Trends Parasitol* [Internet]. Elsevier Ltd; 2018;34:369–77.
597 Available from: <http://dx.doi.org/10.1016/j.pt.2018.02.004>

598 4. Nourrisson C, Scanzi J, Pereira B, NkoudMongo C, Wawrzyniak I, Cian A, et al. Blastocystis
599 is associated with decrease of fecal microbiota protective bacteria: Comparative analysis
600 between patients with irritable bowel syndrome and control subjects. *PLoS One.* 2014;9.

601 5. Castañeda S, Muñoz M, Villamizar X, Hernández PC, Vásquez LR, Tito RY, et al. Microbiota
602 characterization in Blastocystis-colonized and Blastocystis-free school-age children from
603 Colombia. *Parasit Vectors* [Internet]. BioMed Central Ltd; 2020 [cited 2021 Mar 12];13:521.
604 Available from: [https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-020-](https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-020-04392-9)
605 [04392-9](https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-020-04392-9)

606 6. Deng L, Tan KSW. Interactions between Blastocystis subtype ST4 and gut microbiota in vitro.
607 *Parasites Vectors* 2022 151 [Internet]. BioMed Central; 2022 [cited 2022 Mar 13];15:1–9.
608 Available from: <https://link.springer.com/articles/10.1186/s13071-022-05194-x>

609 7. Piperni E, Nguyen LH, Manghi P, Kim H, Pasolli E, Andreu-Sánchez S, et al. Intestinal
610 Blastocystis is linked to healthier diets and more favorable cardiometabolic outcomes in 56,989
611 individuals from 32 countries. *Cell* [Internet]. Elsevier B.V.; 2024 [cited 2024 Sep 16];187:4554-
612 4570.e18. Available from: <http://www.cell.com/article/S0092867424006925/fulltext>

613 8. Stensvold CR, Sørland BA, Berg RPKD, Andersen LO, van der Giezen M, Bowtell JL, et al.

614 Stool Microbiota Diversity Analysis of Blastocystis-Positive and Blastocystis-Negative
615 Individuals. *Microorg* 2022, Vol 10, Page 326 [Internet]. Multidisciplinary Digital Publishing
616 Institute; 2022 [cited 2022 Mar 13];10:326. Available from: [https://www.mdpi.com/2076-](https://www.mdpi.com/2076-2607/10/2/326/htm)
617 [2607/10/2/326/htm](https://www.mdpi.com/2076-2607/10/2/326/htm)

618 9. Audebert C, Even G, Cian A, Blastocystis Investigation Group, Loywick A, Merlin S, et al.
619 Colonization with the enteric protozoa *Blastocystis* is associated with increased diversity of
620 human gut bacterial microbiota. *Sci Rep* [Internet]. Nature Publishing Group; 2016;6:1–11.
621 Available from: <http://dx.doi.org/10.1038/srep25255>

622 10. Beghini F, Pasolli E, Truong TD, Putignani L, Cacciò SM, Segata N. Large-scale
623 comparative metagenomics of *Blastocystis*, a common member of the human gut microbiome.
624 *ISME J*. 2017;11:2848–63.

625 11. Parfrey LW, Walters WA, Lauber CL, Clemente JC, Berg-Lyons D, Teiling C, et al.
626 Communities of microbial eukaryotes in the mammalian gut within the context of environmental
627 eukaryotic diversity. *Front Microbiol*. 2014;5:1–13.

628 12. Higuera A, Villamizar X, Herrera G, Giraldo JC, Vasquez-A LR, Urbano P, et al. Molecular
629 detection and genotyping of intestinal protozoa from different biogeographical regions of
630 Colombia. *PeerJ* [Internet]. 2020 [cited 2022 Jun 2];e8554. Available from:
631 <https://peerj.com/articles/8554>

632 13. Villamizar X, Higuera A, Herrera G, Vasquez-A LR, Buitron L, Muñoz LM, et al. Molecular
633 and descriptive epidemiology of intestinal protozoan parasites of children and their pets in
634 Cauca, Colombia: A cross-sectional study. *BMC Infect Dis*. *BMC Infectious Diseases*;
635 2019;19:1–11.

636 14. Tito RY, Chaffron S, Caenepeel C, Lima-Mendez G, Wang J, Vieira-Silva S, et al.
637 Population-level analysis of *Blastocystis* subtype prevalence and variation in the human gut
638 microbiota. *Gut*. 2019;68:1180–9.

639 15. Castañeda S, Acosta CP, Vasquez-A LR, Patiño LH, Mejía R, Ramírez JD. Molecular
640 detection of intestinal parasites in a rural community of Colombia: A one health approach to
641 explore potential environmental–zoonotic transmission. *Zoonoses Public Health* [Internet]. John

642 Wiley & Sons, Ltd; 2024 [cited 2024 Sep 16];71:723–35. Available from:
643 <https://onlinelibrary.wiley.com/doi/full/10.1111/zph.13138>

644 16. Hernández-Castro C, Maloney JG, Agudelo-López SP, Toro-Londoño MA, Botero-Garcés
645 JH, Orozco MC, et al. Identification and validation of novel Blastocystis subtype ST41 in a
646 Colombian patient undergoing colorectal cancer screening. *J Eukaryot Microbiol* [Internet]. John
647 Wiley & Sons, Ltd; 2023 [cited 2023 Oct 2];70:e12978. Available from:
648 <https://onlinelibrary.wiley.com/doi/full/10.1111/jeu.12978>

649 17. Giraldo-Gómez JM, Lora F, Henao LH, Mejía S, Gómez-Marín JE. Prevalence of giardiasis
650 and intestinal parasites in pre-school children from homes being attended as part of a state
651 programme in Armenia, Colombia. *Rev Salud Publica (Bogota)*. 2005;7:327–38.

652 18. Mejia R, Damania A, Jeun R, Bryan PE, Vargas P, Juarez M, et al. Impact of intestinal
653 parasites on microbiota and cobalamin gene sequences: A pilot study. *Parasit Vectors* [Internet].
654 BioMed Central; 2020 [cited 2021 Apr 5];13:1–9. Available from:
655 <https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-020-04073-7>

656 19. Toro-Londono MA, Bedoya-Urrego K, Garcia-Montoya GM, Galvan-Diaz AL, Alzate JF.
657 Intestinal parasitic infection alters bacterial gut microbiota in children. *PeerJ*. 2019;2019:1–24.

658 20. Barash NR, Maloney JG, Singer SM, Dawson SC. Giardia alters commensal microbial
659 diversity throughout the murine gut. *Infect Immun* [Internet]. American Society for
660 Microbiology; 2017 [cited 2021 Jul 28];85. Available from: <https://journals.asm.org/journal/iai>

661 21. Morton ER, Lynch J, Froment A, Lafosse S, Heyer E, Przeworski M, et al. Variation in Rural
662 African Gut Microbiota Is Strongly Correlated with Colonization by Entamoeba and Subsistence.
663 *PLOS Genet* [Internet]. Public Library of Science; 2015 [cited 2022 Mar 16];11:e1005658.
664 Available from: <https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1005658>

665 22. Yu Y, Lee C, Kim J, Hwang S. Group-specific primer and probe sets to detect methanogenic
666 communities using quantitative real-time polymerase chain reaction. *Biotechnol Bioeng*
667 [Internet]. Biotechnol Bioeng; 2005 [cited 2024 Sep 16];89:670–9. Available from:
668 <https://pubmed.ncbi.nlm.nih.gov/15696537/>

669 23. Krogsgaard LR, Andersen LOB, Johannesen TB, Engsbro AL, Stensvold CR, Nielsen HV, et

670 al. Characteristics of the bacterial microbiome in association with common intestinal parasites in
671 irritable bowel syndrome. *Clin Transl Gastroenterol* [Internet]. American College of
672 Gastroenterology; 2018 [cited 2024 Sep 16];9:161. Available from: [/pmc/articles/PMC6006308/](#)

673 24. Stensvold CR, Berg RPKD, Maloney JG, Molokin A, Santin M. Molecular characterization
674 of *Blastocystis* and *Entamoeba* of muskoxen and sheep in Greenland. *Int J Parasitol*. Pergamon;
675 2023;53:673–85.

676 25. Stensvold CR, Ahmed UN, Andersen LOBB, Nielsen HV. Development and evaluation of a
677 genus-specific, probe-based, internal-process-controlled real-time PCR assay for sensitive and
678 specific detection of *Blastocystis* spp. *J Clin Microbiol* [Internet]. 2012 [cited 2019 Oct
679 4];50:1847–51. Available from: <https://journals.asm.org/doi/full/10.1128/JCM.00007-12>

680 26. McMurdie PJ, Holmes S. Phyloseq: An R Package for Reproducible Interactive Analysis and
681 Graphics of Microbiome Census Data. *PLoS One*. 2013;8.

682 27. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic
683 biomarker discovery and explanation. *Genome Biol* [Internet]. BioMed Central; 2011 [cited
684 2023 Mar 16];12:R60. Available from: [/pmc/articles/PMC3218848/](#)

685 28. Rune C, Lebbad M, Hansen A, Beser J, Belkessa S, Brien LO, et al. Differentiation of
686 *Blastocystis* and parasitic archamoebids encountered in untreated wastewater samples by
687 amplicon-based next-generation sequencing. *Parasite Epidemiol Control* [Internet]. The Authors;
688 2020;9:e00131. Available from: <https://doi.org/10.1016/j.parepi.2019.e00131>

689 29. Su X. Elucidating the Beta-Diversity of the Microbiome: from Global Alignment to Local
690 Alignment. *mSystems*. American Society for Microbiology; 2021;6.

691 30. Community Ecology Package [R package vegan version 2.6-4]. Comprehensive R Archive
692 Network (CRAN); 2022 [cited 2023 Mar 17]; Available from: [https://cran.r-](https://cran.r-project.org/package=vegan)
693 [project.org/package=vegan](https://cran.r-project.org/package=vegan)

694 31. RStudio Team. RStudio: Integrated Development for R. RStudio [Internet]. 2020. [cited 2021
695 Mar 4]. Available from: <https://rstudio.com/>

696 32. Knights D, Costello EK, Knight R. Supervised classification of human microbiota. *FEMS*
697 *Microbiol Rev*. 2011;35:343–59.

- 698 33. Cao Y, Geddes TA, Yang JYH, Yang P. Ensemble deep learning in bioinformatics. *Nat.*
699 *Mach. Intell. Nature Research*; 2020. p. 500–8.
- 700 34. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human
701 gut microbiome correlates with metabolic markers. *Nature* [Internet]. Nature Publishing Group;
702 2013 [cited 2021 May 6];500:541–6. Available from:
703 <https://www.nature.com/articles/nature12506>
- 704 35. Sahu SC, Hayes AW. *The Human Microbiome : History and Future*. 2020;406–11.
- 705 36. de Vos WM, De Vos EAJ. Role of the intestinal microbiome in health and disease: From
706 correlation to causation. *Nutr Rev.* 2012;70:45–56.
- 707 37. López-Almela I, Romani-Pérez M, Bullich-Vilarrubias C, Benítez-Páez A, Gómez Del
708 Pulgar EM, Francés R, et al. *Bacteroides uniformis* combined with fiber amplifies metabolic and
709 immune benefits in obese mice. *Gut Microbes* [Internet]. Taylor & Francis; 2021 [cited 2024 Sep
710 16];13:1–20. Available from:
711 <https://www.tandfonline.com/doi/abs/10.1080/19490976.2020.1865706>
- 712 38. Del Pulgar EMG, Benítez-Páez A, Sanz Y. Safety Assessment of *Bacteroides Uniformis*
713 CECT 7771, a Symbiont of the Gut Microbiota in Infants. *Nutr* 2020, Vol 12, Page 551
714 [Internet]. Multidisciplinary Digital Publishing Institute; 2020 [cited 2024 Sep 16];12:551.
715 Available from: <https://www.mdpi.com/2072-6643/12/2/551/htm>
- 716 39. Li Q, Lauber CL, Czarnecki-Maulden G, Pan Y, Hannah SS. Effects of the dietary protein
717 and carbohydrate ratio on gut microbiomes in dogs of different body conditions. *MBio* [Internet].
718 American Society for Microbiology; 2017 [cited 2023 Mar 20];8. Available from:
719 <https://journals.asm.org/doi/10.1128/mBio.01703-16>
- 720 40. Li C, Stražar M, Mohamed AMT, Pacheco JA, Walker RL, Lebar T, et al. Gut microbiome
721 and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria.
722 *Cell* [Internet]. Elsevier B.V.; 2024 [cited 2024 Sep 16];187:1834-1852.e19. Available from:
723 <http://www.cell.com/article/S0092867424003052/fulltext>
- 724 41. Martin I, Djuardi Y, Sartono E, Rosa BA, Supali T, Mitreva M, et al. Dynamic changes in
725 human-gut microbiome in relation to a placebo-controlled anthelmintic trial in Indonesia. *PLoS*

726 Negl Trop Dis [Internet]. Public Library of Science; 2018;12:1–19. Available from:
727 <http://10.0.5.91/journal.pntd.0006620>

728 42. Gorvitovskaia A, Holmes SP, Huse SM. Interpreting Prevotella and Bacteroides as
729 biomarkers of diet and lifestyle. Microbiome [Internet]. Microbiome; 2016 [cited 2024 Aug 9];4.
730 Available from: <https://pubmed.ncbi.nlm.nih.gov/27068581/>

731 43. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med.
732 Genome Medicine; 2016;8.

733 44. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of
734 the human gut microbiome. Nature. 2011;473:174–80.

735 45. Hu Y, Chen J, Xu Y, Zhou H, Huang P, Ma Y, et al. Alterations of Gut Microbiome and
736 Metabolite Profiling in Mice Infected by *Schistosoma japonicum*. Front Immunol.
737 2020;11:569727.

738 46. Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A. The Genus Alistipes: Gut
739 Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health. Front
740 Immunol. Frontiers Media S.A.; 2020;11:906.

741 47. Jensen AN, Mejer H, Mølbak L, Langkjær M, Jensen TK, Angen Ø, et al. The effect of a diet
742 with fructan-rich chicory roots on intestinal helminths and microbiota with special focus on
743 Bifidobacteria and Campylobacter in piglets around weaning. Animal. England; 2011;5:851–60.

744 48. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk
745 between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc
746 Natl Acad Sci U S A [Internet]. National Academy of Sciences; 2013 [cited 2022 May
747 16];110:9066–71. Available from: [/pmc/articles/PMC3670398/](https://pubmed.ncbi.nlm.nih.gov/24326961/)

748 49. Nourrisson C, Scanzi J, Brunet J, Delbac F, Dapoigny M, Poirier P. Prokaryotic and
749 Eukaryotic Fecal Microbiota in Irritable Bowel Syndrome Patients and Healthy Individuals
750 Colonized With Blastocystis. Front Microbiol. 2021;12.

751 50. Mason KL, Downward JRE, Mason KD, Falkowski NR, Eaton KA, Kao JY, et al. Candida
752 albicans and bacterial microbiota interactions in the cecum during recolonization following
753 broad-spectrum antibiotic therapy. Infect Immun [Internet]. 2012 [cited 2021 Jul 21];80:3371–

754 80. Available from: <http://www.r-project.org>

755 51. Pérez JC. The interplay between gut bacteria and the yeast *Candida albicans*. *Gut Microbes*
756 [Internet]. Taylor & Francis; 2021 [cited 2024 Sep 16];13. Available from:
757 <https://www.tandfonline.com/doi/abs/10.1080/19490976.2021.1979877>

758 52. Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions
759 and role in gastrointestinal diseases. *Nat Rev Gastroenterol Hepatol* [Internet]. Springer US;
760 2019;16:331–45. Available from: <http://dx.doi.org/10.1038/s41575-019-0121-2>

761 53. Jiang Y, Luo T, Tang Y, Chen S, Ni H, Chen Q, et al. Isolation of a novel characterized
762 *Issatchenkia terricola* from red raspberry fruits on the degradation of citric acid and enrichment
763 of flavonoid and volatile profiles in fermented red raspberry juice. *Food Sci Hum Wellness*.
764 Elsevier; 2022;11:1018–27.

765 54. Li Y, Wu Z, Li R, Miao Y, Weng P, Wang L. Integrated transcriptomic and proteomic
766 analysis of the acetic acid stress in *Issatchenkia orientalis*. *J Food Biochem* [Internet]. John
767 Wiley & Sons, Ltd; 2020 [cited 2024 Sep 18];44:e13203. Available from:
768 <https://onlinelibrary.wiley.com/doi/full/10.1111/jfbc.13203>

769 55. Marcos-Zambrano LJ, Karaduzovic-Hadziabdic K, Loncar Turukalo T, Przymus P,
770 Trajkovik V, Aasmets O, et al. Applications of Machine Learning in Human Microbiome
771 Studies: A Review on Feature Selection, Biomarker Identification, Disease Prediction and
772 Treatment. *Front Microbiol* [Internet]. Frontiers; 2021 [cited 2021 Feb 25];12:313. Available
773 from: <https://www.frontiersin.org/articles/10.3389/fmicb.2021.634511/full>

774 56. Loh G, Blaut M, Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel
775 diseases Role of commensal gut bacteria in inflammatory bowel diseases © 2012 Landes
776 Bioscience . Do not distribute. 2012;0976.

777 57. Bermingham EN, Maclean P, Thomas DG, Cave NJ, Young W. Key bacterial families
778 (*Clostridiaceae*, *Erysipelotrichaceae* and *Bacteroidaceae*) are related to the digestion of protein
779 and energy in dogs. *PeerJ*. PeerJ Inc.; 2017;2017.

780 58. Watterlot L, Lakhdari O, Bermu LG, Sokol H, Bridonneau C, Furet J, et al. *Faecalibacterium*
781 *prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of

782 Crohn disease patients ' ne. 2008;105.

783 59. Wexler HM. Bacteroides: The good, the bad, and the nitty-gritty. *Clin Microbiol Rev.*
784 2007;20:593–621.


785 60. Andersen LOB, Bonde I, Nielsen HBHB, Stensvold CR. A retrospective metagenomics
786 approach to studying *Blastocystis*. *FEMS Microbiol Ecol.* 2015;91:1–9.

787 61. Pasolli E, Schiffer L, Manghi P, Renson A, Obenchain V, Truong DT, et al. Accessible,
788 curated metagenomic data through ExperimentHub. *Nat Methods [Internet]. Nature Publishing*
789 *Group*; 2017 [cited 2022 Jan 28];14:1023–4. Available from:
790 <https://waldronlab.github.io/curated->


791 62. Chabé M, Lokmer A, Ségurel L. Gut Protozoa: Friends or Foes of the Human Gut
792 Microbiota? *Trends Parasitol.* 2017;33:925–34.

793


a.




b.



c.




d.




total = 508 variables


a.




b.



c.




d.




total = 431 variables


a.




b.




c.




d.







a.




b.




c.




d.




a.




b.




a.




b.




a.



b.



Most important OTUs for classifying Blastocytis colonization



sample	<i>Blastocystis</i>_Illumina	Blastocystis_reads	na lo	Burden_Illumina
P10	Positive	155	5.0499	Low
P100	Negative	90	4.5109	Negative
P101	Negative	2	1.0986	Negative
P102	Negative	0	0	Negative
P103	Positive	5538	8.6196	Middle
P105	Negative	2	1.0986	Negative
P106	Positive	5799	8.6656	Middle
P108	Positive	1354	7.2116	Middle
P11	Positive	151	5.0239	Low
P110	Positive	860	6.7581	Middle
P111	Positive	7239	8.8874	High
P113	Negative	3	1.3863	Negative
P114	Positive	205	5.3279	Low
P116	Negative	1	0.6931	Negative
P117	Positive	681	6.525	Low
P118	Positive	707	6.5624	Middle
P119	Negative	2	1.0986	Negative
P12	Positive	29299	10.2853	High
P120	Negative	4	1.6094	Negative
P13	Positive	40782	10.616	High
P14	Positive	6438	8.7701	High
P18	Positive	33422	10.417	High
P19	Positive	30841	10.3366	High
P20	Negative	88	4.4886	Negative
P22	Positive	327	5.793	Low
P27	Positive	1837	7.5164	Middle
P28	Positive	1540	7.3402	Middle
P30	Negative	19	2.9957	Negative
P31	Positive	1262	7.1412	Middle
P32	Positive	5228	8.562	Middle
P33	Negative	45	3.8286	Negative
P34	Positive	502	6.2206	Low
P35	Positive	3076	8.0317	Middle
P36	Negative	11	2.4849	Negative
P37	Positive	8088	8.9983	High
P38	Positive	4503	8.4127	Middle
P39	Negative	9	2.3026	Negative
P40	Negative	30	3.434	Negative
P42	Negative	3	1.3863	Negative
P43	Positive	481	6.1779	Low
P44	Negative	3	1.3863	Negative
P45	Negative	3	1.3863	Negative
P46	Negative	83	4.4308	Negative

P47	Negative	11	2.4849	Negative
P48	Positive	1771	7.4799	Middle
P50	Positive	2251	7.7196	Middle
P51	Negative	2	1.0986	Negative
P52	Positive	1112	7.0148	Middle
P53	Negative	21	3.091	Negative
P54	Negative	1	0.6931	Negative
P55	Negative	3	1.3863	Negative
P57	Negative	38	3.6636	Negative
P58	Positive	116	4.7622	Low
P59	Negative	24	3.2189	Negative
P60	Positive	23421	10.0614	High
P61	Negative	14	2.7081	Negative
P62	Negative	13	2.6391	Negative
P64	Positive	1246	7.1285	Middle
P65	Positive	27841	10.2343	High
P66	Negative	24	3.2189	Negative
P68	Negative	0	0	Negative
P69	Negative	0	0	Negative
P70	Negative	0	0	Negative
P71	Negative	0	0	Negative
P72	Negative	0	0	Negative
P73	Negative	0	0	Negative
P74	Positive	6441	8.7706	High
P75	Positive	4885	8.4941	Middle
P77	Negative	24	3.2189	Negative
P78	Negative	1	0.6931	Negative
P79	Positive	3321	8.1083	Middle
P80	Positive	3390	8.1289	Middle
P81	Positive	3258	8.0892	Middle
P82	Negative	4	1.6094	Negative
P83	Negative	0	0	Negative
P84	Positive	143	4.9698	Low
P85	Negative	0	0	Negative
P87	Negative	3	1.3863	Negative
P88	Negative	0	0	Negative
P89	Negative	0	0	Negative
P9	Positive	110	4.7095	Low
P90	Negative	100	4.6151	Negative
P91	Negative	0	0	Negative
P94	Negative	0	0	Negative
P95	Negative	6	1.9459	Negative
P97	Negative	13	2.6391	Negative
P98	Negative	1	0.6931	Negative

P99	Negative	68	4.2341	Negative
-----	----------	----	--------	----------

6.2. Capítulo 2

Objetivo 3: Caracterizar los cambios en el microbioma intestinal del hospedero asociados a la infección por el protozoo *Trypanosoma cruzi* en un modelo animal a partir de un enfoque metagenómico.

Para cumplir con el objetivo 3, en este estudio se propuso evaluar el impacto de la infección por *T. cruzi* en la composición y función del microbioma intestinal en un modelo murino. Para evaluar esta interacción, se utilizó un modelo murino en el que se infectaron ratones de las cepas BALB/c y C57BL/6 con la cepa Tulahuen TcVI de *Trypanosoma cruzi*. Posterior a la infección, se recolectaron muestras fecales para analizar la composición del microbioma intestinal mediante una aproximación metagenómica. Además, se realizaron análisis metagenómicos para reconstruir genomas bacterianos y determinar las funciones metabólicas de las comunidades bacterianas.

Los resultados revelaron alteraciones significativas en la composición y función del microbioma intestinal en los ratones infectados con *T. cruzi*. Se observó una alteración en la estructura de la comunidad microbiana, con una disminución en la abundancia de géneros como *Bacteroides thetaiotaomicron*, *Faecalibaculum rodentium* y *Lactobacillus johnsonii*, que son importantes productores de ácidos grasos de cadena corta (AGCC) y que desempeñan un papel clave en el mantenimiento de la integridad de la barrera intestinal. Por el contrario, se observó un aumento en la abundancia de géneros como *Akkermansia muciniphila* y *Staphylococcus xylosus*, que se han asociado con procesos inflamatorios y desregulación inmunitaria. Los análisis metagenómicos de predicción funcional revelaron una disminución en la abundancia de genes implicados en la síntesis de lípidos y de aminoácidos, lo que sugiere una alteración en las capacidades metabólicas de la microbiota intestinal en los animales infectados. Adicionalmente, se reconstruyeron genomas ensamblados a partir de datos metagenómicos (MAGs) de alta calidad de *L. johnsonii*, *A. muciniphila* entre otras especies, confirmando, cambios funcionales asociados a vías metabólicas que se ven directamente afectadas por la pérdida de abundancia de taxones bacterianos específicos.



Estos hallazgos sugieren que la infección por *T. cruzi* induce un desequilibrio en el microbioma intestinal, que puede contribuir a la patogénesis de la enfermedad de Chagas. Los mecanismos por los cuales *T. cruzi* altera el microbioma intestinal aún no están completamente esclarecidos, pero se han propuesto varios mecanismos, como la competencia por nutrientes, la producción de metabolitos tóxicos y la modulación de la respuesta inmunitaria del hospedero. La comprensión de las interacciones entre el parásito, el hospedero y el microbioma intestinal abre nuevas perspectivas para el desarrollo de estrategias terapéuticas basadas en la modulación de esta microbiota intestinal. Futuras investigaciones deben centrarse en identificar los mecanismos moleculares que subyacen a la disbiosis intestinal inducida por *T. cruzi* y en evaluar el potencial terapéutico de los probióticos, prebióticos y otros tratamientos dirigidos a la microbiota intestinal.

Como producto de este capítulo se adjunta el siguiente artículo científico:

Artículo 3: Castañeda S, Muñoz M, Hotez PJ, Bottazzi ME, Paniz-Mondolfi AE, Jones KM, Mejia R, Poveda C, Ramírez JD. Microbiome Alterations Driven by *Trypanosoma cruzi* Infection in Two Disjunctive Murine Models. Microbiology Spectrum [Internet]. 2023 [cited 2023 Jun 16];11(3). <https://doi.org/10.1128/spectrum.00199-23>



Microbiome Alterations Driven by *Trypanosoma cruzi* Infection in Two Disjunctive Murine Models

Sergio Castañeda,^a  Marina Muñoz,^a Peter J. Hotez,^{b,c,d,e} Maria Elena Bottazzi,^{b,c,d,e} Alberto E. Paniz-Mondolfi,^{f,g} Kathryn M. Jones,^{b,c,d}  Rojelio Mejia,^{b,c} Cristina Poveda,^{b,c}  Juan David Ramírez^{a,f}

^aCentro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia

^bDepartment of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston, Texas, USA

^cTexas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, Texas, USA

^dDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA

^eDepartment of Biology, Baylor University, Waco, Texas, USA

^fMolecular Microbiology Laboratory, Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

^gIncubadora Venezolana de la Ciencia, Barquisimeto, Venezuela

ABSTRACT Alterations caused by *Trypanosoma cruzi* in the composition of gut microbiome may play a vital role in the host-parasite interactions that shapes physiology and immune responses against infection. Thus, a better understanding of this parasite-host-microbiome interaction may yield relevant information in the comprehension of the pathophysiology of the disease and the development of new prophylactic and therapeutic alternatives. Therefore, we implemented a murine model with two mice strains (BALB/c and C57BL/6) to evaluate the impact of *Trypanosoma cruzi* (Tulahuen strain) infection on the gut microbiome utilizing cytokine profiling and shotgun metagenomics. Higher parasite burdens were observed in cardiac and intestinal tissues, including changes in anti-inflammatory (interleukin-4 [IL-4] and IL-10) and proinflammatory (gamma interferon, tumor necrosis factor alpha, and IL-6) cytokines. Bacterial species such as *Bacteroides thetaiotaomicron*, *Faecalibaculum rodentium*, and *Lactobacillus johnsonii* showed a decrease in relative abundance, while *Akkermansia muciniphila* and *Staphylococcus xylosus* increased. Likewise, as infection progressed, there was a decrease in gene abundances related to metabolic processes such as lipid synthesis (including short-chain fatty acids) and amino acid synthesis (including branched-chain amino acids). High-quality metagenomic assembled genomes of *L. johnsonii* and *A. muciniphila* among other species were reconstructed, confirming, functional changes associated with metabolic pathways that are directly affected by the loss of abundance of specific bacterial taxa.

IMPORTANCE Chagas disease (CD) is caused by the protozoan *Trypanosoma cruzi*, presenting acute and chronic phases where cardiomyopathy, megaesophagus, and/or megacolon stand out. During the course of its life cycle, the parasite has an important gastrointestinal tract transit that leads to severe forms of CD. The intestinal microbiome plays an essential role in the immunological, physiological, and metabolic homeostasis of the host. Therefore, parasite-host-intestinal microbiome interactions may provide information on certain biological and pathophysiological aspects related to CD. The present study proposes a comprehensive evaluation of the potential effects of this interaction based on metagenomic and immunological data from two mice models with different genetic, immunological, and microbiome backgrounds. Our findings suggest that there are alterations in the immune and microbiome profiles that affect several metabolic pathways that can potentially promote the infection's establishment, progression, and persistence. In addition, this information may prove essential in the research of new prophylactic and therapeutic alternatives for CD.

KEYWORDS Chagas disease, MAG, microbiome, *Trypanosoma cruzi*

Editor Jian Li, Hubei University of Medicine

Copyright © 2023 Castañeda et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Cristina Poveda, cristina.poveda@bcm.edu, or Juan David Ramírez, juand.ramirez@urosario.edu.co.

The authors declare no conflict of interest.

Received 12 January 2023

Accepted 8 April 2023

Published 4 May 2023

The flagellate protozoan *Trypanosoma cruzi* is the causative agent of Chagas disease, a neglected tropical disease endemic in Latin America that affects eight million people worldwide, causing about 12,500 deaths per year (1–4). Chagas disease has two clinical phases: acute and chronic. The acute phase can be asymptomatic or symptomatic with circulating trypomastigotes in peripheral blood. Decades later, 30 to 40% of patients develop a chronic phase with cardiovascular symptoms, while 10 to 15% present gastrointestinal symptoms (megaesophagus and megacolon) or remain asymptomatic (2).

Different studies have identified that the host gut microbiota composition can influence Chagas disease's physiopathology. Robello et al. found in 2019 that the presence of *T. cruzi* produced alterations in the intestinal microbiota in children, producing an increased fecal abundance of *Streptococcus*, *Blautia*, *Butyrivibrio*, and *Roseburia* and a lower fecal abundance of *Bacteroides* (5). These changes have also been observed in murine models using bioluminescent strains of *T. cruzi*, highlighting a significant intestinal transit that impacts host gut microbiome. In this context, McCall et al., in 2018, observed functional changes in the intestinal chemical environment linked to conjugated linoleic acid derivatives obtained from specific members of the *Ruminococcaceae* and *Lachnospiraceae* families, thus impacting the pathophysiology of Chagas disease, particularly in chronic digestive stages. Likewise, Hossain et al. in 2020 demonstrated that high parasite burdens in the esophagus, colon, and intestine modify the composition of the microbiota (beta diversity) and metabolome (metabolites such as kynurenine and long-chain acylcarnitines). Nevertheless, an essential constraint of these studies is the use of meta-taxonomic strategies through the 16S-rRNA marker with a limited resolution at the genus level. Likewise, using murine models with different genetic and immunological backgrounds can condition the microbiome's composition, leading to results that are not comparable between different studies (6–8).

These findings demonstrate the importance of the interaction of *T. cruzi* with the intestinal microbiome during infection. Also, how its proper understanding may reveal potential physiological and pathophysiological mechanisms associated with Chagas disease. Therefore, we performed a metagenomic analysis in two different mice models (BALB/c and C57BL/6) to evaluate *T. cruzi* infection and its impact on the microbiome. We identified taxa related to infection and functional changes associated with genes and pathways that could explain the possible metabolic alterations related to the infectious process and its interaction with the host. In addition, we were able for the first time to reconstruct MAGs from several bacterial species.

RESULTS

Parasitemia. At the time of euthanasia, by splenocyte cell counting, we found that both BALB/c and C57BL/6 *T. cruzi*-infected mice had splenomegaly. Although blood parasite burden results showed that BALB/c and C57BL/6 had a different progression in accordance with the infection, both contained detectable parasite burdens from day two and a first peak of infection at 10 DPI (Fig. 1a). At 16 days postinfection (dpi), parasite burdens in the heart and intestine showed greater amounts of the parasite in BALB/c mice than in C57BL/6 mice; nevertheless, no statistically significant differences were observed (Fig. 1b).

Immunological profile. We found, as expected, a proinflammatory profile for both C57BL/6 and BALB/c animals infected characterized by cytokines such as gamma interferon (IFN- γ), tumor necrosis factor alpha (TNF- α), and interleukin-6 (IL-6). Furthermore, anti-inflammatory cytokines such as IL-10 were higher in infected mice, mainly in BALB/c mice (Fig. 1c).

To identify the specific response patterns of each mouse strain, the values of the different cytokines were normalized, considering the reference values presented by noninfected mice. Therefore, the comparison between mice strains shows that BALB/c mice have higher values of the proinflammatory cytokines (IFN- γ and IL-6) and the anti-inflammatory cytokines (IL-10 and IL-4) in response to infection than C57BL/6 mice (Welch two-sample *t* test, $P < 0.05$) (see Fig. S1 in the supplemental material).




FIG 1 (a) Parasite burdens from total DNA were calculated by real-time PCR, and a standard curve was used to calculate the parasite equivalents/mL in blood. A solid line represents the parasite (Continued on next page)

Characterization of the gut microbiome. After quality preprocessing and removal of host reads, approximately 14 million reads per sample were obtained for both mice strains. Of the percentage that could be taxonomically classified, more than 99% corresponded to bacteria and less than 1% to viruses. No reads corresponding to eukaryotes were identified. Metagenomic analysis showed the taxonomic identification of 4,782 bacterial species corresponding to BALB/c mice and 4,565 species to C57BL/6 mice. The predominant phyla were *Bacillota* (Firmicutes), *Bacteroidota* (Bacteroidetes), *Pseudomonadota* (Proteobacteria), *Actinomycetota* (Actinobacteria), *Verrucomicrobia*, and *Fusobacteria*. However, the mouse strains showed differences concerning the relative abundances of the different phyla (see https://github.com/gimur/Trypanosoma_cruzi-host-microbiome.git, files summary_taxonomy_BALBc_github.tsv and summary_taxonomy_BL6_github.tsv). The 10 species with the highest relative abundance in BALB/c and C57BL/6 are shown in Fig. 1d and e (left panel), showing changes between the noninfected and infected groups.

Changes in the abundance of the different taxa in BALB/c mice were observed between the noninfected and the infected groups as the infection progressed (Fig. 1d, right panel). A loss in the relative abundance of specific bacterial species such as *Lactobacillus johnsonii*, *Bacteroides thetaiotaomicron*, *Bifidobacterium pseudolongum*, and *Faecalibaculum rodentium* at different time points was observed. In contrast, there was an increase in the relative abundance of other bacterial taxa, such as *Akkermansia muciniphila* and *Staphylococcus xylosum* (Fig. 1d, right panel). On the other hand, a small proportion of viruses were identified, mainly related to *Lactobacillus* phages that decrease as the infection progresses, and *Mus musculus* mobilized endogenous polytropic proviruses that increase with time (see Fig. S2a). These changes were progressive, more evident at 10 dpi when a first peak in the parasite burden was reached.

Since changes in the intestinal microbiota may contribute to the immune response, a correlation analysis was performed between serum cytokine concentrations and the abundance of the top 10 bacterial taxa described above (Fig. 1d and e). Spearman's test showed significant correlations between the abundance of some bacterial taxa and the levels of different cytokines. In BALB/c mice, *Lactobacillus johnsonii* showed a negative correlation with the anti-inflammatory cytokine IL-10 ($P = 0.026$, $R = -0.77$) and with the proinflammatory cytokine TNF- α ($P = 0.036$, $R = -0.76$). Likewise, *Alistipes finegoldii* correlated negatively with the proinflammatory cytokine IL-6 ($P = 0.040$, $R = -0.707$) (Fig. 1f).

Regarding C57BL/6 mice, the differences were not as noticeable as in the case of BALB/c mice. However, some changes were evident. As the *T. cruzi* infection progressed, the abundance of *Bacteroides thetaiotaomicron* increased, reaching its highest proportion 16 dpi. Likewise, a reduction in the relative abundance of *L. johnsonii* and *A. muciniphila* (Fig. 1e, right panel). In C57BL/6 mice, the viruses showed no changes compared to BALB/c (see Fig. S2b). Correlation analysis between serum cytokine concentrations and changes in the abundances of some intestinal microbiota taxa were statistically significant in C57BL/6 mice. *A. muciniphila* and IFN- γ was also evident ($P = 0.040$, $R = -0.72$), and there was also a strong negative correlation with the anti-inflammatory cytokine IL-22 ($P = 0.0011$, $R = -0.95$) (Fig. 1f).

FIG 1 Legend (Continued)

burden in BALB/c infected mice ($n = 5$), and a dashed line represents the parasite burden in C57BL/6 infected mice ($n = 5$). (b) Parasite burden in cardiac tissue and intestinal tissue. A Student *t* test was used to compare burdens in cardiac tissue, and a Wilcoxon signed-rank exact test was used to compare burdens in intestinal tissue. (c) Heatmap showing the profile of anti-inflammatory and proinflammatory cytokines according to the evaluation group. The average linkage was used as the clustering method. (d) The relative abundance of the 10 most abundant bacterial species in BALB/c mice is shown for the control ($n = 5$) and infected ($n = 5$) groups (left) and each of the measurement points (right). (e) The relative abundance of the 10 most abundant bacterial species in C57BL/6 mice is shown for the control ($n = 5$) and infected ($n = 5$) groups (left) and each of the measurement points (right). NI, noninfected; DPI, days postinfection. (f) Correlation analysis between abundance values of *Lactobacillus johnsonii*, *Alistipes finegoldii*, and *Akkermansia muciniphila* and levels of cytokines IL-10, TNF- α , IL-6, IFN- γ , and IL-22. A Spearman correlation test was implemented, the *R* coefficient, and *P* value are indicated.

Beta diversity estimation showed no differences in both cases (infected and noninfected mice). The analysis of nonparametric multidimensional scaling (NMDS) revealed that the overall microbiome profiles did not differ in global terms, and the changes may be related to specific taxa and not to the general microbiota of the different groups (see Fig. S2c).

Functional analysis. The functional analysis performed by Humann3 was evaluated using the multivariate mixed-effects model implemented by Maaslin2 to identify statistically significant differences between infected and noninfected mice. It was found that changes in the abundance of specific genes involved several metabolic pathways between mice before and after infection. As in the case of the microbiota evaluation at the taxonomic level, in the functional analysis, the changes were more evident in BALB/c mice than in C57BL/6 mice (Fig. 2a and d). Genes that showed an adjusted P value of <0.05 were retained for analysis.

We identified 3,838 genes with statistically different abundances between noninfected and infected BALB/c mice. For C57BL/6, only 23 genes showed differences between noninfected and *T. cruzi*-infected mice (material available in https://github.com/gimur/Trypanosoma_cruzi-host-microbiome.git, files significant_results_Humann_BALBc.tsv and significant_results_Humann_BL6.tsv). Table 1 summarizes the major metabolic pathways, the genes involved in these pathways, the taxa associated with these genes, the false discovery rate (FDR) value, the effect size in infected mice, and the P and q statistical significance values. The genes that showed differences were related to metabolic processes such as lipid synthesis (including short-chain fatty acids [SCFAs]), branched-chain amino acid (BCAA) synthesis, purine synthesis, pyrimidine degradation, tryptophan metabolism, cobalamin metabolism, and pyruvate metabolism, among others (Fig. 2a and d). (Material is available at https://github.com/gimur/Trypanosoma_cruzi-host-microbiome.git, files PathTotal_merge_BALBc.csv and PathTotal_merge_BL6.csv).

Regarding lipid metabolism, potential infection-related bacteria such as *Bacteroides thetaiotaomicron* and *Parasutterella excrementihominis* were essential in lipid metabolism, specifically related to beta-oxidation and fatty acid synthesis. We found a reduction in the enzymes such as enoyl coenzyme A hydratase (enoyl-CoA hydratase), tiglyl-CoA hydratase, long-chain fatty acid CoA ligase, acetyl-CoA carboxylase carrier malonyltransferase, and beta-ketoacyl acyl carrier protein in the infected mice (Table 1). Interestingly, some bacterial taxa that increased with infection were associated with a higher abundance of genes that were reduced by the decrease in other taxa. Thus, for example, *Acetatifactor muris*, in infected mice, was associated with a greater abundance of genes related to long-chain fatty acid CoA ligase (Table 1).

In terms of lipid metabolism, the fatty acid synthesis super pathway showed statistically significant differences, showing a higher number of reads in noninfected mice than in infected mice (t test, $P = 0.026$) (Fig. 2b). This strongly correlates with specific enzymes in the functional analysis, such as butyrate kinase, which decreased with infection progress (Fig. 2c). This enzyme in noninfected BALB/c mice was mainly related to *B. thetaiotaomicron*. However, this taxon was reduced as infection progressed and other bacteria increased their relative abundance, mainly *Lachnospiraceae* and *Staphylococcus lentus* (Fig. 2c).

Regarding amino acid metabolism, both BALB/c and C57BL/6 mice showed a decrease in these metabolic pathways (Fig. 2a and d). The most relevant infection-related taxa were *B. thetaiotaomicron*, *Dubosiella newyorkensis*, *F. rodentium*, *Acutalibacter muris*, and *P. excrementihominis*. These bacteria, were significantly related to specific metabolic processes such as the synthesis of short-chain amino acids (leucine, valine, and isoleucine), ornithine, arginine, and synthesis of chorismate (a derivative of shikimic acid metabolism), known as an essential precursor of aromatic amino acids such as phenylalanine, tryptophan, and tyrosine (Fig. 2a and d). Specifically, BALB/c infected mice showed a lower abundance of genes related to aminoacyl-tRNA synthetases, tryptophan synthase, BCAA transaminase, and chorismate synthase (Table 1).

A decrease in purine synthesis was found in infected BALB/c and C57BL/6 mice (Fig. 2a and d). In particular, a lower abundance of genes such as ribonucleoside diphosphate




FIG 2 Functional analysis from metagenomic data. The main results were obtained by Humann3, and the R package, Maaslin2, using a multivariate mixed-effects model. (a and d) Metabolic pathways involving genes with differential abundances between infected and noninfected (Continued on next page)

reductase, hypoxanthine phosphoribosyltransferase, and purine nucleoside phosphorylase related to *B. thetaiotaomicron*, *P. excrementihominis*, and *F. rodentium* was observed (Table 1). In infected BALB/c mice, the abundance of genes associated with the *A. muris*-related ribonucleoside triphosphate reductase enzyme was found.

As for oxidative metabolism, the CoA synthesis pathway changes were evidenced in both BALB/c and C57BL/6 mice (Fig. 2a and d). In BALB/c infected mice, we observed a decrease in this pathway as *T. cruzi* infection progressed. Enzymes belonging to the tricarboxylic acid cycle were in lower abundance in infected mice, such as succinate CoA ligase ADP-forming and dephospho-CoA kinase (Table 1).

Changes in glycolysis and fermentation pathways were observed in BALB/c and C57BL/6 mice (Fig. 2a and d). In BALB/c infected mice, a decrease in the pyruvate fermentation pathway was observed as the infection progressed. In this context, a lower abundance of the genes related to the pyruvate kinase fundamental in glucose metabolism converting phosphoenolpyruvate to pyruvate was observed (Table 1).

Metagenome-assembled genomes and pangenomic analysis. From the metagenomic data for the BALB/c mice, we reconstructed eight high-quality draft metagenome-assembled genomes (MAGs). The quality statistics were evaluated with CheckM, considering completeness (>90%) and contamination (<5%) (see Table S1). The taxonomic assignment was performed with GTDB-Tk through ANI and pplacer analysis recovering genomes from *L. johnsonii*, *A. muciniphila*, *S. lentus*, *A. muris*, *F. rodentium*, *A. finegoldii*, and *S. xylosum* (Fig. 3). The MAG for *B. thetaiotaomicron* corresponded to a medium-quality draft since it showed contamination of 6.6% (see Table S1). Visual reconstruction of MAGs was performed in the process, including a comparative analysis against a reference genome to each case, genome annotation with Prokka, GC percentage, and GC skew (Fig. 3).

Pangenomic analysis of MAGs was made with Panaroo (see Table S2), where *A. muciniphila* showed the lowest value of the core genome with 9.6% ($n = 743/7,645$) (see Fig. S3a), *A. finegoldii* presented a core genome of 11.7%, *L. johnsonii* a core genome of 33.4%, *S. xylosum* a core genome of 42%, and *F. rodentium* a core genome of 59.2%, the highest such value (see Fig. S4). Aligning the extracted amino acid sequences of gene clusters of MAGs with high-quality genomes available in PATRIC indicated a close genetic congruence between each reconstructed MAGs and corresponding downloaded genomes, mainly with isolates from mice (see Fig. S3 and S4).

Functional analysis from MAGs. To evaluate the coding potential of the obtained MAGs, COGs were analyzed for the global data set corresponding to reconstructed MAGs. The overall results show that the highest number of genes are related to carbohydrate metabolism and transport, followed by cell wall structure, biogenesis, outer membranes, and processes associated with cell division, such as transcription, translation, and replication (Fig. 4a).

Comparative analysis concerning each of the MAGs obtained showed that *B. thetaiotaomicron* plays a key role in several essential metabolic processes in host physiology (Fig. 4b). Thus, genes of COGs linked to coenzyme metabolism, carbohydrate metabolism, energy metabolism, amino acid, lipid, and nucleotide metabolism were more abundant in *B. thetaiotaomicron*. The functional pathways (KEGG modules) in the MAGs were reconstructed from Koafm KEGG analysis through the KEGG mapper. Complete modules (functional units of genes) were found in all MAGs mainly related to essential processes such as carbohydrate metabolism, lipid metabolism, nucleotide metabolism, and amino acid metabolism.

FIG 2 Legend (Continued)

mice for BALB/c (a) and C57BL/6 (d) mice. Heatmaps were created with MicrobioSee using Ward's linkage method for hierarchical cluster analysis. The metabolic pathways to which the different processes belong are represented by different colored dots indicated in the legend. (b) Abundance of reads related to the superpathway of fatty acid biosynthesis as observed for noninfected (NI) and infected BALB/c mice. A Student *t* test was used to compare these groups. (c) Bar plot obtained from HUMAnN 3.0 for butyrate kinase that was modified in terms of abundance of reads during *T. cruzi* infection. The figure includes the regrouping of bacterial species and the classification of the samples by evaluation point. *, $P < 0.05$. BALB/c infected mice, $n = 5$; BALB/c noninfected mice, $n = 5$; C57BL/6 infected mice, $n = 5$; C57BL/6 noninfected mice, $n = 5$.

TABLE 1 Functional analysis for gene and metabolic pathway prediction in infected and noninfected mice^a

Metabolic pathway	Gene	Associated bacterium	FDR	Effect size in infected BALB/c mice	P	q	
Lipid metabolism ^b	Enoyl-CoA hydratase	<i>Bacteroides thetaiotaomicron</i>	5.743E-02	-4.6	0.000691712	0.005358871	
	Tiglyl-CoA hydratase	<i>Bacteroides thetaiotaomicron</i>	5.359E-03	-4.64	0.000691712	0.005358871	
	Long-chain fatty acid CoA ligase	<i>Bacteroides thetaiotaomicron</i>	1.835E-0	-3.09	0.003273173	0.018350702	
	Acetyl-CoA carboxylase	<i>Bacteroides thetaiotaomicron</i>	1.463E-02	-3.39	0.002282365	0.014634670	
	Acyl carrier malonyltransferase	<i>Bacteroides thetaiotaomicron</i>	1.110E-02	-3.76	0.001535573	0.011100064	
	Beta ketoacyl acyl carrier protein	<i>Parasutterella excrementihominis</i>	1.182E-02	-3.6	0.001679678	0.011815909	
	Long-chain fatty acid CoA ligase	<i>Acetatifactor muris</i>	2.075E-02	2.1	0.004208897	0.020745468	
	Amino acid metabolism ^c	Isoleucine tRNA ligase	<i>Bacteroides thetaiotaomicron</i>	1.419E-0	-3.43	0.002190388	0.014189590
		Leucine tRNA ligase	<i>Bacteroides thetaiotaomicron</i>	1.566E-02	-3.3	0.002510489	0.015657878
		Tryptophan tRNA ligase	<i>Dubosiella newyorkensis</i>	1.557E-02	-3.31	0.002489752	0.015570720
		Tryptophan synthase	<i>Bacteroides thetaiotaomicron</i>	9.214E-03	-4.01	0.001215979	0.009213813
		Branched-chain amino acid transaminase	<i>Faecalibaculum rodentium</i>	1.951E-02	-2.9	0.003771024	0.019505084
		Chorismate synthase	<i>Acutalibacter muris</i>	1.950E-02	-2.96	0.003768102	0.019500525
	Nucleotide metabolism	Ribonucleoside diphosphate reductase	<i>Parasutterella excrementihominis</i>	2.021E-02	-2.92	0.003967455	0.020212716
Hypoxanthine phosphoribosyltransferase		<i>Parasutterella excrementihominis</i>	6.064E-03	-4.48	0.000787853	0.006064403	
Purine nucleoside phosphorylase		<i>Faecalibaculum rodentium</i>	6.568E-03	-4.39	0.000856150	0.006567651	
Precorrin 2 dehydrogenases		<i>Bacteroides thetaiotaomicron</i>	9.383E-03	-3.98	0.001243739	0.009382987	
Biosynthetic pathway to cobalamin	Succinate CoA ligase ADP forming	<i>Faecalibaculum rodentium</i>	2.315E-02	-2.73	0.005085668	0.023150662	
	Dephospho-CoA kinase	<i>Bacteroides thetaiotaomicron</i>	1.430E-02	-3.42	0.002212495	0.014301774	
Oxidative metabolism and CoA synthesis pathway	Pyruvate kinase	<i>Dubosiella newyorkensis</i>	1.779E-02	-3.14	0.003048271	0.017789402	
		<i>Bacteroides thetaiotaomicron</i>	1.743E-02	-3.16	0.002959204	0.017426635	
Glycolysis and fermentation pathways		<i>Dubosiella newyorkensis</i>	2.144E-02	-2.82	0.004491714	0.021443220	

^aIdentification of genes and associated taxa was performed using the Humann3 tool, and statistical evaluation to determine statistically significant changes was performed with Maaslin2 from a multivariate mixed-effects model. The table shows the metabolic pathway, the genes involved in this pathway, the taxa associated with these genes, the false discovery rate (FDR), the effect size in infected mice, and the P and q statistical significance values. CoA, coenzyme A.

^bThat is, beta-oxidation and fatty acid synthesis and metabolism.

^cThat is, the synthesis of SCFAs (leucine, valine, and isoleucine), the synthesis of ornithine, the synthesis of arginine, and the synthesis of chorismate (a derivative of shikimic acid metabolism and precursor of aromatic amino acids such as phenylalanine, tryptophan, and tyrosine).




FIG 3 (a to e) Genomes (MAGs) reconstructed for *Akkermansia muciniphila* (a), *Lactobacillus johnsonii* (b), *Alistipes finegoldii* (c), *Staphylococcus xylosus* (d), and *Faecalibaculum rodentium* (e). In each of the MAGs, the size in base pairs and the resulting number of contigs of each genome obtained can be seen. For each case, the innermost ring represents the CG skew (green and purple). Subsequently, the %GC value is found (black). The next ring shows the resulting assembled genome (MAG) contigs (gray). Also, the

(Continued on next page)




FIG 4 Functional analysis from MAGs. Ortholog assignment was performed using EggNOG-mapper. The results obtained here were used for clustering according to COGs of proteins in the complete set of reconstructed genomes ($n = 6$) (a) and in the different species obtained (b).

Despite sharing the modules corresponding to common metabolic pathways among these microorganisms, specific differences were evident in some submodules between species associated with noninfected BALB/c mice such as *B. thetaiotaomicron* (see Fig. S5a) and species related to infected BALB/c and C57BL/6 mice such as *S. xylosum* (see Fig. S5b). It was found that in amino acid biosynthesis, *B. thetaiotaomicron* presents complete pathways for the synthesis of histidine mediated by the pentose pathway in its nonoxidative phase. Also, for the biosynthesis of the aromatic amino acid tryptophan from chorismate and lysine from aspartate. In terms of the biosynthesis of BCAAs, the functional analysis of the *B. thetaiotaomicron* genome shows the presence of the complete pathway involved in this process (see Fig. S5a). In contrast, *S. xylosum*, showed an incomplete pathway associated with histidine synthesis, where enzymes such as phosphoribosylformimino-5-aminoimidazole carboxamide were absent. Regarding the synthesis of aromatic amino acids, specifically tryptophan, *S. xylosum* presents an incomplete pathway where it lacks the enzyme anthranilate synthase, fundamental in the final step from anthranilate to indole glycerol phosphate, the precursor of tryptophan. As far as lysine synthesis is concerned, it was observed that *S. xylosum* lacks enzymes such as diaminopimelate epimerase, N-acetyldiaminopimelate deacetylase, and L,L-diaminopimelate aminotransferase, necessary for the passage from tetrahydrodipicolinate to lysine. In the specific case of BCAAs, *S. xylosum* lacks the enzyme belonging to this pathway, specifically citramalate synthase, necessary to obtain 2-methylmalate from pyruvate (see Fig. S5b).

DISCUSSION

We identified that both mouse models showed detectable parasitemia as early as 2 dpi and burdens in both heart and intestine that were higher in BALB/c mice in both cases (Fig. 1a and b). In fact, involvement in both models was evidenced by infected mice developing splenomegaly. This is consistent with previous studies using chemiluminescent strains (6). *T. cruzi* generates high burdens in different portions of the gastrointestinal tract that are relevant during the acute phase, mainly at the level of the large intestine, and that can even be linked to the persistence of the parasite toward chronic digestive forms (6). As expected, the analysis of the cytokines in sera showed a proinflammatory immune response on the C57BL/6 led by IFN- γ , TNF- α , and IL-6 (Fig. 1c). In addition, the BALB/c mice revealed higher levels of anti-inflammatory cytokines such

FIG 3 Legend (Continued)

reference genome for each genome (dark blue), which was aligned by BLAST and the white areas represent regions where no identity with the assembled MAG was found. Finally, in the outer ring, there are the coding regions obtained by Prokka, where coding regions (CDS) (light blue), tRNA (light brown), tmRNA (orange), and rRNA (red) can be identified.

as IL-10 and IL-4 than C57BL/6 mice. This highlights the importance of this intestinal transit and how it may be related to changes in the intestinal microbiome of the infected host, a transit that deserves further investigation (6).

We observed that the structure and composition of the gut microbiome obtained through the metagenomic analyses showed the same taxa with the highest relative abundances for both animal models. These corresponded to *L. johnsonii*, *A. muciniphila*, *B. thetaiotaomicron*, *B. pseudolongum*, *A. finegoldii*, *F. rodentium*, and *S. xylosus*. However, these taxa showed changes in their relative abundance during the *T. cruzi* infection, becoming more prominent in BALB/c mice (Fig. 1d). Changes in the intestinal microbiome have previously been associated with *T. cruzi* infection, even in forms of digestive Chagas disease such as megacolon. Reduced relative abundances of *Bacteroides*, *Akkermansia*, and *Lactobacillus* have been reported (5, 6, 9, 10). This is consistent with our findings, demonstrating that this parasite could directly affect even other taxa that may be key in the interaction with this protozoan and that may have a direct impact on immunological and metabolic changes in the intestinal environment associated with infection.

As a result, these changes in the microbiota can potentially be associated with the immune response. Certain bacteria found in the present study, mainly strict anaerobes, are essential for the maintenance of intestinal health and proper immunoregulation (6, 9–12). This was evident with the correlation analysis between the immune response and microbiome structure, identifying a negative correlation between the reduction of *L. johnsonii* abundance and IL-10 in BALB/c mice (Fig. 1f). Regarding C57BL/6 mice, we found that the decrease of *A. muciniphila* correlated negatively with IL-22 and IFN- γ , explaining to some extent how *Akkermansia* may or may not favor inflammatory processes (13). Bacteria such as *L. johnsonii* and *B. thetaiotaomicron* are known due to their essential activity in the maintenance of the intestinal barrier, the inhibition of pathogen colonization, the reduction of inflammation through the regulation of the immune response, and in pivotal metabolic processes such as short-chain fatty acid (SCFA) biosynthesis (9, 13–22). *T. cruzi* infection directly affects the conditions of the intestinal environment causing a reduction of these populations and concomitantly, allowing the increase of taxa such as those found here. *S. xylosus* and pathobionts reported previously, such as *E. faecalis*, *P. mirabilis*, and *E. coli*, that are facultative anaerobes with the property of growing in this environment and associated with several inflammatory processes (23, 24). These changes favor an aerobic and inflammatory environment that metabolically may benefit the parasite. It is essential to evaluate how these taxa can represent an advantage in the infection's establishment and progression, and whether the microbiome's restructuring and reestablishment can potentially be a key factor in the elimination of the parasite and control of *T. cruzi* infection.

We corroborated the metabolic changes using functional prediction analysis from metagenomic data. The previously described disruption of the relative abundance of bacterial taxa was associated with a decrease in several metabolic processes (Fig. 2). Furthermore, BALB/c mice present a reduction in the biosynthesis of SCFAs (Fig. 2b), correlating with the taxa affected by infection and the immune response profile. An essential function of the biosynthesis of SCFAs involves the maintenance of cell differentiation and proliferation. The potential reduction of this metabolite (SCFA) may prevent proper tissue regeneration in a proinflammatory environment, thus promoting damage to the gut that allows for more efficient colonization by pathogens (25, 26). This suggests that changes in this critical metabolic pathway may favor the establishment and persistence of *T. cruzi* infection and be linked to the pathophysiology of the disease. However, further investigation is required to fulfill this premise.

The reconstruction of genomes from metagenomes (MAGs) supported some of the previously described findings of taxa that can potentially play a vital role in the infectious process (Fig. 3). Pangenome analysis of these MAGs revealed congruence of the reconstructed genomes with previously assembled and reported genomes. In most

cases, they were found to be related to isolates obtained from mice (see Fig. S3 and S4). The analysis of the metabolic pathways performed on MAGs shows how *B. thetaiotaomicron* plays a fundamental role in essential metabolic processes for host physiology, such as amino acid metabolism and transport, and lipid metabolism, among others (16, 27, 28) (Fig. 4b). The observations presented above strengthen the hypothesis that the decrease of the relative abundance of this taxon may be directly implicated in the decrease of these metabolic capacities of the microbiome in *T. cruzi* infection. This highlights the importance of this species within the intestinal microbiome and its potential relevance in the *T. cruzi*-host-microbe interaction. On the other hand, the analysis of the MAG of a bacterium that increased with the progress of the infection such as *S. xylosum* showed that this taxon presents incomplete metabolic pathways suggesting that these bacteria are unable to supply certain biological processes (see Fig. S5). It is necessary thus to direct new studies to corroborate how bacteria such as *B. thetaiotaomicron* can directly modulate *T. cruzi* infection and how their postinfection reestablishment, for example, can favor the response to the parasite, as well as generate less tissue damage through appropriate regulation of the immune response.

It was evidenced that during the *T. cruzi* infection, there was a modification of the gut microbiome structure in which several taxa of interest related to the infection, such as *B. thetaiotaomicron* may play a key role in the interaction with the protozoan. However, with this approach, it is not possible to establish the causality and directionality of the effects evidenced at the level of the immune system and the microbiome. Regarding the above, it can be suggested that *T. cruzi* infection may have indirect effects on the host microbiome related to (i) the inflammatory processes of the immune response against the protozoan and (ii) with the anatomical, histological, and physiological changes associated with the pathophysiology of the disease, as in the case of megacolon, and additionally, direct effects derived directly from the presence and action of the parasite at the intestinal level.

Considering this, infection by *T. cruzi* and its interaction at the gut level with the host could potentially be related to several factors: (i) the generation of modifications in immune profiles that promote an increase in oxidative stress and a proinflammatory environment that favors the parasite and promote an alteration in the structure of the intestinal microbiota; (ii) the changes in this microbiota structure are directly related to functional and metabolic changes (microbiome) involving, for example, the synthesis of SCFAs, having an important relevance in the modulation of the immune response and contributing to the proinflammatory state of the infection that *T. cruzi* is able to evade; (iii) and, finally, *T. cruzi* infection may probably be generating changes in the microbiome that functionally involve biosynthesis pathways of different amino acids and nucleotide metabolism, which are potentially related to their utilization by different stages of this protozoan and are of great relevance in the life cycle of this parasite.

Conclusions. The changes in the intestinal microbiome identified in this study suggest that there are alterations in the immune profiles and in several essential metabolic pathways that favor the immunological and biochemical processes associated with the infection. These results provide valuable insights needed for the research on new prophylactic and therapeutic alternatives in Chagas disease. Previous studies have shown that the use of probiotics based on different species of *Lactobacillus* and *Bifidobacterium* (important in the present study) in infections by *Giardia*, *Cryptosporidium*, *Eimeria*, and even in systemic infections such as malaria, can favor the resolution of the infection by reducing parasitic burdens, interrupting the advance of the parasite's life cycle, among others (29). Therefore, it is a potential area for further research and biotechnological improvement of novel therapeutic strategies for Chagas disease.

It is important to highlight, however, that a limitation of metagenomic studies is that functional analyses are based on the prediction of the genes and metabolic pathways. Therefore, it is necessary to implement transcriptomic and metabolomic studies that can directly corroborate these results and allow the identification of potential biomarkers of infection. Furthermore, the present analysis refers to the acute phase of infection; then, it is essential to also perform this evaluation in the chronic phase and

thus compare the changes caused by this parasite at different times of infection and disease. In addition, it is relevant to establish the causality and directionality of the changes generated by the infection and thus determine whether the immunological effects cause changes in the microbiome or whether, on the contrary, changes in the microbiome promote alterations in the immune response profiles. Nevertheless, our study to the best of our knowledge is the first to report MAGs in hosts during an infection process with *T. cruzi*. Finally, this study provides a relevant overview of parasite-microbiome interactions that deserves attention and should be prioritized in the future to unveil prospective therapeutic alternatives for Chagas disease.

MATERIALS AND METHODS

Mice and parasites. Female C57BL/6 and BALB/c mice from the same vendor (Jackson Laboratories), aged 5 to 8 weeks, were used. Animal experiments were performed in full compliance with the *Guide for the Care and Use of Laboratory Animals*, 8th edition (30), under a protocol approved by Baylor College of Medicine's Institutional Animal Care and Use Committee (IACUC), assurance number and D16-00475. The *Trypanosoma cruzi* strain Tulahuen (ATCC 30208), a discrete typing unit (DTU) VI, was used for infection experiments. Trypomastigotes were obtained from the blood of severe combined immune-deficient (SCID) mice. Animals were injected intraperitoneally with the parasite, and trypomastigotes were isolated from blood at day 16 postinfection. All mice were maintained in the same housing conditions and on the same diet at the Baylor College of Medicine facility.

T. cruzi infection. Groups of five both BALB/c and C57BL/6 mice were kept noninfected in order to allow comparisons of the conditions evaluated throughout the follow-up. In addition, groups of five mice, BALB/c and C57BL/6, were infected with 500 blood-stage trypomastigotes of *T. cruzi* by intraperitoneal injection. Beginning at 3 dpi, blood was collected twice weekly throughout the study by tail vein microsampling to monitor parasitemia by quantitative PCR (qPCR) and stool for metagenome analysis. At 16 dpi, mice were euthanized, and then whole blood was collected by cardiac puncture. Lastly, different tissues (heart, and intestine) were collected and frozen at -80°C .

Sample collection. Fecal samples were collected (in a pool corresponding to each group) on day 0 (prior infection) and at 3, 7, 10, 13, and 16 dpi. In addition, at these time points, blood samples were taken (per mouse) for the evaluation of parasitemia by qPCR twice a week. On day 16, mice were sacrificed, and parasitemia was evaluated in cardiac and intestinal tissue.

Parasite burdens. To evaluate the parasite burden from blood, gut, and cardiac tissue, total DNA was isolated using a PDQeX prepGEM Universal kit (MicroGEM). Parasite burdens from total DNA were calculated by real-time PCR using the TaqMan system amplifying the satellite region of *T. cruzi* nuclear DNA (primers 5'-ASTCGGCTGATCGTTTTTCGA-3' and 5'-AATTCTCCAAGCAGCGGATA-3' and probe 5'-6-FAM-CACACTGGACACCAA-MGB-3'), where FAM is 6-carboxyfluorescein, and MGB is minor groove binder (Life Technologies) (31, 32). To normalize the data, we used the glyceraldehyde-3-phosphate dehydrogenase (GAPDH; primers 5'-CAATGTGTCCGTCGGATCT-3' and 5'-GTCCTCAGTGATGCCAAGATG-3') and probe 5'-6-FAM-CGTGCCGCTGGAGAACTGCC-MGB-3' (Life Technologies) (33). The qPCRs were carried out with 4 ng of DNA from blood and 20 ng of DNA from cardiac tissue and intestine; a standard curve was used to calculate the parasite equivalents in blood, gut, and cardiac tissue (34).

Cytokine evaluation. The levels of IL-2, IL-4, IL-6, IL-10, IL-13, IL-17A, IL-22, IFN- γ , and TNF- α were measured in sera from noninfected and infected mice; a Luminex-based assay was used, as previously described (35). The readout was performed using a MagPix Luminex instrument. Cytokine concentrations in the supernatant were calculated based on a standard curve, and for each sample, duplicate wells were averaged, and further analysis was done.

DNA extraction for metagenome analysis. All stool samples from animals infected and noninfected were collected and immediately stored on ice. Subsequently, DNA was extracted using MP FastDNA spin kits for soil (MP Biomedicals, Irvine, CA) (36, 37). Extracted DNA was resuspended in 50 μL of pyrogen-free water and stored at -20°C . DNA samples were shipped to Novogene for 150-bp PE sequencing by Illumina NovaSeq 6,000 to obtain 4 Gb of raw data per sample.

Bioinformatics analysis. (i) Sequence processing, taxonomic assignment, and functional profiling. From the raw reads, a quality assessment was performed by FastQC (38). Quality and adapter trimming was then conducted by Trimmomatic (39) using the parameters ILLUMINACLIP: TruSeq3-PE.fa:2:30:10:2:keepBothReads MINLEN:150 AVGQUAL:20 TRAILING:20. Mapping to the *Mus musculus* genome (GRCm39) was performed using the Bowtie2 tool (40) to remove reads corresponding to the host.

The Centrifuge tool was used in taxonomic assignment from the cleaned reads (41). The obtained outputs were transformed to Kraken-Report format with the Centrifuge-kreport function. Relative abundance values for each taxon identified at each time of infection were obtained from the Centrifuge report for the corresponding analysis and visualized by Pavian (42). In addition, a beta-diversity analysis was performed to compare the microbiota composition between noninfected and infected mice using NMDS.

Simultaneously, Humann3 (HMP Unified Metabolic Analysis Network) (43) was used for functional profiling, including identifying changes in gene abundance and metabolic pathways. Since this tool receives only one fastq file as input, forward and reverse reads from each sample were concatenated to generate the file. A normalization was made with RPK values to relative abundance values or "copies per million" (cpm) units through the humann_renorm_tablescript function to facilitate comparisons between samples with different

sequencing depths. The default “units” of the HUMAnN microbial function are the UniRef gene families used to calculate reaction and pathway abundances. From the abundance of gene families, reconstruction of the abundance of other functional categories was performed using the `humann_regroup_tablescript` function. Gene family abundance values normalized by cpm to the MetaCyc reaction abundances (RXN), included with the default Humann3 facility, were regrouped. The `humann_rename_table` function was used to generate a readable output, and then the sample outputs were joined with the `humann_join_tables` function. Finally, a stratified table was obtained with `humann_split_stratified_table`. To evaluate the results of Humann3, the R package, Maaslin2 (44) was used to determine the association between measurement times, condition (infected – noninfected), and functional characteristics of the microbiome using a multivariate mixed-effect model. Heatmaps were created with MicrobioSee using Ward’s linkage method for hierarchical cluster analysis.

(ii) MAGs, pangenome reconstruction, and functional analysis. From the clean reads, the assembly process was performed using Spades, with the `–meta` parameter (45) and Megahit (46). MetaQuast was used to determine these assemblies’ quality statistics and to select the best assembly (47). To estimate the coverage of a bowtie2 and thus proceed to binning, reads were mapped for each sample against the corresponding assemblage. The best-quality assemblies with contigs longer than 1,500 nucleotides were binned into MAGs the using MetaBat, Maxbin, and Concoct tools, followed by refinement with DASTool (48). The quality of these final bins was evaluated with CheckM (48–51). Taxonomic assignment of these good-quality bins was performed with Genome Taxonomy Database GTDB-Tk (52). Bins with completeness >90% and contamination <5% that were taxonomically assigned were treated as MAGs for further analysis. MAGs for *Akkermansia muciniphila*, *Lactobacillus johnsonii*, *Alistipes finegoldii*, *Staphylococcus xylosum*, *Faecalibaculum rodentium*, and *Bacteroides thetaiotaomicron* were obtained. The MAGs were annotated using Prokka (53). The process was implemented for visual genome reconstruction. In this case, a BLAST alignment was performed with the default parameters with the reference genome corresponding to each previously defined species, and further downloaded from the NCBI: [NZ_AP021898.1](https://.ncbi.nlm.nih.gov/nucl/NC_021898.1), *Akkermansia muciniphila*; [NZ_CP062068.1](https://.ncbi.nlm.nih.gov/nucl/NZ_CP062068.1), *Lactobacillus johnsonii*; [NZ_JADMWR010000010.1](https://.ncbi.nlm.nih.gov/nucl/NZ_JADMWR010000010.1), *Alistipes finegoldii*; [NZ_CP008724.1](https://.ncbi.nlm.nih.gov/nucl/NZ_CP008724.1), *Staphylococcus xylosum*; [NZ_CP011391.1](https://.ncbi.nlm.nih.gov/nucl/NZ_CP011391.1), *Faecalibaculum rodentium*; and [NZ_CP040530.1](https://.ncbi.nlm.nih.gov/nucl/NZ_CP040530.1), *Bacteroides thetaiotaomicron*. The .gff annotation files obtained for each case were also included in this reconstruction, where the GC percentage and the GC Skew with the default parameters were determined.

The .gff files obtained from the annotation also were used to conduct a pangenome analysis using Panaroo tool (54), considering an identity of 99% and their presence in the compared genomes of 99% (`–clean-mode strict -a core –aligner mafft –core_threshold 0.99`). For this purpose, the complete and good-quality genomes available in PATRIC (Pathosystems Resource Integration Center) were downloaded: 96 genomes of *Akkermansia muciniphila*, 15 of *Lactobacillus johnsonii*, 18 of *Alistipes finegoldii*, 20 of *Staphylococcus xylosum*, and 4 of *Faecalibaculum rodentium*. The results were used to generate phylogenetic trees in iTol (55), based on alignments obtained from the core genome using Panaroo and the .newick files generated from these alignments. For the graphical representation of the core genome was used Phandango (56).

The Kyoto Encyclopedia of Genes and Genomes (KEGG) was used to identify the metabolic capacities present in MAGs (57, 58). KofamKOALA was used to assign K numbers to the sequence data by HMMER/HMMSEARCH against Kofam (a customized HMM database of KEGG Orthologs [KOs]). The outputs were used for visual reconstructions of metabolic pathways using the KEGG Mapper. Complementarily, an evaluation was performed for annotation through ortholog assignment using EggNOG-mapper (59). Finally, the results were used for clustering according to Clusters of Orthologous Groups (COGs) of proteins (60).

Statistical analysis. Statistical analyses were carried out using R software (61). For continuous values (parasite burdens, relative abundance, cytokine levels, and abundance of gene reads), normality hypotheses were evaluated using the Kolmogorov-Smirnov and Shapiro-Wilk tests. A comparison of the values of numerical variables (parasite burdens, relative abundances, cytokine levels, and abundance of gene reads) was performed between study groups (noninfected and infected mice) and between time points of infection. For this purpose, parametric tests (Student *t* test for comparisons between two groups) and non-parametric tests (Wilcoxon signed-exact-ranks test for comparisons between two groups and Kruskal-Wallis test for comparisons between multiple groups with the corresponding Dunn’s test for *post hoc* multiple comparisons adjusted with the Bonferroni method) were used. Likewise, to evaluate the correlation between the numerical variables corresponding to abundances of the different taxa and the pg/mL serum levels of the cytokines, Spearman’s nonparametric test was used. All significance tests, whether parametric or nonparametric, were two tailed, and *P* values of <0.05 were considered statistically significant.

Ethics approval and consent to participate. Animal experiments were performed in full compliance with the *Guide for the Care and Use of Laboratory Animals*, 8th edition (30), under a protocol approved by Baylor College of Medicine’s IACUC, under assurance number D16-00475.

Data availability. Sequence data supporting the conclusions of this article are available in the SRA database under the BioProject [PRJNA915351](https://ncbi.nlm.nih.gov/bioproject/PRJNA915351). Code for generating the figures and the analysis is available at https://github.com/gimur/Trypanosoma_cruzi-host-microbiome.git.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 1.3 MB.

SUPPLEMENTAL FILE 2, XLSX file, 0.01 MB.

SUPPLEMENTAL FILE 3, XLSX file, 0.01 MB.

ACKNOWLEDGMENTS

We thank the Ministerio de Ciencia Tecnología e Innovación (Minciencias) de Colombia under the framework of the Sistema General de Regalías for providing the Ph.D. scholarship of S.C.

We declare that we have no competing interests.

S.C., C.P., and J.D.R. designed the study. S.C., R.M., and C.P. performed the experiments. S.C. and M.M. analyzed the data. P.J.H., M.E.B., A.E.P.-M., and R.M.J. provided recommendations to the results and analysis. S.C., C.P., and J.D.R. drafted the manuscript. All authors read and approved the final version of the manuscript.

This study was funded by Dirección de Investigación e Innovación from Universidad del Rosario.

REFERENCES

- Sandri TL, Lidani KCF, Andrade FA, Carvalho LP, Fontana PD, de Melo EJT, de Messias-Reason IJ. 2021. Trypanosoma cruzi reference module in biomedical sciences. Elsevier, Inc., Philadelphia, PA. <http://dx.doi.org/10.1016/B978-0-12-818731-9.00042-2>.
- Rassi A, Rassi A, Marin-Neto JA. 2010. Chagas disease. Lancet 375: 1388–1402. [https://doi.org/10.1016/S0140-6736\(10\)60061-X](https://doi.org/10.1016/S0140-6736(10)60061-X).
- Rassi A, Rassi A, Marcondes de Rezende J. 2012. American trypanosomiasis (Chagas disease). Infect Dis Clin North Am 26:275–291. <https://doi.org/10.1016/j.idc.2012.03.002>.
- WHO. 2022. Chagas disease (American trypanosomiasis). World Health Organization, Geneva, Switzerland. https://www.who.int/health-topics/chagas-disease?tab=tab_1. Accessed 14 March 2022.
- Robello C, Maldonado DP, Hevia A, Hoashi M, Frattaroli P, Montacutti V, Heguy A, Dolgalev I, Mojica M, Iraola G, Dominguez-Bello MG. 2019. The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole. PLoS One 14:e0215199. <https://doi.org/10.1371/journal.pone.0215199>.
- Hossain E, Khanam S, Dean DA, Wu C, Lostracco-Johnson S, Thomas D, Kane SS, Parab AR, Flores K, Katemauswa M, Gosmanov C, Hayes SE, Zhang Y, Li D, Woelfel-Monsivais C, Sankaranarayanan K, McCall LL. 2020. Mapping of host-parasite-microbiome interactions reveals metabolic determinants of tropism and tolerance in Chagas disease. Sci Adv 6: eaaz2015. <https://doi.org/10.1126/sciadv.aaz2015>.
- Flórez O, Esper J, Higuera S, Barraza MF, Cabrera HB, Mantilla JC, González Rugeles CI. 2010. Chagasitic megacolon associated with Trypanosoma cruzi i in a Colombian patient. Parasitol Res 107:439–442. <https://doi.org/10.1007/s00436-010-1874-2>.
- Pajeccki D, Zilberstein B, dos Santos MAA, Ubriaco JA, Quintanilha AG, Ceconello I, Gama-Rodrigues J. 2002. Megaesophagus microbiota: a qualitative and quantitative analysis. J Gastrointest Surg 6:723–729. [https://doi.org/10.1016/s1091-255x\(02\)00028-8](https://doi.org/10.1016/s1091-255x(02)00028-8).
- de Souza-Basqueira M, Ribeiro RM, de Oliveira LC, Moreira CHV, Martins RCR, Franco DC, Amado PPP, Mayer MPA, Sabino EC. 2020. Gut dysbiosis in Chagas disease: a possible link to the pathogenesis. Front Cell Infect Microbiol 10. <https://doi.org/10.3389/fcimb.2020.00402>.
- McCall L-I, Tripathi A, Vargas F, Knight R, Dorrestein PC, Siqueira-Neto JL. 2018. Experimental Chagas disease-induced perturbations of the fecal microbiome and metabolome. PLoS Negl Trop Dis 12:e0006344. <https://doi.org/10.1371/journal.pntd.0006344>.
- Poveda C, Bottazzi ME, Jones KM. 2021. Mining the metabolome for new and innovative Chagas disease treatments. Trends Pharmacol Sci 42:1–3. <https://doi.org/10.1016/j.tips.2020.11.007>.
- Hu Y, Xie H, Gao M, Huang P, Zhou H, Ma Y, Zhou M, Liang J, Yang J, Lv Z. 2020. Dynamic of composition and diversity of gut microbiota in Triatoma rubrofasciata in different developmental stages and environmental conditions. Front Cell Infect Microbiol 10:1. <https://doi.org/10.3389/fcimb.2020.587708>.
- Guo X, Li S, Zhang J, Wu F, Li X, Wu D, Zhang M, Ou Z, Jie Z, Yan Q, Li P, Yi J, Peng Y. 2017. Genome sequencing of 39 Akkermansia muciniphila isolates reveals its population structure, genomic and functional diversity, and global distribution in mammalian gut microbiotas. BMC Genomics 18. <https://doi.org/10.1186/s12864-017-4195-3>.
- Li K, Hao Z, Du J, Gao Y, Yang S, Zhou Y. 2021. Bacteroides thetaiotaomicron relieves colon inflammation by activating aryl hydrocarbon receptor and modulating CD4⁺ T cell homeostasis. Int Immunopharmacol 90: 107183. <https://doi.org/10.1016/j.intimp.2020.107183>.
- Wexler AG, Goodman AL. 2017. An insider's perspective: Bacteroides as a window into the microbiome. Nat Microbiol 2. <https://doi.org/10.1038/nmicrobiol.2017.26>.
- Zocco MA, Ainora ME, Gasbarrini G, Gasbarrini A. 2007. Bacteroides thetaiotaomicron in the gut: molecular aspects of their interaction. Dig Liver Dis 39:707–712. <https://doi.org/10.1016/j.dld.2007.04.003>.
- Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, Choi YO, Lee SY, Ahn KM, Ji GE. 2010. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr Allergy Immunol 21(2 Pt 2):e386–e393. <https://doi.org/10.1111/j.1399-3038.2009.00958.x>.
- Humen MA, De Antoni GL, Benyacoub J, Costas ME, Cardozo MI, Kozubsky L, Saudan KY, Boenzli-Bruand A, Blum S, Schiffrin EJ, Pérez PF. 2005. Lactobacillus johnsonii La1 antagonizes Giardia intestinalis in vivo. Infect Immun 73: 1265–1269. <https://doi.org/10.1128/AI.73.2.1265-1269.2005>.
- Liu HY, Roos S, Jonsson H, Ahl D, Dicksved J, Lindberg JE, Lundh T. 2015. Effects of Lactobacillus johnsonii and Lactobacillus reuteri on gut barrier function and heat shock proteins in intestinal porcine epithelial cells. Physiol Rep 3:e12355. <https://doi.org/10.14814/phy2.12355>.
- Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, De Vos WM, Cani PD. 2013. Crosstalk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110:9066–9071. <https://doi.org/10.1073/pnas.1219451110>.
- Zagato E, Pozzi C, Bertocchi A, Schioppa T, Saccheri F, Guglietta S, Fosso B, Melocchi L, Nizzoli G, Troisi J, Marzano M, Oresta B, Spadoni I, Atarashi K, Carloni S, Arioli S, Fornasa G, Asnicar F, Segata N, Guglielmetti S, Honda K, Pesole G, Vermi W, Penna G, Rescigno M. 2020. Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat Microbiol 5:511–524. <https://doi.org/10.1038/s41564-019-0649-5>.
- Bereswill S, Ekmekciu I, Escher U, Fiebiger U, Stingl K, Heimesaat MM. 2017. Lactobacillus johnsonii ameliorates intestinal, extra-intestinal and systemic proinflammatory immune responses following murine Campylobacter jejuni infection. Sci Rep 7:2138. <https://doi.org/10.1038/s41598-017-02436-2>.
- Leclerc M, Bedu-Ferrari C, Etienne-Mesmin L, Mariadassou M, Lebreuilly L, Tran S-L, Brazeau L, Mayeur C, Delmas J, Rué O, Denis S, Blanquet-Diot S, Ramarao N. 2021. Nitric oxide impacts human gut microbiota diversity and functionalities. mSystems 6:e00558-21. <https://doi.org/10.1128/mSystems.00558-21>.
- Cardoso MS, Reis-Cunha JL, Bartholomeu DC. 2015. Evasion of the immune response by Trypanosoma cruzi during acute infection. Front Immunol 6:659. <https://doi.org/10.3389/fimmu.2015.00659>.
- Venegas DP, De La Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, Harmsen HJM, Faber KN, Hermoso MA. 2019. Short chain fatty acids (SCFAs) mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol 10:277. <https://doi.org/10.3389/fimmu.2019.01486>.
- Shute A, Callejas BE, Li S, Wang A, Jayme TS, Ohland C, Lewis IA, Layden BT, Buret AG, McKay DM. 2021. Cooperation between host immunity and the gut bacteria is essential for helminth-evoked suppression of colitis. Microbiome 9:1–18. <https://doi.org/10.1186/s40168-021-01146-2>.
- Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. 2001. Molecular analysis of commensal host-microbial relationships in the intestine. Science 291:881–884. <https://doi.org/10.1126/science.291.5505.881>.

28. Porter NT, Luis AS, Martens EC. 2018. *Bacteroides thetaiotaomicron*. Trends Microbiol 26:966–967. <https://doi.org/10.1016/j.tim.2018.08.005>.
29. Darwesh OM, El-Sayed HS. 2022. Perspective chapter: application of probiotics to inactivate helminth parasitic zoonosis. In Morales-Montor J, Del Rio-Araiza VH, Hernández-Bello R (ed), Parasitic helminths and zoonoses: from basic to applied research. <https://www.intechopen.com/chapters/80961>.
30. National Research Council. 2010. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
31. Melo MF, Moreira OC, Tenório P, Lorena V, Lorena-Rezende I, Júnior WO, Gomes Y, Britto C. 2015. Usefulness of real time PCR to quantify parasite load in serum samples from chronic Chagas disease patients. Parasit Vectors 8:1–7. <https://doi.org/10.1186/s13071-015-0770-0>.
32. Piron M, Fisa R, Casamitjana N, López-Chejade P, Puig L, Vergés M, Gascón J, Prat JI, Portús M, Sauleda S. 2007. Development of a real-time PCR assay for *Trypanosoma cruzi* detection in blood samples. Acta Trop 103:195–200. <https://doi.org/10.1016/j.actatropica.2007.05.019>.
33. Gangisetty O, Reddy DS. 2009. The optimization of TaqMan real-time RT-PCR assay for transcriptional profiling of GABA-A receptor subunit plasticity. J Neurosci Methods 181:58–66. <https://doi.org/10.1016/j.jneumeth.2009.04.016>.
34. Cencig S, Coltel N, Truyens C, Carlier Y. 2011. Parasitic loads in tissues of mice infected with *Trypanosoma cruzi* and treated with AmBisome. PLoS Negl Trop Dis 5:e1216. <https://doi.org/10.1371/journal.pntd.0001216>.
35. Versteeg L, Le Guezennec X, Zhan B, Liu Z, Angagaw M, Woodhouse JD, Biswas S, Beaumier CM. 2017. Transferring Luminex cytokine assays to a wall-less plate technology: validation and comparison study with plasma and cell culture supernatants. J Immunol Methods 440:74–82. <https://doi.org/10.1016/j.jim.2016.11.003>.
36. Cimino RO, Jeun R, Juarez M, Cajal PS, Vargas P, Echazú A, Bryan PE, Nasser J, Krolewiecki A, Mejia R. 2015. Identification of human intestinal parasites affecting an asymptomatic peri-urban Argentinian population using multi-parallel quantitative real-time polymerase chain reaction. Parasit Vectors 8:1–7. <https://doi.org/10.1186/s13071-015-0994-z>.
37. Cooper P, Walker AW, Reyes J, Chico M, Salter SJ, Vaca M, Parkhill J. 2013. Patent human infections with the whipworm, *Trichuris trichiura*, are not associated with alterations in the faecal microbiota. PLoS One 8:e76573. <https://doi.org/10.1371/journal.pone.0076573>.
38. Babraham Bioinformatics. 2022. FastQC: a quality control tool for high throughput sequence data. Babraham Institute, Cambridge, United Kingdom. <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>. Accessed 16 May 2022.
39. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120. <https://doi.org/10.1093/bioinformatics/btu170>.
40. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357–359. <https://doi.org/10.1038/nmeth.1923>.
41. Kim D, Song L, Breitwieser FP, Salzberg SL. 2016. Centrifuge: rapid and sensitive classification of metagenomic sequences. Genome Res 26:1721–1729. <https://doi.org/10.1101/gr.210641.116>.
42. Breitwieser FP, Salzberg SL. 2020. Pavian: interactive analysis of metagenomics data for microbiome studies and pathogen identification. Bioinformatics 36:1303–1304. <https://doi.org/10.1093/bioinformatics/btz715>.
43. Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, Mailyan A, Manghi P, Scholz M, Thomas AM, Valles-Colomer M, Weingart G, Zhang Y, Zolfo M, Huttenhower C, Franzosa EA, Segata N. 2021. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with biobakey 3. Elife 10. <https://doi.org/10.7554/eLife.65088>.
44. Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, Tickle TL, Weingart G, Ren B, Schwager EH, Chatterjee S, Thompson KN, Wilkinson JE, Subramanian A, Lu Y, Waldron L, Paulson JN, Franzosa EA, Bravo HC, Huttenhower C. 2021. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol 17:e1009442. <https://doi.org/10.1371/journal.pcbi.1009442>.
45. Nurk S, Meleshko D, Korobeynikov A, Pevzner P. 2017. metaSPAdes: a new versatile *de novo* metagenomics assembler. Genome Res 27:824–834. <https://doi.org/10.1101/gr.213959.116>.
46. Li D, Liu CM, Luo R, Sadakane K, Lam TW. 2015. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics 31:1674–1676. <https://doi.org/10.1093/bioinformatics/btv033>.
47. Mikheenko A, Saveliev V, Gurevich A. 2016. MetaQUAST: evaluation of metagenome assemblies. Bioinformatics 32:1088–1090. <https://doi.org/10.1093/bioinformatics/btv697>.
48. Sieber CMK, Probst AJ, Sharrar A, Thomas BC, Hess M, Tringe SG, Banfield JF. 2018. Recovery of genomes from metagenomes via a dereplication, aggregation and scoring strategy. Nat Microbiol 3:836–843. <https://doi.org/10.1038/s41564-018-0171-1>.
49. Kang DD, Froula J, Egan R, Wang Z. 2015. MetaBAT, an efficient tool for accurately reconstructing single genomes from complex microbial communities. PeerJ 3:e1164. <https://doi.org/10.7717/peerj.1165>.
50. Wu Y-W, Tang Y-H, Tringe SG, Simmons BA, Singer SW. 2014. MaxBin: an automated binning method to recover individual genomes from metagenomes using. Microbiome 2:4904–4909. <https://doi.org/10.1186/2049-2618-2-26>.
51. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. 2015. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Res 25:1043–1055. <https://doi.org/10.1101/gr.186072.114>.
52. Chaumeil PA, Mussig AJ, Hugenholtz P, Parks DH. 2019. GTDB-Tk: a toolkit to classify genomes with the Genome Taxonomy Database. Bioinformatics 36:1925–1927. <https://doi.org/10.1093/bioinformatics/btz848>.
53. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2068–2069. <https://doi.org/10.1093/bioinformatics/btu153>.
54. Tonkin-Hill G, MacAlasdair N, Ruis C, Weimann A, Horesh G, Lees JA, Gladstone RA, Lo S, Beaudoin C, Floto RA, Frost SDW, Corander J, Bentley SD, Parkhill J. 2020. Producing polished prokaryotic pangenomes with the Panaroo pipeline. Genome Biol 21:1–21. <https://doi.org/10.1186/s13059-020-02090-4>.
55. Letunic I, Bork P. 2007. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation. Bioinformatics 23:127–128. <https://doi.org/10.1093/bioinformatics/btl529>.
56. Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM, Harris SR. 2018. Phandango: an interactive viewer for bacterial population genomics. Bioinformatics 34:292–293. <https://doi.org/10.1093/bioinformatics/btx610>.
57. Kanehisa M, Sato Y, Morishima K. 2016. BlastKOALA and GhostKOALA: KEGG tools for functional characterization of genome and metagenome sequences. J Mol Biol 428:726–731. <https://doi.org/10.1016/j.jmb.2015.11.006>.
58. Kanehisa M, Goto S. 2000. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27–30. <https://doi.org/10.1093/nar/28.1.27>.
59. Cantalapiedra CP, Hernández-Plaza A, Letunic I, Bork P, Huerta-Cepas J. 2021. eggNOG-mapper v2: functional annotation, orthology assignments, and domain prediction at the metagenomic scale. Mol Biol Evol 38:5825–5829. <https://doi.org/10.1093/molbev/msab293>.
60. Galperin MY, Kristensen DM, Makarova KS, Wolf YI, Koonin EV. 2019. Microbial genome analysis: the COG approach. Brief Bioinform 20:1063–1070. <https://doi.org/10.1093/bib/bbx117>.
61. Allaire JJ. 2020. RStudio: integrated development for R. RStudio. <https://www.r-project.org/conferences/useR-2011/abstracts/180111-allairejj.pdf>. Accessed 4 March 2021.

6.3. Capítulo 3

Objetivo 4: Evaluar los cambios en la microbiota del hospedero y del helminto asociados a la infección por *Ascaris suum* en un modelo animal a partir de un enfoque de metabarcoding.

Objetivo 5: Identificar el proteoma de los productos de excreción-secreción (ES) de diferentes etapas larvales de *Ascaris suum* (L3-huevo, L3-pulmón, L3-tráquea) a partir de un enfoque proteómico.

Para cumplir con el objetivo 4, el estudio se centró en caracterizar la microbiota asociada a diversas etapas de desarrollo de *Ascaris* y su impacto en la microbiota del hospedero durante la migración larval en un modelo murino. Se infectaron quince ratones con 2500 huevos embrionados de *A. suum*. A los 4, 8 y 14 días post-infección (DPI), se realizó la eutanasia de cinco ratones infectados con *Ascaris* y ratones control de la misma edad. Se recolectaron muestras de heces, intestino, hígado y pulmones. Las larvas se aislaron de los huevos embrionados in vitro, así como del hígado a los 4 DPI y del pulmón a los 8 DPI. Utilizando la secuenciación del 16S rRNA, analizamos la diversidad bacteriana en muestras de diferentes etapas de *Ascaris* y en tejidos del hospedero. Nuestros resultados revelaron un total de 8,040 variantes de secuencias de amplicones (ASVs), siendo las muestras de *Ascaris* las que mostraron la mayor diversidad. Es notable que la microbiota asociada a *Ascaris* difería significativamente de la del hospedero, observándose una mayor diversidad en el parásito.

El análisis de abundancia diferencial identificó patrones taxonómicos distintos, destacando géneros específicos como *Bradyrhizobium*, *Achromobacter* y *Pseudomonas* en *Ascaris*. Nuestros hallazgos sugieren que *Ascaris* alberga una microbiota única que podría intercambiar bacterias con el hospedero durante la migración larval. Estas perspectivas abren camino para investigaciones adicionales sobre la dinámica ecológica y funcional de las interacciones helminto-microbiota, lo que podría informar estrategias terapéuticas novedosas dirigidas a estas relaciones microbianas para mitigar las infecciones por helmintos y mejorar los resultados de salud en los hospederos.

Los resultados obtenidos indican que *Ascaris* puede modular activamente su microbiota, creando un microambiente favorable para su supervivencia y desarrollo dentro del hospedero. Además, el estudio sugiere que existe un intercambio dinámico de microorganismos entre el parásito y el hospedero durante el ciclo de vida de *Ascaris*. Este intercambio podría tener implicaciones importantes para la salud del hospedero, ya que la microbiota asociada a *Ascaris* podría influir en la respuesta inmunitaria y en su susceptibilidad a otras infecciones.

Para el objetivo 5, se llevó a cabo un análisis con el fin de caracterizar el proteoma de los productos de excreción-secreción (ES) de diferentes etapas larvales de *Ascaris suum* (L3-huevo, L3-pulmón, L3-tráquea) que puedan resultar relevantes en la interacción parásito-hospedero-microbioma y que puedan resultar como potenciales objetivos de intervención que reduzcan la morbilidad global inducida por *Ascaris*. Se aislaron larvas específicas por etapa, que fueron cultivadas in vitro y de las cuales se recolectaron los productos ES.

Las larvas L3 se aislaron de huevos embrionados (L3-huevo), del pulmón de ratones Balb/c infectados con huevos de *Ascaris suum* a los 8 días post-infección (L3-pulmón), y de la tráquea de ratones Balb/c infectados a los 12 días post-infección (L3-tráquea). Los productos ES se obtuvieron mediante el cultivo de larvas. Se realizó un análisis proteómico utilizando cromatografía líquida-espectrometría de masas en tándem (LC-MS/MS) y herramientas bioinformáticas como MaxQuant, Perseus y Andromeda, siguiendo un protocolo detallado disponible en GitHub. Este análisis incluyó la identificación de péptidos, puntuación y cuantificación contra una base de datos específica del organismo, junto con controles de calidad, evaluación de correlación y determinación de abundancia diferencial mediante el algoritmo Amica.

En total, se identificaron 58 proteínas únicas en los productos ES. De estas, 14 proteínas fueron comunes a todas las etapas, mientras que otras fueron específicas de cada etapa. El análisis de componentes principales reveló perfiles proteicos distintos para cada etapa, sugiriendo que los proteomas son cualitativamente diferentes. El análisis de ontología genética indicó un enriquecimiento GO específico por etapa en diversas clases de proteínas, como las proteínas nucleares en los productos ES de L3-huevo y las enzimas metabólicas en los productos ES de L3-pulmón y L3-tráquea. Este estudio pone de manifiesto las diferencias específicas por etapa en la composición de los productos ES de *Ascaris*. Es esencial investigar más a fondo los roles funcionales de estas proteínas y sus interacciones con las células del hospedero para desarrollar estrategias terapéuticas y diagnósticas innovadoras contra la ascariasis.

Como producto de este capítulo se adjuntan los siguientes artículos científicos:

Artículo 4: **Castañeda S**, R,Poveda Charlie Suarez-Reyes, Yifan Wu, Noah Haugen, Patiño, Luz H, Weatherhead JE, Ramírez JD. Microbiota Dynamics During *Ascaris* Larval Migration: Implications for Host Microbial Communities. *Sometido a Microbial Pathogenesis (Q1)*.

Artículo 5: **Castañeda S**, Adeniyi-Ipadeola G, Wu Y, Suarez-Reyes C, Jain A, Ramírez JD, Weatherhead JE. Characterizing Excretory-Secretory Products Proteome Across Larval Development Stages in *Ascaris suum*. *Sometido a Microbes and Infection (Q1)* <https://doi.org/10.1101/2024.07.03.601870>.

Artículo 6: **Castañeda S**, Paniz-Mondolfi A, Ramírez JD. 2024. Detangling the Crosstalk Between *Ascaris*, *Trichuris*, and Gut Microbiota: What's Next? *Frontiers in Cellular and Infection Microbiology* [Internet]. 2022. <https://doi.org/10.3389/fcimb.2022.852900>.

Artículo 7: Ramírez JD, **Castañeda S**, Weatherhead JE, R,Poveda. 2024. Parasite-Microbiota Interactions: A Pathway to Innovative Interventions for Chagas Disease, Leishmaniasis, and Ascariasis. *Sometido a Future Microbiology (Q1)*.

1 **Microbiota Dynamics During *Ascaris* Larval Migration: Implications for Host**
2 **Microbial Communities**

3
4 Sergio Castañeda¹, Cristina Poveda^{2,3,4}, Charlie Suarez-Reyes², Yifan Wu², Noah Haugen^{2,3}, Luz
5 H. Patiño¹, Jill E. Weatherhead^{2,5,6*}, Juan David Ramírez^{1,7*}
6

7 ¹Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de
8 Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia
9

10 ²Department of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston,
11 TX, USA
12

13 ³ Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine,
14 Houston, Texas, USA.
15

16 ⁴Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston,
17 Texas, USA.
18

19 ⁵National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA
20

21 ⁶Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston,
22 TX, USA
23

24 ⁷Molecular Microbiology Laboratory, Department of Pathology, Molecular and Cell-based
25 Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
26

27 *Corresponding authors: jill.weatherhead@bcm.edu, juand.ramirez@urosario.edu.co,
28 juan.ramirezgonzalez@mssm.edu
29
30
31
32
33
34
35

36 **Abstract**

37 The complex interactions between parasites, their hosts, and associated microbiota hold significant
38 implications for host health and disease outcomes. Helminths like *Ascaris lumbricoides* and
39 *Ascaris suum* can significantly alter the host's intestinal microbiota, affecting both parasite biology
40 and host pathology. Despite extensive research on host-microbiota changes due to helminth
41 infections, the study of helminth-associated microbiota remains limited. This study aims to
42 characterize the microbiota associated with various developmental stages of *Ascaris* and its impact
43 on the host's microbiota during larval migration in a murine model. Fifteen mice were infected
44 with 2500 embryonated *A. suum* eggs via oral gavage. Five *Ascaris*-infected mice and age-matched
45 naïve mice were euthanized at 4-, 8-, and 14-days post-infection (DPI). Stool, intestine, liver, and
46 lung samples were collected. Larvae were isolated from embryonated eggs *in vitro*, from the liver
47 at 4 DPI, and the lung at 8 DPI. Utilizing 16S rRNA sequencing, we analyzed bacterial diversity
48 in samples from different *Ascaris* stages and host tissues. Our results revealed a total of 8,040
49 amplicon sequence variants (ASVs) with *Ascaris* samples displaying the highest diversity.
50 Notably, *Ascaris*-associated microbiota differed significantly from that of the host, with higher
51 diversity observed in the parasite. Differential abundance analysis identified distinct taxonomic
52 patterns, highlighting specific genera such as *Bradyrhizobium*, *Achromobacter*, and *Pseudomonas*
53 in *Ascaris*. Our findings suggest that *Ascaris* harbors a unique microbiota that potentially
54 exchanges bacteria with the host during larval migration. These insights pave the way for further
55 research into the ecological and functional dynamics of helminth-microbiota interactions, which
56 may inform novel therapeutic strategies targeting these microbial relationships to mitigate
57 helminth infections and improve host health outcomes.

58

59 **Key Words**

60 *Ascaris*, microbiome, parasite-host interactions

61

62

63

64

65

66

67

68

69

1. Introduction

The interactions between parasites, their hosts, and their associated microbiota form a complex and dynamic system that have significant implications for host health and disease outcomes [1–3]. Helminths, such as *Ascaris lumbricoides* and *Ascaris suum*, are of particular interest due to their widespread prevalence and the considerable burden they impose on human and animal populations [4–9]. Evidence suggests that these helminths can alter the composition and structure of the host's intestinal microbiota, potentially playing a critical role in the parasite's biology and pathophysiology [10–18].

Studies evaluating the host-helminth-intestinal microbiota relationship have found that alterations in bacterial taxa abundance and diversity of the host intestinal microbiota in the presence of helminths can significantly influence the parasite's life cycle, promoting infectiveness, dissemination, and modulation of the host immune response [2,13,15,19–25]. However, contrasting findings from descriptive studies on human populations reveal that helminth infections do not consistently impact the host microbiota, suggesting that different methodological approaches may lead to heterogeneous results [14,21,26]. Researchers have developed and implemented murine and porcine models of *Ascaris* infection to address these inconsistencies and control potential confounding variables. These models aim to model the infection process in humans, allowing for a controlled study of parasite-host-microbiota interactions. Through these models, researchers can evaluate the changes in microbiota composition and structure caused by helminths and examine the dynamic interactions between helminth infections and host viscera microbiota [27–32].

Ascaris infection involves complex biological characteristics including an essential extra-intestinal migration, during which infective larvae (L3) invade gastrointestinal mucosal tissue and migrate through the liver and lungs before returning to the intestines to develop into adult worms [12,33–35]. This larval migration likely alters the composition and structure of host microbiota in extra-intestinal viscera like the liver and lung. However, no studies to date have explored alterations of host microbiota during the larval migratory phase. While minimal data exists regarding the impact of *Ascaris* on extra-intestinal viscera, adult *Ascaris* worms in the intestines have been found to reshape the host intestinal microbiota structure. Adult worms in the intestines cause a decrease in essential anaerobic bacteria like *Faecalibacterium* and *Ruminococcus*, and an increase in facultative anaerobes like *Streptococcus* creating a favorable metabolic environment for long-term parasite survival in the intestines [2,13,15,19–25]. While *Ascaris* infection has been shown to alter host microbiota, data on these complex interactions has not been consistent. Using an *Ascaris suum* infected pig model, Wang et al. (2019) [13] reported reduced alpha diversity in intestinal tissue while Williams et al. (2017), also in pigs [36], observed increased alpha diversity but decreased relative abundance of *Lactobacillus*, *Ruminococcus*, and *Catenibacterium* genera.

110 Despite numerous studies exploring changes in host microbiota due to helminth infections,
111 research on helminth-associated microbiota remains limited [37–39]. Investigating the helminth's
112 own microbiota is crucial, as it defines stage-specific transient microbiota and their interactions
113 with the host, uncovering mutualistic relationships between specific bacterial groups and the
114 parasite essential for its biology, infectivity, and dissemination [39,40]. For example, *Wolbachia*
115 bacteria found in Onchocercidae nematodes, causing lymphatic filariasis and onchocerciasis,
116 provide vital metabolites in a symbiotic relationship crucial for the parasite [41]. Despite these
117 insights, few studies have explored *Ascaris*-microbiota composition and its role in parasite-host
118 interactions. Midha et al. (2020) conducted a study analyzing the intestinal microbiome of adult
119 *Ascaris suum* in pigs, comparing it with the host's gut microbiome during infection [37]. Using
120 16S rRNA sequencing, they observed lower diversity in the parasite's gut compared to the host's,
121 with reduced diversity specifically at the infection site in the jejunum. The host's microbiome at
122 this site influenced the parasite's microbiome, although distinct microbial signatures differentiated
123 the nematodes from their hosts. This study provided the first insights into *Ascaris*-associated
124 microbiota dynamics during host interaction [37].

125

126 Prior research underscores the complexity of the *Ascaris*-host-microbiota interaction and
127 highlights the need for more robust research on the host and parasite microbiota and how they
128 influence each other over time. Here, we characterize the microbiota associated with different
129 *Ascaris* developmental stages and examining the influence of the *Ascaris* microbiota on host
130 microbiota during larval migration through the intestine, liver, and lungs in a murine model.
131 Employing metabarcoding via 16S rRNA gene sequencing, we aim to elucidate dynamic changes
132 in microbiota composition within the parasite and the host, enhancing our understanding of
133 helminth-microbiota's ecological and functional dynamics. Exploring these interactions may
134 uncover new strategies for managing *Ascaris* infections and mitigating their impacts on host
135 health.

136

137 **2. Methods**

138 ***2.1. Mice and parasites***

139 8-week-old female BALB/c mice were obtained from Jackson Laboratories. All animal
140 experiments were carried out following the guidelines outlined in the 8th edition of the Guide for
141 the Care and Use of Laboratory Animals under the approval protocol by Baylor College of
142 Medicine's Institutional Animal Care and Use Committee (IACUC), AN-9173. Embryonated
143 *Ascaris suum* eggs for the experiments were obtained from adult female worms collected from
144 *Ascaris* infected pigs maintained at Baylor College of Medicine under IACUC AN-8544. All the
145 mice were maintained in the same housing conditions and on the same diet at the Baylor College
146 of Medicine facility.

147 ***2.2. Hatching *Ascaris suum* larvae (L3) in vitro***

148 To determine the larvae' inherited microbiome, embryonated eggs were hatched *in vitro*. Eggs were
149 placed in H₂SO₄ solution and centrifuged. The pellet was resuspended in a sodium hypochlorite
150 solution and incubated for a 2-hour. After incubation, eggs were collected by centrifugation and
151 washed three times with ultrapure water. Eggs were resuspended in Hanks Balanced Salt Solution
152 (HBSS) with a pH of 2.0, adjusted using hydrogen chloride, and incubated for 30 minutes at 37°C
153 with 5% CO₂. Then, eggs were centrifuged and resuspended in HBSS with a pH of 7.0 to neutralize
154 the eggs for 30 minutes. Finally, eggs were centrifuged and resuspended in culture media (RPMI-
155 1640 + 44% penicillin-streptomycin), placed in a 6-well plate, and incubated for 96 hours. Egg
156 hatching was monitored using light microscopy. Once the larvae hatched, the larva was pelleted
157 by centrifuge and were stored at -80°C.

158

159 **2.3. *Ascaris suum* infection**

160 15 Balb/c mice were infected with embryonated 2500 *A.suum* eggs in PBS via oral gavage and 15
161 Balb/c mice were sham infected with PBS via oral gavage. A group of 5 *Ascaris*-infected mice and
162 5 age-matched naïve mice were euthanized at 4-, 8-, and 14-days post-infection (DPI). Stool,
163 duodenum, liver, and lung were collected and frozen at -80°C. Larvae were isolated from host
164 tissue from the liver at 4 DPI and the lung at 8 DPI.

165

166 **2.4. *Ascaris suum* larvae (L3) isolation from tissues**

167 Liver tissue was collected at 4 DPI, and lung tissue was collected at 8 DPI and macerated with 1X
168 PBS. The macerated mixture, tissue+PBS, was transferred into a Baermann apparatus equipped
169 with a conical tube and incubated at 37°C with 5% CO₂ for 4 hours. After incubation, samples
170 were filtered to let larvae settle at the bottom. The supernatant was removed, and the pellet was
171 washed with ultra-pure water three times by centrifugation at 800g for 10 minutes at 4°C. After
172 the final wash, the supernatant was removed, and the isolated larvae from lungs or livers were
173 stored at -80°C.

174

175 **2.5. DNA extraction for microbiota analysis**

176 Larvae, tissues, and stool were homogenized mechanically, disrupting them with beads and
177 shaking, using the MP FastPrep-24 homogenizer (MP Biomedicals, Eschwege, Germany). DNA
178 was isolated with a specific kit selected to ensure the extraction of high-quality DNA for further
179 analysis. DNA from stool samples was isolated using the stool nucleic acid isolation kit (Norgen
180 Biotek Corp., Thorold, Canada). DNA from 25-35 mg of lung and liver was obtained using
181 DNEasy (Qiagen, Germany). Finally, larvae isolations from invitro hatching, lungs, and livers
182 were isolated with the DNeasy PowerSoil Pro Kits (Qiagen, Germany). Each isolation was

183 performed by following the manufacturer's protocol. All extracted DNA was resuspended in 100
184 μ L of pyrogen-free water, quantified in a Nanodrop (Thermo Scientific), and kept at -80°C .

185

186 ***2.6. 16S rRNA-amplicon-based sequencing and microbiome analysis***

187 All samples ($n = 49$) were subjected to amplicon sequencing of the V4 hypervariable region of 16S
188 rRNA gene using the Illumina NovaSeq platform, paired-end, PE 150pb. The bioinformatics
189 pipeline began with the extraction of barcodes and primers from the resulting paired-end sequences
190 using the Quantitative Insights Into Microbial Ecology (QIIME) analysis program [42]. Using
191 DADA2, the quality profile of the reads was evaluated to select the length with quality greater than
192 30 and, thus, minimize erroneous reads [43]. Normalization and rarefaction curves were
193 implemented to prepare and normalize the data and to confirm that the sequencing depth was
194 sufficient to capture the diversity of the samples analyzed. DADA2 was also employed to
195 determine the central sample inference algorithm of the reads for inferring amplicon sequence
196 variants (ASVs). This process eliminated duplications by combining all identical sequencing reads
197 into single sequences, and chimeras were removed before taxonomic allocation. Finally, the
198 taxonomic assignment was performed using the sequences of the Silva v138 formatted reference
199 database [44,45].

200 The analysis of microbiota diversity, including the calculation of diversity indices and relative
201 abundances, as well as the construction of corresponding graphs, was carried out using the R
202 *Phyloseq* and *Vegan* packages [46]. Additionally, linear discriminant analysis (LDA) effect size
203 (LEfSe) analysis and DESeq2, were employed to identify taxa with differential abundance [47].
204 The threshold of the logarithmic LDA score was 4.0 with a maximum kw value of 0.01 for LEfSe
205 analysis. For DESeq2, a pCutoff of 0.05 and an FCcutoff of 1.0 were used.

206

207 ***2.7. Statistical analysis***

208 The number of reads in each sample was normalized using the average sequence depth. Relative
209 abundance and alpha diversity metrics, including observed richness, Shannon, and Simpson
210 indices, were used to compare groups [48]. Depending on the number of comparison groups, alpha
211 diversity indices were compared using non-parametric Mann-Whitney-Wilcoxon and Kruskal-
212 Wallis tests. To explore differences in the general composition of the microbial community (beta
213 diversity) concerning groups, Bray-Curtis taxonomic distances were calculated. A principal
214 coordinates analysis (PCoA) diagram was also generated, where Bray-Curtis distances between
215 samples were used to visualize group compartment. Permutational multivariate analysis of
216 variance using distance matrices (PERMANOVA) was conducted to test for multivariate effects,
217 employing the adonis function from the vegan package[49]. Statistical analyses were performed
218 using R software[50]. All significance tests were two-tailed, and P-values < 0.05 were considered
219 statistically significant.

220

221 **3. Results**

222 **3.1. Sequencing results**

223 We obtained a total of 9,573,891 raw reads from all samples, with a mean of 195,385 reads per
224 sample. After DADA2 filtration, denoising, merging, and chimeric removal, we retained 7,944,034
225 reads, representing 83% of the total, with a mean of 162,123 reads per sample (Table S1). The
226 DADA2 pipeline enabled us to identify 8,040 amplicon sequence variants (ASVs). The general
227 profile, encompassing all samples, unveiled the prevalence of bacteria from the phyla
228 Bacteroidota, Firmicutes, Proteobacteria, and Actinobacteria (Fig. 1a).

229

230 **3.2. Alpha Diversity Analysis Reveals Elevated Microbial Diversity in *Ascaris* Larvae-Associated** 231 **Microbiota**

232 We conducted alpha diversity analysis using observed richness, the Shannon index, and the
233 Simpson index to elucidate overall composition and diversity differences among sample groups—
234 specifically *Ascaris* stages, feces, intestine, liver, and lung. *Ascaris* samples showcased the highest
235 diversity, followed by feces and intestine, exhibiting similar values. As anticipated, the liver and
236 lung displayed the lowest diversity, attributable to their limited bacterial burden (Fig. 1b).

237 We compared the diversity between *Ascaris* infected and non-infected mice and evaluated each
238 tissue group based on infection status (Fig. 1 c-g). Overall, we did not observe significant
239 differences in diversity in varying tissues between infected and non-infected mice. When
240 comparing tissue samples to *Ascaris* larva, the feces and intestine sample groups had no significant
241 differences in diversity related to infection status or between the tissue groups and the *Ascaris*
242 larvae stages (Fig. 1c, d). In contrast, the liver and lung host tissue samples exhibited statistically
243 significant differences in diversity compared to *Ascaris* larvae. In both cases, *Ascaris* larvae
244 displayed higher diversity than each independent host tissue group (Kruskal Wallis test, p-value <
245 0.01) (Fig. 1e, f). Moving forward, to analyze diversity specifically in different *Ascaris* stages, we
246 compared the Shannon index among *in vitro* larvae, larvae 4 day post-infection (DPI) (liver), and
247 larvae 8 DPI (lung). Although we did not detect statistically significant differences, it is noteworthy
248 that diversity increased with the progression of the life cycle from day 4 to day 8 post infection
249 (Fig. 1g, S1).

250 To complement the previous evaluation, we aimed to compare the diversity between the host and
251 *Ascaris* at various days post-infection (naïve, 4 DPI, 8 DPI, and 14 DPI). For this purpose, we
252 evaluated diversity by examining each sample group (feces, intestine, liver, lung) and each larval
253 stage (larva *in vitro*, larvae in the liver 4 DPI, and larvae in the lung 8 DPI). Although we did not
254 detect statistically significant differences, it is remarkable that diversity in the liver and lung
255 increased after larval passage through these organs on days 4 DPI and 8 DPI, respectively. This

256 suggests a potential microbiota exchange from the *Ascaris* larvae to the host, considering our
257 previous demonstration of higher diversity in *Ascaris*-associated microbiota (Fig. S1 a,b).

258

259 ***3.3. Beta Diversity Analysis Indicates Distinct Microbiota Composition in Ascaris Compared to*** 260 ***Host***

261 We have observed that the *Ascaris*-associated microbiota exhibited higher diversity values
262 regardless of the larval stages, and even when compared with the intestine and feces, these values
263 were quite similar. The migration of larvae from the intestine to the liver and lung likely contributes
264 to the increase in *Ascaris* diversity. Additionally, it is plausible that *Ascaris* shares bacteria with
265 the host at the liver and lung levels, further contributing to the increased diversity in these organs.
266 Given these findings, we aimed to determine the similarity between the microbiota of *Ascaris* and
267 the host tissue groups. We first performed rarefaction on the samples to control for potential bias
268 to achieve this objective. Then, we conducted a permutational analysis of variance
269 (PERMANOVA) based on Bray-Curtis dissimilarities (Fig S2a). Subsequently, we performed
270 Principal Coordinates Analysis (PCoA) to visualize clusters corresponding to sample groups:
271 *Ascaris*, feces, intestine, liver, and lung (Fig. 2a).

272 We discovered that despite transversing the tissue durations during the life cycle, the *Ascaris*
273 microbiota differs significantly from that of the host, regardless of the organ tissue (Fig. 2a).
274 Additionally, we observed that the microbiota of the liver and lung form a distinct cluster that is
275 more similar to the intestines than to the feces. Interestingly, the intestinal microbiota differed
276 significantly from the bacterial composition of feces (PERMANOVA: adonis2 p= 0.001).
277 Complementary beta diversity analyses were conducted to identify compositional differences
278 between groups of infected and non-infected mice and *Ascaris* larvae. We found that the microbiota
279 composition were similar between *Ascaris* infected and non-infected mice, suggesting that *Ascaris*
280 infection may not be associated with global changes in the microbiota structure of the host.
281 However, once again, we observed that the host microbiota differed substantially from the *Ascaris*-
282 associated microbiota (PERMANOVA: adonis2 p= 0.003) (Fig. S2b).

283

284 ***3.4. Microbiota Composition: Unique and Shared Taxa between Ascaris and Host***

285 Understanding that the global composition of microbiota differs between the host and *Ascaris*
286 larvae, we determined a relative abundance profile of tissue groups by DPI to identify potential
287 differences. We observed that the overall microbiota of *Ascaris* stages was primarily characterized
288 by the Proteobacteria phylum, followed by Firmicutes and Bacteroidota. Intriguingly, the
289 microbiota of the lung and liver were quite similar at the phylum level, showing a high relative
290 abundance of Proteobacteria and Bacteroidota phyla. The intestine was mainly composed of
291 Proteobacteria, Firmicutes, and Bacteroidota, while the feces primarily consisted of Firmicutes,
292 Bacteroidota, and Verrucomicrobia (Fig. 2b).

293 Considering these characteristics, we performed a specific analysis of each tissue group by DPI
294 and of each *Ascaris* larval stage at several taxonomical levels (Fig. 2 b, c, Fig. S2 c,d). The *Ascaris*
295 larva in vitro showed that the most abundant genera were *Delftia*, *Sphingomonas*, *Achromobacter*,
296 *Chryseobacterium*, and *Pseudomonas*, all of which belong to the Proteobacteria phylum.
297 Interestingly, larval migration is associated with changes in the microbial composition. We
298 observed in larvae isolated from the liver at 4 DPI and larvae isolated from the lung at 8 DPI had
299 an increase in the relative abundance of taxa such as *Bradyrhizobium*, but also of *Lactobacillus*,
300 and the *Lachnospiraceae NK4136 group*, which are likely derived from the host (Fig. 2c). These
301 findings again support the early finding of increased alpha diversity in the *Ascaris* larvae as the
302 larval life cycle progresses. Conversely, the lungs and liver tissue microbiota did not demonstrate
303 any changes in the bacterial composition during the larval life cycle progression. Throughout the
304 study, both organs were mainly constituted by the genus *Delftia* and *Chryseobacterium* (Fig. 2c).

305 In the non-infected intestine, we observed a relative abundance of taxa such as the *Muribaculaceae*
306 *family*, *Akkermansia*, and *Lactobacillus* at 4 DPI and 8 DPI, which partially reduced by 14 DPI.
307 Conversely, in the infected intestine, we observed an increase in the relative abundance of *Delftia*
308 and *Chryseobacterium* at 4 DPI and 8 DPI after infection, likely originating from *Ascaris* larvae
309 (Fig. 2c). In both non-infected and infected feces, we observed higher relative abundances of taxa
310 such as the *Muribaculaceae family*, *Lachnospiraceae NK4A136*, *Akkermansia*, *Lactobacillus*,
311 *Alistipes*, and the *Oscillospiraceae family*, which are commonly found in host feces (Fig. 2c).

312 Considering these results, we propose that despite beta diversity analysis showing that *Ascaris*
313 possesses a distinct overall microbiota compared to the host, certain taxa are shared between them.
314 We evaluated the microbiota common to *Ascaris* stages, *Ascaris* infected host tissues and non-
315 infected host tissues to establish core microbiota for the helminth and the host (Fig. 2d). We
316 identified 273 taxa comprising the *Ascaris*-core microbiota, 111 taxa in *Ascaris* infected mice, and
317 178 taxa in non-infected mice. Seventy-seven taxa were shared across these three groups.
318 Regarding condition-specific Amplicon Sequence Variants (ASVs), 147 taxa were unique to
319 *Ascaris*, 7 were exclusive to infected hosts, and 41 were found only in non-infected hosts.
320 Interestingly, 8 ASVs were exclusively shared between *Ascaris* and infected hosts (Fig. 2d). These
321 8 ASVs, identified at the genus level and characterized at species level individually using BLAST,
322 included *Achromobacter xylosoxidans*, *Pseudomonas fluorescens*, *Blautia wexlerae*, *Blautia*
323 *coccoides* and *Lachnospiraceae NK4A136* (Fig 2 c,d). These bacteria may play a significant role
324 in the infection process and could have unique behaviors that facilitate colonization, life cycle
325 progression, and infection, representing a notable aspect of the parasite-host-microbiota
326 interaction.

327

328 **3.5. Differential Abundance Analysis: Revealing Microbial Profiles Across *Ascaris* and its host**

329 To identify microbiota members exhibiting differential abundance across sample groups—*Ascaris*
330 larvae, Feces, Intestine, Liver, and Lung—we employed a linear discriminant analysis effect size

331 (LEFSe) and DEseq2. Our analysis unveiled distinct taxa: in *Ascaris*, the genera *Bradyrhizobium*,
332 *Achromobacter*, and *Pseudomonas* exhibited notable differential abundance. Conversely, the
333 genus *Delftia* and the family Comamonadaceae displayed distinct differential abundance in the
334 liver. Likewise, the genus *Chryseobacterium* emerged as a differentially abundant taxon in the
335 lung. The intestine exhibited differential abundance in the Lactobacillaceae family. Finally,
336 differentially abundant taxa in feces included *Muribaculaceae*, *Lachnospiraceae* NK4A136 group,
337 and the family Oscillospiraceae (Fig 3a, Fig S3a). We extended this approach to discern taxa
338 exhibiting differential abundance between infected and non-infected hosts and *Ascaris* larvae. We
339 found that in infected hosts, the genera *Alistipes*, *Eisenbergiella*, and *Faecalibacterium* were
340 abundant, while the genus *Delftia* was characteristic of non-infected hosts. In the case of *Ascaris*,
341 consistent with previous findings, the genera *Achromobacter*, *Pseudomonas*, *Sphingomonas*,
342 *Bradyrhizobium*, *Rhodococcus*, and *Blautia* were differentially abundant. (Fig. 3c,d, S3b-d).

343 When scrutinizing the pattern of differentially abundant taxa across sample groups, notable
344 similarities appeared particularly between the liver and lung, delineating a distinct cluster
345 characteristic of these organs, predominantly composed of Proteobacteria, notably genus *Delftia*
346 and *Chryseobacterium*. This shared taxonomic composition partially extended to the intestine,
347 where taxa associated with Firmicutes and Bacteroidota were also prominent, reflective of typical
348 intestinal microbial profiles. Likewise, this intestinal pattern shared similarities with the
349 differentially abundant taxa observed in fecal samples, where taxa such as *Lachnospiraceae*
350 NK4A136 and *Akkermansia* were notably abundant. Conversely, *Ascaris* larvae displayed a unique
351 profile of differentially abundant taxa, exhibiting partial overlap with the host, particularly in terms
352 of Proteobacteria. Additionally, as previously noted, representatives of Firmicutes and
353 Bacteroidota were also discernible in the *Ascaris* larvae groups (Fig 3b).

354

355 **4. Discussion**

356 To date, parasite-host-microbiota interactions focus on how the parasite influences the microbiota
357 within the host organism [1,51–54]. Various methodological approaches have been employed to
358 identify host microbiota changes induced by *Ascaris*, specifically adult worms in the intestines,
359 often yielding contradictory results [10,55–57]. It is well-established that *Ascaris* can modulate
360 the immune response in the intestines allowing for survival of up to 2 years within the host
361 intestines [58]. However, there is limited information about the *Ascaris* larvae-associated
362 microbiota and its potential relationship with the host, particularly during the essential larval
363 migratory cycle [37]. This relationship could be crucial for understanding the infection's success
364 and the parasite's biological cycle within the host [40,59,60]. Given this context, our study focused
365 on characterizing the *Ascaris*-associated microbiota at different developmental stages and
366 examining its impact on the host's microbiota during the larval migration phase through the
367 intestine, liver, and lung in a murine model.

368 Regarding the potential microbiota changes produced in the host, we did not find alpha diversity
369 differences between infected and non-infected mice with any tissue group (Fig 1c-g). Previous
370 studies have shown discordant results regarding the impact of *Ascaris* on the structure and
371 composition of the host microbiota in the intestines. For example, Wang et al. (2019) and Midha
372 (2022) demonstrated that infection with *Ascaris* significantly reduced the alpha diversity of the
373 intestinal microbiota in pigs, and this effect was independent of the parasite burden [13,37].
374 Conversely, studies like those conducted by Stracke et al. (2021) have shown that *Ascaris* infection
375 does not affect alpha diversity values [61]. These discrepancies likely arise from differences in
376 experimental models, approaches, and other methodological factors such as sample size, which
377 can introduce variability. For instance, the differences in host species (pigs vs. mice), the nature of
378 the microbiota in these hosts, and the specifics of experimental conditions (e.g., diet, housing
379 conditions, infection load) could all contribute to the observed variations in results [27,29,30].
380 Moreover, the stages of infection and the timing of sample collection can significantly influence
381 microbiota diversity. Addressing these variations necessitates longitudinal studies and suitable
382 animal models. Developing robust animal models that can be followed over time will allow for
383 more standardized results that could be extrapolated to other hosts, such as humans.

384 Our study found higher alpha diversity in *Ascaris* larvae-associated microbiota compared to the
385 host tissues (intestine, liver, lung) (Fig. S1), suggesting a diverse microbial community within the
386 larvae. Diversity within *Ascaris* the *Ascaris* larvae increased during the larval migration cycle,
387 indicating progressive microbiota accumulation across different host tissues. This aligns with
388 lower diversity observed in vitro, recently hatched *Ascaris* larvae compared to more mature
389 developmental staged larvae in the liver and lung. While helminth microbiota may originate
390 through vertical transmission, horizontal acquisition from the environment, both outside and inside
391 of the host, is likely [64]. Our findings suggest that specific bacterial populations are acquired
392 during *Ascaris* larval migration through the host likely via horizontal acquisition. Further research
393 is needed to explore these mechanisms and determine the integration of acquired bacteria into the
394 *Ascaris* larvae, and ultimately the adult worm, microbiota.

395 The higher diversity observed in *Ascaris*-larvae associated microbiota compared to host tissues
396 could have several implications (Fig 1 b-e, Fig S1). A more diverse microbial community within
397 the parasite may offer several advantages, including increased resilience to environmental changes,
398 a heightened ability to exploit host resources, and the production of metabolites crucial for immune
399 evasion in the host. This diverse microbiota might also modulate the host immune response, aiding
400 the parasite in evading immune detection and establishing chronic infection in the intestines
401 following the larval migration cycle [37,40]. Confirming these findings requires designing studies
402 to unravel helminths' microbiota acquisition and transmission mechanisms.

403 Beta diversity analysis revealed that the microbiota composition of *Ascaris* is markedly different
404 from that of the host (Fig 2a, S2b). Recent studies have corroborated these findings, indicating that
405 helminths possess a distinct microbiota compared to their hosts, sharing only a limited number of
406 taxa. For instance, a recent study demonstrated that the gut microbial structure of adult *A.*

407 *lumbricoides* significantly differs from that of the human hosts, exhibiting clear separation in beta
408 diversity analysis [62]. Similarly, in a pig model, adult *Ascaris*-microbiota composition across
409 various intestinal tract segments detected both shared and differential bacteria between the *Ascaris*
410 microbiome and host microbiome [37]. These findings underscore that *Ascaris* harbors its distinct
411 microbiota and influences the microbial ecosystem within its host and vice versa. The unique
412 microbiota within *Ascaris* may facilitate the parasite's survival and adaptation by providing
413 essential functions not available from the host's microbiota alone [37,60,62].

414 The unique microbial communities within *Ascaris* larvae likely play a role in modulating the host's
415 immune responses, facilitating the establishment and persistence of the parasite. . We performed
416 taxonomic characterization of *Ascaris* stages and host tissues to elucidate unique microbial
417 communities, yielding insightful findings. *Ascaris* microbiota was predominantly Proteobacteria,
418 followed by Firmicutes and Bacteroidota, consistent with studies on *C. elegans* showing Gamma-
419 proteobacteria and Bacteroidetes dominance [63,64]. Proteobacteria's prominence highlights its
420 metabolic versatility and immunomodulatory potential, crucial for nutrient acquisition and energy
421 metabolism in *Ascaris* within the host [24,63,64]. Lung and liver microbiota exhibited similar
422 phylum-level compositions, rich in Proteobacteria and Bacteroidota, suggesting comparable
423 niches for bacterial communities. In contrast, the intestine contained diverse Proteobacteria,
424 Firmicutes, and Bacteroidota, while feces were mainly Firmicutes, Bacteroidota, and
425 Verrucomicrobia. These unique compositions underscore *Ascaris*' distinct bacterial environment
426 and emphasize the need for organ-level studies to understand parasite-host-microbiota interactions
427 fully. Further studies on host organ level and *Ascaris* developmental stage microbiota are critical
428 to understanding parasite-host-microbiota interactions and could inform the development of novel
429 strategies to prevent helminth infections.

430 At the genus level, we observed significant changes during *Ascaris* larval migratory cycle. *In vitro*,
431 the most abundant genera in *Ascaris* larvae were *Delftia*, *Sphingomonas*, *Achromobacter*,
432 *Chryseobacterium*, and *Pseudomonas*, all of which belong to the Proteobacteria phylum. The
433 initial microbial community in the early-stage larvae may be derived from vertical acquisition or
434 the external environment [60]. However, larvae isolated from the liver at 4 DPI and larvae isolated
435 from the lung at 8 DPI, had increased relative abundance of other taxa, such as *Bradyrhizobium*,
436 *Lactobacillus*, and the *Lachnospiraceae* NK4A136 group, with the latter two likely derived from
437 the host [60]. This shift in *Ascaris* microbiota after infection aligns with models such as
438 *Heligmosomoides polygyrus*, where worm-associated microbes were similar to those in the
439 infected host ileum and dominated by Lactobacillaceae, while infective larvae-associated microbes
440 were unique and dominated by Pseudomonadaceae. This supports likely horizontal bacterial
441 acquisition by *Ascaris* from the host [15,60,65,66], incorporating and modifying their microbiota
442 to gain advantageous microbial populations. Studies that elucidate whether the acquired bacteria
443 are transient or integrated into *Ascaris*' own microbiota longitudinally are essential.

444 The presence of genera such as *Delftia* and *Chryseobacterium* within host tissues, particularly the
445 liver and lung, underscores their significant roles in modulating host immune responses and

446 shaping tissue microenvironments. These findings align with previous studies characterizing the
447 lung microbiota in mice, where the *Delftia* genus was identified as one of the most prevalent taxa
448 in this model [67]. Moreover, these bacteria are known for interacting with immune cells and fine-
449 tuning inflammatory processes, which may contribute to parasite persistence and pathogenesis
450 [68]. However, further research is warranted to elucidate the functional implications of these
451 microbiota changes and their specific roles in *Ascaris* biology and host health. Understanding the
452 mechanisms by which these bacteria influence host-parasite interactions could provide valuable
453 insights into novel therapeutic strategies for combating parasitic infections.

454 A core microbiota analysis unveiled eight ASVs shared between *Ascaris* larvae and infected host
455 tissues. Four of these ASVs were identified at the genus level, and further characterized at the
456 species level using BLAST: *Achromobacter xylosoxidans*, *Pseudomonas fluorescens*, *Blautia*
457 *wexlerae*, *Blautia coccoides*, and *Lachnospiraceae NK4A136*. These common taxa might be
458 essential in *Ascaris* pathogenicity, required for promoting infection, supporting the organism
459 during the essential but metabolically taxing larval migratory cycle, and facilitating parasite
460 establishment and survival [37,60]. The potential transfer of microbiota from *Ascaris* to the host
461 during migration, particularly genera like *Lactobacillus* and *Lachnospiraceae*, raises intriguing
462 questions about their impact on parasite and host cross-talk. These bacteria could influence gut
463 barrier function, nutrient absorption, or host susceptibility to other pathogens [69–71].
464 *Pseudomonas* specifically has been demonstrated in *C. elegans* models to have the ability to
465 protect the worm against infection with *B. thuringiensis* through production of massetolide E and
466 limiting worm-induced damage in the host [63]. *Pseudomonas*, *Achromobacter*, and *Blautia* can
467 collectively create an anti-inflammatory environment that contributes to immunomodulation.
468 Additionally, *Blautia*'s production of metabolites, including those derived from tryptophan, may
469 play a pivotal role in the pathogenicity of *Ascaris* [63,72]. These findings propose novel insights
470 into the function of the native and acquired microbiota in helminths, highlighting the role of
471 microbes in supporting the worms' development and survival in the host. Shared ASVs suggest
472 that certain bacterial taxa may be integral to the parasite's life cycle and pathogenicity. These
473 findings underscore the need for further research to elucidate the specific mechanisms by which
474 these bacteria influence both the parasite and the host. Moreover, they represent a crucial step in
475 identifying potential taxa necessary for the larval migratory cycle and long-term survival of the
476 worms in the host intestines, thereby paving the way for developing microbiota-modulation
477 strategies in helminth infections.

478 The results of the differential abundance analysis revealed distinct taxonomic patterns across
479 different sample groups, shedding light on the microbial dynamics within the *Ascaris*-infected
480 host. Specific genera such as *Bradyrhizobium*, *Achromobacter*, and *Pseudomonas* exhibited
481 notable differential abundance in *Ascaris* larvae. Notably, distinct clusters of taxa, predominantly
482 Proteobacteria like *Delftia* and *Chryseobacterium*, were observed in the host organs, particularly
483 the liver and lung, delineating organ-specific microbial profiles. Interestingly, similarities were
484 also observed between the intestine and fecal samples, indicating shared taxa associated with

485 Firmicutes and Bacteroidota, typical of intestinal microbial communities [73]. However, the
486 helminth exhibited a unique taxonomic profile, with partial overlap with the host microbiota,
487 especially in terms of Proteobacteria, and representatives of Firmicutes and Bacteroidota. These
488 findings underscore the complex interplay between *Ascaris* and the host microbiota, highlighting
489 organ-specific microbial signatures and potential interactions that warrant further investigation.
490 Moreover, the lack of significant differences in abundance patterns between infected and non-
491 infected hosts and *Ascaris* suggests that the presence of the parasite may not significantly alter the
492 overall microbial composition in the host during larval migration.

493 This study lays the groundwork for further exploration of *Ascaris*–host-microbiota interactions
494 that could provide significant insight into the pathogenicity of *Ascaris*. However, this study has
495 several limitations. First, 16S rRNA-amplicon-based sequencing was used in this study.
496 Nevertheless, whole-genome sequencing could provide more robust taxonomic resolution and
497 functional characterization of the microbiota. This study used a well-established mouse model;
498 nonetheless, mice are not native hosts of ascariasis, which may reduce the applicability of these
499 findings. Alternatively, the porcine model is a native host of ascariasis and has distinct similarities
500 to humans, making it the optimal host for confirming our findings. This study was conducted for
501 14 days and highlights changes in microbiota during the acute period. However, longitudinal
502 studies are required to gain a more in-depth analysis of the long-term consequences of the *Ascaris*-
503 host-microbiota interaction. Lastly, supporting the microbiome analysis with metagenomics,
504 transcriptomics, and metabolomics will offer a comprehensive view of the *Ascaris*–host-
505 microbiota interaction to inform helminth control strategies.

506

507 **5. Conclusions**

508 In summary, this study characterized the microbiota of *Ascaris* larvae at various developmental
509 stages in the context of host tissues during the larval migration cycle. The outcomes of this study
510 revealed significant differences in microbiota composition and diversity amongst groups. The
511 prevalence of Proteobacteria in the *Ascaris* microbiota emphasizes its pivotal role in parasite
512 biology, while the varied microbiota profiles across host tissues underscore the intricate interplay
513 between host and parasite-associated microbial communities. This research also included an
514 evaluation of *Ascaris* larvae microbiota and its changes during the larval life cycle, as well as an
515 evaluation of the host microbiota in extra-intestinal organs and how they change over time. These
516 findings allow further exploration into helminth-microbiota interactions' ecological and functional
517 dynamics. Future research should unravel the functional roles of these bacterial communities
518 within *Ascaris*, as well as elucidating the mechanisms involved in the horizontal and vertical
519 acquisition of certain bacterial populations.

520

521

522 **Data availability**

523 Sequence data supporting this article's conclusions are available in the SRA database under
524 BioProject PRJNA1117354. The code for generating the figures and the analysis is available
525 at https://github.com/scastanedag/Ascaris_Microbiome.git.

526

527 **Declaration of Competing Interest**

528 The authors declare that no competing interests exist.

529

530 **Authors' contributions**

531 SC, JW and JDR conceived the study; CP, CSR, YW, NH performed the
532 experiments; SC and LHP analyzed the data. SC, JW and JDR drafted the
533 manuscript. All authors approved the final version of the manuscript.

534 **Acknowledgments**

535 We thank the Ministerio de Ciencia Tecnología e Innovación (Minciencias) of
536 Colombia under the framework of the Sistema General de Regalías for providing the
537 PhD scholarship of Sergio Castañeda.

538 **Funding**

539 This study was funded by Dirección de Investigación e Innovación from Universidad
540 del Rosario.

541

542 **Ethics approval**

543 All animal experiments were carried out following the guidelines outlined in the 8th edition of the
544 Guide for the Care and Use of Laboratory Animals under the approval protocol by Baylor College
545 of Medicine's Institutional Animal Care and Use Committee (IACUC), AN-9173.

546

547 **Figure Legends**

548 **Figure 1.** (a) Proportion of samples by total reads to show abundance by phylum. Main phyla are
549 highlighted with dashed red lines. (b) Diversity metrics—richness, Shannon, and Simpson
550 indices—were observed by sample groups (*Ascaris*, feces, intestine, liver, lung). (c) Boxplot of the

551 Shannon index comparing *Ascaris* diversity against infected and non-infected host feces, **(d)**
552 intestine, **(e)** liver, and **(f)** lung. **(g)** Shannon index comparison between *Ascaris* larval stages
553 evaluated. Statistical analyses were performed using the Kruskal-Wallis (KW) test and a multiple
554 comparison post hoc Mann-Whitney-Wilcoxon (MWW) test. Plotted are interquartile ranges
555 (IQRs; boxes), medians (lines in the boxes), and the lowest and highest values within 1.5 times
556 IQR from the first and third quartiles (whiskers above and below the boxes). * p-values <0.05, **
557 p-values <0.01, ns: not significant

558 **Figure 2.** **(a)** Principal coordinates analysis (PCoA) ordination of Bray-Curtis distances of the
559 microbial communities by sample groups. Permutational analysis of variance (PERMANOVA)
560 test for multivariate effect was done using the adonis function from the vegan package. *** p-
561 values <0.001. **(b)** Bar chart of the relative abundance of top taxa at the phylum level between
562 sample groups. **(c)** Bar chart of the relative abundance of top taxa at the genus level between
563 samples by day of infection (DPI: Days post-infection). **(d)** Venn diagram of core microbiota in
564 *Ascaris* and infected and non-infected hosts. The arrows from panel (c) to panel (d) include ASVs
565 characterized at the species level that are part of shared taxa between *Ascaris* and infected mice.
566 *Blautia* is also part of these ASVs, although it is not included in the top genus taxa in the bar plot.

567 **Figure 3.** Linear discriminant analysis (LDA) effect size (LEfSe) analysis is used to identify taxa
568 enriched in different sample groups. **(a)** Bar plot of taxa enriched at various taxonomic levels. **(b)**
569 Heatmap of differentially abundant taxa across sample groups to evaluate distribution and patterns.
570 The threshold for the logarithmic LDA score was 4.0, and the maximum Kruskal-Wallis (KW)
571 value was 0.01. Volcano plots of differentially abundant taxa across sample groups to evaluate
572 distribution and patterns concerning *Ascaris* and infection status based on DESeq2 analysis,
573 comparing (a) host infected mice and *Ascaris*, and (b) host non-infected mice and *Ascaris*.

574

575 **Supplementary Material**

576 **Table S1.** Summary of the preprocessing of sequencing data, which included quality assessment,
577 trimming, and other steps performed using DADA2.

578 **Figure S1.** **(a)** Diversity Shannon index by sample day of infection and larvae stage in liver **(b)**
579 lung **(c)** intestine, **(d)** and feces. Plotted are interquartile ranges (IQRs; boxes), medians (lines in
580 the boxes), and the lowest and highest values within 1.5 times IQR from the first and third quartiles
581 (whiskers above and below the boxes).

582 **Figure S2.** **(a).** The rarefaction curve of the samples was evaluated. The dotted line shows the
583 approximate number of reads at which the sequences increase and then plateau. **(b)** Principal
584 coordinates analysis (PCoA) ordination of Bray-Curtis distances of the microbial communities by
585 infection status. Permutational analysis of variance (PERMANOVA) test for multivariate effect
586 was done using the adonis function from the vegan package. ** p-values <0.003. **(c)** Bar chart of

587 the relative abundance of top taxa at the class and **(d)** family level between samples by day of
588 infection (DPI: Days post infection).

589 **Figure S3.** Linear discriminant analysis (LDA) effect size (LEfSe) analysis is used to identify taxa
590 enriched in different sample groups. **(a)** Cladogram of taxa enriched at various taxonomic levels.
591 **(b)** Bar plot of taxa enriched at various taxonomic levels regarding *Ascaris* and infection status.
592 **(c)** Heatmap of differentially abundant taxa across sample groups to evaluate distribution and
593 patterns concerning *Ascaris* and infection status. **(e)** Boxplot of differentially abundant taxa across
594 sample groups to evaluate abundance involving *Ascaris* and infection status. The threshold for the
595 logarithmic LDA score was 4.0, and the maximum Kruskal-Wallis (KW) value was 0.01.

596

597 **References**

- 598 [1] O. Partida-Rodríguez, A. Serrano-Vázquez, M.E. Nieves-Ramírez, P. Moran, L. Rojas, T.
599 Portillo, E. González, E. Hernández, B.B. Finlay, C. Ximenez, Human Intestinal
600 Microbiota: Interaction Between Parasites and the Host Immune Response, *Arch. Med.*
601 *Res.* 48 (2017) 690–700. <https://doi.org/10.1016/j.arcmed.2017.11.015>.
- 602 [2] L. Glendinning, N. Nausch, A. Free, D.W. Taylor, F. Mutapi, The microbiota and
603 helminths: Sharing the same niche in the human host, *Parasitology* 141 (2014) 1255–1271.
604 <https://doi.org/10.1017/S0031182014000699>.
- 605 [3] A. Chudnovskiy, A. Mortha, V. Kana, A. Kennard, J.D. Ramirez, A. Rahman, R. Remark,
606 I. Mogno, R. Ng, S. Gnjatic, E.D. Amir, A. Solovyov, B. Greenbaum, J. Clemente, J.
607 Faith, Y. Belkaid, M.E. Grigg, M. Merad, Host-protozoan interactions protect from
608 mucosal infections through activation of the inflammasome, *Cell* 167 (2016) 444.
609 <https://doi.org/10.1016/J.CELL.2016.08.076>.
- 610 [4] M.O. Harhay, J. Horton, P.L. Olliaro, Epidemiology and control of human gastrointestinal
611 parasites in children, *Expert Rev. Anti. Infect. Ther.* 8 (2010) 219–234.
612 <https://doi.org/10.1586/eri.09.119>.
- 613 [5] P.J. Hotez, P.J. Brindley, J.M. Bethony, C.H. King, E.J. Pearce, J. Jacobson, Helminth
614 infections: The great neglected tropical diseases, *J. Clin. Invest.* 118 (2008) 1311–1321.
615 <https://doi.org/10.1172/JCI34261>.
- 616 [6] P.J. Hotez, M. Alvarado, M.-G. Basáñez, I. Bolliger, R. Bourne, M. Boussinesq, S.J.
617 Brooker, A.S. Brown, G. Buckle, C.M. Budke, H. Carabin, L.E. Coffeng, E.M. Fèvre, T.
618 Fürst, Y.A. Halasa, R. Jasrasaria, N.E. Johns, J. Keiser, C.H. King, R. Lozano, M.E.
619 Murdoch, S. O’Hanlon, S.D.S. Pion, R.L. Pullan, K.D. Ramaiah, T. Roberts, D.S.
620 Shepard, J.L. Smith, W.A. Stolk, E.A. Undurraga, J. Utzinger, M. Wang, C.J.L. Murray,
621 M. Naghavi, The Global Burden of Disease Study 2010: Interpretation and Implications
622 for the Neglected Tropical Diseases, *PLoS Negl. Trop. Dis.* 8 (2014) e2865.
623 <https://doi.org/10.1371/JOURNAL.PNTD.0002865>.
- 624 [7] S.C. Ojha, C. Jaide, N. Jinawath, P. Rotjanapan, P. Baral, Geohelminths: Public health
625 significance, *J. Infect. Dev. Ctries.* 8 (2014) 5–16. <https://doi.org/10.3855/JIDC.3183>.

- 626 [8] Z.A. Silver, S.P. Kaliappan, P. Samuel, S. Venugopal, G. Kang, R. Sarkar, S.S.R.
627 Ajjampur, Geographical distribution of soil transmitted helminths, (2018) 7–16.
- 628 [9] D.F. de L. Corvino, S. Horrall, Ascariasis, StatPearls (2021).
629 <https://www.ncbi.nlm.nih.gov/books/NBK430796/> (accessed February 8, 2022).
- 630 [10] P.H. Gazzinelli-Guimaraes, T.B. Nutman, B. Ogretmen, P.R. Giacomini, M. Zakrzewski, J.
631 Croese, X. Su, J. Sotillo, L. McCann, S. Navarro, M. Mitreva, L. Krause, A. Loukas, C.
632 Cantacessi, C. Shimokawa, S. Obi, M. Shibata, A. Olia, T. Imai, K. Suzue, H. Hisaeda, K.
633 Yasuda, K. Nakanishi, G. Deslyper, O.A. Sowemimo, J. Beresford, C. V. Holland, D.
634 Ramanan, R. Bowcutt, S.C. Lee, M.S. Tang, D. Zachary, Y. Ding, W.C. Gause, M.J.
635 Blaser, A. Richard, Y.A.L.L. Lim, P. Loke, K. Cadwell, M. Ali Mubarak, M. Ahmad,
636 T.A. Hafiz, M.A. Marie, K. Sobotková, W. Parker, J. Levá, J. Růžková, J. Lukeš, K. Jirků
637 Pomajbíková, C. Cantacessi, P.R. Giacomini, J. Croese, M. Zakrzewski, J. Sotillo, L.
638 McCann, M.J. Nolan, M. Mitreva, L. Krause, A. Loukas, R.M. Maizels, H.H. Smits, H.J.
639 McSorley, M.A. Duque-Correa, N.A. Karp, C. McCarthy, S. Forman, D. Goulding, G.
640 Sankaranarayanan, T.P. Jenkins, A.J. Reid, E.L. Cambridge, C. Ballesteros Reviriego, W.
641 Müller, C. Cantacessi, G. Dougan, R.K. Grencis, M. Berriman, Y. Wang, F. Liu, J.F.
642 Urban, O. Paerewijck, P. Geldhof, R.W. Li, C.A. Gordon, L. Krause, D.P. McManus, M.
643 Morrison, K.G. Weerakoon, M.C. Connor, R.M. Olveda, A.G. Ross, G.N. Gobert, M.
644 Walker, A. Hall, M.G. Basáñez, L.S. Mansfield, D.T. Gauthier, S.R. Abner, K.M. Jones,
645 S.R. Wilder, J.F. Urban, C.C. Motran, L. Silvano, L.S. Chiapello, M.G. Theumer, L.F.
646 Ambrosio, X. Volpini, D.P. Celas, L. Cervi, J.E. Klementowicz, M.A. Travis, R.K.
647 Grencis, C. Richarté, C. Barra, A. Hartmann-Virnich, R. Mejia, A. Damania, R. Jeun, P.E.
648 Bryan, P. Vargas, M. Juarez, P.S. Cajal, J. Nasser, A. Krolewiecki, E. Lefoulon, C. Long,
649 E. Drake, R.O. Cimino, B.E. Slatko, J.C. Dunn, H.C. Turner, A. Tun, R.M. Anderson,
650 T.P. Jenkins, Y. Rathnayaka, P.K. Perera, L.E. Peachey, M.J. Nolan, L. Krause, R.S.
651 Rajakaruna, C. Cantacessi, R. Martín, L.G. Bermúdez-Humarán, P. Langella, T.P.
652 Jenkins, L.E. Peachey, N.J. Ajami, A.S. MacDonald, M.H. Hsieh, P.J. Brindley, C.
653 Cantacessi, G. Rinaldi, K.S. Hayes, A.J. Bancroft, M. Goldrick, C. Portsmouth, I.S.
654 Roberts, R.K. Grencis, J.B. Holm, D. Sorobetea, P. Kiilerich, Y. Ramayo-Caldas, J.
655 Estellé, T. Ma, L. Madsen, K. Kristiansen, M. Svensson-Frej, Z.A. Silver, S.P. Kaliappan,
656 P. Samuel, S. Venugopal, G. Kang, R. Sarkar, S.S.R. Ajjampur, N. Palevich, P.H.
657 Maclean, Y.J. Choi, M. Mitreva, P.R. Giacomini, J. Croese, L. Krause, A. Loukas, C.
658 Cantacessi, I.M. Cattadori, A. Sebastian, H. Hao, R. Katani, I. Albert, K.E. Eilertson, V.
659 Kapur, A. Pathak, S. Mitchell, F. Chammartin, R.G.C. Scholte, L.H. Guimarães, M.
660 Tanner, J. Utzinger, P. Vounatsou, F. Berrilli, D. Di Cave, S. Cavallero, S. D’Amelio, L.J.
661 Myhill, S. Stolzenbach, T.V.A. Hansen, K. Skovgaard, C.R. Stensvold, L.O.B. Andersen,
662 P. Nejsum, H. Mejer, S.M. Thamsborg, A.R. Williams, N. Mohebal, K. Ekat, B.
663 Kreikemeyer, A. Breitrück, S. Helminths, S.C. Pan, D. V. Ward, Y. Yin, Y. Hu, M.A.
664 Elfawal, R.E. Clark, R. V. Aroian, C. Su, L. Su, Y. Li, S.R. Long, J. Chang, W. Zhang,
665 W.A. Walker, R.J. Xavier, B.J. Cherayil, H.N. Shi, I. Martin, M.M.M. Kaiser, A.E. Wiria,
666 F. Hamid, Y. Djuardi, E. Sartono, B.A. Rosa, M. Mitreva, T. Supali, J.J. Houwing-
667 Duistermaat, M. Yazdanbakhsh, L.J. Wammes, L.K. Newbold, S.J. Burthe, A.E. Oliver,
668 H.S. Gweon, C.J. Barnes, F. Daunt, C.J. Van Der Gast, M.M. Zaiss, A. Rapin, L. Lebon,
669 L.K. Dubey, I. Mosconi, K. Sarter, A. Piersigilli, L. Menin, A.W. Walker, J. Rougemont,
670 O. Paerewijck, P. Geldhof, K.D. McCoy, A.J. Macpherson, J. Croese, P.R. Giacomini, A.

671 Loukas, T. Junt, B.J. Marsland, N.L. Harris, O. Partida-Rodríguez, A. Serrano-Vázquez,
672 M.E. Nieves-Ramírez, P. Moran, L. Rojas, T. Portillo, E. González, E. Hernández, B.B.
673 Finlay, C. Ximenez, R. Lewis, J.M. Behnke, P. Stafford, C. V. Holland, B. Šiška, M.
674 Simon, I. Machač, A. Surý, N. Palevich, C. Britton, L. Kamenetzky, M. Mitreva, M. de
675 Moraes Mourão, S. Bennuru, T. Quack, L.L.S. Scholte, R. Tyagi, B.E. Slatko, P. Loke,
676 Y.A.L.L. Lim, R.W. Li, S. Wu, W. Li, Y. Huang, L.C. Gasbarre, A. Midha, J. Schlosser,
677 S. Hartmann, V. Marzano, L. Mancinelli, G. Bracaglia, F. Del Chierico, P. Vernocchi, F.
678 Di Girolamo, S. Garrone, H. Tchidjou Kuekou, P. D’Argenio, B. Dallapiccola, A. Urbani,
679 L. Putignani, A. Rapin, N.L. Harris, F. Formenti, A. Cortés, P.J. Brindley, C. Cantacessi,
680 G. Rinaldi, R.B. Wescott, P.R. Giacomini, M. Zakrzewski, T.P. Jenkins, X. Su, R. Al-
681 Hallaf, J. Croese, S. De Vries, A. Grant, M. Mitreva, A. Loukas, L. Krause, C. Cantacessi,
682 M.A. Rubel, A. Abbas, L.J. Taylor, A. Connell, C. Tanes, K. Bittinger, V.N. Ndze, J.Y.
683 Fonsah, E. Ngwang, A. Essiane, C. Fokunang, A.K. Njamnshi, F.D. Bushman, S.A.
684 Tishkoff, G.L. Kay, A. Millard, M.J. Sergeant, N. Midzi, R. Gwisai, T. Mduluza, A.
685 Ivens, N. Nausch, F. Mutapi, M. Pallen, J. Lorimer, T.P. Jenkins, P.J. Brindley, R.B.
686 Gasser, C. Cantacessi, K.J. Else, J. Keiser, C. V. Holland, R.K. Grensis, D.B. Sattelle,
687 R.T. Fujiwara, L.L. Bueno, S.O. Asaolu, O.A. Sowemimo, P.J. Cooper, A. Easton, S. Gao,
688 S. Lawton, S. Bennuru, A. Khan, E. Dahlstrom, R. Oliveira, S. Kepha, S. Porcella, J.
689 Webster, R.M. Anderson, M. Grigg, R. Davis, J. Wang, T.B. Nutman, A.J. Bancroft, C.W.
690 Levy, T.A. Jowitt, K.S. Hayes, S. Thompson, E.A. Mckenzie, M.D. Ball, E. Dubaissi,
691 A.P. France, B. Bellina, C. Sharpe, A. Mironov, S.L. Brown, P.C. Cook, A. S.
692 MacDonald, D.J. Thornton, R.K. Grensis, J. Sotillo, R. Toledo, J. Mulvenna, A. Loukas,
693 J. Schachter, A. De Oliveira, C. Miranda, D.B. Alencar, A. Cortés, L.E. Peachey, R.
694 Scotti, T.P. Jenkins, C. Cantacessi, E.C. White, A. Houlden, A.J. Bancroft, K.S. Hayes,
695 M. Goldrick, R.K. Grensis, I.S. Roberts, A.R. Williams, L. Krych, H.F. Ahmad, P.
696 Nejsum, K. Skovgaard, D.S. Nielsen, S.M. Thamsborg, A.E. Douglas, M.A. Duque-
697 Correa, R.M. Maizels, R.K. Grensis, M. Berriman, S. Min, S. Kim, S.W. Cho, J. Rubert,
698 P.J. Schweiger, F. Mattivi, K. Tuohy, K.B. Jensen, A. Lunardi, P.K. Korhonen, N.D.
699 Young, R.B. Gasser, A. Houlden, K.S. Hayes, A.J. Bancroft, J.J. Worthington, P. Wang,
700 R.K. Grensis, I.S. Roberts, J. Kreisinger, G. Bastien, H.C. Hauffe, J. Marchesi, S.E.
701 Perkins, L.A. Reynolds, B.B. Finlay, R.M. Maizels, L. Glendinning, N. Nausch, A. Free,
702 D.W. Taylor, F. Mutapi, S.C. Lee, M.S. Tang, Y.A.L.L. Lim, S.H. Choy, Z.D. Kurtz,
703 L.M. Cox, U.M. Gundra, I. Cho, R. Bonneau, M.J. Blaser, K.H. Chua, P. Loke, P.J.
704 Cooper, A.W. Walker, J. Reyes, M. Chico, S.J. Salter, M. Vaca, J. Parkhill, S.R. Doyle,
705 M.J. Broadhurst, A. Ardeshir, B. Kanwar, J. Mirpuri, U.M. Gundra, J.M. Leung, K.E.
706 Wiens, I. Vujkovic-Cvijin, C.C. Kim, F. Yarovinsky, N.W. Lerche, J.M. McCune, P.
707 Loke, S. Wu, R.W. Li, W. Li, E. Beshah, H.D. Dawson, J.F. Urban, S. Wu, W. Li, K.
708 Navarro, R.D. Couch, D. Hill, J.F. Urban, V.B. Young, Therapeutic Helminth Infection of
709 Macaques with Idiopathic Chronic Diarrhea Alters the Inflammatory Signature and
710 Mucosal Microbiota of the Colon, PLoS One 8 (2020) 1–10.
711 <https://doi.org/10.1371/journal.pone.0076573>.

712 [11] E. Ramírez-Carrillo, O. Gaona, J. Nieto, A. Sánchez-Quinto, D. Cerqueda-García, L.I.
713 Falcón, O.A. Rojas-Ramos, I. González-Santoyo, Disturbance in human gut microbiota
714 networks by parasites and its implications in the incidence of depression., Sci. Rep. 10
715 (2020) 1–12. <http://10.0.4.14/s41598-020-60562-w>.

- 716 [12] A. Midha, F. Ebner, J. Schlosser-Brandenburg, S. Rausch, S. Hartmann, Trilateral
717 Relationship: *Ascaris*, Microbiota, and Host Cells., *Trends Parasitol.* 37 (2021) 251–262.
718 <https://doi.org/10.1016/j.pt.2020.09.002>.
- 719 [13] Y. Wang, F. Liu, J.F. Urban, O. Paerewijck, P. Geldhof, R.W. Li, *Ascaris suum* infection
720 was associated with a worm-independent reduction in microbial diversity and altered
721 metabolic potential in the porcine gut microbiome, *Int. J. Parasitol.* 49 (2019) 247–256.
722 <https://doi.org/10.1016/j.ijpara.2018.10.007>.
- 723 [14] S. Castañeda, A. Paniz-Mondolfi, J.D. Ramírez, Detangling the Crosstalk Between
724 *Ascaris*, *Trichuris* and Gut Microbiota: What’s Next?, *Front. Cell. Infect. Microbiol.* 0
725 (2022) 615. <https://doi.org/10.3389/FCIMB.2022.852900>.
- 726 [15] M.M. Zaiss, A. Rapin, L. Lebon, L.K. Dubey, I. Mosconi, K. Sarter, A. Piersigilli, L.
727 Menin, A.W. Walker, J. Rougemont, O. Paerewijck, P. Geldhof, K.D. McCoy, A.J.
728 Macpherson, J. Croese, P.R. Giacomin, A. Loukas, T. Junt, B.J. Marsland, N.L. Harris,
729 The Intestinal Microbiota Contributes to the Ability of Helminths to Modulate Allergic
730 Inflammation, *Immunity* 43 (2015) 998–1010.
731 <https://doi.org/10.1016/j.immuni.2015.09.012>.
- 732 [16] O. Ajibola, A.D. Rowan, C.O. Ogedengbe, M.B. Mshelia, D.J. Cabral, A.A. Eze, S.
733 Obaro, P. Belenky, Urogenital schistosomiasis is associated with signatures of
734 microbiome dysbiosis in Nigerian adolescents, *Sci. Rep.* 9 (2019) 1–15.
735 <https://doi.org/10.1038/s41598-018-36709-1>.
- 736 [17] A. Cortés, S. Clare, A. Costain, A. Almeida, C. McCarthy, K. Harcourt, C. Brandt, C.
737 Tolley, J. Rooney, M. Berriman, T. Lawley, A.S. MacDonald, G. Rinaldi, C. Cantacessi,
738 Baseline Gut Microbiota Composition Is Associated With *Schistosoma mansoni* Infection
739 Burden in Rodent Models., *Front. Immunol.* 11 (2020) 593838.
740 <https://doi.org/10.3389/fimmu.2020.593838>.
- 741 [18] J. Schachter, A. De Oliveira, C. Miranda, D.B. Alencar, Whipworm Infection Promotes
742 Bacterial Invasion, Intestinal Microbiota Imbalance, and Cellular Immunomodulation, 88
743 (2020) 1–24.
- 744 [19] F. Berrilli, D. Di Cave, S. Cavallero, S. D’Amelio, Interactions between parasites and
745 microbial communities in the human gut., *Front. Cell. Infect. Microbiol.* 2 (2012) 141.
746 <https://doi.org/10.3389/fcimb.2012.00141>.
- 747 [20] R.W. Li, S. Wu, W. Li, K. Navarro, R.D. Couch, D. Hill, J.F. Urban, Alterations in the
748 porcine colon microbiota induced by the gastrointestinal nematode *Trichuris suis*, *Infect.*
749 *Immun.* 80 (2012) 2150–2157. <https://doi.org/10.1128/IAI.00141-12>.
- 750 [21] P. Cooper, A.W. Walker, J. Reyes, M. Chico, S.J. Salter, M. Vaca, J. Parkhill, Patent
751 Human Infections with the Whipworm, *Trichuris trichiura*, Are Not Associated with
752 Alterations in the Faecal Microbiota, *PLoS One* 8 (2013) e76573.
753 <https://doi.org/10.1371/journal.pone.0076573>.
- 754 [22] C. Cantacessi, P. Giacomin, J. Croese, M. Zakrzewski, J. Sotillo, L. McCann, M.J. Nolan,
755 M. Mitreva, L. Krause, A. Loukas, Impact of experimental hookworm infection on the
756 human gut microbiota, *J. Infect. Dis.* 210 (2014) 1431–1434.








- 757 <https://doi.org/10.1093/infdis/jiu256>.
- 758 [23] G.L. Kay, A. Millard, M.J. Sergeant, N. Midzi, R. Gwisai, T. Mduluza, A. Ivens, N.
759 Nausch, F. Mutapi, M. Pallen, Differences in the faecal microbiome in schistosoma
760 haematobium infected children vs. uninfected children, *PLoS Negl. Trop. Dis.* 9 (2015)
761 e0003861. <https://doi.org/10.1371/journal.pntd.0003861>.
- 762 [24] A. Midha, J. Schlosser, S. Hartmann, Reciprocal interactions between nematodes and their
763 microbial environments, *Front. Cell. Infect. Microbiol.* 7 (2017) 144.
764 <https://doi.org/10.3389/fcimb.2017.00144>.
- 765 [25] B.A. Rosa, T. Supali, L. Gankpala, Y. Djuardi, E. Sartono, Y. Zhou, K. Fischer, J. Martin,
766 R. Tyagi, F.K. Bolay, P.U. Fischer, M. Yazdanbakhsh, M. Mitreva, Differential human
767 gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and
768 Liberia, *Microbiome* 6 (2018) 1–19. <https://doi.org/10.1186/s40168-018-0416-5>.
- 769 [26] R. Mejia, A. Damania, R. Jeun, P.E. Bryan, P. Vargas, M. Juarez, P.S. Cajal, J. Nasser, A.
770 Krolewiecki, E. Lefoulon, C. Long, E. Drake, R.O. Cimino, B. Slatko, Impact of intestinal
771 parasites on microbiota and cobalamin gene sequences: A pilot study, *Parasit. Vectors* 13
772 (2020) 1–9. <https://doi.org/10.1186/s13071-020-04073-7>.
- 773 [27] A.E. Douglas, Simple animal models for microbiome research, *Nat. Rev. Microbiol.* 17
774 (2019) 764–775. <https://doi.org/10.1038/s41579-019-0242-1>.
- 775 [28] M.A. Duque-Correa, R.M. Maizels, R.K. Grencis, M. Berriman, Organoids – New Models
776 for Host–Helminth Interactions, *Trends Parasitol.* 36 (2020) 170–181.
777 <https://doi.org/10.1016/j.pt.2019.10.013>.
- 778 [29] C. Zhang, C.L. Franklin, A.C. Ericsson, Consideration of Gut Microbiome in Murine
779 Models of Diseases, *Microorg.* 2021, Vol. 9, Page 1062 9 (2021) 1062.
780 <https://doi.org/10.3390/MICROORGANISMS9051062>.
- 781 [30] J.C. Park, S.H. Im, Of men in mice: the development and application of a humanized
782 gnotobiotic mouse model for microbiome therapeutics, *Exp. Mol. Med.* 2020 529 52
783 (2020) 1383–1396. <https://doi.org/10.1038/s12276-020-0473-2>.
- 784 [31] Z.B. Bjornson-Hooper, G.K. Fragiadakis, M.H. Spitzer, H. Chen, D. Madhireddy, K. Hu,
785 K. Lundsten, D.R. McIlwain, G.P. Nolan, A Comprehensive Atlas of Immunological
786 Differences Between Humans, Mice, and Non-Human Primates, *Front. Immunol.* 0 (2022)
787 908. <https://doi.org/10.3389/FIMMU.2022.867015>.
- 788 [32] Y. Wang, J. V Li, J. Saric, J. Keiser, J. Wu, J. Utzinger, E. Holmes, Advances in
789 metabolic profiling of experimental nematode and trematode infections., *Adv. Parasitol.*
790 73 (2010) 373–404. [https://doi.org/10.1016/S0065-308X\(10\)73012-8](https://doi.org/10.1016/S0065-308X(10)73012-8).
- 791 [33] M. Sultan Khuroo, ASCARIASIS, *Gastroenterol. Clin. North Am.* 25 (1996) 553–577.
792 [https://doi.org/10.1016/S0889-8553\(05\)70263-6](https://doi.org/10.1016/S0889-8553(05)70263-6).
- 793 [34] D.S. Nogueira, P.H. Gazzinelli-Guimarães, F.S. Barbosa, N.M. Resende, C.C. Silva, L.M.
794 de Oliveira, C.C.O. Amorim, F.M.S. Oliveira, M.S. Mattos, L.R. Kraemer, M.V. Caliari,
795 S. Gaze, L.L. Bueno, R.C. Russo, R.T. Fujiwara, Multiple Exposures to *Ascaris suum*
796 Induce Tissue Injury and Mixed Th2/Th17 Immune Response in Mice, *PLoS Negl. Trop.*





- 797 Dis. 10 (2016) e0004382. <https://doi.org/10.1371/JOURNAL.PNTD.0004382>.
- 798 [35] C. V. Holland, The long and winding road of *Ascaris* larval migration: the role of mouse
799 models, *Parasitology* 148 (2021) 1735–1743.
800 <https://doi.org/10.1017/S0031182021000366>.
- 801 [36] A.R. Williams, L. Krych, H.F. Ahmad, P. Nejsum, K. Skovgaard, D.S. Nielsen, S.M.
802 Thamsborg, H. Fauzan Ahmad, P. Nejsum, K. Skovgaard, D.S. Nielsen, S.M. Thamsborg,
803 A polyphenol-enriched diet and *Ascaris suum* infection modulate mucosal immune
804 responses and gut microbiota composition in pigs, *PLoS One* 12 (2017) 1–21.
805 <https://doi.org/10.1371/journal.pone.0186546>.
- 806 [37] A. Midha, V.H. Jarquín-Díaz, F. Ebner, U. Löber, R. Hayani, A. Kundik, A. Cardilli, E.
807 Heitlinger, S.K. Forslund, S. Hartmann, Guts within guts: the microbiome of the intestinal
808 helminth parasite *Ascaris suum* is derived but distinct from its host, *Microbiome* 10
809 (2022) 1–21. <https://doi.org/10.1186/S40168-022-01399-5/FIGURES/6>.
- 810 [38] J.D. Whitman, J.A. Sakanari, M. Mitreva, Areas of Metabolomic Exploration for
811 Helminth Infections, 7 (2021) 206–214. <https://doi.org/10.1021/acsinfecdis.0c00658>.
- 812 [39] F. Formenti, A. Cortés, P.J. Brindley, C. Cantacessi, G. Rinaldi, A bug’s life: Delving into
813 the challenges of helminth microbiome studies, *PLoS Negl. Trop. Dis.* 14 (2020) 1–7.
814 <https://doi.org/10.1371/journal.pntd.0008446>.
- 815 [40] T.P.P. Jenkins, P.J.J. Brindley, R.B.B. Gasser, C. Cantacessi, Helminth Microbiomes – A
816 Hidden Treasure Trove?, *Trends Parasitol.* 35 (2019) 13–22.
817 <https://doi.org/10.1016/j.pt.2018.10.007>.
- 818 [41] T. Bouchery, E. Lefoulon, G. Karadjian, A. Nieguitsila, C. Martin, The symbiotic role of
819 *Wolbachia* in *Onchocercidae* and its impact on filariasis, *Clin. Microbiol. Infect.* 19
820 (2013) 131–140. <https://doi.org/10.1111/1469-0691.12069>.
- 821 [42] Caporaso JG et al, QIIME allows analysis of high-throughput community sequencing
822 data, *Nat Methods* 7 (2011) 1–12. <https://doi.org/10.1038/nmeth.f.303.QIIME>.
- 823 [43] B.J. Callahan, P.J. McMurdie, M.J. Rosen, A.W. Han, A.J.A. Johnson, S.P. Holmes,
824 DADA2: High-resolution sample inference from Illumina amplicon data, *Nat. Methods*
825 2016 137 13 (2016) 581–583. <https://doi.org/10.1038/nmeth.3869>.
- 826 [44] E. Pruesse, C. Quast, K. Knittel, B.M. Fuchs, W. Ludwig, J. Peplies, F.O. Glöckner,
827 SILVA: A comprehensive online resource for quality checked and aligned ribosomal
828 RNA sequence data compatible with ARB, *Nucleic Acids Res.* 35 (2007) 7188–7196.
829 <https://doi.org/10.1093/nar/gkm864>.
- 830 [45] C. Quast, E. Pruesse, P. Yilmaz, J. Gerken, T. Schweer, P. Yarza, J. Peplies, F.O.
831 Glöckner, The SILVA ribosomal RNA gene database project: Improved data processing
832 and web-based tools, *Nucleic Acids Res.* 41 (2013) 590–596.
833 <https://doi.org/10.1093/nar/gks1219>.
- 834 [46] P.J. McMurdie, S. Holmes, Phyloseq: An R Package for Reproducible Interactive
835 Analysis and Graphics of Microbiome Census Data, *PLoS One* 8 (2013).
836 <https://doi.org/10.1371/journal.pone.0061217>.

- 837 [47] N. Segata, J. Izard, L. Waldron, D. Gevers, L. Miropolsky, W.S. Garrett, C. Huttenhower,
838 Metagenomic biomarker discovery and explanation, *Genome Biol.* 12 (2011) R60.
839 <https://doi.org/10.1186/GB-2011-12-6-R60>.
- 840 [48] X. Su, Elucidating the Beta-Diversity of the Microbiome: from Global Alignment to Local
841 Alignment, *MSystems* 6 (2021). <https://doi.org/10.1128/MSYSTEMS.00363-21>.
- 842 [49] Community Ecology Package [R package vegan version 2.6-4], (2022). [https://cran.r-](https://cran.r-project.org/package=vegan)
843 [project.org/package=vegan](https://cran.r-project.org/package=vegan) (accessed March 17, 2023).
- 844 [50] RStudio Team, RStudio: Integrated Development for R. RStudio, 2020 (n.d.).
845 <https://rstudio.com/> (accessed March 4, 2021).
- 846 [51] M.M. Zaiss, N.L. Harris, Interactions between the intestinal microbiome and helminth
847 parasites, *Parasite Immunol.* 38 (2016) 5–11. <https://doi.org/10.1111/pim.12274>.
- 848 [52] J. Rubert, P.J. Schweiger, F. Mattivi, K. Tuohy, K.B. Jensen, A. Lunardi, Intestinal
849 Organoids: A Tool for Modelling Diet–Microbiome–Host Interactions, *Trends*
850 *Endocrinol. Metab.* 31 (2020) 848–858. <https://doi.org/10.1016/j.tem.2020.02.004>.
- 851 [53] I. Martin, Y. Djuardi, E. Sartono, B.A. Rosa, T. Supali, M. Mitreva, J.J. Houwing-
852 Duistermaat, M. Yazdanbakhsh, Dynamic changes in human-gut microbiome in relation
853 to a placebo-controlled anthelmintic trial in Indonesia., *PLoS Negl. Trop. Dis.* 12 (2018)
854 1–19. <http://10.0.5.91/journal.pntd.0006620>.
- 855 [54] E.A. McKenney, L. Williamson, A.D. Yoder, J.F. Rawls, S.D. Bilbo, W. Parker,
856 Alteration of the rat cecal microbiome during colonization with the helminth *Hymenolepis*
857 *diminuta*, *Gut Microbes* 6 (2015) 182–193.
858 <https://doi.org/10.1080/19490976.2015.1047128>.
- 859 [55] R. Lewis, J.M. Behnke, P. Stafford, C. V. Holland, The development of a mouse model to
860 explore resistance and susceptibility to early *Ascaris suum* infection, *Parasitology* 132
861 (2006) 289–300. <https://doi.org/10.1017/S0031182005008978>.
- 862 [56] W. Peng, C.D. Criscione, Ascariasis in people and pigs: new inferences from DNA
863 analysis of worm populations, *Infect. Genet. Evol.* 12 (2012) 227–235.
864 <https://doi.org/10.1016/J.MEEGID.2012.01.012>.
- 865 [57] A. Springer, L. Wagner, S. Koehler, S. Klinger, G. Breves, D.A. Brüggemann, C. Strube,
866 Modulation of the porcine intestinal microbiota in the course of *Ascaris suum* infection,
867 *Parasites and Vectors* 15 (2022) 1–21. [https://doi.org/10.1186/S13071-022-05535-](https://doi.org/10.1186/S13071-022-05535-W/TABLES/6)
868 [W/TABLES/6](https://doi.org/10.1186/S13071-022-05535-W/TABLES/6).
- 869 [58] P.J. Cooper, C.A. Figuieredo, Immunology of *Ascaris* and Immunomodulation, in:
870 *Ascaris: The Neglected Parasite*, Elsevier Inc., 2013: pp. 3–19.
871 <https://doi.org/10.1016/B978-0-12-396978-1.00001-X>.
- 872 [59] N.M. Dheilly, D. Bolnick, S. Bordenstein, P.J. Brindley, C. Figuères, E.C. Holmes, J.
873 Martínez Martínez, A.J. Phillips, R. Poulin, K. Rosario, Parasite Microbiome Project:
874 Systematic Investigation of Microbiome Dynamics within and across Parasite-Host
875 Interactions, *MSystems* 2 (2017). <https://doi.org/10.1128/msystems.00050-17>.


- 876 [60] P.M. Salloum, F. Jorge, N.M. Dheilly, R. Poulin, Eco-evolutionary implications of
877 helminth microbiomes, *J. Helminthol.* 97 (2023) e22.
878 <https://doi.org/10.1017/S0022149X23000056>.
- 879 [61] K. Stracke, P. Adisakwattana, S. Phuanukoonnon, T. Yoonuan, A. Poodeepiyasawat, P.
880 Dekumyoy, K. Chaisiri, A.R. Schulze, S. Wilcox, H. Karunajeewa, R.J. Traub, A.R. Jex,
881 Field evaluation of the gut microbiome composition of pre-school and school-aged
882 children in Tha Song Yang, Thailand, following oral MDA for STH infections, *PLoS*
883 *Negl. Trop. Dis.* 15 (2021) e0009597. <https://doi.org/10.1371/JOURNAL.PNTD.0009597>.
- 884 [62] A. Muslim, S. Aazmi, Y.X. Er, S. Shahrizal, Y.A.L. Lim, *Ascaris lumbricoides* harbors a
885 distinct gut microbiota profile from its human host: Preliminary insights, *Food*
886 *Waterborne Parasitol.* 34 (2024) e00223.
887 <https://doi.org/10.1016/J.FAWPAR.2024.E00223>.
- 888 [63] K.A.B. Kissoyan, M. Drechsler, E.L. Stange, J. Zimmermann, C. Kaleta, H.B. Bode, K.
889 Dierking, Natural *C. elegans* Microbiota Protects against Infection via Production of a
890 Cyclic Lipopeptide of the Viscosin Group, *Curr. Biol.* 29 (2019) 1030-1037.e5.
891 <https://doi.org/10.1016/j.cub.2019.01.050>.
- 892 [64] F. Zhang, M. Berg, K. Dierking, M.A. Félix, M. Shapira, B.S. Samuel, H. Schulenburg,
893 *Caenorhabditis elegans* as a model for microbiome research, *Front. Microbiol.* 8 (2017)
894 241616. <https://doi.org/10.3389/FMICB.2017.00485/BIBTEX>.
- 895 [65] L.A. Reynolds, K.A. Smith, K.J. Filbey, Y. H Marcus, J.P. Hewitson, S.A. Redpath, Y.
896 Valdez, M.J. Yebra, B. Brett Finlay, R.M. Maizels, Commensal-pathogen interactions in
897 the intestinal tract lactobacilli promote infection with, and are promoted by, helminth
898 parasites, *Gut Microbes* 5 (2014) 522–532. <https://doi.org/10.4161/gmic.32155>.
- 899 [66] V.B. Young, Alteration of the murine gut microbiota during infection with the parasitic
900 helminth, *Heligmosomoides polygyrus*, *System* 16 (2011) 1841–1849.
901 <https://doi.org/10.1002/ibd.21299.Alteration>.
- 902 [67] M. Kostic, K. Milger, S. Krauss-Etschmann, M. Engel, G. Vestergaard, M. Schloter, A.
903 Schöler, Development of a Stable Lung Microbiome in Healthy Neonatal Mice, *Microb.*
904 *Ecol.* 75 (2018) 529–542. <https://doi.org/10.1007/S00248-017-1068-X/FIGURES/5>.
- 905 [68] S. V. Bhat, H. Maughan, A.D.S. Cameron, C.K. Yost, Phylogenomic analysis of the genus
906 *Delftia* reveals distinct major lineages with ecological specializations, *Microb. Genomics*
907 8 (2022). <https://doi.org/10.1099/MGEN.0.000864>.
- 908 [69] Q. Mu, V.J. Tavella, X.M. Luo, Role of *Lactobacillus reuteri* in human health and
909 diseases, *Front. Microbiol.* 9 (2018) 757.
910 <https://doi.org/10.3389/FMICB.2018.00757/BIBTEX>.
- 911 [70] A. Cortés, L. Peachey, R. Scotti, T.P. Jenkins, C. Cantacessi, Helminth-microbiota cross-
912 talk – A journey through the vertebrate digestive system, *Mol. Biochem. Parasitol.* 233
913 (2019) 111222. <https://doi.org/10.1016/j.molbiopara.2019.111222>.
- 914 [71] J.B. Holm, D. Sorobetea, P. Kiilerich, Y. Ramayo-Caldas, J. Estellé, T. Ma, L. Madsen, K.
915 Kristiansen, M. Svensson-Frej, Chronic *Trichuris muris* infection decreases diversity of

- 916 the intestinal microbiota and concomitantly increases the abundance of lactobacilli, PLoS
917 One 10 (2015) 1–22. <https://doi.org/10.1371/journal.pone.0125495>.
- 918 [72] Y. Niu, X. Hu, Y. Song, C. Wang, P. Luo, S. Ni, F. Jiao, J. Qiu, W. Jiang, S. Yang, J.
919 Chen, R. Huang, H. Jiang, S. Chen, Q. Zhai, J. Xiao, F. Guo, *Blautia Coccoides* is a
920 Newly Identified Bacterium Increased by Leucine Deprivation and has a Novel Function
921 in Improving Metabolic Disorders, *Adv. Sci.* 11 (2024) 2309255.
922 <https://doi.org/10.1002/ADVS.202309255>.
- 923 [73] P.C. Barko, M.A. McMichael, K.S. Swanson, D.A. Williams, The Gastrointestinal
924 Microbiome: A Review, *J. Vet. Intern. Med.* 32 (2018) 9–25.
925 <https://doi.org/10.1111/jvim.14875>.
- 926
- 927


a.**b.****d.****f.****c.****e.****g.**











a.




b.




a.**b.****c.****d.**




a.




b.



c.



d.



	input	filtered	denoisedF	denoisedR	merged	nonchim
B1	208401	176629	176358	176334	175237	172842
B10	162311	152782	152550	152569	151120	145113
B11	210233	198233	198046	198058	196453	181178
B12	103352	97557	97462	97461	96536	90756
B13	205338	154422	154315	154263	152925	151468
B14	205757	193886	193758	193772	192238	186185
B15	163505	153978	153591	153504	151874	147984
B16	204509	191614	191447	191463	190110	182380
B17	166512	157738	157437	157339	155598	150331
B18	120337	112905	112703	112696	111578	104144
B19	204196	117196	117022	117050	116365	114806
B2	203965	192333	191135	191202	187203	179359
B20	312938	294399	293417	293340	289095	278456
B21	141283	132785	132678	132647	131572	127715
B22	203826	191612	191524	191529	190110	184284
B23	197683	186507	186279	186276	184610	176793
B24	210850	198778	198622	198579	196973	189002
B25	205690	196739	196338	196138	194615	189293
B26	204456	195514	195141	195036	193562	188627
B27	204111	194806	194518	194503	193155	187876
B28	206656	197098	196465	196276	193936	187351
B29	206418	193268	193172	193165	191695	187969
B3	108050	101853	101627	101615	100490	96885
B30	208537	136502	136402	136310	135331	133997
B31	205680	195039	194818	194683	191813	189738
B32	164545	155310	155234	155238	154193	147759
B4	193912	183213	183128	183120	181795	172704
B5	218772	205259	205138	205138	203424	190365
B6	156937	147951	147692	147749	146270	142484
B7	189508	178298	178082	178052	176340	169869
B8	188411	177194	176890	176834	175183	166262
B9	206231	193665	193098	193054	190718	183181
Feces_	203331	194285	193305	192949	187844	166657
Feces_	203749	194767	192630	192059	181061	143646
Feces_	216809	205942	204633	204161	197048	169056
Feces_	203424	193351	191529	190972	182313	150789
Feces_	204225	194955	193188	192723	184741	156447
Feces_	210816	201487	199967	199596	191878	161127
Feces_	203676	193529	191432	190664	181664	152265
Feces_	206132	196203	195026	194424	187656	160356
LarLiv_	205162	179476	177669	177285	169995	152787
LarLiv_	206295	180099	178861	178310	171603	153604
LarLiv_	204036	188767	185903	185387	176158	158673

LarLun_	204983	182557	181645	181336	176294	160462
LarLun_	202088	176575	175287	174930	168529	150847
LarLun_	213737	192562	190990	190828	182825	157450
Larvaln	181497	156028	155410	155119	150032	137700
PreInfF	205797	195628	193906	193344	185897	159957
PreInfF	205224	194969	193547	193038	185714	155055

1 **Characterizing Excretory-Secretory Products Proteome Across Larval Development Stages in *Ascaris***
2 ***suum***

3 ¹Sergio Castañeda, ²Grace Adeniyi-Ipadeola, ²Yifan Wu, ²Charlie Suarez-Reyes, ³Antrix Jain, ^{1,4}Juan David
4 Ramírez, ^{2,5,6}Jill E. Weatherhead

5 ¹Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de Ciencias
6 Naturales, Universidad del Rosario, Bogotá, Colombia

7 ²Department of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA

8 ³Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX, USA

9 ⁴Molecular Microbiology Laboratory, Department of Pathology, Molecular and Cell-based Medicine,
10 Icahn School of Medicine at Mount Sinai, New York, NY, USA

11 ⁵Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA

12 ⁶National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA

13

14 **Corresponding Author:** Jill E. Weatherhead

15 weatherh@bcm.edu

16

17 **Key words:** Ascariasis, Excretory-secretory products, proteome

18

19 **Abstract**

20 **Introduction:** *Ascaris lumbricoides* and *Ascaris suum* are parasitic nematodes that primarily infest the
21 small intestines of humans and pigs, respectively. Ascariasis poses a significant threat to human health
22 and swine health. Understanding *Ascaris* larval development is crucial for developing novel therapeutic
23 interventions that will prevent ascariasis in both humans and pigs. This study aimed to characterize the
24 excretory-secretory (ES) proteome of different *Ascaris suum* larval stages (L3-egg, L3-lung, L3-trachea) to
25 identify potential targets for intervention to prevent *Ascaris*-induced global morbidity.

26 **Methods:** Stage-specific larvae were isolated, cultured in vitro and ES-product was collected. Third-stage

27 *Ascaris* larvae (L3) were isolated from embryonated eggs (L3-egg), isolated from the lungs of Balb/c mice
28 infected with *Ascaris suum* eggs at day 8 post infection (L3-lungs) and isolated from the trachea of Balb/c
29 mice infected with *Ascaris suum* eggs at day 12 post infection (L3-trachea). ES products were obtained by
30 culturing larvae. Proteomic analysis was conducted using liquid chromatography-tandem mass
31 spectrometry (LC-MS/MS) and bioinformatic tools including MaxQuant, Perseus, and Andromeda,
32 following a detailed protocol available on GitHub. The analysis encompassed peptide identification,
33 scoring, and quantification against an organism-specific database, with subsequent quality control,
34 correlation assessment, and differential abundance determination using the Amica algorithm.
35 **Results:** A total of 58 unique proteins were identified in the ES products. Fourteen proteins were common
36 across all stages, while others were stage-specific. Principal component analysis revealed distinct protein
37 profiles for each stage, suggesting qualitatively different proteomes. Gene ontology analysis indicated
38 stage-specific GO enrichment of specific protein classes, such as nuclear proteins in L3-egg ES products
39 and metabolic enzymes in L3-lung and L3-trachea ES products.
40 **Discussion:** This study revealed stage-specific differences in the composition of *Ascaris* ES products.
41 Further investigation into the functional roles of these proteins and their interactions with host cells is
42 crucial for developing novel therapeutic and diagnostic strategies against ascariasis.

43

44 **Introduction**

45 *Ascaris lumbricoides* is a highly prevalent parasite globally [1]. According to the latest prevalence
46 estimates there are approximately 800 million cases of ascariasis globally [2, 3]. Ascariasis
47 disproportionately affects young children, with pre-school and school-aged children harboring the
48 greatest worm burden [4–7]. In endemic regions, the use of anthelmintic preventive chemotherapy,
49 through mass drug administration programs, aims to reduce worm burden and disease prevalence [2, 8,

50 9]. However, due to the ubiquitous contamination of *Ascaris* eggs in the environment, children endure
51 recurrent infections throughout childhood [2, 9–12]. High worm burden and frequent re-infection of
52 ascariasis results in a significant level of global morbidity, leading to nearly 754,000 Disability Adjusted
53 Life Years (DALYs) [9, 13]. As a result of *Ascaris*-induced long-term morbidity, there is an urgent need to
54 develop novel therapeutic interventions, like vaccines, to prevent ascariasis. However, developing
55 therapeutic interventions that prevent a high burden of disease and reinfection will require an in-depth
56 understanding of how *Ascaris* larvae develop into adult worms and how they interact with the host
57 immune response [14]. Similarly, *Ascaris suum* presents significant health and economic challenges to the
58 swine industry due to its widespread infection among pigs worldwide [1, 15]. *A. suum* can affect pigs of
59 all age groups, but its prevalence within specific age categories, particularly young pigs, is often influenced
60 by housing conditions and management practices. Overall ascariasis in pig populations leads to significant
61 economic losses due to reduced feed conversion efficiency and increased condemnation resulting in
62 production losses [16, 17].

63 *Ascaris lumbricoides* and *Ascaris suum* are nearly identical morphologically and genetically and routinely
64 cause cross-infection between hosts [1, 18, 19]. Both *Ascaris* spp. larvae undergo an essential migratory
65 phase that promotes development from larvae to mature adult worm [20]. What distinguishes the life
66 cycle of *Ascaris* spp. from other soil-transmitted helminths is its hepato-tracheal migration. Following
67 ingestion of embryonated *Ascaris* eggs from the environment, third-stage larvae (L3) emerge from the
68 eggs in the intestines. L3 migrate from the intestines to the liver, then proceeds to the lungs via the
69 circulatory system. Within the lung parenchyma, L3 larvae develop into mature L3 as they are ascending
70 the trachea and swallowed back into the intestines. In the intestines, L3 mature first into L4 larvae and
71 than into adult worms [20, 21].

72 Throughout its migration, *Ascaris* spp larvae release a wide range of molecules termed excretory-
73 secretory (ES) products. These products encompass antimicrobial peptides, proteins, lipids, metabolites,

74 among others, and are integral in shaping the intricate interactions between the host and the parasite.
75 They influence key aspects such as worm survival, migration, and immune modulation, ultimately aiding
76 in the successful establishment and persistence of the parasite within the host [22–25].

77 With significant advancements in mass spectrometry and genomic technologies, numerous challenges
78 and constraints in the proteomic analysis of parasite ES proteins have been effectively addressed.
79 Consequently, ES proteomes for parasitic nematodes such as *Ancylostoma caninum*, *Brugia malayi*,
80 *Haemonchus contortus*, *Teladorsagia circumcincta*, and *Trichinella spiralis* have been successfully
81 characterized [26–32]. Unraveling the composition and functional significance of ES products across
82 *Ascaris* life cycle presents a compelling avenue to advance our understanding of parasite biology and
83 potential targets for intervention strategies.

84 Given the close relation between *A. suum* and *A. lumbricoides*, and the availability of the *A. suum* genome,
85 we undertook the characterization of the protein composition of ES in three distinct larval stages of *Ascaris*
86 (L3-egg, L3-lung, and L3-trachea) using tandem mass spectrometry annotated with the *A. suum* genome
87 in a mouse model. Identifying highly abundant and conserved, stage-specific proteins within the *Ascaris*
88 ES proteome presents a promising avenue for discovering novel targets that could be utilized in the
89 development of preventive and therapeutic interventions against *Ascaris* infection.

90

91 **Methods**

92 ***Stage-specific larval isolation***

93 *Hatching of third-stage larvae (L3 egg stage):* Embryonated eggs in H₂SO₄ solution were centrifuged, the
94 supernatant was removed, and the pellet was re-suspended in sodium hypochlorite solution and
95 incubated for 2 hours. After incubation, the eggs were centrifuged with subsequent removal of the
96 supernatant. The eggs were washed with ultra-pure water 3 times and re-suspended in Hanks Balanced

97 Salt Solution (HBSS) with pH 2.0 using hydrogen chloride to achieve the desired pH and incubated for 30
98 minutes in 37°C + 5% CO₂. The eggs were centrifuged, the supernatant was removed while the pellet was
99 re-suspended in 10 mL of HBSS solution pH 7.0 to neutralize eggs for 30 minutes. The eggs were
100 centrifuged, and the egg pellet was re-suspended in culture media (RPMI-1640) with penicillin-
101 streptomycin (4% pen/strep). The egg solution was placed in 6-well culture plate (4mL per well) and
102 incubated over 96 hours. Egg hatching was monitored using light microscopy. Once the larvae hatched,
103 new media was placed in the culture plates and incubated overnight at 37°C +5% for 48 hours. The
104 experiment was completed in triplicate.

105 Collection of third stage larvae from the lungs (L3-lung): 5 Balb/c mice were infected with 2500 *Ascaris*
106 *suum* eggs in a total volume of 100 µL distilled water by oral gavage. After 8 days of infection, mice were
107 euthanized by intraperitoneal injection of ketamine (up to 150 mg/kg) and xylazine (up to 15 mg/kg). After
108 euthanasia, the lungs were removed, macerated in a petri dish, placed in a modified Baermann apparatus
109 in warm PBS and incubated at 37°C +5% CO₂ for 4 hours. The fluid in the Baermann apparatus was
110 transferred to a 50 mL conical tube and centrifuged. The supernatant was removed, and the pellet was
111 washed with ultra-pure water three times. After the final wash and removal of supernatant, the larvae
112 were transferred into a 6-well culture plate with 4 mL of culture media to each well. The culture plates
113 were incubated at 37°C +5% CO₂ for 48 hours. The experiment was completed in triplicate.

114 Collection of fourth-stage larvae from the trachea (L3 trachea): 5 Balb/c mice were infected as described
115 above. On post-infection day 12, the mice were euthanized, and a tracheostomy was created by placing a
116 20-gauge angiocatheter into the trachea. The angiocatheter was flushed with 0.8 mL of PBS three times,
117 all returned fluid was collected and passed through a 40µm cell strainer. The 40µm cell strainers were
118 washed using 4mL of PBS to release the larvae into a 6 well cell culture plate. Culture plates were rested
119 for 5 minutes to allow larvae to settle to bottom of the culture plate with gravity. PBS was removed from
120 the wells. The larvae were then washed with 4mL distilled water a total of three times. After completion

121 of the wash, 4 mL of culture media was added to each well and the 6-well culture plates were incubated
122 at 37°C +5% CO₂ for 48 hours. The experiment was completed in triplicate.

123 ***Preparation and proteomic analysis of ES products***

124 After 48 hours the supernatant was pooled, filtered through a 0.45 µm filter (PALL Corporation), frozen in
125 liquid nitrogen and stored until use as ES product. This process was repeated in three separate
126 experiments. Using mass spectrometry at the Baylor College of Medicine Mass Spectrometry Proteomics
127 core a total of 40ml volume of ES product from each developmental stage was lyophilized and trypsin
128 digested using S-Trap™ (Protifi, NY) according to manufacturer's protocol. Digested peptides were cleaned
129 using a C18 disk plug (3M Empore C18) and dried in a speed vac. The peptide concentration was
130 normalized to a total of 1 ug prior to the mass spectrometry run. Liquid chromatography-tandem mass
131 spectrometric (LC-MS/MS) analysis was carried out using a nano-LC 1200 system (Thermo Fisher Scientific,
132 San Jose, CA) coupled to Orbitrap Fusion™ Lumos ETD mass spectrometer (Thermo Fisher Scientific, San
133 Jose, CA). Peptides were loaded on a C-18 trap-column (Reprosil-Pur Basic C18, 2cm X 100µm, ID 1.9 µm,
134 Dr. Maisch GmbH, Germany) and eluted using a 75min gradient of 5-28% acetonitrile/0.1% formic acid at
135 a flow rate of 750nl/min on a C-18 analytical column (Reprosil-Pur Basic C18, 5cm x 150µm, ID 1.9 µm, Dr.
136 Maisch GmbH, Germany). The peptides were directly electro-sprayed into the mass spectrometer
137 operated in a data-dependent mode with 'top 30' method. The full MS scan was acquired in Orbitrap in
138 the range of 300-1400m/z at 120,000 resolution followed by MS2 in Ion Trap (HCD 28% collision energy)
139 with 15sec dynamic exclusion time.

140 ***Bioinformatic analysis of ES products***

141 The analytical framework employed MaxQuant, Perseus, and Andromeda, as detailed at
142 <https://github.com/FredHutch/maxquant-pipeline>. This protocol encompassed the identification of

143 peptides, determination of mass, and intensity of peptide peaks in mass spectrometry (MS) spectra,
144 thereby facilitating the identification of isotopic patterns [33–35].

145 Search parameters were a precursor tolerance of 20 ppm, MS/MS tolerance of 0.05 Da, Dynamic
146 modification of Oxidation and protein N-terminal Acetylation was allowed. The query of peptide and
147 fragment masses was conducted against a database housing organism-specific sequences of *Ascaris*,
148 obtained from UniProt
149 ([https://www.uniprot.org/uniprotkb?facets=reviewed:false&query=\(taxonomy_id:6253\)](https://www.uniprot.org/uniprotkb?facets=reviewed:false&query=(taxonomy_id:6253)))

150 PMID:21685128. Subsequently, scoring through a probability-based method termed peptide scoring was
151 performed, with the implementation of a false discovery rate (FDR) approach to limit the occurrence of
152 matches by chance. FDR was ascertained through statistically rigorous methodologies addressing multiple
153 hypothesis testing. Additionally, the database search incorporated not only target sequences but also
154 their reverse and contaminant counterparts, aiding in the establishment of a statistical cutoff for
155 acceptable spectral matches. Peptides were accepted based on a false discovery rate (FDR) of <0.05 at
156 both the peptide and protein levels. Proteins were quantified using the LFQ value from MaxQuant
157 employing default settings [33–35].

158 Following this preprocessing, the acquired outputs are undergoing a comprehensive analysis
159 encompassing quality control (QC), correlation assessment, density analysis, differential abundance
160 determination, and group comparisons, facilitated by the Amica algorithm
161 (<https://github.com/tbaccata/amica>) [36], using default parameters: Log2 fold change threshold 1.5;
162 significance cutoff (which value to use) 0.05.

163 To perform gene ontology analysis, the software QuickGO and PROTEINSIDE was used to determine GO
164 Biological Process and Cellular Component ontology enrichments using the *Ascaris suum* genome as a

165 reference (PRJNA62057). Additionally, DeepLoc was employed to identify proteins with signal peptides
166 within the dataset, thereby identifying secreted proteins [37].

167 Subsequent analyses of the output obtained by MaxQuant were evaluated also by Perseus [33–35].
168 Finally, we implement the open-source tool Protter, for visualization of proteoforms and interactive
169 integration of annotated and predicted sequence features [38].

170

171 **Results**

172 ***Protein identification***

173 The proteins within the ES products of different *Ascaris* larval stages (L3-egg, L3-lung, L3-trachea) were
174 characterized using LC-MS/MS. MaxQuant searches of the data identified 58 unique proteins by Gene ID
175 in the ES products of all three larval developmental stages combined (Table 1).

176 **Table 1.** Quantification values for each protein were calculated using the LFQ values obtained from
177 MaxQuant at each larval stage.


L3-egg	L3-lung	L4-Trachae	UniprotID
27.04009303	20.74246405	0	H2BIV5
25.41225377	25.84699386	0	F1KR40
22.84943946	0	0	F1LBV5
22.10939071	20.74517534	0	F1L344
21.91936237	0	0	F1KVQ9
21.57934356	0	0	F1KSS5
21.47565824	0	0	F1LBT0
21.12578173	22.23467712	0	F1L9F1
20.37517522	0	0	F1KS54
19.81000358	22.3112727	0	F1L8A5
0	22.76131667	0	A1BQ59
0	22.13276328	0	F1LEG5
0	23.73003389	0	E5D7U6
0	28.43614924	0	F1KPF6
0	24.14615969	0	F1KPQ7

0	23.15489844	0	F1KPR0
0	21.00319396	0	F1KTM8
0	22.2581922	0	F1KVV3
0	23.34516265	0	F1KW99
0	20.23420932	0	F1KY56
0	19.65308998	0	F1L0P6
0	19.73080511	0	F1L458
0	21.06375055	0	F1L4D2
0	20.71883385	0	F1L5H2
0	21.55173267	0	F1L6I9
0	22.7215273	0	F1L719
0	18.54105879	0	F1L8Z9
0	22.88675116	0	F1LA47
0	17.8615716	0	F1L9N2
0	22.31318419	0	F1LGZ3
18.28301598	24.94422663	19.19770144	F1L4H4
20.44394718	0	19.82074614	F1KY69
0	22.50671145	19.99327565	F1LEM8
0	20.26979329	20.67564353	F1L5G6
0	0	21.02093112	F1L3T3
17.82538119	0	21.86996729	F1KTX5
0	22.31418049	22.1747197	F1L5E5
0	21.38869003	22.27489111	F1KQZ7
21.14730928	26.45290204	22.28872642	F1LG13
18.99733387	26.98901884	22.59204088	F1L183
0	0	23.31049629	F1L3P9
0	20.93099138	23.87605224	Q17092
0	27.15034974	24.27717784	F1KZM0
23.36932896	26.90161692	24.360046	F1KYQ7
21.99851881	25.92036685	24.38455928	C1KG49
21.83259956	27.01669575	24.91948058	F1KXW6
0	27.67229379	24.95965144	F1L5S2
18.55730663	27.53519491	25.18744692	B5RHZ9
22.1978154	26.01624942	25.54176662	F1L1W1
20.94941923	27.96675257	25.73034492	F1L6S0
0	27.78338006	25.75692173	F1LGK7
0	28.90844769	25.920435	F1LC49
23.61851724	29.11812855	26.47830872	F1LHE9
0	0	26.52578865	F1L965
23.79530883	24.89513517	27.2341618	F1L676
24.89901388	28.13692198	27.274621	F1L3U5
25.63994896	28.31613649	28.07729697	F1LEJ7

23.37848643	29.99010154	29.48346905	F1L8W7
-------------	-------------	-------------	--------

178

179 Specifically, 5 proteins were exclusively identified in L3-egg, while L3-lung exhibited 20 unique proteins,
180 and L3-trachea displayed 3 proteins exclusive to its stage. Additionally, 14 proteins were detected in ES
181 products conserved across all three larval development stages (Figure 1a). The protein profiles of the ES
182 products from each larval developmental stage were compared using principal component analysis (PCA)
183 to assess their relatedness. The PCA revealed three distinct proteome clusters corresponding to each
184 stage (Figure 1b).




185

186 **Figure 1.** (a) The Venn diagram illustrates the distribution of unique and shared proteins across the ES
187 product of *Ascaris* stages. (b) Principal Component Analysis (PCA) reveals that the overall composition
188 remains distinctive for each developmental stage ES product.

189 **Comparative analysis**

190 We further compared the proteomic profiles between different larval stages using volcano plots and heat
191 maps. It is noteworthy that, although statistically significant differences were not observed among the
192 analyzed samples, distinct groups of proteins associated with L3-egg, L3-lung, and L3-Trachea ES products
193 were identified, alongside some shared proteins (Figure 2a). The lack of difference in protein enrichment

194 between stages' ES products may be attributed to the similarity between the proteomes or to an
195 insufficient number of proteins for a robust comparison due to the heterogeneity in the samples.
196 Additionally, based on the obtained results, Spearman's correlation analysis reveals distinct correlation
197 coefficients among the various protein groups across stages. Specifically, a correlation of 0.54 is observed
198 between L3-lung and L3-trachea ES proteins. In contrast, the correlation between L3-egg and L3-lung ES
199 proteins is determined to be 0.21, while the correlation between L3-egg and L3-trachea ES proteins is
200 calculated to be 0.32 (Figure 2b).



201
202 **Figure 2.** (a) HeatMap of protein profile identified by each developmental ES product stage of *Ascaris*. (b)
203 Spearman's correlation analysis among the *Ascaris*-related protein groups.

204 **Gene ontology**

205 The Gene Ontology (GO) annotation of proteins enriched in the ES product was analyzed by molecular
206 function, cellular component, and biological process (Table 2, Figure S1), as well as according to their
207 property of being secreted proteins (Table S1).


208 **Table 2.** Identified protein function, implicated biological processes, and subcellular localization.

Stage	UniProt ID	Protein Name	Function	Molecular Function	Biological Process	Cellular Localization
Egg	F1LBV5	EII-associated factor Eaf	Transcription	Transcription	regulation of DNA-templated transcription	nucleus
Egg	F1KVQ9	Protein SDA1	ribosomal large subunit biogenesis	ribosomal large subunit biogenesis	ribosomal large subunit export from nucleus	nucleus
Egg	F1KSS5	BLTP2/FMP27/Hobbit C-terminal domain-containing protein	-	-	-	-
Egg	F1LBT0	Chondroitin proteoglycan 3	-	-	-	-
Egg	F1KS54	Metalloendopeptidase	metalloendopeptidase activity	zinc ion binding	proteolysis	membrane
Egg/Lung	H2BIV5	Trehalose-6-phosphate synthase	trehalose synthesis	catalytic activity	trehalose biosynthesis	cytosol
Egg/Lung	F1KR40	Structural maintenance of chromosomes protein	Hydrolase	atp-dependent activity	-	nucleus
Egg/Lung	F1L344	Pleiotropic regulator 1	mRNA splicing, via spliceosome	mRNA splicing, via spliceosome	mRNA splicing, via spliceosome	nucleus
Egg/Lung	F1L9F1	Phosphoglycerate kinase	plasma membrane	phosphoglycerate kinase activity	glycolytic process	cytosol
Egg/Lung	F1L8A5	Tubulin beta chain	structural constituent of cytoskeleton	GTPase activity	microtubule-based process	cytosol
Egg/Lung/Trachae	F1LEJ7	Polyubiquitin	peptidase activity	proteolytic activity	protein degradation	cytosol
Egg/Lung/Trachae	F1L3U5	Actin-2	protein binding	protein binding	signal transduction	cytosol
Egg/Lung/Trachae	F1L676	Triosephosphate isomerase	isomerase activity	isomerase activity	gluconeogenesis	-
Egg/Lung/Trachae	F1LHE9	Calmodulin	calcium ion binding	protein binding	calcium signaling	cytosol
Egg/Lung/Trachae	F1L8W7	Histone H2B type 1-W	nucleosome assembly	dna-binding	chromatin organization	nucleus
Egg/Lung/Trachae	F1KYQ7	Heat shock 70 kDa protein A	ATP-dependent protein folding chaperone	ATP-dependent protein folding chaperone	Stress response	membrane
Egg/Lung/Trachae	F1L1W1	Heat shock protein 70 B2	ATP-dependent protein folding chaperone	ATP-dependent protein folding chaperone	Stress response	cytosol
Egg/Lung/Trachae	C1KG49	Heat shock protein 90	ATP-dependent protein folding chaperone	ATP-dependent protein folding chaperone	Stress response	cytosol
Egg/Lung/Trachae	F1KXW6	14-3-3-like protein	-	-	-	-

Egg/Lung/Trachae	F1LG13	Peptidyl-prolyl cis-trans isomerase	endoplasmic reticulum	peptidyl-prolyl cis-trans isomerase activity	protein folding	endoplasmic reticulum
Egg/Lung/Trachae	F1L6S0	Fructose-bisphosphate aldolase	catalytic activity	fructose-bisphosphate aldolase activity	glycolytic process	cytosol
Egg/Lung/Trachae	F1L183	Heat shock 70 kDa protein C	ATP binding	ATP-dependent protein folding chaperone	Stress response	endoplasmic reticulum
Egg/Lung/Trachae	B5RHZ9	Elongation factor 1-alpha	Elongation factor	GTPase activity	Protein biosynthesis	cytosol
Egg/Lung/Trachae	F1L4H4	ATP synthase subunit beta	Translocase	ATP hydrolysis activity	ATP synthesis	membrane
Egg/Trachae	F1KY69	Moesin/ezrin/radixin homolog 1	actin binding	actin binding	actin binding	cytosol
Egg/Trachae	F1KT X5	Neurexin-2-alpha	-	-	-	membrane
Lung	A1BQ59	Translationally-controlled tumor protein homolog	-	-	-	-
Lung	F1LEG5	Protein disulfide-isomerase 2	isomerase	protein disulfide isomerase activity	protein disulfide isomerase activity	endoplasmic reticulum
Lung	E5D7U6	phosphopyruvate hydratase	phosphopyruvate hydratase activity	phosphopyruvate hydratase activity	Glycolysis	cytosol
Lung	F1KPF6	Muscle M-line assembly protein unc-89	ATP binding	protein kinase activity	Neurogenesis	membrane
Lung	F1KPQ7	227 kDa spindle- and centromere-associated protein	-	-	-	nucleus
Lung	F1KPR0	Spectrin alpha chain	calmodulin binding	Calmodulin-binding	actin filament capping	cytosol
Lung	F1KTM8	Intermediate filament protein ifa-1	-	-	-	cytosol
Lung	F1KVV3	Collagen alpha-5(VI) chain	-	-	collagen trimer	cytosol
Lung	F1KW99	H(+)-transporting two-sector ATPase	Translocase	proton-transporting ATPase activity, rotational mechanism	Hydrogen ion transport	-
Lung	F1KY56	Ras-related protein Rab-1A	GTP binding	GTPase activity	GTPase activity	-
Lung	F1L0P6	Dihydrolipoyl dehydrogenase	Oxidoreductase	Oxidoreductase	Oxidoreductase	cytosol
Lung	F1L458	Disorganized muscle protein 1	-	-	-	-
Lung	F1L4D2	Troponin T	regulation of muscle contraction	regulation of muscle contraction	regulation of muscle contraction	cytosol

Lung	F1L5H2	Fructose-bisphosphate aldolase	fructose-bisphosphate aldolase activity	fructose-bisphosphate aldolase activity	Glycolysis	cytosol
Lung	F1L6I9	Calumenin-A	calcium ion binding	calcium ion binding	calcium ion binding	cytosol
Lung	F1L7I9	inorganic diphosphatase	Hydrolase	magnesium ion binding	phosphate-containing compound metabolic process	cytosol
Lung	F1L8Z9	Malate dehydrogenase	Oxidoreductase	L-malate dehydrogenase activity	Tricarboxylic acid cycle	cytosol
Lung	F1LA47	Serine/threonine-protein phosphatase	Hydrolase	myosin phosphatase activity	myosin phosphatase activity	-
Lung	F1L9N2	Enoyl-CoA hydratase	catalytic activity	catalytic activity	catalytic activity	-
Lung	F1LGZ3	Peptidyl-prolyl cis-trans isomerase	Isomerase	peptidyl-prolyl cis-trans isomerase activity	protein folding	-
Lung/Tracheae	F1KQZ7	Protein abnormal spindle	-	-	-	-
Lung/Tracheae	F1L5G6	Tubulin alpha chain	GTP binding	structural constituent of cytoskeleton	microtubule-based process	cytosol
Lung/Tracheae	F1KZM0	Myosin regulatory light chain	calcium ion binding	calcium ion binding	calcium ion binding	-
Lung/Tracheae	F1LEM8	Polyadenylate-binding protein 1	RNA-binding	RNA-binding	RNA-binding	nucleus
Lung/Tracheae	F1L5S2	Histone H3	DNA binding	structural constituent of chromatin	structural constituent of chromatin	nucleus
Lung/Tracheae	F1LC49	Histone H4	DNA binding	structural constituent of chromatin	structural constituent of chromatin	nucleus
Lung/Tracheae	F1L5E5	Venom allergen 3	-	-	-	-
Lung/Tracheae	F1LGK7	Tropomyosin	-	-	-	-
Lung/Tracheae	Q17092	Intermediate filament protein	Intermediate filament protein	Intermediate filament protein	Intermediate filament protein	cytosol
Tracheae	F1L3P9	1-Cys peroxiredoxin	Antioxidant	Antioxidant	Antioxidant	-
Tracheae	F1L3T3	26S proteasome non-ATPase regulatory subunit 3	enzyme regulator activity	enzyme regulator activity	regulation of protein catabolic process	cytosol
Tracheae	F1L965	Homeobox protein lin-39	DNA binding	DNA binding	DNA binding	nucleus

210 Additionally, based on annotated and predicted protein sequences derived from previous analyses, we
211 conducted a visual reconstruction of proteoforms of the main proteins identified. This aimed to represent
212 protein sequence characteristics within the context of protein topology and experimental proteomic
213 evidence (Figure 3). Notably, proteins identified in L3-egg ES product exhibit a pronounced association
214 with nuclear proteins engaged in replicative and transcriptional processes, including E11-associated factor
215 Eaf, Protein SDA1, BLTP2/FMP27/Hobbit C-terminal domain-containing protein, Chondroitin proteoglycan
216 3, and Metalloendopeptidase. Conversely, proteins identified in L3-lung and L3-trachea ES products
217 predominantly pertain to cytoplasmic proteins involved in energetic processes, such as glycolysis, and
218 proteins related to the cytoskeleton (Figure S2, S3). For L3-lung ES products, the identified proteins include
219 translationally-controlled tumor protein homolog, Protein disulfide-isomerase 2, phosphopyruvate
220 hydratase, Muscle M-line assembly protein unc-89, 227 kDa spindle-and centromere-associated protein,
221 Spectrin alpha chain, Intermediate filament protein ifa-1, Collagen alpha-5(VI) chain, H(+)-transporting
222 two-sector ATPase, Ras-related protein Rab-1A, Dihydrolipoyl dehydrogenase, Disorganized muscle
223 protein 1, Troponin T, Fructose-bisphosphate aldolase, Calumenin-A, inorganic diphosphatase, Malate
224 dehydrogenase, Serine/threonine-protein phosphatase, Enoyl-CoA hydratase, and Peptidyl-prolyl cis-
225 trans isomerase (Figure S2, S3). On the other hand, for L3-trachea ES products, proteins found include 1-
226 Cys peroxiredoxin, 26S proteasome non-ATPase regulatory subunit 3, and Homeobox protein lin-39. These
227 findings underscore distinct molecular emphases and functional roles across different developmental
228 stages of *Ascaris*, shedding light on the nuanced biological processes characterizing each stage.



229

230 **Figure 3.** Visualization of proteoforms and interactive integration of annotated and predicted sequence

231 features of main proteins. Nuclear proteins associated with replication and transcription, such as (a) EII-

232 associated factor Eaf (UniProt ID F1LBV5) and (b) Protein SDA1 (UniProt ID F1KVQ9) in L3-egg ES product.

233 Glycolytic enzymes like (c) fructose-bisphosphate aldolase (UniProt ID F1L5H2) and (d) malate

234 dehydrogenase (UniProt ID F1L8Z9) in L3-lung ESP. Cytoskeletal proteins such as (e) spectrin alpha chain

235 (UniProt ID F1KPR0) and (f) intermediate filament protein ifa-1 (UniProt ID F1KTM8) in both L3-lung and

236 L3-trachea ES product. (g) Peptidyl-prolyl cis-trans isomerase (UniProt ID F1LGZ3), an immunophilin found

237 in L3-Lung ES product. Identified (h) Ezrin-radixin-moesin (ERM) proteins (UniProt ID F1KY69) in the

238 secreted proteomes of larval development stages L3-lung and L3-trachea ES product.

239 Discussion

240 This study employed LC-MS/MS to characterize the protein profiles of excretory-secretory (ES) products

241 from different *Ascaris* larval stages (L3-egg, L3-lung, L3-trachea). This is the most comprehensive

242 evaluation of stage-specific ES proteomes during *Ascaris* larval migration to date. Findings reveal intriguing

243 insights into the stage-specific composition of these secretions, potentially reflecting distinct biological

244 functions during development. The migration of *Ascaris* larvae through the host is a crucial developmental
245 process for the parasite. This study elucidates the similarities and differences in the secreted proteome
246 among L3 developmental stages, offering valuable insights that could spur research focused on identifying
247 novel diagnostic and vaccine targets essential for controlling and eradicating ascariasis [22, 39–41].

248 Prior research has investigated ES proteins derived from adult worms, uncovering a diverse array of
249 proteins, enzymes, and biomolecules with roles in immunomodulation, immunoevasion, and tissue
250 degradation. Among these are Glycosyl hydrolases, crucial for breaking down complex carbohydrates and
251 integral to the parasite's energy metabolism. Additionally, C-type lectins exhibit a wide range of functions
252 including cell-cell adhesion, immune responses to pathogens, and involvement in apoptosis. Furthermore,
253 Heat shock proteins (HSPs) have been identified, which may modulate host responses to facilitate and
254 sustain infection, among other functions. [22, 40–43]. Furthermore, a study evaluating ES protein of
255 *Ascaris* L3-egg, L3-lung and L4-intestines was completed in two pigs. The majority of the proteins identified
256 were stage-specific but 14-3-3-like protein and a serpin-like protein were conserved amongst the three
257 different larval stages. While pigs are a natural host of ascariasis, use of a pig model is limiting due to size
258 and cost [26]. Here, we used a highly replicated mouse model of ascariasis in order to repeat the
259 experiment in triplicate and identify variation between each larval development stage as well as within
260 each larval development stage.

261 The identification of stage-specific proteins in our study aligns with previous observations in other
262 parasitic nematodes, where ES products exhibit dynamic changes throughout the life cycle [27, 43–48].
263 For instance, in *Trichinella spiralis*, infective larvae secrete proteins like excretory-secretory antigen-like
264 protein (TES) and cystatin inhibitor during muscle invasion, potentially aiding tissue penetration and
265 immune modulation [49, 50]. Similarly, *Angiostrongylus cantonensis* ES products change significantly
266 between different developmental stages, with glutathione S-transferase and superoxide dismutase
267 enriched in adult stages, suggesting roles in detoxification and stress management [51, 52].

268 In the current analysis, a total of 58 unique proteins were identified in the *Ascaris* ES products. Notably, 5
269 proteins were exclusively identified in L3-egg ES product, 20 proteins unique to proteins were unique to
270 L3-lung ES product, and 3 proteins were distinct to L3-trachea ES product. Additionally, 14 detected
271 proteins were conserved across all three larval developmental stages (Figure 1a, 2a). Protein diversity and
272 protein abundance may be secondary to the active migration. In comparison to the intraluminal L3 egg
273 stage, the L3-trachea stage and L3 lung stage, which require migration through tissue and molting, may
274 necessitate upregulation and secretion of proteins to facilitate these metabolically taxing processes [21,
275 27, 53, 54].

276 Our research into L3-egg ES product supports the idea that the GO enrichment of nuclear proteins
277 associated with replication and transcription, such as E11-associated factor Eaf (UniProt ID F1LBV5) and
278 Protein SDA1 (UniProt ID F1KVQ9), correlates with active cell division and differentiation during this early
279 developmental stage (Figure 2, 3). This finding aligns with previous studies on *Ascaris suum*
280 embryogenesis, where similar proteins were identified [27, 41, 53]. Thus, it appears that ES products in
281 L3-egg may play a crucial role in establishing the foundation for further larval development. Conversely,
282 in L3-lung and L3-trachea ES products, we observed a dominance of cytoplasmic proteins related to energy
283 metabolism and cytoskeletal functions, which aligns well with the increased demands of these later stages
284 [27, 41, 53]. For example, the presence of glycolytic enzymes like fructose-bisphosphate aldolase (UniProt
285 ID F1L5H2) and malate dehydrogenase (UniProt ID F1L8Z9) in L3-lung ES product suggests an adaptation
286 to anaerobic environments during lung migration (Figure 2, 3) [55, 56]. Moreover, the detection of
287 cytoskeletal proteins such as spectrin alpha chain (UniProt ID F1KPR0) and intermediate filament protein
288 ifa-1 (UniProt ID F1KTM8) in both L3-lung and L3-trachea ES product suggests their role in preserving cell
289 shape and aiding in active movement within the host, as has been observed in various nematode models,
290 including *Trichinella britovi* and *Caenorhabditis elegans* (Figure 2, 3) [57–59]. These findings underscore
291 the potential significance of ES products in facilitating the heightened metabolic activity and motility

292 crucial for the successful migration and establishment of larvae within the host. Further exploration of
293 these specific proteins could yield therapeutic and diagnostic targets for *Ascaris* larval migration, offering
294 valuable insights into proteins essential for helminthic metabolic and motility processes vital to *Ascaris*
295 development.

296 Furthermore, our analysis revealed several interesting proteins within the ES products specific to
297 particular larval stages. For instance, peptidyl-prolyl cis-trans isomerase (UniProt ID F1LGZ3), an
298 immunophilin found in L3-lung ES product, exhibits activities that isomerize peptidyl-proline bonds,
299 thereby facilitating enhanced protein folding (Figure 2, 3) [60, 61]. Immunophilins, major binding proteins
300 for certain immunosuppressive drugs, have been found in other helminth ES products, including
301 *Trichinella spiralis* early larval development stages [62]. While detailed functional analysis is available for
302 many protozoal immunophilins, relatively little is known about the functionality of helminth
303 immunophilins outside of *Caenorhabditis elegans*, although they are widely expressed within helminth
304 species [61]. Parasite-derived immunophilins could serve as potential targets for diagnostic assays or drug
305 development, especially when considering non-immunosuppressive analogs. Cyclosporin A, along with its
306 non-immunosuppressive counterparts, has demonstrated inhibitory effects on parasites, suggesting
307 promising avenues for therapeutic intervention [60, 61].

308 Additionally, we identified Ezrin-radixin-moesin (ERM) proteins (UniProt ID F1KY69) in the secreted
309 proteomes of larval development stages L3-lung and L3-trachea ES proteins (Figure 2, 3). ERMs are
310 proteins at the intersection of the cytoskeleton and the extracellular membrane, traditionally considered
311 structural proteins allowing cross-linking of actin to the apical cellular membrane [63]. However, recent
312 studies have revealed significant roles for ERMs in metabolic processes, cell signaling, and activation of
313 the immune response [63, 64]. While several studies have emphasized the role of ERM in protozoa
314 infectivity, particularly in *Trypanosoma cruzi*, there is currently no indication of the involvement of ERM
315 in helminth larval migration in the context of ascariasis [65]. It has been identified that ERM proteins could

316 be associated with various parasite processes, including invasion, potentially regulating F-actin dynamics
317 and plasma membrane interplay. Additionally, their involvement in the development of several structures
318 has been observed in models such as *C. elegans* [66]. Furthermore, changes in the phosphorylation state
319 of these proteins may be linked to interactions with specific tissues, offering valuable insights into larval
320 changes associated with specific anatomical and parasite-host-tissue interactions during larval migration
321 [63–67].

322 Although statistically significant differences in protein abundance between stages were not detected,
323 several lines of evidence suggest qualitative differences in the ES proteomes. First, principal component
324 analysis (PCA) revealed distinct clusters for each stage, indicating unique protein profiles (Figure 1b). For
325 instance, L3-egg ES product clustered separately due to the presence of embryonic development proteins
326 like Eaf and SDA1, absent in later stages [39, 41]. Conversely, L3-lung and L3-trachea ES product formed a
327 separate cluster enriched in metabolic enzymes like aldolase and malate dehydrogenase, suggesting a
328 shared focus on energy production. Second, the identification of unique proteins in each stage further
329 supports qualitative differences. For example, L3-egg ES product exclusively contained chromatin
330 remodeling proteins, essential for early development, while L3-lung ES product exhibited specific
331 cytoskeletal proteins like spectrin and intermediate filament proteins, potentially involved in motility
332 during lung migration [55, 56]. Additionally, L3-trachea ES product uniquely possessed stress response
333 proteins like peroxiredoxin, suggesting adaptation to the host environment [55, 56]. Third, the
334 heterogeneity of ES products and inherent variability could mask subtle abundance differences between
335 stages, making statistical detection challenging. For instance, the presence of immunomodulatory
336 proteins in all stages might mask stage-specific variations in their abundance, requiring targeted analyses
337 for accurate comparisons. It is important to highlight the relatively small number of identified proteins
338 might not capture the full complexity of the proteomes [68–72]. Focusing on a broader range of proteins
339 or employing targeted approaches might reveal significant differences between stages. Therefore, while

340 statistically significant differences in protein abundance weren't observed, the distinct clustering, stage-
341 specific protein groups, and potential limitations suggest qualitative differences in the proteomes of
342 *Ascaris* ES products across developmental stages. Further studies with larger sample sizes and targeted
343 protein analyses are crucial to fully understand these qualitative variations and their functional
344 implications.

345 These findings pave the way for further investigations into the specific functions of individual proteins and
346 their contributions to the overall biological processes of each larval stage. Studying the downstream
347 effects of E11-associated factor Eaf through gene expression analysis could elucidate its role in regulating
348 cell cycle genes in L3-egg [39, 41]. While enzyme activity assays could measure the specific activity of
349 fructose-bisphosphate aldolase and malate dehydrogenase in different stages, providing direct evidence
350 for their contribution to energy production [56]. Furthermore, for instance, immunofluorescence
351 microscopy could visualize the localization of spectrin alpha chain and intermediate filament protein ifa-
352 1 in migrating larvae, revealing their role in maintaining specific cellular structures and facilitating
353 movement [58, 59]. Beyond individual proteins, exploring the interactions between ES products and host
354 cells could provide valuable insights into the mechanisms underlying *Ascaris* pathogenesis. For example,
355 investigating how cytokines secreted by host immune cells in response to specific ES proteins could reveal
356 their immunomodulatory potential. Additionally, studying the binding of ES proteins to host cell receptors
357 could identify potential targets for therapeutic intervention [27, 51, 52, 73, 74]. While further
358 investigations are necessary to fully elucidate the functional significance of these proteins and their
359 interactions with host cells, these findings contribute to a deeper understanding of the complex biology
360 of *Ascaris* and its adaptations to the parasitic life cycle.

361

362 **Funding:** This study was funded by NIH NIAID K08 (K08AI143968). We thank the Ministerio de Ciencia
363 Tecnología e Innovación (Minciencias) of Colombia under the framework of the Sistema General de
364 Regalías for providing the PhD scholarship of Sergio Castañeda. BCM Mass Spectrometry Proteomics Core
365 is supported by the Dan L. Duncan Comprehensive Cancer Center NIH award (P30 CA125123), CPRIT Core
366 Facility Award (RP210227).

367

368 **Author contributions**

369 SC, GAI, YFW, JDR, JW conceived and designed experiments. GAI, CSR, YFW performed laboratory
370 experiments or clinical sampling. SC, AJ, JDR provided technical support and assisted with data collection.
371 SC, AJ, performed data analysis. SC, GAI, YW, JDR, JW wrote the manuscript. All authors contributed to
372 reviewing the paper and agreed on the present version for submission.

373

374 **Data availability.**

375 Preprocessing and processing results data are available
376 at https://github.com/scastanedag/Proteome_Larval_Development-Stages_Ascaris_suumv

377

378 **Supplementary material**

379 **Figure S1.** ES product proteins and their corresponding subcellular locations at each larval stage.

380 **Figure S2.** GO enrichment analysis by Cellular Component. It shows significant results obtained in a. L3-
381 egg and L3-lung.

382 **Figure S3.** GO enrichment analysis by Biological Process. It shows significant results obtained in a. L3-egg
383 and L3-lung.

384

385 **Table S1.** Secreted proteins identified. The Predicted localizations and Predicted signals display the
386 subcellular localizations and sorting signals predicted for the query protein, respectively. The Probability
387 table displays the probability assigned by the model to each of the subcellular localizations.

388

389 **References**

- 390 1. Zhou C, Chen J, Niu H, Ouyang S, Wu X (2020) Study on the population evolution of *Ascaris*
391 *lumbricoides* and *Ascaris suum* based on whole genome resequencing. *Vet Parasitol* 279:109062
- 392 2. Specht S, Keiser J (2022) Helminth infections: Enabling the World Health Organization Road Map.
393 *Int J Parasitol*. <https://doi.org/10.1016/j.ijpara.2022.10.006>
- 394 3. Holland C, Sepidarkish M, Deslyper G, et al (2022) Global prevalence of *Ascaris* infection in
395 humans (2010–2021): a systematic review and meta-analysis. *Infect Dis Poverty* 11:1–16
- 396 4. Giraldo-Gómez JM, Lora F, Henao LH, Mejía S, Gómez-Marín JE (2005) Prevalence of giardiasis
397 and intestinal parasites in pre-school children from homes being attended as part of a state
398 programme in Armenia, Colombia. *Rev Salud Publica (Bogota)* 7:327–338
- 399 5. Jourdan PM, Lamberton PHL, Fenwick A, Addiss DG (2018) Soil-transmitted helminth infections.
400 *Lancet* 391:252–265
- 401 6. Crompton DWT (2001) *Ascaris* and ascariasis. *Adv Parasitol* 48:285–375
- 402 7. Ojha SC, Jaide C, Jinawath N, Rotjanapan P, Baral P (2014) Geohelminths: Public health
403 significance. *J Infect Dev Ctries* 8:5–16
- 404 8. Harhay MO, Horton J, Olliaro PL (2010) Epidemiology and control of human gastrointestinal
405 parasites in children. *Expert Rev Anti Infect Ther* 8:219–234
- 406 9. Jia TW, Melville S, Utzinger J, King CH, Zhou XN (2012) Soil-Transmitted Helminth Reinfection

- 407 after Drug Treatment: A Systematic Review and Meta-Analysis. *PLoS Negl Trop Dis* 6:e1621
- 408 10. Schüle SA, Clowes P, Kroidl I, et al (2014) *Ascaris lumbricoides* Infection and Its Relation to
409 Environmental Factors in the Mbeya Region of Tanzania, a Cross-Sectional, Population-Based
410 Study. *PLoS One* 9:1–10
- 411 11. Clarke NE, Clements ACA, Doi SA, Wang D, Campbell SJ, Gray D, Nery S V. (2017) Differential
412 effect of mass deworming and targeted deworming for soil-transmitted helminth control in
413 children: a systematic review and meta-analysis. *Lancet* 389:287–297
- 414 12. Else KJ, Keiser J, Holland C V., Grensis RK, Sattelle DB, Fujiwara RT, Bueno LL, Asaolu SO,
415 Sowemimo OA, Cooper PJ (2020) Whipworm and roundworm infections. *Nat Rev Dis Prim.*
416 <https://doi.org/10.1038/s41572-020-0171-3>
- 417 13. Ascariasis — Level 4 cause | Institute for Health Metrics and Evaluation.
418 https://www.healthdata.org/results/gbd_summaries/2019/ascariasis-level-4-cause. Accessed 7
419 Feb 2024
- 420 14. Yasuda K, Nakanishi K (2018) Host responses to intestinal nematodes. *Int Immunol* 30:93–102
- 421 15. Boes J, Kanora A, Havn KT, Christiansen S, Vestergaard-Nielsen K, Jacobs J, Alban L (2010) Effect
422 of *Ascaris suum* infection on performance of fattening pigs. *Vet Parasitol* 172:269–276
- 423 16. Peng W, Criscione CD (2012) Ascariasis in people and pigs: new inferences from DNA analysis of
424 worm populations. *Infect Genet Evol* 12:227–235
- 425 17. Ózsvári L (2018) Production impact of parasitisms and coccidiosis in swine. *J Dairy, Vet Anim Res.*
426 <https://doi.org/10.15406/JDVAR.2018.07.00214>
- 427 18. King KC, Stelkens RB, Webster JP, Smith DF, Brockhurst MA (2015) Hybridization in Parasites:
428 Consequences for Adaptive Evolution, Pathogenesis, and Public Health in a Changing World. *PLOS*

- 429 Pathog 11:e1005098
- 430 19. Rafaluk-Mohr C, Ashby B, Dahan DA, King KC (2018) Mutual fitness benefits arise during
431 coevolution in a nematode-defensive microbe model. *Evol Lett* 2:246–256
- 432 20. Corvino DF de L, Horrall S (2021) Ascariasis. *StatPearls*
- 433 21. Deslyper G, Sowemimo OA, Beresford J, Holland C V. (2020) *Ascaris lumbricoides* and *Ascaris*
434 *suum* vary in their larval burden in a mouse model. *J Helminthol.*
435 <https://doi.org/10.1017/S0022149X20000127>
- 436 22. Chehayeb JF, Robertson AP, Martin RJ, Geary TG (2014) Proteomic Analysis of Adult *Ascaris suum*
437 Fluid Compartments and Secretory Products. *PLoS Negl Trop Dis* 8:e2939
- 438 23. Shears RK, Grecis RK (2022) Whipworm secretions and their roles in host-parasite interactions.
439 *Parasit Vectors* 15:348
- 440 24. Castañeda S, Paniz-Mondolfi A, Ramírez JD (2022) Detangling the Crosstalk Between *Ascaris*,
441 *Trichuris* and Gut Microbiota: What’s Next? *Front Cell Infect Microbiol* 0:615
- 442 25. Midha A, Ebner F, Schlosser-Brandenburg J, Rausch S, Hartmann S (2021) Trilateral Relationship:
443 *Ascaris*, Microbiota, and Host Cells. *Trends Parasitol* 37:251–262
- 444 26. Wang T, Van Steendam K, Dhaenens M, Vlaminck J, Deforce D, Jex AR, Gasser RB, Geldhof P
445 (2013) Proteomic Analysis of the Excretory-Secretory Products from Larval Stages of *Ascaris suum*
446 Reveals High Abundance of Glycosyl Hydrolases. *PLoS Negl Trop Dis* 7:e2467
- 447 27. Chehayeb JF, Robertson AP, Martin RJ, Geary TG (2014) Proteomic Analysis of Adult *Ascaris suum*
448 Fluid Compartments and Secretory Products. *PLoS Negl Trop Dis* 8:e2939
- 449 28. Bennuru S, Semnani R, Meng Z, Ribeiro JMC, Veenstra TD, Nutman TB (2009) *Brugia malayi*
450 Excreted/Secreted Proteins at the Host/Parasite Interface: Stage- and Gender-Specific Proteomic

- 451 Profiling. PLoS Negl Trop Dis. <https://doi.org/10.1371/JOURNAL.PNTD.0000410>
- 452 29. J M, B H, SH N, D S, A L, JJ G (2009) Proteomics analysis of the excretory/secretory component of
453 the blood-feeding stage of the hookworm, *Ancylostoma caninum*. Mol Cell Proteomics.
454 <https://doi.org/10.1074/MCP.M800206-MCP200>
- 455 30. Liu G, Liu Q, Han Z, Wang P, Li Y (2023) Comparative proteomics analysis of adult *Haemonchus*
456 *contortus* isolates from *Ovis ammon*. Front Cell Infect Microbiol.
457 <https://doi.org/10.3389/FCIMB.2023.1087210/FULL>
- 458 31. Smith SK, Nisbet AJ, Meikle LI, Inglis NF, Sales J, Beynon RJ, Matthews JB (2009) Proteomic
459 analysis of excretory/secretory products released by *Teladorsagia circumcincta* larvae early post-
460 infection. Parasite Immunol 31:10–19
- 461 32. Wang L, Wang ZQ, Hu DD, Cui J (2013) Proteomic analysis of *Trichinella spiralis* muscle larval
462 excretory-secretory proteins recognized by early infection sera. Biomed Res Int.
463 <https://doi.org/10.1155/2013/139745>
- 464 33. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-
465 range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008 2612
466 26:1367–1372
- 467 34. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen J V., Mann M (2011) Andromeda: A peptide
468 search engine integrated into the MaxQuant environment. J Proteome Res 10:1794–1805
- 469 35. Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J (2016) The Perseus
470 computational platform for comprehensive analysis of (prote)omics data. Nat Methods 2016 139
471 13:731–740
- 472 36. Didusch S, Madern M, Hartl M, Baccarini M (2022) amica: an interactive and user-friendly web-

- 473 platform for the analysis of proteomics data. *BMC Genomics* 23:1–9
- 474 37. Kaspric N, Picard B, Reichstadt M, Tournayre J, Bonnet M (2015) ProteINSIDE to Easily Investigate
475 Proteomics Data from Ruminants: Application to Mine Proteome of Adipose and Muscle Tissues
476 in Bovine Foetuses. *PLoS One* 10:e0128086
- 477 38. Omasits U, Ahrens CH, Müller S, Wollscheid B (2014) Protter: interactive protein feature
478 visualization and integration with experimental proteomic data. *Bioinformatics* 30:884–886
- 479 39. Phuphisut O, Poodeepiyasawat A, Yoonuan T, Watthanakulpanich D, Chotsiri P, Reamtong O,
480 Mousley A, Gobert GN, Adisakwattana P (2022) Transcriptome profiling of male and female
481 *Ascaris lumbricoides* reproductive tissues. *Parasites and Vectors* 15:1–18
- 482 40. Whitman JD, Sakanari JA, Mitreva M (2021) Areas of Metabolomic Exploration for Helminth
483 Infections. *7:206–214*
- 484 41. Ma X, Zhu Y, Li C, Shang Y, Meng F, Chen S, Miao L (2011) Comparative transcriptome sequencing
485 of germline and somatic tissues of the *Ascaris suum* gonad. *BMC Genomics* 12:1–11
- 486 42. Hansen EP, Fromm B, Andersen SD, et al (2019) Exploration of extracellular vesicles from *Ascaris*
487 *suum* provides evidence of parasite–host cross talk. *J Extracell Vesicles*.
488 <https://doi.org/10.1080/20013078.2019.1578116>
- 489 43. Xu MJ, Fu JH, Zhou DH, Elsheikha HM, Hu M, Lin RQ, Peng LF, Song HQ, Zhu XQ (2013) *Ascaris*
490 *lumbricoides* and *Ascaris suum*: Comparative proteomic studies using 2-DE coupled with mass
491 spectrometry. *Int J Mass Spectrom* 339–340:1–6
- 492 44. Sato O, Uzoechi SC, Rosa BA, et al (2023) Excretory/Secretory Proteome of Females and Males of
493 the Hookworm *Ancylostoma ceylanicum*. *Pathog* 2023, Vol 12, Page 95 12:95
- 494 45. Winkelmann F, Gesell Salazar M, Hentschker C, Michalik S, Macháček T, Scharf C, Reisinger EC,


- 495 Völker U, Sombetzki M (2022) Comparative proteome analysis of the tegument of male and
496 female adult *Schistosoma mansoni*. *Sci Reports* 2022 12:1–10
- 497 46. Cruz K, Marcilla A, Kelly P, Vandenplas M, Osuna A, Trelis M (2021) *Trichuris trichiura* egg extract
498 proteome reveals potential diagnostic targets and immunomodulators. *PLoS Negl Trop Dis*
499 15:e0009221
- 500 47. Tritten L, Tam M, Vargas M, Jardim A, Stevenson MM, Keiser J, Geary TG (2017)
501 Excretory/secretory products from the gastrointestinal nematode *Trichuris muris*. *Exp Parasitol*
502 178:30–36
- 503 48. Abuzeid AMI, Zhou X, Huang Y, Li G (2020) Twenty-five-year research progress in hookworm
504 excretory/secretory products. *Parasites Vectors* 2020 13:1–18
- 505 49. Cui J, Liu RD, Wang L, Zhang X, Jiang P, Liu MY, Wang ZQ (2013) Proteomic analysis of surface
506 proteins of *Trichinella spiralis* muscle larvae by two-dimensional gel electrophoresis and mass
507 spectrometry. *Parasit Vectors* 6:355
- 508 50. Guiliano DB, Oksov Y, Lustigman S, Gounaris K, Selkirk ME (2009) Characterisation of novel
509 protein families secreted by muscle stage larvae of *Trichinella spiralis*. *Int J Parasitol* 39:515
- 510 51. Chen KY, Chen YJ, Cheng CJ, Jhan KY, Wang LC, Wang LC, Wang LC (2020) Excretory/secretory
511 products of *Angiostrongylus cantonensis* fifth-stage larvae induce endoplasmic reticulum stress
512 via the Sonic hedgehog pathway in mouse astrocytes. *Parasites and Vectors* 13:1–11
- 513 52. Chen KY, Lu PJ, Cheng CJ, Jhan KY, Yeh SC, Wang LC (2019) Proteomic analysis of excretory-
514 secretory products from young adults of *Angiostrongylus cantonensis*. *Mem Inst Oswaldo Cruz*.
515 <https://doi.org/10.1590/0074-02760180556>
- 516 53. Phuphisut O, Poodeepiyasawat A, Yoonuan T, Watthanakulpanich D, Chotsiri P, Reamtong O,

- 517 Mousley A, Gobert GN, Adisakwattana P (2022) Transcriptome profiling of male and female
518 *Ascaris lumbricoides* reproductive tissues. *Parasit Vectors*. <https://doi.org/10.1186/S13071-022->
519 05602-2
- 520 54. Weatherhead JE, Porter P, Coffey A, et al (2018) *Ascaris* larval infection and lung invasion directly
521 induce severe allergic airway disease in mice. *Infect Immun* 86:533–551
- 522 55. Parvatham K, Veerakumari L (2013) Drug target prediction using elementary mode analysis in
523 *Ascaris lumbricoides* energy metabolism. *Biotechnol Bioprocess Eng* 18:491–500
- 524 56. Prasad CS, Gupta S, Kumar H, Tiwari M (2013) Evolutionary and functional analysis of fructose
525 bisphosphate aldolase of plant parasitic nematodes. *Bioinformation* 9:1
- 526 57. Grzelak S, Moskwa B, Bień J (2018) *Trichinella britovi* muscle larvae and adult worms: Stage-
527 specific and common antigens detected by two-dimensional gel electrophoresis-based
528 immunoblotting 06 Biological Sciences 0601 Biochemistry and Cell Biology. *Parasites and Vectors*
529 11:1–17
- 530 58. Karabinos A (2019) Intermediate filament (IF) proteins IFA-1 and IFB-1 represent a basic
531 heteropolymeric IF cytoskeleton of nematodes: A molecular phylogeny of nematode IFs. *Gene*
532 692:44–53
- 533 59. Ono S (2014) Regulation of Structure and Function of Sarcomeric Actin Filaments in Striated
534 Muscle of the Nematode *Caenorhabditis elegans*. *Anat Rec* 297:1548–1559
- 535 60. Bell A, Wernli B, Franklin RM (1994) Roles of peptidyl-prolyl CIS-trans isomerase and calcineurin
536 in the mechanisms of antimalarial action of cyclosporin a, FK506, and rapamycin. *Biochem*
537 *Pharmacol* 48:495–503
- 538 61. Bell A, Monaghan P, Page AP (2006) Peptidyl-prolyl cis–trans isomerases (immunophilins) and


- 539 their roles in parasite biochemistry, host–parasite interaction and antiparasitic drug action. *Int J*
540 *Parasitol* 36:261–276
- 541 62. Bermúdez-Cruz RM, Fonseca-Liñán R, Grijalva-Contreras LE, Mendoza-Hernández G, Ortega-
542 Pierres MG (2016) Proteomic analysis and immunodetection of antigens from early
543 developmental stages of *Trichinella spiralis*. *Vet Parasitol* 231:22–31
- 544 63. Neisch AL, Fehon RG (2011) Ezrin, Radixin and Moesin: key regulators of membrane–cortex
545 interactions and signaling. *Curr Opin Cell Biol* 23:377–382
- 546 64. Shabardina V, Kashima Y, Suzuki Y, Makalowski W (2020) Emergence and Evolution of ERM
547 Proteins and Merlin in Metazoans. *Genome Biol Evol* 12:3710–3724
- 548 65. Ferreira ÉR, Bonfim-Melo A, Cordero EM, Mortara RA (2017) ERM proteins play distinct roles in
549 cell invasion by extracellular amastigotes of *Trypanosoma cruzi*. *Front Microbiol* 8:309048
- 550 66. Van Fürden D, Johnson K, Segbert C, Bossinger O (2004) The *C. elegans* ezrin-radixin-moesin
551 protein ERM-1 is necessary for apical junction remodelling and tubulogenesis in the intestine.
552 *Dev Biol* 272:262–276
- 553 67. Polesello C, Payre F (2004) Small is beautiful: What flies tell us about ERM protein function in
554 development. *Trends Cell Biol* 14:294–302
- 555 68. Mitreva M (2022) Parasite OMICS, the grand challenges ahead. *Front Parasitol* 1:995302
- 556 69. McVeigh P (2020) Post-genomic progress in helminth parasitology. *Parasitology* 147:835–840
- 557 70. Cho WCS (2007) Proteomics Technologies and Challenges. *Genomics Proteomics Bioinformatics*
558 5:77–85
- 559 71. Patterson SD, Aebersold RH (2003) Proteomics: the first decade and beyond. *Nat Genet* 2003 333
560 33:311–323

- 561 72. Marcilla A, Martin-Jaular L, Trelis M, Menezes-Neto A de, Osuna A, Bernal D, Fernandez-Becerra
562 C, Almeida IC, Portillo HA del (2014) Extracellular vesicles in parasitic diseases.
563 <https://doi.org/10.3402/JEV.V3.25040>. <https://doi.org/103402/jev.v325040>. <https://doi.org/10.3402/JEV.V3.25040>
- 564 73. Motran CC, Silvane L, Chiapello LS, Theumer MG, Ambrosio LF, Volpini X, Celas DP, Cervi L (2018)
565 Helminth infections: Recognition and modulation of the immune response by innate immune
566 cells. *Front Immunol* 9:1–12
- 567 74. Abuzeid AMI, Zhou X, Huang Y, Li G (2020) Twenty-five-year research progress in hookworm
568 excretory/secretory products. *Parasites Vectors* 2020 131 13:1–18
- 569


a.




b.











a.



b.



a.**b.****c.****d.****e.****f.****g.****h.**



Detangling the Crosstalk Between *Ascaris*, *Trichuris* and Gut Microbiota: What's Next?

Sergio Castañeda¹, Alberto Paniz-Mondolfi² and Juan David Ramírez^{1,2*}

¹ Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia, ² Molecular Microbiology Laboratory, Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States

OPEN ACCESS

Edited by:

María Esther Ramírez Moreno,
Instituto Politécnico Nacional, Mexico

Reviewed by:

Peter Geldhof,
Ghent University, Belgium
Grace Mulcahy,
University College Dublin, Ireland
Daniel Cerqueda-García,
Instituto de Ecología (INECOL), Mexico

*Correspondence:

Juan David Ramírez
juand.ramirez@urosario.edu.co;
juan.ramirezgonzalez@mountsinai.org

Specialty section:

This article was submitted to
Parasite and Host,
a section of the journal
Frontiers in Cellular and
Infection Microbiology

Received: 11 January 2022

Accepted: 21 April 2022

Published: 25 May 2022

Citation:

Castañeda S, Paniz-Mondolfi A and
Ramírez JD (2022) Detangling the
Crosstalk Between *Ascaris*, *Trichuris*
and Gut Microbiota: What's Next?
Front. Cell. Infect. Microbiol. 12:852900.
doi: 10.3389/fcimb.2022.852900

Helminth infections remain a global public health issue, particularly in low- and middle-income countries, where roundworms from the *Trichuris* and *Ascaris* genera are most prevalent. These geohelminths not only impact human health but most importantly also affect animal well-being, in particular the swine industry. Host-helminth parasite interactions are complex and at the same time essential to understand the biology, dynamics and pathophysiology of these infections. Within these interactions, the immunomodulatory capacity of these helminths in the host has been extensively studied. Moreover, in recent years a growing interest on how helminths interact with the intestinal microbiota of the host has sparked, highlighting how this relationship plays an essential role in the establishment of initial infection, survival and persistence of the parasite, as well as in the development of chronic infections. Identifying the changes generated by these helminths on the composition and structure of the host intestinal microbiota constitutes a field of great scientific interest, since this can provide essential and actionable information for designing effective control and therapeutic strategies. Helminths like *Trichuris* and *Ascaris* are a focus of special importance due to their high prevalence, higher reinfection rates, resistance to anthelmintic therapy and unavailability of vaccines. Therefore, characterizing interactions between these helminths and the host intestinal microbiota represents an important approach to better understand the nature of this dynamic interface and explore novel therapeutic alternatives based on management of host microbiota. Given the extraordinary impact this may have from a biological, clinical, and epidemiological public health standpoint, this review aims to provide a comprehensive overview of current knowledge and future perspectives examining the parasite-microbiota interplay and its impact on host immunity.

Keywords: microbiota, helminths, *Trichuris*, *Ascaris*, host-parasite interactions

INTRODUCTION

Helminth infections represent a major global public health burden, primarily in developing countries, where lack of basic water, hygiene and sanitation conditions are widespread (Harhay et al., 2010; Hotez et al., 2014; Ojha et al., 2014; Silver et al., 2018) due to stressed socioeconomic conditions. Although many helminth infections are asymptomatic, they can display a variety of

clinical presentations, particularly in children, where they are usually associated with growth retardation, malnutrition, and diarrheal disease, among other conditions. Helminth infections have also been linked with a decreased occurrence of autoimmune diseases presumably based on their immunomodulatory capacity (Cooper and Figueredo, 2013; Girgis et al., 2013; Giacomini et al., 2015a; Maizels et al., 2018; White et al., 2020). It has been largely hypothesized that individuals with increased exposure to helminths during their first years of life are prone to immunomodulatory effects and immunological tolerance induced by parasites, thus decreasing their chances to develop allergic and autoimmune diseases, a phenomenon also known as the “hygiene hypothesis”, later called the “old friends hypothesis” (Altmann, 2009; Chammartin et al., 2013; Stiemsma et al., 2015; Gazzinelli-Guimaraes and Nutman, 2018). It has also been proposed that for certain specific infections such as tuberculosis, helminths may play a relevant role in susceptibility to infection and disease progression, which is correlated with the immunomodulatory properties attributed to helminths (Karo-Atar et al., 2021). Among the most prevalent soil-transmitted helminths worldwide are the genera *Trichuris* and *Ascaris*, which not only affect human health but also have a significant impact on animals and livestock production (Hotez et al., 2008; Harhay et al., 2010; Pullan et al., 2014; Schüle et al., 2014; Else et al., 2020; Gordon et al., 2020).

Studies on the interaction between *Ascaris* and *Trichuris* helminths and host has allowed to determine that in addition to their recognized immunomodulatory capacity, these helminths reveal complex interfaces with the hosts gastrointestinal microbiota, a key factor that may play a fundamental role in parasite survival and persistence (Lee et al., 2014; Zaiss et al., 2015; Zaiss and Harris, 2016; Jenkins et al., 2017; Brosschot and Reynolds, 2018). This host-parasite relationship represents an emerging field of great scientific interest in helminthology and has therefore been subject of intensive scrutiny in recent years. Further evidence showing how the presence of these helminths can relate with changes in the composition and structure of host intestinal microbiota suggests that such interaction may play a determining part in the biology and pathophysiology of the parasite (Lee et al., 2014; Zaiss and Harris, 2016; Ajibola et al., 2019; Cortés et al., 2020; Schachter et al., 2020; Rosa et al., 2021; von Huth et al., 2021). However, contrasting evidence obtained mainly from descriptive studies examining human populations reveals that helminth infections do not exert a significant impact on their interaction with the host microbiota, highlighting that the use of different methodological approaches may derive in heterogeneous results (Cooper et al., 2013; Mejia et al., 2020). Nevertheless, to control potential confusion variables, both for *Trichuris* and *Ascaris*, murine and porcine animal models have been developed and implemented to model the infection process in humans and thus study parasite-host-microbiota interactions, evaluating the changes caused by these helminths in the microbiota in relation to its composition and structure and in order to examine helminth infections and their dynamic interaction

with the intestinal microbiota. However, it is also important to highlight the limitations of animal studies, since the similarities and differences in terms of genetics, physiology, diet, etc. must be considered, which is why the use of humanized murine models has been chosen to replicate infection scenarios in humans more efficiently (Lewis et al., 2006; Klementowicz et al., 2012; Nguyen et al., 2015; Williams et al., 2017; Wang et al., 2019; Park and Im, 2020; Yousefi et al., 2021). Likewise, the development and advancement of new sequencing platforms and techniques has promoted a great increase in the availability of data from different approaches. This, together with the continuous innovation of bioinformatics tools, has established novel frameworks that offer interesting strategies in the field of parasite-host-microbiota interactions (Wooley et al., 2010; Simon and Daniel, 2011; Vollmers et al., 2017; Wajid et al., 2022).

Considering the relevance of this field of research, this review will examine in detail the interaction between the intestinal microbiota and helminth parasites, *Trichuris* and *Ascaris*, as well as how these interactions can be potentially influence infection, dissemination, persistence, and survival in the human host.

RELEVANCE OF *TRICHURIS* AND *ASCARIS* HELMINTHS

Trichuriasis is caused by the human whipworm *Trichuris trichiura*, which typically exhibits high parasite burdens that usually translate clinically into a severe constellation of symptoms including diarrhea, abdominal pain, malnutrition, stunted growth and developmental arrest of infected children (Chammartin et al., 2013; World Health Organization Soil-transmitted helminth infections, 2021). The *Trichuris* (Nematoda: Trichuridae) parasite is one of the most highly prevalent intestinal helminths worldwide, mainly in Africa and South America, and is estimated to infect about 500 million people globally (Hotez et al., 2014; Pullan et al., 2014; World Health Organization Soil-transmitted helminth infections, 2021). *Trichuris* was predicted to be responsible for the loss of 0.64 million disability-adjusted life years between 1990 and 2010, ranking tenth amongst all neglected tropical diseases (Hotez et al., 2014).

Similarly, infections to *Ascaris* (Nematoda: Ascarididae) species are also amongst the most cosmopolitan helminth infections worldwide and also included within the Neglected Tropical Diseases roster (Saboyá et al., 2013; Pullan et al., 2014; World Health Organization Soil-transmitted helminth infections, 2021). The overall prevalence of helminth infections exceeds 10% in most developing countries with a large percentage of these attributable to *Ascaris lumbricoides* infections, mostly in endemic regions of Africa and South America (Hotez et al., 2014; Pullan et al., 2014; World Health Organization Soil-transmitted helminth infections, 2021). Ascariidiasis has also been associated with malnutrition and developmental delay due to persistent infections, and the

disease burden is estimated at around 60,000 deaths per year, mostly in children (Harhay et al., 2010; Hotez et al., 2014; Pullan et al., 2014; Jourdan et al., 2018; Corvino et al., 2021).

A challenging aspect in the management of this parasitic infections is its well-known resistance to routine anti-helminth therapy and thus, their proneness for reinfections, which has stirred the search for new therapeutic alternatives and the development of potential vaccines. This acquires more relevance in endemic regions, where recurrent infections with low parasite loads may lead to chronic and persistent infections (Harhay et al., 2010; Ramanan et al., 2016; Midha et al., 2017; Papaikovou et al., 2021; Whitman et al., 2021). Factors such as the highly resistant nature of the eggs in moist soil, long standing patency, high rate of reinfections despite effective anti-helminth therapy and the unavailability of vaccines, have all been associated with a high dispersal of *Ascaris* and *Trichuris*, not only in human hosts but also in other vertebrate hosts (Schüle et al., 2014; Easton et al., 2019; Cools et al., 2021). In addition to the human parasite *A. lumbricoides*, ascariasis infection of swine by the highly prevalent species *Ascaris suum* is also known for its pathogenic effects in domestic pigs and its impact in livestock productivity (Dold and Holland, 2011; Velasco et al., 2011; Cooper and Figueredo, 2013; Miller et al., 2015; Katakam et al., 2016; Williams et al., 2017; Midha et al., 2018; Hansen et al., 2019; Arora et al., 2020; Easton et al., 2020).

HOST-HELMINTH-GUT MICROBIOTA INTERACTIONS

In an attempt to better understand the host-helminth-gut microbiota relationships, most studies have focused on deciphering interactions between helminths and the host immune system given the important immunomodulatory and immunoregulatory effects exerted by these parasites and how this dynamic regulation influences infectiveness, dissemination and persistence in the infected host (McSorley and Maizels, 2012; Giacomini et al., 2015a; Briggs et al., 2016; Maizels et al., 2018; Yasuda and Nakanishi, 2018; White et al., 2020). Also, recent studies have explored the functional consequences of helminth-induced changes in microbiota and its impact in parasite biology and infection dynamics. Interestingly, changes in the relative abundance of certain bacterial taxa as well as the diversity of the intestinal microbiota in presence of helminths have shown to display profound effects on the parasite life cycle by inducing metabolic changes that could promote infectiveness and dissemination, while modulating the host immune response leading to persistence (Berrilli et al., 2012; Li et al., 2012; Cooper et al., 2013; Cantacessi et al., 2014; Glendinning et al., 2014; Lee et al., 2014; Kay et al., 2015; Zaiss et al., 2015; Giacomini et al., 2015b; Midha et al., 2017; Midha et al., 2018; Rosa et al., 2018; Su et al., 2018; Ajibola et al., 2019; Easton et al., 2019; Wang et al., 2019; Mejia et al., 2020; Rosa et al., 2021). Understanding the mechanisms by which helminth parasites influence the complex microbiota ecosystem of the host and how these changes functionally impact the host intestinal microbiota

is critically important, as it will pave the way in search of new control strategies and therapeutic approaches.

Studies addressing the relationship of parasites with host microbiota have shown variable results, particularly in human-based descriptive studies (Cooper et al., 2013; Cantacessi et al., 2014; Jenkins et al., 2017; Cortés et al., 2020). This in part, because many methodological and inherent aspects within study groups are prone to introducing biases, thus generating diverse results and conclusions, such as those related to the study population, impact of diet, environmental factors as well as genetic background (Cooper et al., 2013; Rosa et al., 2018; Rinninella et al., 2019). A critical evaluation of current methodologies deserves a separate and dedicated review. However, in light of the above, the use of animal models, essentially pigs and mice, despite certain limitations that must be carefully considered, has allowed to evaluate changes caused on the intestinal microbiota in presence of helminths, which will potentially provide relevant and applicable information to understand infection in humans (Nguyen et al., 2015; Park and Im, 2020). Such approach lends itself to better monitor and control the infectious process and the many variables that influence the composition of the intestinal microbiota of the host (Lewis et al., 2006; Klementowicz et al., 2012; Houlden et al., 2015; Kreisinger et al., 2015; Martín et al., 2016; Douglas, 2019; Wang et al., 2019; Rosa et al., 2021).

One of the first approaches attempting to identify potential relationships between helminth infections and the host derived factors dates back to 1967 by Wescott *et al*, who using a comparative murine model including both germ-free versus conventional mice, showed that infection by the roundworm *Heligmosomoides polygyrus*, (previously *Nematospiroides dubius*) evolved and persisted in conventional mice, thus suggesting, that factors related to the microbiota were directly related to the development and pathophysiology of this parasite (Wescott, 1968). Since then, numerous studies have been carried out with a variety of other helminths to elucidate how this parasite-mammalian microbiota-host relationship influences host immunity and disease course (Glendinning et al., 2014; Reynolds et al., 2015; Gause and Maizels, 2016; Leung et al., 2018; Midha et al., 2021).

HOST-HELMINTH-GUT MICROBIOTA INTERACTIONS: *TRICHURIS*

Several descriptive animal model studies have been implemented in an effort to characterize helminth and host microbiota interactions and to determine the effects of infection on host microbiota composition. One of these studies, which implemented a murine model aiming to evaluate helminth-microbiota interactions in *Trichuris muris* infection, offered the view that infection, persistence, and chronicity with this parasite were associated with changes in the composition of the host microbiota. Moreover, further evidence from *Escherichia coli* cultures revealed that the presence of this bacterium allowed a much quicker and more efficient hatching of *T. muris* eggs, hence

promoting the establishment of infection (Hayes et al., 2010). Subsequently, analyses carried out in a swine animal model, reinforced the idea that the presence of *Trichuris*, in this specific case of *Trichuris suis*, was also associated with changes related to the intestinal host microbiota. Here the researchers identified that changes occurred mainly in the proximal colon exhibiting an increased presence of the *Mucispirillum*, *Succinivibrio* and *Ruminococcus* genera. Likewise, alterations in fatty acid and carbohydrate metabolism were also evident suggesting a possible link to changes at the microbiota level and providing evidence on the potential effects of parasite influence on the enteric microbiota (Li et al., 2012; Wu et al., 2012).

In 2015, Houlden et al. examined how chronic *Trichuris muris* infection could potentially induce changes in microbiota of C57BL/6 mice (Houlden et al., 2015). Here, the authors identified significant microbiota changes occurring between 14- and 28-days post-infection and which persisted up to 91 days of follow up. Such changes were reflected in the relative abundance of certain taxa, alpha and beta diversity of infected mice and predominantly in *Prevotella* and *Parabacteroides* populations. Most importantly, these changes in the microbiota correlated with changes at the metabolome level, which in agreement with previous studies, revealed a reduction in carbohydrate metabolism and a concomitant increase in certain amino acids, a scenario known to promote a permissive environment for parasite development. However, one of the most interesting findings of this study was the fact that, upon elimination of *Trichuris* infection, a complete recovery of the host intestinal microbiota followed with a simultaneous regaining of the Th1 cell population, which was initially skewed to a Th2 profile during the course of infection. This finding is of utmost importance from the helminth-host interface perspective, since it suggests that *Trichuris* infection is capable of evoking immune regulatory mechanisms and adaptations to the host enteric niche as well as modifying the intestinal microbiota composition favoring parasite persistence, with subsequent restoration of homeostasis after infection (Houlden et al., 2015).

Unquestionably, results obtained from animal models offer very interesting observations that fuel knowledge on parasite-microbiota-host interactions while providing fertile ground for further investigations in the field. However, and despite that animal models may accurately replicate *Trichuris* infection as seen in humans, to date, no experimental comparisons have been trialed in order to validate consistent microbiota changes between animal and human models. In a more recent study, Rosa et al. were able to identify changes in the relative abundances of certain bacterial taxa in the context of *Trichuris* infection, which were consistent in both mouse and human microbiota (Rosa et al., 2021). This study is of particular significance as it allowed to experimentally validate the use of *Trichuris muris* infection in mice as a model to assess *Trichuris*-induced modifications of the human gut microbiome (Rosa et al., 2021). Eleven specific bacterial genera of interest were identified, mainly *Escherichia* and *Blautia*; hence, reinforcing the hypotheses of synergy among *Trichuris* and certain bacterial genera to promote infection by inducing changes in the

composition and structure of the intestinal host microbiota (Rosa et al., 2021). At the same time, this study served to validate how animal models offer an important methodological advantage in picturing the many aspects related to host-helminth-gut Microbiota interactions, and its application specifically for the case of *Trichuris* sp. Likewise, a study conducted in Tanzania that sought to determine interactions between parasitic helminths and intestinal microbiota in wild tropical primates from Tanzanian habitats, showed that *Trichuris* sp. was associated with a higher bacterial richness and diversity. These findings could have a relevant ecological impact on different primate populations, highlighting again the importance of interactions between helminths and host microbiota (Barelli et al., 2021).

One of the most conclusive studies examining the *Trichuris*-host microbiota regulation hypothesis was recently published by Schachter et al., in 2020 (Schachter et al., 2020). In their study, using a Swiss Webster mouse model, the authors confirmed the occurrence of changes in the intestinal microbiota and the important immunomodulatory effects induced by *Trichuris muris*, which are essential for the establishment of infection, progression of the parasite's life cycle and persistence, as well as to promote chronic infections (Schachter et al., 2020). Furthermore, a subset of dexamethasone-induced tolerant mice mirroring a stage of chronic infection, was followed in order to record changes in the intestinal microenvironment. Here, *T. muris* infected mice developed weight loss, anemia, imbalance of the intestinal microbiota with a significant increase of *Escherichia coli* and *Bacteroides* bacteria, enhanced tissue damage at the intestinal level and changes in the Th1/Th2 immune profile (Schachter et al., 2020). These findings reinforce the fact that certain bacterial taxa are essential for an adequate development of the helminth, while concurrently promoting a permissive intestinal environment for it to thrive. It also emphasizes the need to better understand these interactions in order to elucidate those mechanisms linked to clinical progression of the infection and ultimately to evaluate and implement novel control and treatment strategies (Gazzinelli-Guimaraes et al., 2020; Schachter et al., 2020).

Many of the results found in previously described animal models have been consistent with those evidenced in studies with human populations. Lee et al., 2014, conducted an analysis in an indigenous human population in Malaysia, where they observed an increase in the diversity and abundance of the intestinal microbiota in *Trichuris*-infected subjects, with a preponderance of members of the Paraprevotellaceae family, raising evidence that helminths may have an impact in modulating diversity, bacterial community structure and function of the intestinal microbiota of human hosts, being consistent with findings in mice and primates (Lee et al., 2014; Houlden et al., 2015; Barelli et al., 2021). Interestingly, a previous study carried by Lee et al. hypothesized that the presence of *Trichuris trichiura* was not associated with alterations in the host microbiota, as opposed to *Ascaris lumbricoides* (Cooper et al., 2013). This study conducted in Ecuadorian children failed to demonstrate any changes in the composition and structure of the intestinal microbiota,

highlighting the variation across human studies and demonstrating that discrepancies may be related to other aspects inherent to the populations evaluated such as age, diet, lifestyle, etc.

A recent systematic review evaluated the impact on the microbiota caused by helminths. This study found that in the case of *Trichuris* infection there was a positive association with *Treponema* sp., *Anaerovibrio* sp., *Rikenellaceae* and multiple species of Prevotellaceae. The authors propose that changes in the Firmicutes/Bacteroidetes (Bacillota/Bacteroidota) ratio, which has been shown to be a biologically relevant ratio, are strongly related to the presence of helminths, causing a shift from Bacteroidetes (Bacteroidota) to Firmicutes (Bacillota) and Clostridia, suggesting that helminth-induced enterotyping may have implications for host health (Whitman et al., 2018; Kupritz et al., 2021). Likewise, in general, helminth infections are associated with greater richness and abundance and this difference is even more tailored when co-infections between different helminths occur, thus highlighting that the interaction of helminths with the host has a great relevance in the changes that can be potentially associated with health and disease (Kupritz et al., 2021).

Despite the number of studies carried out so far, the specific mechanisms involved in the *Trichuris*- enteric microbiota interaction remain largely unexplored. Evidence from different studies suggests that *Trichuris* infection is associated with changes in the host microbiota that can potentially lead to increased susceptibility to infection and persistence (Houlden et al., 2015; Vejzagić et al., 2015; Gazzinelli-Guimaraes et al., 2020; Rubel et al., 2020; Rosa et al., 2021), however, further studies are needed to confirm this hypothesis and to understand the mechanisms involved (Figure 1). Remarkably, the predominance of certain bacterial taxa has been associated with a better and more efficient hatching of *Trichuris* eggs, as demonstrated in the case of *Escherichia coli* (Wescott, 1968; Rosa et al., 2021). Survival and persistence of the parasite in the intestinal niche is in part driven by modulation of the immune response as a consequence of changes induced at the microbiota level. Likewise, changes related with bacterial composition of the microbiota, particularly the Bacteroidetes (Bacteroidota) (Whitman et al., 2018), including the genera *Prevotella*, *Parabacteroides*, *Paraprevotella*, among others, press for directing further studies in this area since the mechanisms involved in the relationship with specific taxa are yet unclear.




FIGURE 1 | Potential mechanisms of interaction between *Trichuris* and the host intestinal microbiota. (1) After ingestion of the infective stage of *Trichuris*, it has been demonstrated that certain bacteria, such as *Escherichia coli*, can improve the hatching of the eggs, contributing to the establishment of the infection and the development of the parasite. (2) The presence of eggs and released larval stages could cause changes by direct interaction with the host microbiota and by the inflammatory response generated by the parasite (3) Likewise, damage to the intestinal epithelium caused by *Trichuris* can cause translocation of bacteria into the intestinal lumen that may trigger localized inflammatory responses that could potentially affect certain commensal bacterial community of the microbiota influencing the composition and structures of the host bacterial communities. (4) The presence of the parasite in the intestine, together with the changes previously caused in the microbiota, generate an increase in oxygen availability and cause a decrease in strict anaerobic bacteria essential for intestinal health (such as *Faecalibacterium*) and facilitate the increase of facultative aerobes such as some Enterobacteriaceae that in turn contribute to the development of the infection. (5) Adult forms of *Trichuris* can generate Excretory/Secretory (E/S) products that, in addition to having an immunomodulatory effect, can have an impact on certain bacterial groups of the intestinal microbiota, modifying its structure and composition. (6) The adult forms produce eggs that will be eliminated in the feces. Created with BioRender.com.

In addition to that concerning to the composition and structure of the microbiota, defining the changes related to the metabolome is perhaps another prominent field of study. Available evidence suggests that in presence of chronic *Trichuris* infection, there is an increased concentration in fresh stool samples of amino acids such as phenylalanine, serine, threonine, leucine, ornithine and glycine, with a decrease in the abundance of vitamin D2/D3 derivatives, fatty acids such as butyrate and glycerophospholipid metabolites related with the mice control group (Houlden et al., 2015). These changes appear to be associated with distinct metabolic profiles in *Trichuris* infection while reflecting how this parasite in context of an altered microbiota may utilize different host resources to enable infection and survival. In this sense, *Trichuris* infection seems to trigger a number of helminth-induced changes in the intestine that lead to a less favorable environment for strict anaerobic bacteria, which are responsible for butyrate production and maintenance of intestinal homeostasis, thus, altering bacterial composition and structure to promote its survival. An example of this is the increase in abundance of facultative anaerobes such as *Escherichia coli*, which has shown to be a determinant factor in the hatching of *Trichuris* eggs.

It is also worth mentioning that beyond direct parasite-bacteria interactions, indirect interactions mediated by parasite derived molecules, can also play a role in the immunomodulatory effects leading to modifications of the structure and composition of the host microbiota. For example, it has been described that *Trichuris* exhibits the ability to generate excretion/secretion (E/S) products containing different molecules to facilitate survival and persistence of the helminth. A recent study demonstrated that amongst these E/S products, the p43 protein shows the ability to inhibit IL-13, which is an essential effector cytokine necessary for parasite clearance (Bancroft et al., 2019). Thus p43 exerts its immunomodulatory effects by allowing not only the survival of *Trichuris*, but also progression to chronic stages of infection (Bancroft et al., 2019). These types' of helminth-derived immunomodulatory molecules may also interact indirectly with the host microbiota leading to possible changes in diversity and abundance and at the same time favoring parasite invasion with its consequent pathophysiological chain of events (Bancroft et al., 2019; Schachter et al., 2020; Lawson et al., 2021; Midha et al., 2021).

It is evident from the different studies carried out on *Trichuris*-microbiota-host interactions that this helminth inflicts significant effects on the intestinal microbiota by means of different mechanisms (Figure 1). These changes affecting the composition and structure of the host microbiota may lead to a complex regulatory cascade in the intestinal niche which favor helminth infection, survival and persistence, ultimately impacting the course of infection. More studies focusing on how this parasite affects the composition of the enteric microbiota and its impact on host biology are required.

HOST-HELMINTH-GUT MICROBIOTA INTERACTIONS: ASCARIS

Studies on *Ascaris*-Microbiota-Host interactions have also been carried out from descriptive designs, both in human populations

and animal-based models. A distinct feature for *Ascaris* is that, during this nematode's life cycle, short after ingestion of eggs, the larvae (L3) have the ability to invade mucosal tissue of the gastrointestinal tract and subsequently migrate towards hepatic and pulmonary tissues (Sultan Khuroo, 1996; Nogueira et al., 2016; Midha et al., 2021; Wu et al., 2021). In the lung, infection triggers and inflammatory response characterized by eosinophil infiltration (Wu et al., 2021). The migratory nature of certain parasite stages has also been linked to possible modifications on the composition and structure of the intestinal microbiota. An evidence of this is the fact that translocation of helminth associated bacteria through the intestine barriers can be traced short after, to the lung mucosa. In fact, bacterial translocation can trigger localized inflammatory responses that can potentially affect certain commensal bacterial community of the microbiota (Adedeji et al., 1989; Hübner et al., 2013; Midha et al., 2021). In a study by Cooper et al. in 2013, conducted in Ecuadorian populations the authors present evidence that *Ascaris lumbricoides* in contrast to *Trichuris* does impact intestinal microbiota of the host (Cooper et al., 2013). The authors also suggest that a single infection with *Ascaris lumbricoides* or co-infection with other helminths can lead to alteration of the microbiota profile by exhibiting lower relative abundances of certain taxa, predominantly Clostridia class and higher relative abundances of bacteria belonging to the genus *Streptococcus*. Similarly, they propose that the presence of this helminth is linked to a lower diversity in the host microbiota (Cooper et al., 2013). These differences between *Ascaris* and *Trichuris*, may be influenced by several factors such as studying samples from a rural population or evaluating the presence of *Ascaris* in context of mixed infections with *Trichuris* and not as a single infection. The results described above were subsequently addressed in a swine model infected with *Ascaris suum*, which sought to find potential effects that could be extrapolated to studies in human infection (Wang et al., 2019). Here, the authors demonstrated that infection with this helminth significantly reduced the alpha diversity of the intestinal microbiota of pigs and that this effect was independent of the parasite load. Also, they were able to determine a differential relative abundance associated with a profile of at least 49 bacterial genera, including *Prevotella* and *Faecalibacterium* (Wang et al., 2019). Additionally, changes in the metabolic profile of stool samples from helminth-infected pigs was observed, noticing a decrease in carbohydrate and amino acid metabolism, in accordance with those studies conducted in *Trichuris* infections (Houlden et al., 2015). As for the case *Trichuris*, discordant results stand out amongst different studies. For example, while the study by (Wang et al., 2019) found a reduced alpha diversity in the intestinal microbiota of pigs infected with *Ascaris suum*, a previous study by Williams et al. in 2017 found that *Ascaris* modified the host's intestinal microbiota with an increased alpha diversity but a concomitant reduction in the relative abundance of the genera *Lactobacillus*, *Ruminococcus* and *Catenibacterium* (Williams et al., 2017). These observations underscore the importance of using appropriate epidemiological designs and animal models inclusive of a greater number of infection-associated variables

that can be controlled and impact on host intestinal microbiota changes, as well as the need to establish experimental protocols and reproducible bioinformatic analyses to allow validation of the results obtained in these research studies.

A recent study carried out in a Thai population, which assessed the presence of helminths, including roundworms (*Ascaris lumbricoides*), whipworms (*Trichuris trichiura*) and hookworms (*Ancylostoma* spp. and *Necator americanus*), allowed to identify changes in the microbiota of infected individuals (Stracke et al., 2021). Although no differences were apparent in reference to alpha diversity at the bacterial level, marked changes impacting beta diversity were noticeable. Likewise, modifications were found for certain bacterial taxa, where a greater abundance of *Akkermansia*, *Prevotella*, *Bacteroides coprophilus* and *Ruminococcus* and a decrease in *Bifidobacterium* was observed. The foregoing facts signal the influence that the presence of helminths such as *Ascaris* and *Trichuris* have on the composition and structure of the host's intestinal microbiota and how this may translate into the pathophysiology of the disease (Stracke et al., 2021). As previously discussed, a key aspect of this study is that it emphasizes that the uncertainty associated with the evaluation on the impact of helminth infection on the intestinal microbiome is probably not only related to the complexity of the interaction but also linked to the technical aspects of the experimental design and analytical approach, weighing the complex limitations involved in the process such as size sampling, collection, preservation and transport of samples, among others (Stracke et al., 2021).

One main aspect that needs to be considered in *Ascaris*-microbiota-host interactions is the fact that infection by this parasite can increase susceptibility to infection by other pathogens, mainly bacterial. In swine models, it has been shown that infection by *Ascaris suum* (Wang et al., 2019) and *Trichuris suis* (Li et al., 2012) are related to a higher relative abundance of *Campylobacter jejuni*, suggesting that these helminths could potentially increase the risk for secondary infections to this bacteria, an aspect of great relevance from a clinical and public health perspective.


As for the case of *Trichuris*, *Ascaris* derived excretory-secretory products may also promote an immunomodulatory response linked to indirect interactions with the intestinal microbiota of the host. E/S products, extracellular vesicles and other metabolites have been identified which may interact in different ways with the host microbiota and may play a key role in parasite biology and pathophysiology of infection (Hansen et al., 2019). In these lines, studies have confirmed that *Ascaris suum* has the ability to induce production of ASABF (*Ascaris suum* antibacterial factor) type antimicrobial peptides (Pillai et al., 2003; Midha et al., 2018) and microbial peptides of the cecropin family (P1 to P4) in the host. These substances have shown to exhibit bactericidal effect against a wide range of microbes, such as gram-positive (*Staphylococcus aureus*, *Bacillus subtilis* and *Micrococcus luteus*) and gram-negative (*Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Serratia marcescens* and *Escherichia coli*) bacteria (Pillai et al., 2005). This highlights the ability of *Ascaris* to produce a number of nematode-derived metabolites which can exert important

modulating effects on the host intestinal microbiota, thus constituting one of the most trending aspects in the field of helminth biology.

The biological characteristics of *Ascaris* infection, which includes multifaceted aspects such as extra-intestinal migration, modulation of the host immune response, and in context of this review, the changes it can inflict on the host's microbiota, altogether blends into a complex network of mechanisms that subvert the helminth-mammalian host relationship allowing the parasite to establish infection and promote its survival in the host (Figure 2). Studies in both humans and animal models have defined how *Ascaris* displays its ability to generate changes in both the structure and composition of the host microbiota via direct interaction or through production of metabolites and different E/S products, such as antimicrobial peptides, that can further restructure predominant bacterial community. This has a particularly detrimental effect on strict anaerobic bacteria which are essential for proper intestinal functioning such as the case of *Faecalibacterium* (Wang et al., 2019) and *Ruminococcus* (Williams et al., 2017). Alongside, a concomitant increase of facultative anaerobes such as *Streptococcus* (Cooper et al., 2013), which coupled with the immunomodulatory effects of this helminth, allows it to provide a suitable metabolic environment to ensure its survival and reproduction. Thus, it is evident that alterations and subsequent effects on the host microbiota have a fundamental role in the biology and pathophysiology of the parasite paving the way in search for therapeutic alternatives based on the reestablishment of normal host microbiota. Likewise, it is important to highlight that the immunomodulatory capacity of this helminth and its impact on the host microbiota can also promote a greater susceptibility to suffer reinfections or co-infections by other bacterial pathogens. Therefore, enhancing our knowledge on the mechanisms in play during early phases of infection are crucial to succeed in preventing adult worm establishment and the deleterious effects of helminth and host-derived factors during their interaction in the enteric milieu.

CONCLUSIONS AND FUTURE PERSPECTIVES

The study of parasite-host-microbiota interactions is part of a field of great interest as it can provide new insights and provide key aspects in the biology, dynamics and pathophysiology of infection. The high prevalence of helminths in developing countries, high rates of reinfection and resistance to anthelmintics and current unavailability of vaccines against these parasites, stress the need to focus research into elucidating the mechanisms involved in these interactions and thus identify essential aspects pertaining the design of new strategies to control the spread of these helminths as well as novel therapeutic alternatives. In this review, we have included the nematodes *Trichuris* and *Ascaris* since they exhibit the highest prevalence and level of endemicity in low and middle-income countries, as well as to their notorious impact on animal



health and the swine industry (Sayasone et al., 2011; Walker et al., 2013; Ojha et al., 2014; Pullan et al., 2014; Dunn et al., 2016; Cortés et al., 2019; Hernández et al., 2019; Sobotková et al., 2019; Else et al., 2020; Gordon et al., 2020).

Different studies have shown that both *Trichuris* and *Ascaris* interact in important ways over the host microbiota through several direct or indirect mechanisms. This interaction provokes profound changes in the composition and structure of the microbiota allowing the parasite to establish, thrive and progress to chronic stages of infection. These changes promote a favorable metabolic, microbial and immunological environment for these parasites, which may lead to a greater susceptibility to acquire superinfections by other pathogenic bacteria such as *Campylobacter*, as has been demonstrated in swine models (Glendinning et al., 2014; Kreisinger et al., 2015; Loke and Lim, 2015; Giacomini et al., 2016; Midha et al., 2017, 2021; Williams et al., 2017; Leung et al., 2018; Lawson et al., 2021; Rosa et al., 2021). In light of these observations, it is essential to continue to conduct studies that allow us assess the potential benefits of probiotics as a novel and effective therapeutic alternative against helminth infections.


In addition, it is necessary to carry out studies, which examine not only bacterial community of the intestinal microbiota, but also eukaryotic community that are also an important component of this microenvironment. Despite advances in sequencing technologies and bioinformatics tools, most studies involving the intestinal microbiota are still limited to bacterial communities and very little is known about how eukaryotes and virus influence and determine the composition, structure and functioning of the host gut microbiota and its interaction with parasites. To date, different protozoa and fungi have been linked with potential changes in the host gut microbiota (Mason et al., 2012; Iebba et al., 2016; Nagel et al., 2016; Stensvold and van der Giezen, 2018; Partida-Rodriguez et al., 2019; Castañeda et al., 2020). Also, it is important to consider that helminth infections can coincide with other protozoa defining intestinal polyparasitism events (Sayasone et al., 2011; Salcedo-Cifuentes et al., 2012; Cimino et al., 2015; Donohue et al., 2019; Geus et al., 2019; Gordon et al., 2020). For example, studies have demonstrated how the presence of the protozoan parasite *Blastocystis* can induce changes in the diversity and abundance of the bacterial microbiota, favoring an increase in taxa such as

Faecalibacterium while decreasing others such as *Bacteroides*. This is similar to the well-known beneficial relationship of this protozoan with the host microbiota by generating an anti-inflammatory environment (Audebert et al., 2016; Iebba et al., 2016; Castañeda et al., 2020). Another case of mutualistic interaction has been described for the protozoan *Tritrichomonas musculus*. This eukaryote shows the ability to activate the host epithelial inflammasome inducing the production of IL 8, which in turn promotes activation of the Th1/Th17 axis, eliciting protection against bacterial infections of the mucous membranes, and ultimately preventing the potential increased risk of suffering inflammatory diseases (Chudnovskiy et al., 2016). Both animal and *in vitro* studies have equally demonstrated that protozoa such as *Giardia* exhibit the capacity to promote alterations in host microbiota, leading to an increased predisposition to develop inflammatory and metabolic diseases (Iebba et al., 2016; Barash et al., 2017; Toro-Londono et al., 2019). As well as eukaryotes interact with the intestinal microbiota, viruses can also influence changes in its composition. The main proportion of the human virome is constituted by bacteriophages which play a key role in the structuring and flow of information amongst bacterial and microbiota components, thus, regulating in a critical way co-evolution events shared between both of these components (Moreno-Gallego et al., 2019; Mukhopadhyaya et al., 2019; Hufsky et al., 2020). Similarly, it has been hypothesized that the enteric virome may be intimately linked to the etiopathogenesis of gastrointestinal diseases. Both bacteriophages and eukaryote derived viruses may infect host cells and undermine the host's own bacterial microbiota under certain conditions, triggering immunological responses which induce changes in the structure and composition of the microbiota. Therefore, it is essential to recognize not only the role of bacteria, but also eukaryotes and viruses and their interaction across the host-helminth-gut Microbiota interface, as this may reveal key information about the mechanisms associated with these interactions.

Furthermore, it is imperative to look into the helminth's own microbiota, since it not only defines the transient microbiota specific to each stage of the life cycle and its relationship with the host, but also because it can reveal mutualistic associations between certain bacterial groups and the parasite which may prove essential to its biology and ability to infect and disseminate (Jenkins et al., 2019; Formenti et al., 2020). For example, *Wolbachia* bacteria have been found in nematodes of the family Onchocercidae, a family of filarial nematodes, which includes clinically relevant species known to cause lymphatic filariasis and onchocerciasis and which are of vital importance to the parasite since they provide essential metabolites to the filariae as part of a symbiotic relationship (Bouchery et al., 2013). Bacteria of the genus *Neorickettsia* have also been identified in *Fasciola* trematodes through genomic analysis, thus, suggesting a potential mutualistic relationship between these organisms (McNulty et al., 2017). Very little is known about the establishment, structure and function of the microbiota residing in these nematode parasites and therefore, there is a critical need to evaluate these characteristics in an

attempt to better decipher the interactions between the parasite and the host microbiota.

There are still many gaps in knowledge on how interactions between the parasite and host microbiota may confer biological advantages that facilitate infection and dissemination, and how these relate to the pathophysiology and clinical manifestations of infection and disease. In order to better understand the complex mechanisms involved in these parasite-microbiota-host interfaces, both in humans and animal models, it becomes critical to design multifaceted investigative approaches (Figure 3). Metagenomic analyses using second- and third-generation sequencing technologies can yield key information related to the structure and composition of the microbiota, including prokaryotic, eukaryotic and viral profiles. Such approach can also facilitate the prediction of genes and metabolic pathways that may be differentially expressed in helminth-infected individuals. Transcriptomic and spatial transcriptomic (that enables high-resolution assessment of spatial gene expression across tissue sections) studies will allow evaluation on the differential behavior of gene expression in the enteric niche (or respiratory tract as for the case of *Ascaris*), provide information related to tissue tropism, location and migration patterns of the parasite. Finally, metabolomics mass spectrometry-based studies, for example, from feces and blood samples, could potentially contribute to our knowledge on chemical and metabolic changes related to helminth infections, and how these correlate with alterations in the composition and structure of microbial communities. It is important to emphasize at this point that it is indispensable to carry out these studies under these methodological approaches in such a way that their reproducibility can be assured. It is essential to control, mainly in descriptive studies with humans, the multiple variables that can influence the composition of the microbiota and that can produce biases in the results if they are not appropriately controlled (age, gender, rural or urban population, diet, breastfeeding, route of birth, among others) (Sadowsky et al., 2017; Rinninella et al., 2019). The use of animal models has favored standardization of processes allowing adequate control of most of the variables involved in microbiota analysis. However, it is important to emphasize that in order to translate results derived from mouse studies into a human context, it is necessary to take into account similarities and differences between the gut microbiota of both mice and humans. The comparative physiology of the intestinal tract, the effect of dietary patterns, and differences in genetic backgrounds must also be considered. It is therefore essential to continue to develop and implement humanized gnotobiotic mouse models that allow more concrete and efficient extrapolation of knowledge to the human context (Nguyen et al., 2015; Hugenholtz and de Vos, 2018; Park and Im, 2020). Additionally, the ever-increasing availability of bioinformatics tools should be carefully examined to define their relevance according to the protocols and types of methodologies and analyses, allowing for greater comparability of studies and results. The information obtained from approaches such as those mentioned above are essential for the generation, evaluation and implementation of possible therapeutic alternatives and potential improvements in control mechanisms particularly in areas with



high prevalence of these parasites and where reinfections are frequent despite anthelmintic treatment

It has been identified that the microbiome can offer important advantages in the prediction and diagnosis based on the characterization of certain markers, both associated with health and with different types of diseases such as gastric cancer, and it has also been sought to extrapolate this advantage to the prediction of aspects related to parasitic infections in order to establish relationships and even to predict factors such as the parasitic load and the prognosis of the infection (Gupta et al., 2020; Zhang et al., 2021). In this context, Rubel et al. in 2021, in Cameroonian populations, from metataxonomic and metagenomic analyses and through the implementation of machine learning strategies such as Random Forest, managed to identify those members of the order Bacteroidales, which are common members of the intestinal mucosal surfaces, and are known as an important predictive taxon of infections caused by soil-transmitted helminths and conversely, that the presence of *Ruminococcus bromii*, may be a marker of protection against helminth infection (Rubel et al., 2020). This highlights the importance of focusing studies to identify markers that can facilitate the prediction, prognosis and diagnosis of parasitic infections caused by helminths.

Further studies are needed to validate this hypothesis and to establish an appropriate management framework for the potentially applicability and safe use of these alternatives. Thanks to advances in sequencing methodologies and

bioinformatics tools and analyses, the development of these studies in humans and animal models will facilitate the integration of essential knowledge for the understanding of parasite-host interactions.

AUTHOR CONTRIBUTIONS

JR and SC conceived the objective of the review. SC, AP-M, and JR wrote and revised the final version of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

SC is funded by Programa de Becas de Excelencia Doctoral del Bicentenario, definido en el artículo 45 de la Ley 1942 de 2018 from the Ministerio de Ciencia, Tecnología e Innovación de Colombia.

ACKNOWLEDGMENTS

We thank Direccion de Innovacion e Investigacion from Universidad del Rosario for covering the publication fees of this manuscript.

REFERENCES

- Adedeji, S. O., Ogunba, E. O., and Dipeolu, O. O. (1989). Synergistic Effect of Migrating Ascaris Larvae and Escherichia Coli in Piglets. *J. Helminthol.* 63, 19–24. doi: 10.1017/S0022149X00008671
- Ajibola, O., Rowan, A. D., Ogedengbe, C. O., Mshelia, M. B., Cabral, D. J., Eze, A. A., et al. (2019). Urogenital Schistosomiasis Is Associated With Signatures of Microbiome Dysbiosis in Nigerian Adolescents. *Sci. Rep.* 9, 1–15. doi: 10.1038/s41598-018-36709-1
- Altmann, D. M. (2009). Review Series on Helminths, Immune Modulation and the Hygiene Hypothesis: Nematode Coevolution With Adaptive Immunity, Regulatory Networks and the Growth of Inflammatory Diseases. *Immunology* 126, 1–2. doi: 10.1111/j.1365-2567.2008.03006.x
- Arora, P., Moll, J. M., Andersen, D., Workman, C. T., Williams, A. R., Kristiansen, K., et al. (2020). Body Fluid From the Parasitic Worm Ascaris Suum Inhibits Broad-Acting Pro-Inflammatory Programs in Dendritic Cells. *Immunology* 159, 322–334. doi: 10.1111/imm.13151
- Audebert, C., Even, G., Cian, A., Blastocystis Investigation Group, Loywick, A., Merlin, S., et al. (2016). Colonization With the Enteric Protozoa Blastocystis Is Associated With Increased Diversity of Human Gut Bacterial Microbiota. *Sci. Rep.* 6, 1–11. doi: 10.1038/srep25255
- Bancroft, A. J., Levy, C. W., Jowitz, T. A., Hayes, K. S., Thompson, S., McKenzie, E. A., et al. (2019). The Major Secreted Protein of the Whipworm Parasite Tethers to Matrix and Inhibits Interleukin-13 Function. *Nat. Commun.* 10, 1–11. doi: 10.1038/s41467-019-09996-z
- Barash, N. R., Maloney, J. G., Singer, S. M., and Dawson, S. C. (2017). Giardia Alters Commensal Microbial Diversity Throughout the Murine Gut. *Infect. Immun.* 85. doi: 10.1128/IAI.00948-16
- Barelli, C., Donati, C., Albanese, D., Pafčo, B., Modrý, D., Rovero, F., et al. (2021). Interactions Between Parasitic Helminths and Gut Microbiota in Wild Tropical Primates From Intact and Fragmented Habitats. *Sci. Rep.* 11, 1–10. doi: 10.1038/s41598-021-01145-1
- Berrilli, F., Di Cave, D., Cavallero, S., and D'Amelio, S. (2012). Interactions Between Parasites and Microbial Communities in the Human Gut. *Front. Cell. Infect. Microbiol.* 2. doi: 10.3389/fcimb.2012.00141
- Bouchery, T., Lefoulon, E., Karadjian, G., Nieguitsila, A., and Martin, C. (2013). The Symbiotic Role of Wolbachia in Onchocercidae and Its Impact on Filariasis. *Clin. Microbiol. Infect.* 19, 131–140. doi: 10.1111/1469-0691.12069
- Briggs, N., Weatherhead, J., Sastry, K. J., and Hotez, P. J. (2016). The Hygiene Hypothesis and Its Inconvenient Truths About Helminth Infections. *PLoS Negl. Trop. Dis.* 10, e0004944. doi: 10.1371/journal.pntd.0004944
- Brosschot, T. P., and Reynolds, L. A. (2018). The Impact of a Helminth-Modified Microbiome on Host Immunity Review-Article. *Mucosal Immunol.* 11, 1039–1046. doi: 10.1038/s41385-018-0008-5
- Cantacessi, C., Giacomini, P., Croese, J., Zakrzewski, M., Sotillo, J., McCann, L., et al. (2014). Impact of Experimental Hookworm Infection on the Human Gut Microbiota. *J. Infect. Dis.* 210, 1431–1434. doi: 10.1093/infdis/jiu256
- Castañeda, S., Muñoz, M., Villamizar, X., Hernández, P. C., Vásquez, L. R., Tito, R. Y., et al. (2020). Microbiota Characterization in Blastocystis-Colonized and Blastocystis-Free School-Age Children From Colombia. *Parasitol. Vectors* 13, 521. doi: 10.1186/s13071-020-04392-9
- Chammartin, F., Scholte, R. G. C., Guimarães, L. H., Tanner, M., Utzinger, J., and Vounatsou, P. (2013). Soil-Transmitted Helminth Infection in South America: A Systematic Review and Geostatistical Meta-Analysis. *Lancet Infect. Dis.* 13, 507–518. doi: 10.1016/S1473-3099(13)70071-9
- Chudnovskiy, A., Mortha, A., Kana, V., Kennard, A., Ramirez, J. D., Rahman, A., et al. (2016). Host-Protozoan Interactions Protect From Mucosal Infections Through Activation of the Inflammasome. *Cell* 167, 444. doi: 10.1016/j.cell.2016.08.076
- Cimino, R. O., Jeun, R., Juarez, M., Cajal, P. S., Vargas, P., Echazú, A., et al. (2015). Identification of Human Intestinal Parasites Affecting an Asymptomatic Peri-Urban Argentinian Population Using Multi-Parallel Quantitative Real-Time Polymerase Chain Reaction. *Parasites Vectors* 8, 1–7. doi: 10.1186/s13071-015-0994-z
- Cools, P., Vlamincck, J., Verweij, J. J., and Levecke, B. (2021). Quantitative PCR in Soil-Transmitted Helminth Epidemiology and Control Programs: Toward a Universal Standard. *PLoS Negl. Trop. Dis.* 15, e0009134. doi: 10.1371/journal.pntd.0009134
- Cooper, P. J., and Figueredo, C. A. (2013). “Immunology of Ascaris and Immunomodulation,” in *Ascaris* (The Netherlands: The Neglected Parasite (The Netherlands:Elsevier Inc), 3–19. doi: 10.1016/B978-0-12-396978-1.00001-X
- Cooper, P., Walker, A. W., Reyes, J., Chico, M., Salter, S. J., Vaca, M., et al. (2013). Patent Human Infections With the Whipworm, Trichuris Trichiura, Are Not Associated With Alterations in the Faecal Microbiota. *PLoS One* 8, e76573. doi: 10.1371/journal.pone.0076573
- Cortés, A., Clare, S., Costain, A., Almeida, A., McCarthy, C., Harcourt, K., et al. (2020). Baseline Gut Microbiota Composition Is Associated With Schistosoma Mansoni Infection Burden in Rodent Models. *Front. Immunol.* 11. doi: 10.3389/fimmu.2020.593838
- Cortés, A., Peachey, L., Scotti, R., Jenkins, T. P., and Cantacessi, C. (2019). Helminth-Microbiota Cross-Talk – A Journey Through the Vertebrate Digestive System. *Mol. Biochem. Parasitol.* 233, 111222. doi: 10.1016/j.molbiopara.2019.111222
- Corvino, D. F., de, L., and Horrall, S. (2021) *Ascariasis* (StatPearls). Available at: <https://www.ncbi.nlm.nih.gov/books/NBK430796/> (Accessed February 8, 2022).
- Dold, C., and Holland, C. V. (2011). Investigating the Underlying Mechanism of Resistance to Ascaris Infection. *Microbes Infect.* 13, 624–631. doi: 10.1016/J.MICINF.2010.09.013
- Donohue, R. E., Cross, Z. K., and Michael, E. (2019). The Extent, Nature, and Pathogenic Consequences of Helminth Poly-parasitism in Humans: A Meta-Analysis. *PLoS Negl. Trop. Dis.* 13, e0007455. doi: 10.1371/journal.pntd.0007455
- Douglas, A. E. (2019). Simple Animal Models for Microbiome Research. *Nat. Rev. Microbiol.* 17, 764–775. doi: 10.1038/s41579-019-0242-1
- Dunn, J. C., Turner, H. C., Tun, A., and Anderson, R. M. (2016). Epidemiological Surveys of, and Research on, Soil-Transmitted Helminths in Southeast Asia: A Systematic Review. *Parasites Vectors* 9, 1–13. doi: 10.1186/s13071-016-1310-2
- Easton, A., Gao, S., Lawton, S., Bennuru, S., Khan, A., Dahlstrom, E., et al. (2020). Extensive Hybridization Between Pig and Human Ascaris Identifies a Highly Interbred Species Complex Infecting Humans. *eLife* 1–26. doi: 10.1101/2020.04.17.047407
- Easton, A. V., Quiñones, M., Vujkovic-Cvijin, I., Oliveira, R. G., Kepha, S., Odiere, M. R., et al. (2019). The Impact of Anthelmintic Treatment on Human Gut Microbiota Based on Cross-Sectional and Pre- and Postdeworming Comparisons in Western Kenya. *MBio* 10, 1–14. doi: 10.1128/mBio.00519-19
- Else, K. J., Keiser, J., Holland, C. V., Grecnis, R. K., Sattelle, D. B., Fujiwara, R. T., et al. (2020). Whipworm and Roundworm Infections. *Nat. Rev. Dis. Prim.* 6. doi: 10.1038/s41572-020-0171-3
- Formenti, F., Cortés, A., Brindley, P. J., Cantacessi, C., and Rinaldi, G. (2020). A Bug's Life: Delving Into the Challenges of Helminth Microbiome Studies. *PLoS Negl. Trop. Dis.* 14, 1–7. doi: 10.1371/journal.pntd.0008446
- Gause, W. C., and Maizels, R. M. (2016). Microbiota - Helminths as Active Participants and Partners of the Microbiota in Host Intestinal Homeostasis. *Curr. Opin. Microbiol.* 32, 14–18. doi: 10.1016/j.mib.2016.04.004
- Gazzinelli-Guimaraes, P. H., and Nutman, T. B. (2018). Helminth Parasites and Immune Regulation [Version 1; Peer Review: 2 Approved]. *F1000Research* 7, 1685 doi: 10.12688/F1000RESEARCH.15596.1
- Gazzinelli-Guimaraes, P. H., Nutman, T. B., Ogetmen, B., Giacomini, P. R., Zakrzewski, M., Croese, J., et al. (2020). Therapeutic Helminth Infection of Macaques With Idiopathic Chronic Diarrhea Alters the Inflammatory Signature and Mucosal Microbiota of the Colon. *PLoS One* 8, 1–10. doi: 10.1371/journal.pone.0076573
- Geus, D., Sift, K. C., Habarugira, F., Mugisha, J. C., Mukampunga, C., Ndoli, J., et al. (2019). Co-Infections With Plasmodium, Ascaris and Giardia Among Rwandan Schoolchildren. *Trop. Med. Int. Heal.* 24, 409–420. doi: 10.1111/TMI.13206
- Giacomini, P., Croese, J., Krause, L., Loukas, A., and Cantacessi, C. (2015a). Suppression of Inflammation by Helminths: A Role for the Gut Microbiota? *Philos. Trans. R. Soc. B Biol. Sci.* 370. doi: 10.1098/rstb.2014.0296
- Giacomini, P., Zakrzewski, M., Croese, J., Su, X., Sotillo, J., McCann, L., et al. (2015b). Experimental Hookworm Infection and Escalating Gluten Challenges Are Associated With Increased Microbial Richness in Celiac Subjects. *Sci. Rep.* 5, 4–11. doi: 10.1038/srep13797

- Giacomin, P., Zakrzewski, M., Jenkins, T. P., Su, X., Al-Hallaf, R., Croese, J., et al. (2016). Changes in Duodenal Tissue-Associated Microbiota Following Hookworm Infection and Consecutive Gluten Challenges in Humans With Coeliac Disease. *Sci. Rep.* 6, 1–10. doi: 10.1038/srep36797
- Girgis, N. M., Gundra, U. M., and Loke, P. (2013). Immune Regulation During Helminth Infections. *PLoS Pathog.* 9, e1003250–e1003250. doi: 10.1371/journal.ppat.1003250
- Glendinning, L., Nausch, N., Free, A., Taylor, D. W., and Mutapi, F. (2014). The Microbiota and Helminths: Sharing the Same Niche in the Human Host. *Parasitology* 141, 1255–1271. doi: 10.1017/S0031182014000699
- Gordon, C. A., Krause, L., McManus, D. P., Morrison, M., Weerakoon, K. G., Connor, M. C., et al. (2020). Helminths, Poly-parasitism, and the Gut Microbiome in the Philippines. *Int. J. Parasitol.* 50, 217–225. doi: 10.1016/j.ijpara.2019.12.008
- Gupta, V. K., Kim, M., Bakshi, U., Cunningham, K. Y., Davis, J. M., Lazaridis, K. N., et al. (2020). A Predictive Index for Health Status Using Species-Level Gut Microbiome Profiling. *Nat. Commun.* 11, 1–16. doi: 10.1038/s41467-020-18476-8
- Hansen, E. P., Fromm, B., Andersen, S. D., Marcilla, A., Andersen, K. L., Borup, A., et al. (2019). Exploration of Extracellular Vesicles From *Ascaris Suum* Provides Evidence of Parasite–Host Cross Talk. *J. Extracell. Vesicles* 8. doi: 10.1080/20013078.2019.1578116
- Harhay, M. O., Horton, J., and Ollario, P. L. (2010). Epidemiology and Control of Human Gastrointestinal Parasites in Children. *Expert Rev. Anti Infect. Ther.* 8, 219–234. doi: 10.1586/eri.09.119
- Hayes, K. S., Bancroft, A. J., Goldrick, M., Portsmouth, C., Roberts, I. S., and Grenicis, R. K. (2010). Exploitation of the Intestinal Microflora by the Parasitic Nematode *Trichuris Muris*. *Science* 328, 1391–1394. doi: 10.1126/science.1187703
- Hernández, P. C., Morales, L., Chaparro-Olaya, J., Sarmiento, D., Jaramillo, J. F., Ordoñez, G. A., et al. (2019). Intestinal Parasitic Infections and Associated Factors in Children of Three Rural Schools in Colombia. A Cross-Sectional Study. *PLoS One* 14, e0218681. doi: 10.1371/journal.pone.0218681
- Hotez, P. J., Alvarado, M., Basañez, M.-G., Bolliger, I., Bourne, R., Boussinesq, M., et al. (2014). The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases. *PLoS Negl. Trop. Dis.* 8, e2865. doi: 10.1371/JOURNAL.PNTD.0002865
- Hotez, P. J., Brindley, P. J., Bethony, J. M., King, C. H., Pearce, E. J., and Jacobson, J. (2008). Helminth Infections: The Great Neglected Tropical Diseases. *J. Clin. Invest.* 118, 1311–1321. doi: 10.1172/JCI34261
- Houlden, A., Hayes, K. S., Bancroft, A. J., Worthington, J. J., Wang, P., Grenicis, R. K., et al. (2015). Chronic *Trichuris Muris* Infection in C57BL/6 Mice Causes Significant Changes in Host Microbiota and Metabolome: Effects Reversed by Pathogen Clearance. *PLoS One* 10. doi: 10.1371/journal.pone.0125945
- Hübner, M. P., Layland, L. E., and Hoerauf, A. (2013). Helminths and Their Implication in Sepsis – A New Branch of Their Immunomodulatory Behaviour? *Pathog. Dis.* 69, 127–141. doi: 10.1111/2049-632X.12080
- Hufsky, F., Beerenwinkel, N., Meyer, I. M., Roux, S., Cook, G. M., Kinsella, C. M., et al. (2020). The International Virus Bioinformatics Meeting 2020. *Viruses* 12, 1398. doi: 10.3390/v12121398
- Hugenholtz, F., and de Vos, W. M. (2018). Mouse Models for Human Intestinal Microbiota Research: A Critical Evaluation. *Cell. Mol. Life Sci.* 75, 149. doi: 10.1007/S00018-017-2693-8
- Iebba, V., Santangelo, F., Totino, V., Pantanella, F., Monsia, A., Di Cristanziano, V., et al. (2016). Gut Microbiota Related to *Giardia Duodenalis*, *Entamoeba Spp.* and *Blastocystis Hominis* Infections in Humans From Côte D’Ivoire. *J. Infect. Dev. Ctries.* 10, 1035–1041. doi: 10.3855/jidc.8179
- Jenkins, T. P., Brindley, P. J., Gasser, R. B., and Cantacessi, C. (2019). Helminth Microbiomes – A Hidden Treasure Trove? *Trends Parasitol.* 35, 13–22. doi: 10.1016/j.pt.2018.10.007
- Jenkins, T. P., Rathnayaka, Y., Perera, P. K., Peachey, J. E., Nolan, M. J., Krause, L., et al. (2017). Infections by Human Gastrointestinal Helminths Are Associated With Changes in Faecal Microbiota Diversity and Composition. *PLoS One* 12, 1–18. doi: 10.1371/journal.pone.0184719
- Jourdan, P. M., Lamberton, P. H. L., Fenwick, A., and Addiss, D. G. (2018). Soil-Transmitted Helminth Infections. *Lancet* 391, 252–265. doi: 10.1016/S0140-6736(17)31930-X
- Karo-Atar, D., Khan, N., Divangahi, M., and King, I. L. (2021). Helminth-Mediated Disease Tolerance in TB: A Role for Microbiota? *PLoS Pathog.* 17, e1009690. doi: 10.1371/JOURNAL.PPAT.1009690
- Katakam, K. K., Thamsborg, S. M., Dalsgaard, A., Kyvsgaard, N. C., and Mejer, H. (2016). Environmental Contamination and Transmission of *Ascaris Suum* in Danish Organic Pig Farms. *Parasites Vectors* 9, 1–12. doi: 10.1186/S13071-016-1349-0/FIGURES/6
- Kay, G. L., Millard, A., Sergeant, M. J., Midzi, N., Gwisai, R., Mdlulza, T., et al. (2015). Differences in the Faecal Microbiome in *Schistosoma Haematobium* Infected Children vs. Uninfected Children. *PLoS Negl. Trop. Dis.* 9, e0003861. doi: 10.1371/journal.pntd.0003861
- Klementowicz, J. E., Travis, M. A., and Grenicis, R. K. (2012). *Trichuris Muris*: A Model of Gastrointestinal Parasite Infection. *Semin. Immunopathol.* 34, 815–828. doi: 10.1007/s00281-012-0348-2
- Kreisinger, J., Bastien, G., Hauffe, H. C., Marchesi, J., and Perkins, S. E. (2015). Interactions Between Multiple Helminths and the Gut Microbiota in Wild Rodents. *Philos. Trans. R. Soc B Biol. Sci.* 370. doi: 10.1098/rstb.2014.0295
- Kupritz, J., Angelova, A., Nutman, T. B., and Gazzinelli-Guimaraes, P. H. (2021). Helminth-Induced Human Gastrointestinal Dysbiosis: A Systematic Review and Meta-Analysis Reveals Insights Into Altered Taxon Diversity and Microbial Gradient Collapse. *MBio* 12. doi: 10.1128/MBIO.02890-21
- Lawson, M. A. E., Roberts, I. S., and Grenicis, R. K. (2021). The Interplay Between *Trichuris* and the Microbiota. *Parasitology* 1–8. doi: 10.1017/S0031182021000834
- Lee, S. C., Tang, M. S., Lim, Y. A., Choy, S. H., Kurtz, Z. D., Cox, L. M., et al. (2014). Helminth Colonization Is Associated With Increased Diversity of the Gut Microbiota. *PLoS Negl. Trop. Dis.* 8, e2880–e2880. doi: 10.1371/journal.pntd.0002880
- Leung, J. M., Graham, A. L., and Knowles, S. C. L. (2018). Parasite-Microbiota Interactions With the Vertebrate Gut: Synthesis Through an Ecological Lens. *Front. Microbiol.* 9. doi: 10.3389/fmicb.2018.00843
- Lewis, R., Behnke, J. M., Stafford, P., and Holland, C. V. (2006). The Development of a Mouse Model to Explore Resistance and Susceptibility to Early *Ascaris Suum* Infection. *Parasitology* 132, 289–300. doi: 10.1017/S0031182005008978
- Li, R. W., Wu, S., Li, W., Navarro, K., Couch, R. D., Hill, D., et al. (2012). Alterations in the Porcine Colon Microbiota Induced by the Gastrointestinal Nematode *Trichuris Suis*. *Infect. Immun.* 80, 2150–2157. doi: 10.1128/IAI.00141-12
- Loke, P., and Lim, Y. A. L. (2015). Helminths and the Microbiota: Parts of the Hygiene Hypothesis. *Parasite Immunol.* 37, 314–323. doi: 10.1111/pim.12193
- Maizels, R. M., Smits, H. H., and McSorley, H. J. (2018). Modulation of Host Immunity by Helminths: The Expanding Repertoire of Parasite Effector Molecules. *Immunity* 49, 801–818. doi: 10.1016/j.immuni.2018.10.016
- Martín, R., Bermúdez-Humarán, L. G., and Langella, P. (2016). Gnotobiotic Rodents: An *In Vivo* Model for the Study of Microbe-Microbe Interactions. *Front. Microbiol.* 7. doi: 10.3389/fmicb.2016.00409
- Mason, K. L., Downward, J. R. E., Mason, K. D., Falkowski, N. R., Eaton, K. A., Kao, J. Y., et al. (2012). *Candida Albicans* and Bacterial Microbiota Interactions in the Cecum During Recolonization Following Broad-Spectrum Antibiotic Therapy. *Infect. Immun.* 80, 3371–3380. doi: 10.1128/IAI.00449-12
- McNulty, S. N., Tort, J. F., Rinaldi, G., Fischer, K., Rosa, B. A., Smircich, P., et al. (2017). Genomes of *Fasciola Hepatica* From the Americas Reveal Colonization With Neorickettsia Endobacteria Related to the Agents of Potomac Horse and Human Sennetsu Fevers. *PLoS Genet.* 13, e1006537. doi: 10.1371/JOURNAL.PGEN.1006537
- McSorley, H. J., and Maizels, R. M. (2012). Helminth Infections and Host Immune Regulation. *Clin. Microbiol. Rev.* 25, 585–608. doi: 10.1128/CMR.05040-11
- Mejia, R., Damania, A., Jeun, R., Bryan, P. E., Vargas, P., Juarez, M., et al. (2020). Impact of Intestinal Parasites on Microbiota and Cobalamin Gene Sequences: A Pilot Study. *Parasitol. Vectors* 13, 1–9. doi: 10.1186/s13071-020-04073-7
- Midha, A., Ebner, F., Schlosser-Brandenburg, J., Rausch, S., and Hartmann, S. (2021). Trilateral Relationship: *Ascaris*, Microbiota, and Host Cells. *Trends Parasitol.* 37, 251–262. doi: 10.1016/j.pt.2020.09.002
- Midha, A., Janek, K., Niewianda, A., Henklein, P., Guenther, S., Serra, D. O., et al. (2018). The Intestinal Roundworm *Ascaris Suum* Releases Antimicrobial Factors Which Interfere With Bacterial Growth and Biofilm Formation. *Front. Cell. Infect. Microbiol.* 8. doi: 10.3389/fcimb.2018.00367

- Midha, A., Schlosser, J., and Hartmann, S. (2017). Reciprocal Interactions Between Nematodes and Their Microbial Environments. *Front. Cell. Infect. Microbiol.* 7. doi: 10.3389/fcimb.2017.00144
- Miller, L. A., Colby, K., Manning, S. E., Hoenig, D., McEvoy, E., Montgomery, S., et al. (2015). Ascariasis in Humans and Pigs on Small-Scale Farms, Maine, US—2013. *Emerg. Infect. Dis.* 21, 332. doi: 10.3201/EID2102.140048
- Moreno-Gallego, J. L., Chou, S. P., Di Rienzi, S. C., Goodrich, J. K., Spector, T. D., Bell, J. T., et al. (2019). Virome Diversity Correlates With Intestinal Microbiome Diversity in Adult Monozygotic Twins. *Cell Host Microbe* 25, 261–272.e5. doi: 10.1016/j.chom.2019.01.019
- Mukhopadhyay, I., Segal, J. P., Carding, S. R., Hart, A. L., and Hold, G. L. (2019). The Gut Virome: The ‘Missing Link’ Between Gut Bacteria and Host Immunity? *Therap. Adv. Gastroenterol.* 12. doi: 10.1177/1756284819836620
- Nagel, R., Traub, R. J., Allcock, R. J. N., Kwan, M. M. S., and Bielefeldt-Ohmann, H. (2016). Comparison of Faecal Microbiota in Blastocystis-Positive and Blastocystis-negative Irritable Bowel Syndrome Patients. *Microbiome* 4, 1–9. doi: 10.1186/s40168-016-0191-0
- Nguyen, T. L. A., Vieira-Silva, S., Liston, A., and Raes, J. (2015). How Informative Is the Mouse for Human Gut Microbiota Research? *DMM Dis. Model. Mech.* 8, 1–16. doi: 10.1242/DMM.017400/-/DC1
- Nogueira, D. S., Gazzinelli-Guimarães, P. H., Barbosa, F. S., Resende, N. M., Silva, C. C., Oliveira, L. M., et al. (2016). Multiple Exposures to Ascaris Suum Induce Tissue Injury and Mixed Th2/Th17 Immune Response in Mice. *PLoS Negl. Trop. Dis.* 10, e0004382. doi: 10.1371/JOURNAL.PNTD.0004382
- Ojha, S. C., Jaide, C., Jinawath, N., Rotjanapan, P., and Baral, P. (2014). Geohelminths: Public Health Significance. *J. Infect. Dev. Ctries.* 8, 5–16. doi: 10.3855/JIDC.3183
- Papaikovou, M., Littlewood, D. T. J., Gasser, R. B., and Anderson, R. M. (2021). How qPCR Complements the WHO Roadmap–2030 for Soil-Transmitted Helminths. *Trends Parasitol.* doi: 10.1016/j.pt.2021.04.005
- Park, J. C., and Im, S. H. (2020). Of Men in Mice: The Development and Application of a Humanized Gnotobiotic Mouse Model for Microbiome Therapeutics. *Exp. Mol. Med.* 52 (9), 1383–1396. doi: 10.1038/s12276-020-0473-2
- Partida-Rodriguez, O., Nieves-Ramirez, M., Laforest-Lapointe, I., Brown, E., Parfrey, L., Reynolds, L., et al. (2019). Exposure to Parasitic Protists and Helminths Changes the Intestinal Community Structure of Bacterial Microbiota But Not of Eukaryotes in a Cohort of Mother-Child Binomial From a Semi-Rural Setting in Mexico. *bioRxiv* 717165. doi: 10.1101/717165
- Pillai, A., Ueno, S., Zhang, H., and Kato, Y. (2003). Induction of ASABF (Ascaris Suum Antibacterial Factor)-Type Antimicrobial Peptides by Bacterial Injection: Novel Members of ASABF in the Nematode *Ascaris Suum*. *Biochem. J.* 371, 663–668. doi: 10.1042/BJ20021948
- Pillai, A., Ueno, S., Zhang, H., Lee, J. M., and Kato, Y. (2005). Cecropin P1 and Novel Nematode Cecropins: A Bacteria-Inducible Antimicrobial Peptide Family in the Nematode *Ascaris Suum*. *Biochem. J.* 390, 207–214. doi: 10.1042/BJ20050218
- Pullan, R. L., Smith, J. L., Jasrasaria, R., and Brooker, S. J. (2014). Global Numbers of Infection and Disease Burden of Soil Transmitted Helminth Infections in 2010. *Parasites Vectors* 7. doi: 10.1186/1756-3305-7-37
- Ramanan, D., Bowcutt, R., Lee, S. C., Tang, M. S., Zachary, D., Ding, Y., et al. (2016). Helminth Infection Promotes Colonization Resistance via Type 2 Immunity. *Science* 352, 608–612. doi: 10.1126/science.aaf3229
- Reynolds, L. A., Finlay, B. B., and Maizels, R. M. (2015). Cohabitation in the Intestine: Interactions Among Helminth Parasites, Bacterial Microbiota, and Host Immunity. *J. Immunol.* 195, 4059–4066. doi: 10.4049/jimmunol.1501432
- Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G., Gasbarrini, A., et al. (2019). What Is the Healthy Gut Microbiota Composition? A Changing Ecosystem Across Age, Environment, Diet, and Diseases. *Microorganisms* 7, 14. doi: 10.3390/microorganisms7010014
- Rosa, B. A., Snowden, C., Martin, J., Fischer, K., Kupritz, J., Beshah, E., et al. (2021). Whipworm-Associated Intestinal Microbiome Members Consistent Across Both Human and Mouse Hosts. *Front. Cell. Infect. Microbiol.* 11. doi: 10.3389/fcimb.2021.637570
- Rosa, B. A., Supali, T., Gankpala, L., Djuardi, Y., Sartono, E., Zhou, Y., et al. (2018). Differential Human Gut Microbiome Assemblages During Soil-Transmitted Helminth Infections in Indonesia and Liberia. *Microbiome* 6, 1–19. doi: 10.1186/s40168-018-0416-5
- Rubel, M. A., Abbas, A., Taylor, L. J., Connell, A., Tanes, C., Bittinger, K., et al. (2020). Lifestyle and the Presence of Helminths Is Associated With Gut Microbiome Composition in Cameroonians. *Genome Biol.* 21, 1–32. doi: 10.1186/s13059-020-02020-4
- Saboyá, M. I., Catalá, L., Nicholls, R. S., and Ault, S. K. (2013). Update on the Mapping of Prevalence and Intensity of Infection for Soil-Transmitted Helminth Infections in Latin America and the Caribbean: A Call for Action. *PLoS Negl. Trop. Dis.* 7. doi: 10.1371/journal.pntd.0002419
- Sadowsky, M. J., Staley, C., Heiner, C., Hall, R., Kelly, C. R., Brandt, L., et al. (2017). Analysis of Gut Microbiota - An Ever Changing Landscape. *Gut Microbes* 8, 268–275. doi: 10.1080/19490976.2016.1277313
- Salcedo-Cifuentes, M., Florez, O., Bermúdez, A., Hernández, L., Araujo, C., and Bolaños, M. V. (2012). Intestinal Parasitism Prevalence Amongst Children From Six Indigenous Communities Residing in Cali, Colombia. *Rev. Salud Pública* 14, 156–168. doi: 10.1590/s0124-00642012000100013
- Sayasone, S., Mak, T. K., Vanmany, M., Rasphone, O., Vounatsou, P., Utzinger, J., et al. (2011). Helminth and Intestinal Protozoa Infections, Multiparasitism and Risk Factors in Champasack Province, Lao People’s Democratic Republic. *PLoS Negl. Trop. Dis.* 5, e1037. doi: 10.1371/JOURNAL.PNTD.0001037
- Schachter, J., Oliveira, A., Miranda, C., and Alencar, D. B. (2020). Whipworm Infection Promotes Bacterial Invasion, Intestinal Microbiota Imbalance, and Cellular Immunomodulation. *Infect. Immun.* 88, 1–24. doi: 10.1128/IAI.00642-19
- Schüle, S. A., Clowes, P., Kroidl, I., Kowuor, D. O., Nsojo, A., Mangu, C., et al. (2014). *Ascaris Lumbricoides* Infection and Its Relation to Environmental Factors in the Mbeya Region of Tanzania, a Cross-Sectional, Population-Based Study. *PLoS One* 9, 1–10. doi: 10.0591/journal.pone.0092032
- Silver, Z. A., Kaliappan, S. P., Samuel, P., Venugopal, S., Kang, G., Sarkar, R., et al. (2018). Geographical Distribution of Soil Transmitted Helminths. *PLoS Negl. Trop. Dis.* 7–16. doi: 10.1371/journal.pntd.0006153
- Simon, C., and Daniel, R. (2011). Metagenomic Analyses: Past and Future Trends. *Appl. Environ. Microbiol.* 77, 1153–1161. doi: 10.1128/AEM.02345-10
- Sobotková, K., Parker, W., Levá, J., Růžková, J., Lukeš, J., and Jirků Pomajbíková, K. (2019). Helminth Therapy – From the Parasite Perspective. *Trends Parasitol.* 35, 501–515. doi: 10.1016/j.pt.2019.04.009
- Stensvold, C. R., and van der Giezen, M. (2018). Associations Between Gut Microbiota and Common Luminal Intestinal Parasites. *Trends Parasitol.* 34, 369–377. doi: 10.1016/j.pt.2018.02.004
- Stiemsma, L., Reynolds, L., Turvey, S., and Finlay, B. (2015). The Hygiene Hypothesis: Current Perspectives and Future Therapies. *ImmunoTargets Ther.* 4, 143. doi: 10.2147/itt.s61528
- Stracke, K., Adisakwattana, P., Phuanukoonnon, S., Yoonuan, T., Poodeepiyasawat, A., Dekumyoy, P., et al. (2021). Field Evaluation of the Gut Microbiome Composition of Pre-School and School-Aged Children in Tha Song Yang, Thailand, Following Oral MDA for STH Infections. *PLoS Negl. Trop. Dis.* 15, e0009597. doi: 10.1371/JOURNAL.PNTD.0009597
- Sultan Khuroo, M. (1996). ASCARIASIS. *Gastroenterol. Clin. North Am.* 25, 553–577. doi: 10.1016/S0889-8553(05)70263-6
- Su, C., Su, L., Li, Y., Long, S. R., Chang, J., Zhang, W., et al. (2018). Helminth-Induced Alterations of the Gut Microbiota Exacerbate Bacterial Colitis. *Mucosal Immunol.* 11, 144–157. doi: 10.1038/mi.2017.20
- Toro-Londono, M. A., Bedoya-Urrego, K., Garcia-Montoya, G. M., Galvan-Diaz, A. L., and Alzate, J. F. (2019). Intestinal Parasitic Infection Alters Bacterial Gut Microbiota in Children. *PeerJ* 2019, 1–24. doi: 10.7717/peerj.6200
- Vežgagić, N., Adelfio, R., Keiser, J., Kringel, H., Thamsborg, S. M., and Kapel, C. M. O. (2015). Bacteria-Induced Egg Hatching Differs for *Trichuris Muris* and *Trichuris Suis*. *Parasites Vectors* 8, 1–7. doi: 10.1186/S13071-015-0986-Z
- Velasco, C. A., Méndez, F., and López, P. (2011). Cryptosporidiosis in Colombian Children With HIV/AIDS Infection. *Colomb. Med.* 42, 418–429. doi: 10.25100/cm.v42i4.942
- Vollmers, J., Wiegand, S., and Kaster, A. K. (2017). Comparing and Evaluating Metagenome Assembly Tools From a Microbiologist’s Perspective - Not Only Size Matters! *PLoS One* 12, e0169662. doi: 10.1371/journal.pone.0169662
- von Huth, S., Thingholm, L. B., Kofoed, P.-E., Bang, C., Rühlemann, M. C., Franke, A., et al. (2021). Intestinal Protozoan Infections Shape Faecal Bacterial Microbiota in Children From Guinea-Bissau. *PLoS Negl. Trop. Dis.* 15, e0009232. doi: 10.1371/journal.pntd.0009232

- Wajid, B., Anwar, F., Wajid, I., Nisar, H., Meraj, S., Zafar, A., et al. (2022). Music of Metagenomics—A Review of Its Applications, Analysis Pipeline, and Associated Tools. *Funct. Integr. Genomics* 22, 3–26. doi: 10.1007/s10142-021-00810-y
- Walker, M., Hall, A., and Basañez, M. G. (2013). *Ascaris Lumbricoides: New Epidemiological Insights and Mathematical Approaches*. (Elsevier) doi: 10.1016/B978-0-12-396978-1.00007-0
- Wang, Y., Liu, F., Urban, J. F., Paerewijck, O., Geldhof, P., and Li, R. W. (2019). Ascaris Suum Infection was Associated With a Worm-Independent Reduction in Microbial Diversity and Altered Metabolic Potential in the Porcine Gut Microbiome. *Int. J. Parasitol.* 49, 247–256. doi: 10.1016/j.ijpara.2018.10.007
- Wescott, R. B. (1968). Experimental Nematospiroides Dubius Infection in Germfree and Conventional Mice. *Exp. Parasitol.* 22, 245–249. doi: 10.1016/0014-4894(68)90099-4
- White, M. P. J., McManus, C. M., and Maizels, R. M. (2020). Regulatory T-Cells in Helminth Infection: Induction, Function and Therapeutic Potential. *Immunology* 160, 248–260. doi: 10.1111/imm.13190
- Whitman, W. B., Oren, A., Chuvochina, M., da Costa, M. S., Garrity, G. M., Rainey, F. A., et al. (2018). Proposal of the Suffix -ota to Denote Phyla. Addendum to 'Proposal to Include the Rank of Phylum in the International Code of Nomenclature of Prokaryotes.' *Int. J. Syst. Evol. Microbiol.* 68, 967–969. doi: 10.1099/IJSEM.0.002593/CITE/REFWORKS
- Whitman, J. D., Sakanari, J. A., and Mitreva, M. (2021). Areas of Metabolomic Exploration for Helminth Infections. *ASC Infect. Dis.* 7, 206–214. doi: 10.1021/acsinfectdis.0c00658
- Williams, A. R., Krych, L., Ahmad, H. F., Nejsum, P., Skovgaard, K., Nielsen, D. S., et al. (2017). A Polyphenol-Enriched Diet and Ascaris Suum Infection Modulate Mucosal Immune Responses and Gut Microbiota Composition in Pigs. *PLoS One* 12, 1–21. doi: 10.1371/journal.pone.0186546
- Wooley, J. C., Godzik, A., and Friedberg, I. (2010). A Primer on Metagenomics. *PLoS Comput. Biol.* 6. doi: 10.1371/journal.pcbi.1000667
- World Health Organization Soil-transmitted helminth infections (2021) WHO. Available at: <https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections> (Accessed July 15, 2021).
- Wu, Y., Li, E., Knight, M., Adeniyi-Ipadeola Id, G., Song, L.-Z., Burns, A. R., et al. (2021). Transient Ascaris Suum Larval Migration Induces Intractable Chronic Pulmonary Disease and Anemia in Mice. *PLoS Negl. Trop. Dis.* 15, e0010050. doi: 10.1371/JOURNAL.PNTD.0010050
- Wu, S., Li, R. W., Li, W., Beshah, E., Dawson, H. D., and Urban, J. F. (2012). Worm Burden-Dependent Disruption of the Porcine Colon Microbiota by Trichuris Suis Infection. *PLoS One* 7. doi: 10.1371/journal.pone.0035470
- Yasuda, K., and Nakanishi, K. (2018). Host Responses to Intestinal Nematodes. *Int. Immunol.* 30, 93–102. doi: 10.1093/intimm/dxy002
- Yousefi, Y., Haq, S., Banskota, S., Kwon, Y. H., and Khan, W. I. (2021). Trichuris Muris Model: Role in Understanding Intestinal Immune Response, Inflammation and Host Defense. *Pathogens* 10, 925. doi: 10.3390/PATHOGENS10080925
- Zaiss, M. M., and Harris, N. L. (2016). Interactions Between the Intestinal Microbiome and Helminth Parasites. *Parasite Immunol.* 38, 5–11. doi: 10.1111/pim.12274
- Zaiss, M. M., Rapin, A., Lebon, L., Dubey, L. K., Mosconi, I., Sarter, K., et al. (2015). The Intestinal Microbiota Contributes to the Ability of Helminths to Modulate Allergic Inflammation. *Immunity* 43, 998–1010. doi: 10.1016/j.immuni.2015.09.012
- Zhang, Y., Shen, J., Shi, X., Du, Y., Niu, Y., Jin, G., et al. (2021). Gut Microbiome Analysis as a Predictive Marker for the Gastric Cancer Patients. *Appl. Microbiol. Biotechnol.* 105, 803–814. doi: 10.1007/S00253-020-11043-7

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Castañeda, Paniz-Mondolfi and Ramírez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

1 **Parasite-Microbiota Interactions: A Pathway to Innovative Interventions for Chagas**
2 **Disease, Leishmaniasis, and Ascariasis**

3
4 Juan David Ramírez^{1,2*}, Sergio Castañeda¹, Jill Weatherhead^{3,4,5}, Cristina Poveda^{3,4,5*}

5
6 ¹Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de
7 Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia.

8 ²Molecular Microbiology Laboratory, Department of Pathology, Molecular and Cell-based
9 Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

10 ³Department of Pediatrics, Division of Tropical Medicine, Baylor College of Medicine, Houston,
11 TX, USA

12 ⁴Texas Children´s Hospital, Center for Vaccine Development, Houston, TX, USA

13 ⁵Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX,
14 USA

15
16 *Corresponding authors: juan.ramirezgonzalez@mssm.edu.co, juand.ramirez@urosario.edu.co,
17 cristina.poveda@bcm.edu

18
19 **Abstract**

20
21 Parasitic infections remain a significant global health challenge, largely due to their complex
22 interactions with host microbiota and immune responses. Advances in microbiome research have
23 revealed that the microbiota significantly influences disease outcomes and treatment efficacy. This
24 perspective delves into how microbiota dynamics affect parasite transmission, pathogenesis, and
25 treatment responses, with a focus on diseases like Chagas disease, leishmaniasis, and ascariasis.
26 The microbiota can either exacerbate or mitigate disease severity, depending on its composition,
27 providing critical insights for novel therapeutic strategies. Emerging approaches discussed include
28 the use of targeted probiotics, prebiotics, and microbiota-modulating drugs to influence parasite
29 dynamics and enhance conventional therapies. The perspective also explores the potential of
30 integrating microbiota knowledge into vaccine design and immunotherapy, aiming to develop
31 vaccines that elicit stronger immune responses and identify new therapeutic targets. A
32 multidisciplinary approach is essential for translating these findings into effective clinical
33 solutions, with future research focusing on validating microbiota-based interventions in clinical
34 settings. In conclusion, the interaction between microbiota and parasitic infections presents a
35 promising avenue for innovative therapies, with the potential to significantly improve global health
36 outcomes.

37
38 **Key words:** Microbiota, Chagas disease, leishmaniasis, *Ascaris*, probiotics, vaccines

39
40 **Article Highlights**

- 41
42
43
44
- Parasite-microbiota interactions are crucial in understanding disease outcomes and developing therapeutic strategies.
 - *Trypanosoma cruzi* (Chagas disease), prevalent in Latin America, leading to chronic complications like cardiomyopathy and gastrointestinal disorders.

- 45 • *Leishmania* spp. (leishmaniasis), affecting over 12 million people globally, causing
46 significant morbidity and mortality.
- 47 • *Ascaris lumbricoides* (ascariasis), affecting nearly a quarter of the global population,
48 particularly in regions with poor sanitation, causing malnutrition and stunted growth in
49 children.
- 50 • *Trypanosoma cruzi* infection alters the gut microbiota, causing immune dysregulation
51 that exacerbates disease symptoms, particularly in chronic stages like cardiomyopathy.
- 52 • Gut and skin microbiota can modulate immune responses, where certain bacterial
53 communities may suppress or enhance inflammation, impacting disease outcomes.
- 54 • A more diverse gut microbiota is linked to improved immune regulation, potentially
55 reducing infection severity in ascariasis.
- 56 • These parasitic infections share similarities in their interactions with the host microbiota,
57 despite their distinct biological characteristics.
- 58 • The potential of microbiota-targeted therapies to improve disease outcomes is being
59 recognized:
- 60 • Manipulating the gut microbiota could enhance immune responses and improve treatment
61 efficacy for these parasitic diseases.
- 62 • Modulating the microbiota may help mitigate disease progression, providing a
63 complementary therapeutic approach to conventional treatments.
- 64 • Comparative research across these three diseases highlights the possibility of broader
65 microbiota-modulating strategies that could be effective across different parasitic
66 infections, particularly in vulnerable tropical and subtropical populations.
- 67 • Understanding the interactions between the gut and skin microbiota and parasites like *T.*
68 *cruzi*, *Leishmania* spp., and *A. lumbricoides* can inform novel therapeutic approaches.
- 69 • This review aims to shed light on the mechanisms through which microbial communities
70 influence immune responses and disease outcomes, offering potential microbiota-targeted
71 therapies that could benefit multiple parasitic diseases.
- 72 • By comparing the effects of microbiota across different parasitic infections, the review
73 seeks to explore cross-cutting strategies for treating diseases that disproportionately affect
74 at-risk populations.

75

76 1. Introduction

77 The study of parasite-microbiota interactions is gaining significant attention due to its profound
78 implications for disease outcomes and therapeutic strategies. Parasites such as *Trypanosoma cruzi*
79 (Chagas disease), *Leishmania* spp. (leishmaniasis), and *Ascaris lumbricoides* (ascariasis) are major
80 global health threats [1–3]. Chagas disease (CD), endemic to Latin America, is notorious for its
81 chronic complications, including cardiomyopathy and gastrointestinal disorders [2,4,5].
82 Leishmaniasis, which affects over 12 million people globally, presents in visceral and cutaneous
83 forms, leading to significant morbidity and mortality [3,6]. Ascariasis, caused by the intestinal
84 roundworm *A. lumbricoides*, affects nearly a quarter of the world’s population, particularly in areas
85 with poor sanitation, leading to malnutrition and impaired growth in children [1,7].

86 Recent studies have highlighted the crucial role of the microbiota in these infections. The gut
87 microbiota significantly influences host immunity and parasite survival, impacting the severity

88 and progression of these diseases [8,9]. For instance, *T. cruzi* infection has been shown to alter the
89 gut microbiota, leading to immune dysregulation that exacerbates disease symptoms [10,11].
90 Similarly, the microbiota influences the immune responses in leishmaniasis, where certain
91 bacterial communities can either suppress or enhance inflammation, thus affecting disease
92 outcomes [12,13]. In ascariasis, a diverse gut microbiota has been linked to better immune
93 regulation, potentially reducing the severity of infection [14,15]. The potential of microbiota-
94 targeted therapies to modulate these interactions presents a promising avenue for improving
95 treatment efficacy and patient outcomes in parasitic diseases [16,17].

96 In examining the interactions among *Ascaris lumbricoides*, *Trypanosoma cruzi*, and *Leishmania*
97 species, it is crucial to highlight both their commonalities and differences, particularly regarding
98 their relationships with the host microbiota. While these pathogens differ significantly in their
99 biology—*Ascaris* being a helminth and the other protozoans—they all interact with the host
100 microbiota in ways that can influence disease severity and progression. Research indicates that
101 alterations in the gut and skin microbiota can affect immune responses, potentially exacerbating
102 infection outcomes. For example, changes in microbial composition may modulate inflammatory
103 processes, affecting how the host responds to each pathogen. Understanding these complex
104 microbiota interactions not only sheds light on the mechanisms underlying disease pathogenesis
105 but also opens avenues for innovative therapeutic strategies that leverage microbiota modulation
106 to enhance treatment efficacy across these diverse parasitic infections.

107 This review seeks to elucidate how these parasitic infections alter the gut microbiota and skin
108 microbiota in the case of leishmaniasis, in turn, how these changes affect the disease's progression
109 and outcomes [18–22]. Although *T. cruzi* (Chagas disease), *Leishmania* species (leishmaniasis),
110 and *Ascaris lumbricoides* (ascariasis) are distinct pathogens, they share significant commonalities:
111 they affect vulnerable populations in similar tropical and subtropical regions and interact with the
112 host microbiota in ways that impact disease severity, immunity, and treatment outcomes. Focusing
113 on these seemingly dissimilar pathogens allows us to explore broader microbiota-modulating
114 strategies that could be effective across multiple parasitic diseases. This comparative approach
115 enriches our understanding of parasite-microbiota interactions, potentially leading to innovative,
116 cross-cutting therapeutic interventions for diseases affecting overlapping at-risk populations.

117
118 By examining the multifaceted relationships between the gut microbiota and these parasites, the
119 review aims to provide insights into the mechanisms through which microbial communities
120 influence immune responses and disease severity. Such understanding could inform new
121 therapeutic strategies that leverage microbiota-targeted interventions to improve patient
122 management and treatment efficacy for these prevalent parasitic diseases.

123 124 **2. Chagas Disease and the Microbiota**

125
126 CD can manifest with various complications, including cardiomyopathy, gastrointestinal issues,
127 and neurological problems [2]. The diversity in clinical manifestations and outcomes makes CD
128 challenging to manage and study. In addition, the clinical course of CD is highly variable, and not
129 all individuals infected with *T. cruzi* will develop the same severe symptoms or complications.
130 Some differences in the severity of the disease are due to the genetic variability of the *T. cruzi*
131 strain, the geographical distribution, and the genetic variability of the host; however, other

132 considerations, including the altitude, ethnicity, drug use, and diet, have been associated with the
133 severity of CD. Experimental models showed that mice acutely infected with high parasitemia
134 developed a most severe digestive form of CD, which was associated with a *T. cruzi*-induced
135 intestinal inflammatory response [23–26]. Recently, chronically infected mice showed significant
136 gut tropism with the GI tract as the primary site of *T. cruzi* persistence, possibly contributing to
137 chronic inflammation. In addition, heart disease severity was higher when the infection was
138 disseminated and not restricted to the GI [24,27,28]. However, the mechanisms by which *T. cruzi*
139 infection leads to GI pathology remain unclear, as well as the immune responses, tissue damage,
140 and specific alterations to the GI-specific immunity.

141
142 The potential impact of CD on the gut microbiome is still poorly understood. Recent studies have
143 started to uncover the role of gut microbiota in CD, underscoring the need for further research to
144 fully understand how the composition and function of the gut microbiome may influence disease
145 progression and patient outcomes [18,25,26,29,30]. Molina *et al.*, demonstrated that individuals
146 with CD exhibit distinct alterations in their gut microbiota compared to healthy controls [31].
147 Notably, *Parabacteroides* species are consistently enriched among patients with CD. Other
148 bacterial species, such as *Enterococcus hirae* and *Lactobacillus buchneri*, have also been
149 implicated, although their specific roles remain less clear [31]. These microbiota changes could be
150 linked to the intestinal inflammation and denervation caused by *T. cruzi*, potentially contributing
151 to the gastrointestinal symptoms observed in chronic CD [32]. The perturbations in the gut
152 microbiome during *T. cruzi* infection can result from various factors: (1) Direct parasite-mediated
153 modulation (2) Indirect modulation due to the host’s systemic anti-parasitic immune responses
154 [18,25,27,29].

155 The pathogenesis of CD is driven by *T. cruzi* infection and the host immune response, which is
156 initiated when *T. cruzi* triggers pattern recognition receptors (PRRs) such as toll-like receptors
157 (TLRs) and NOD-like receptors. While these receptors detect microbial signals to initiate
158 protective immune responses during infection, they also recognize ligands produced by
159 commensal microbiota, helping to maintain microbial balance and tissue integrity [33]. TLRs play
160 a dual role in both host defense against pathogens like *T. cruzi* and the regulation of gut microbiota,
161 with TLR5 being particularly important for shaping the microbiota during early life [34].
162 Commensal-derived molecules, such as polysaccharide A (PSA), engage the TLR2/TLR1
163 heterodimer and Dectin-1, promoting anti-inflammatory gene expression and regulatory T cell
164 (Treg) differentiation and maintaining immune homeostasis during infection [35]. Early defense
165 against *T. cruzi* involves natural killer (NK) cells and neutrophils, whose activity can be enhanced
166 by gut microbiota via PRR activation. *T. cruzi* evades immune detection by antigenic variation,
167 inducing immune cell apoptosis and modulating cytokine responses, leading to chronic infection
168 [36].

169 The balance between M1 and M2 macrophages is crucial for determining whether *T. cruzi* infection
170 is controlled or leads to chronic disease. M1 macrophages, which produce proinflammatory
171 cytokines and nitric oxide (NO), are essential for fighting infection, while M2 macrophages,
172 characterized by the expression of arginase 1, act as permissive host cells that allow the parasite
173 to persist [37]. This M1/M2 balance is integral to maintaining gut homeostasis, as macrophages
174 and dendritic cells (DCs), both important antigen-presenting cells, help regulate microbial balance
175 following episodes of inflammation or infection [38]. Microbiota-derived antigens prime dendritic

176 cells to activate adaptive immunity, though dysbiosis impairs antigen presentation and weakens
177 immune responses [39]. The gut microbiome further regulates the balance between pro-
178 inflammatory Th1 and anti-inflammatory Th2 responses. Beneficial bacteria, such as *Bacteroides*
179 and *Lactobacillus*, produce short-chain fatty acids (SCFAs) like butyrate, which promote
180 regulatory T cell (Treg) differentiation. Tregs and SCFA-producing bacteria induce interleukin-10
181 (IL-10), which helps control inflammation and prevent tissue damage during *T. cruzi* infection
182 [18].

183 Castaneda *et al.* have revealed notable changes in the gut microbiome of mice acutely infected
184 with *T. cruzi* compared to healthy controls (Naïve). These alterations include shifts in the
185 abundance of specific bacterial taxa, microbial diversity changes, and microbial community
186 structure disruptions [18]. The perturbations in the gut microbiome during *T. cruzi* infection can
187 result from various factors, the parasite-mediated modulations, as a consequence of the parasite
188 itself directly altering the local GI microenvironment and the host's anti-parasitic immune
189 responses, where the host's immune system responds to combat the *T. cruzi* infection, it can release
190 reactive oxygen and nitrogen species which can have a profound impact on the gut microbiome
191 composition [25] (Figure 1). Understanding the modifications induced by *T. cruzi* in the gut
192 microbiome's composition might hold an alternative strategy for controlling the parasite by
193 manipulating the gut microbiome [10].

194
195 Several key proteins in the excretory/secretory (E/S) products of *Trypanosoma cruzi* are involved
196 in host interactions but their effects on the microbiota in Chagas disease remain unexplored.
197 Cruzipain, a cysteine protease, modulates immune responses and aids parasite entry into non-
198 phagocytic cells, promoting survival and replication [40] P21, present in all *T. cruzi* stages, affects
199 phagocytosis signaling [40]. Mucins and trans-sialidases (TS) are crucial for immune evasion and
200 parasite propagation [41]. TSSA is highly antigenic and linked to *T. cruzi* lineages [42].
201 Additionally, phospholipase A influences host cell signaling, while proteins like superoxide
202 dismutase (SOD) help defend against oxidative stress [43]. Despite these molecules' roles in
203 infection, their interactions with the microbiota in Chagas disease are yet to be investigated.

204

205 **3. *Leishmania* modulates gut and skin microbiota**

206 The microbiota plays a pivotal role in influencing the pathogenesis of cutaneous leishmaniasis
207 (CL) and visceral leishmaniasis (VL), caused by *Leishmania* parasites. The effect of *Leishmania*
208 infection on the skin microbiota, particularly in relation to dysbiosis and its implications, is
209 increasingly recognized as a critical factor in the pathology of CL. Research has shown that CL
210 significantly alters the skin microbiota, leading to a dysbiotic state that influences disease
211 progression and inflammation. Infection with *Leishmania braziliensis* and *L. major* results in a
212 skin microbiota characterized by increased *Staphylococcus* and *Streptococcus* species, with this
213 dysbiosis spreading beyond the lesion site to normal skin. In murine models, cutaneous microbiota
214 changes found in mice with CL have been found to be transferred to co-housed naïve mice,
215 indicating a transmissible component. This dysbiosis is associated with enhanced inflammatory
216 responses. In *Leishmania braziliensis* infections, a microbiome dominated by *Staphylococcus spp.*
217 is associated with delayed healing and heightened IL-1 cytokine responses, suggesting that altered
218 skin microbiota modulates immune responses and worsens clinical outcomes. Specifically,
219 *Leishmania* infection increases the abundance of bacterial families like *Staphylococcaceae* and

220 *Streptococcaceae* in cutaneous lesions, contributing to local inflammation [44][45]. Additionally,
221 the generation of dysbiotic microbiota in CL is shown to enhance skin inflammation, underscoring
222 the role of microbial imbalance in worsening disease pathology [46]. These studies demonstrate
223 that *Leishmania* infection induces significant modifications in the skin microbiota, contributing to
224 inflammation and potentially influencing the progression and severity of cutaneous leishmaniasis.

225 Research has increasingly highlighted the relationship between the microbiome and disease
226 severity in leishmaniasis. Studies show that *Leishmania* infection alters the gut microbiota,
227 particularly in the ileum, while the colon microbiota remains more stable [47]. In cutaneous
228 leishmaniasis, lesions exhibit a less diverse microbiome compared to unaffected skin, with larger
229 wounds and those harboring high parasite loads showing greater abundances of potentially
230 pathogenic organisms, such as *Staphylococcus aureus*, which delays healing by promoting
231 inflammatory responses, including elevated IL-1 β markers [22,48]. In visceral leishmaniasis,
232 microbiome disturbances have been linked to histoarchitectural changes in the colon and
233 alterations in the enteric nervous system [49]. Additionally, symptomatic leishmaniasis cases,
234 particularly in dogs, show a shift in microbiome composition, with an overrepresentation of
235 Proteobacteria and reduced Firmicutes, correlating with weakened immune responses [50]. These
236 findings suggest that microbiome alterations may influence the immune response, contributing to
237 disease progression and severity in leishmaniasis [46,51].

238 Our recent study further underscores the importance of microbial balance in CL pathogenesis [44].
239 We explored the spatial-temporal distribution of *Leishmania* species and the influence of skin
240 microbiota on disease progression. We observed significant alterations in both prokaryotic and
241 eukaryotic communities within the lesions. Notably, there was an increase in bacterial families
242 such as *Staphylococcaceae* and *Streptococcaceae*, suggesting their role in local inflammation.
243 Additionally, *L. naiffi* emerged as a significant discovery in regions with high CL incidence. These
244 findings highlight the potential contribution of microbial dysbiosis, including fungal components,
245 to the pathogenesis of CL and the need for understanding the *Leishmania* species in skin dysbiosis
246 (Table 1) [44].

247 Research into the impact of VL on gut microbiota highlights several significant findings
248 [49,52,53]. VL, caused by *Leishmania infantum/donovani* parasites, affects the gut microbiota
249 composition, which is crucial for systemic immune responses necessary to control the infection
250 [13,22]. Studies have shown that *L. infantum* infection in hamsters leads to changes in the gut
251 microbiota, particularly affecting the ileum while the colon remains unchanged. Infected hamsters
252 displayed histoarchitectural changes in the colon, with increased intraepithelial lymphocytes and
253 alterations in the enteric nervous system, suggesting a link between gut microbiota and immune
254 modulation [49,52]. Additionally, canine studies have shown significant differences in gut
255 microbiota composition among infected dogs, particularly in the Firmicutes and Proteobacteria
256 phyla, suggesting that microbiota composition could influence immune responses and disease
257 outcomes [47,50]. These findings underscore the complex interactions between gut microbiota and
258 VL, highlighting the potential for microbiota-targeted interventions to modulate immune
259 responses and improve disease outcomes.

260 The identification of microbiota-derived biomarkers presents a promising approach for early
261 diagnosis and monitoring of leishmaniasis, with specific shifts in the host microbiota composition

262 in response to *Leishmania* infection serving as potential early indicators of the disease, even before
263 clinical symptoms appear. For VL, changes in gut microbial populations, such as a decrease in
264 Firmicutes and an increase in Bacteroidetes, have been associated with disease onset, while
265 microbial metabolites like SCFAs or specific microbial DNA signatures in blood or stool could
266 act as non-invasive biomarkers for monitoring progression or therapeutic response. In the context
267 of CL, alterations in skin microbiota, such as increases in bacterial families like *Staphylococcaceae*
268 and *Streptococcaceae* within lesions, highlight the potential role of skin microbes in disease
269 progression and their utility as biomarkers. Given the diverse species of *Leishmania* infecting
270 humans, future studies should systematically investigate the effects of different *Leishmania*
271 species on skin microbiota in CL and gut microbiota in VL to better understand the interplay
272 between microbial communities and disease pathogenesis. Moreover, microbiota-targeted
273 therapies, including probiotics, prebiotics, and fecal microbiota transplants (FMT), offer
274 innovative strategies to enhance the treatment of both CL and VL by improving drug efficacy,
275 reducing side effects, and potentially overcoming drug resistance.

276 There is limited information regarding how *Leishmania* excretory/secretory (E/S) products
277 specifically interact with the microbiota, but potential mechanisms can be inferred. *Leishmania*
278 E/S products likely modulate host immune responses, indirectly influencing microbiota
279 composition by altering the immune environment [54]. These products may interact with
280 antimicrobial peptides (AMPs), which are produced in response to infections and could affect
281 microbial balance [55]. Additionally, *Leishmania* E/S products may compete with bacteria for
282 nutrients or binding sites in the gut, shaping the microbiota indirectly [56]. Although not well-
283 characterized, *Leishmania* E/S products could also alter the gut environment or metabolic
284 pathways, further influencing microbiota dynamics [57]. However, detailed investigations into
285 these interactions are still lacking.

286 **4. Current Knowledge on the Interaction between *Ascaris* and the Intestinal Microbiota**

287 The interaction between *Ascaris* and the intestinal microbiota is a burgeoning area of research with
288 potential for novel therapeutic interventions. Understanding these interactions can elucidate key
289 aspects of the biology and pathophysiology of these parasites that could be potentially useful in
290 therapeutic and prophylactic control strategies [58–60]. Most studies to date have focused on the
291 interactions between *Ascaris* and the host immune system due to the parasite's significant
292 immunomodulatory and immunoregulatory capacities, which enable it to infect, disseminate, and
293 persist within the host [61–65].

294 It has been observed that *Ascaris* infection can alter the composition and diversity of the gut
295 microbiota. Adult worms in the intestines cause a decrease in essential anaerobic bacteria such as
296 *Faecalibacterium* and *Ruminococcus*, while increasing facultative anaerobes like *Streptococcus*.
297 This, combined with the immunomodulation generated by the helminth, creates a favorable
298 metabolic environment for the parasite's long-term survival in the intestines [14,20,66–73].
299 Additionally, a relevant aspect of *Ascaris* infection is that its larvae (L3), after hatching, can invade
300 the mucosal tissue of the gastrointestinal tract and subsequently migrate to hepatic and pulmonary
301 tissues [74]. The migration of these larval stages has been linked to mechanisms that alter the
302 composition and structure of the intestinal microbiota, promoting the translocation of bacteria
303 across intestinal barriers and affecting the liver and lung mucosa [75,76].

304 The mechanisms by which *Ascaris* influences the gut microbiota are not yet fully understood
305 (Figure 2). However, it is hypothesized that the parasite's metabolic activities, secretions, and the
306 physical presence of its larvae and adults create an environment conducive to the growth of specific
307 microbial populations [64,77]. Additionally, the host's immune response to *Ascaris*, including
308 inflammation and cytokine production, may also contribute to modulating the microbiota
309 composition [75,76,78–80]. Research has shown that *Ascaris* excretory-secretory (E/S) products,
310 such as extracellular vesicles and other metabolites, may elicit an immunomodulatory response,
311 indirectly affecting the host's intestinal microbiota [65]. Various E/S products have been identified,
312 interacting in different ways with the host microbiota and potentially playing critical roles in
313 parasite biology and the infection's pathophysiology [65]. Studies have confirmed that *Ascaris*
314 *suum* can induce the production of antimicrobial peptides, such as the *Ascaris suum* antibacterial
315 factor (ASABF) and cecropin family peptides (P1 to P4), in the host [75,81–83]. These peptides
316 exhibit bactericidal effects against a broad range of microbes, including gram-positive bacteria
317 (*Staphylococcus aureus*, *Bacillus subtilis*, and *Micrococcus luteus*) and gram-negative bacteria
318 (*Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Serratia marcescens*, and *Escherichia coli*)
319 [75,81–83]. This highlights the roundworm's ability to produce nematode-derived metabolites that
320 significantly modulate the host's intestinal microbiota. This area of research is increasingly gaining
321 prominence and is becoming a key focus in the study of helminth biology.

322 To fully comprehend the interplay between *Ascaris* and the intestinal microbiota, it is essential to
323 investigate how each influences the other. Very little is known about the establishment, structure,
324 and function of the microbiota residing within the parasite. Therefore, it is a priority to evaluate
325 these characteristics to better decipher the interactions between the parasite and the host microbiota
326 [76,84,85]. Investigating the microbiota associated with *Ascaris* is crucial, as it helps define stage-
327 specific transient microbiota and their interactions with the host. This research uncovers
328 mutualistic relationships between specific bacterial groups and the parasite that are essential for
329 its biology, infectivity, and dissemination [76,84,85]. Studies employing advanced metagenomic
330 and metabolomic techniques in animal models can provide insights into the microbial changes
331 induced by *Ascaris* and the functional consequences of these alterations.

332 One promising avenue for controlling *Ascaris* infections is the development of probiotics or
333 prebiotics designed to modulate the gut microbiota in favor of the host. Probiotics, which are live
334 beneficial bacteria, or prebiotics, which are non-digestible fibers that promote the growth of
335 beneficial microbes, could be tailored to restore microbial balance disrupted by *Ascaris* infection
336 [86–88]. For instance, identifying and testing probiotic strains that enhance gut barrier function or
337 stimulate anti-helminthic immune responses could be beneficial. Clinical trials assessing the
338 efficacy of specific probiotic or prebiotic formulations in reducing *Ascaris* burden and improving
339 host health outcomes would be essential for translating these findings into practical interventions.
340 Another innovative strategy involves manipulating the gut microbiota to create an environment
341 hostile to *Ascaris* colonization and survival, potentially through dietary interventions or
342 microbiota-modulating drugs. Exploring dietary interventions rich in fibers and polyphenols,
343 which support beneficial gut bacteria, could offer protective effects against *Ascaris*. Additionally,
344 identifying and targeting microbial taxa and pathways essential for *Ascaris* survival with specific
345 drugs could provide a novel therapeutic approach [86,89]. Understanding the complex and
346 bidirectional interactions between *Ascaris* and the intestinal microbiota has significant
347 implications for infection outcomes and host health. Advancing our understanding of these

348 interactions, developing microbiota-based interventions, and exploring innovative strategies for
349 microbiota manipulation could pave the way for novel and effective approaches to controlling
350 *Ascaris* infections and enhance our broader understanding of host-parasite-microbiota interactions.

351
352 Understanding how changes in the gut microbiota impact *Ascaris* infection outcomes and host
353 immune responses is crucial for developing targeted interventions [83]. Research should aim to
354 identify key microbial taxa or metabolites that modulate the host's immune response to *Ascaris*.
355 For instance, certain bacterial species may produce metabolites that enhance anti-helminthic
356 immunity or, conversely, promote immunosuppression, aiding parasite survival [75,76,79,83,90].
357 Experimental models, such as gnotobiotic animals with controlled microbiota compositions, can
358 be employed to dissect these complex interactions and identify potential microbial biomarkers of
359 infection susceptibility or resistance.

360

361 **5. Common Themes and Future Directions**

362

363 The alterations caused by these parasites may significantly influence the host's immune response,
364 disease progression, and treatment outcomes [18,44,75]. Despite these shared characteristics, the
365 mechanisms by which each parasite interacts with the microbiota can vary considerably. For
366 instance, *T. cruzi*, the causative agent of CD, may indirectly alter the gut microbiota through
367 systemic immune modulation. In contrast, *Leishmania* species, responsible for leishmaniasis, may
368 directly interact with gut microbes due to their close association with macrophages and dendritic
369 cells. *Ascaris*, being a gastrointestinal helminth, directly impacts the gut microbiota through
370 physical interactions and metabolic products [18,44,75].

371 Common mechanisms across these infections include the disruption of gut barrier integrity,
372 immune modulation, and metabolic alterations. Unique features involve specific immune
373 pathways activated, such as the Th1/Th2 response balance in helminth infections versus
374 inflammatory responses in protozoan infections. Additionally, the route of entry and localization
375 of the parasites influence their interactions with the gut microbiota—intestinal for *Ascaris*,
376 cutaneous and visceral for *Leishmania*, and systemic for *T. cruzi* [18,44,75].

377 Future research should leverage multi-omics approaches, including genomics, transcriptomics,
378 proteomics, and metabolomics, to comprehensively map the interaction networks between
379 parasites and the microbiota. This integrative approach can uncover crucial molecular pathways
380 and biomarkers essential for understanding parasite-host-microbiota dynamics [18,75,84,91].
381 Longitudinal studies both in humans and in animal models which favored standardization of
382 processes allowing adequate control of most of the variables involved in microbiota analysis, are
383 vital for capturing the temporal dynamics of parasite-microbiota interactions, revealing how
384 microbiota changes throughout infection, during treatment, and post-clearance, thus providing
385 insights into optimal stages for microbiota modulation [75,92,93]. Additionally, research should
386 focus on the microbiota's role in modulating host resistance to infections and vaccine efficacy, as
387 understanding how different microbiota compositions influence immune responses can lead to
388 improved vaccine formulations and strategies [18,94]. Personalized medicine approaches, which
389 tailor microbiota-based therapies to individual microbiome profiles, offer promising potential for
390 more effective treatments. Customizing probiotics, prebiotics, and microbiota transplants to
391 enhance host resilience against specific parasites could improve infection outcomes and reduce
392 disease burden [86,95,96]. Comparative analyses of parasite-microbiota interactions across

393 diseases such as Chagas disease, leishmaniasis, and *Ascaris* infections highlight the complexity
394 and specificity of these relationships. Future research should focus on multi-omics, longitudinal
395 studies, vaccine interactions, and personalized therapies to develop innovative interventions and
396 enhance control and treatment of parasitic diseases (Figure 3).

397

398 **6. Therapeutic Implications and Innovation**

399 Current treatments for *T. cruzi*, *Leishmania*, and *Ascaris* infections vary significantly but have
400 common challenges, including side effects and limited efficacy in chronic or severe cases. For *T.*
401 *cruzi* (Chagas disease), benznidazole and nifurtimox are the primary drugs used. These are most
402 effective in the acute phase but less so in chronic infections [97]. Common side effects include
403 skin reactions, gastrointestinal disturbances, and potential neurological toxicity, which often
404 limits their use in some patients. *Leishmania* infections (leishmaniasis) are treated with
405 pentavalent antimonials (e.g., sodium stibogluconate), amphotericin B, and miltefosine [98]. Side
406 effects vary by treatment but can include pancreatitis, nephrotoxicity, hepatotoxicity, and
407 gastrointestinal issues, making long-term or high-dose treatments difficult for patients. For
408 *Ascaris* infections (ascariasis), treatment typically involves albendazole or mebendazole. These
409 drugs are generally well-tolerated, but side effects can include mild gastrointestinal discomfort,
410 dizziness, and, in rare cases, liver function alterations [99]. Each of these treatments, while
411 essential, presents challenges in terms of efficacy and tolerability, highlighting the need for safer
412 and more effective therapeutic options.

413 Understanding the components of the microbiota and their mechanisms of action in inducing
414 pathological changes or exerting beneficial effects, along with disease-protective activities, is
415 crucial for influencing microbiota composition [100]. The microbiota plays a critical role in
416 training and modulating the immune system [8]. Higher microbial diversity can prevent the
417 colonization of pathogenic organisms, limiting their ability to establish and proliferate through
418 competitive exclusion and the production of antimicrobial substances [101]. Additionally, a
419 diverse microbiota helps maintain immune homeostasis, reducing inappropriate inflammatory
420 responses and improving the body's ability to respond to infections [8], enhancing and promoting
421 the development of regulatory T cells and the production of anti-inflammatory cytokines.
422 Microbiota-target interventions such as prebiotics, probiotics, symbiotics, antibiotic gut depletion,
423 and fecal transplants can delay the onset and progression of parasitic diseases.

424
425 The development of probiotics, prebiotics, and synbiotics specifically targeted at parasitic
426 infections holds significant promise [102,103]. By understanding the intricate interactions between
427 gut microbiota and parasites, tailored probiotic strains can be engineered to enhance the
428 microbiota's ability to outcompete or inhibit parasites. Prebiotics can be designed to selectively
429 stimulate beneficial microbial populations that could suppress parasitic growth or enhance host
430 immune responses [104]. Synbiotics, combining both probiotics and prebiotics, could
431 synergistically modulate the microbiota to achieve therapeutic outcomes. These interventions have
432 the potential to offer adjunctive treatments that complement existing antiparasitic therapies,
433 potentially improving efficacy and reducing side effects [86].

434
435 Integrating microbiota-modulating drugs with conventional antiparasitic treatments is a promising
436 avenue for enhancing therapeutic efficacy [103,105]. Drugs that specifically target and modify the

437 microbiota could improve drug absorption, metabolism, and activity of antiparasitic agents. For
438 example, microbiota-modulating drugs could enhance the bioavailability of antiparasitics or
439 reduce drug resistance by altering microbial composition. The idea that drugs targeting and
440 modifying the microbiota could improve drug absorption, metabolism, and activity of antiparasitic
441 agents is supported by several studies, which highlight the role of the gut microbiota in drug
442 metabolism and its potential to influence drug efficacy and resistance [106]. The gut microbiota
443 can significantly impact the pharmacokinetics of drugs, including their absorption, distribution,
444 metabolism, and excretion (ADME), potentially altering therapeutic effects and toxicity. This
445 suggests that modulating the microbiota could enhance drug bioavailability and reduce resistance.
446 The microbiome's enzymatic transformation of drugs affects their bioavailability, bioactivity, and
447 toxicity, and understanding these interactions could lead to strategies for modulating the
448 microbiome to improve drug efficacy [107]. Thus, the gut microbiota is considered a key metabolic
449 organ that can affect drug efficacy by altering drug bioavailability and bioactivity, opening up
450 possibilities for regulating gut microbes to enhance therapeutic effects and clinical outcomes [108].
451 Understanding the microbiota's role in drug metabolism and parasite-host interactions could lead
452 to innovative therapies that optimize treatment regimens and outcomes.

453
454 The interplay between microbiota and immune responses is crucial for vaccine development and
455 immunotherapy. By leveraging insights into how microbiota influence immune system priming
456 and pathogen interactions, researchers can design vaccines that harness these microbial effects to
457 enhance immunity against parasitic infections. The gut microbiota plays a significant role in
458 modulating immune responses to vaccines, acting as a natural adjuvant and potentially enhancing
459 vaccine efficacy by influencing both mucosal and systemic immune responses [109,110]. For
460 instance, oral vaccines using genetically modified bacteria have demonstrated improved immune
461 responses, indicating that microbiota-targeted interventions could boost vaccine effectiveness
462 against parasitic infections [111,112]. Additionally, the microbiota influences vaccine-induced
463 immune responses by shaping B cell and T cell repertoires essential for effective antigen-specific
464 responses, which can be leveraged to design vaccines that harness microbial effects to enhance
465 immunity against parasitic diseases [112]. Strategies like prebiotics, probiotics, and synbiotics are
466 being explored to modulate the microbiota and improve vaccine immunogenicity, providing a
467 novel approach to enhance disease prevention and treatment when used alongside immunotherapy
468 [110,111]. Integrating microbiota knowledge into vaccine and immunotherapy development could
469 thus significantly enhance the effectiveness of treatments for parasitic diseases.

470
471 The concept of fecal microbiota transplantation (FMT) as a potential treatment for parasitic
472 infections is an emerging area of research. Although FMT is primarily utilized for treating
473 recurrent *Clostridioides difficile* infections, there is growing interest in its application for parasitic
474 diseases [113]. FMT has been proposed as a potential treatment for intestinal parasite infections,
475 such as giardiasis and worm infections, with the idea that restoring a healthy microbial community
476 could disrupt parasite life cycles or enhance the host's natural defenses against these infections
477 [114]. While research into FMT's efficacy for other conditions, including parasitic diseases, is
478 ongoing, the potential for FMT to address chronic or drug-resistant parasitic infections is being
479 explored, though more scientific evidence is needed to establish its safety and effectiveness [115].
480 This evidence highlights the potential of FMT as an innovative approach to treating parasitic
481 infections by modulating the gut microbiota, although further research is necessary to fully
482 understand its therapeutic capabilities and limitations in this context.

483
484 The therapeutic options discussed here are largely speculative. While exploring novel treatments
485 is essential, a clear connection to these particular pathogens is necessary for advancing therapeutic
486 development. Current therapies, although effective in some cases, face significant challenges
487 related to toxicity, limited efficacy in chronic infections, and the emergence of drug resistance,
488 underscoring the need for more targeted and evidence-based interventions tailored to each disease.
489 Continued efforts are needed to study and develop new therapeutic interventions for these diseases.

490 491 **7. Conclusions**

492
493 The study of parasite-microbiota interactions holds significant promise for advancing therapeutic
494 strategies against parasitic diseases. Our findings underscore the crucial role that microbiota play
495 in modulating parasite infections and influencing treatment efficacy. Future research should
496 prioritize the development of tailored probiotics, prebiotics, and synbiotics specifically designed
497 to target parasitic infections, as well as explore microbiota-modulating drugs that can enhance
498 conventional therapies. Additionally, fecal microbiota transplantation presents a novel therapeutic
499 option worth investigating.

500
501 To fully realize these potential advancements, a concerted effort is needed from the scientific
502 community and funding agencies. By adopting a multidisciplinary approach that integrates
503 microbiology, immunology, and therapeutic development, we can uncover new therapeutic
504 avenues and significantly improve disease management. Investing in this research will not only
505 advance our understanding but also lead to more effective and sustainable strategies for combating
506 parasitic diseases.

507 508 **Future perspective**

509
510 The future of parasitic disease management may well hinge on a deeper understanding of the
511 intricate relationships between parasites and the microbiota. The exploration of these interactions
512 could lead to the development of innovative therapies, such as targeted probiotics, prebiotics, and
513 synbiotics, designed specifically to combat parasitic infections. Additionally, the potential of
514 microbiota-modulating drugs and fecal microbiota transplantation as therapeutic tools should not
515 be underestimated. Moving forward, a collaborative, multidisciplinary approach that brings
516 together microbiology, immunology, and therapeutic development will be crucial. Such an
517 approach will not only deepen our comprehension of these complex biological systems but also
518 pave the way for more effective and sustainable interventions, ultimately transforming the
519 landscape of parasitic disease treatment.

520 521 **Acknowledgements**

522
523 We thank the Vicerectoria de investigaciones from Universidad del Rosario in Bogota, Colombia
524 for funding our research program.

525 526 **Author contributions**

527

528 JDR and CP conceived the idea, JDR, CP, SC, JW wrote the manuscript. All authors approved the
529 final version of the manuscript.

530

531 **Disclosures**

532

533 None

534

535 **Figures/Tables**

536

537 **Figure 1. A schematic overview of the proposed interplay mechanism between gut**
538 **microbiome, host immunity, and *T. cruzi*.** The microbiota resides in the lumen and outer mucus
539 layer of the intestine. A. Naïve B. *T.cruzi* Infection Acute phase: Parasite infection disrupts gut
540 microbiota. Dysregulated microbiota signals are transmitted via DCs and macrophages, promoting
541 inflammatory T-cell subsets (Th1, Th2, Th17) and B-cell activation, yielding protective IgA to
542 restore microbial balance. C. Early chronic phase: *T. cruzi* infects the intestinal epithelium,
543 controlled by a balanced Th1/Th2/Th17 response. Parasite-driven mechanisms affect B cell-
544 mediated responses. D. Late chronic phase: Parasites disseminate, causing dysbiosis with Th1 and
545 Th17 reduction and Th2 increase. Elevated inflammatory cytokines (IFN- γ , TNF α) result from *T.*
546 *cruzi* actions on DC functionality, impacting adaptive immune responses.

547 **Figure 2. Interaction between *Ascaris* and the host intestinal microbiota.** After ingestion of
548 the infective stage of *Ascaris*, L3 larvae are released from embryonated eggs into the host intestine
549 and begin their life cycle. During migration, the interplay between *Ascaris* and the intestinal
550 microbiota is essential to understand not only changes in the host but also the microbiota residing
551 within the parasite. These interactions involve mutualistic relationships between specific bacterial
552 groups and the parasite that are crucial for its biology, infectivity, and dissemination.

553 **Figure 3. Future Directions.** Future research from longitudinal studies in animal models and
554 natural hosts must implement multi-omics approaches, including genomics, transcriptomics,
555 proteomics, and metabolomics. To better understand parasite-host-microbiome interactions, it is
556 essential to use metabarcoding and metagenomics analyses. These approaches can identify
557 metabolic pathways and differentially abundant taxa that may be relevant to parasite infection and
558 persistence. Understanding these functional features and parasite-host-microbiome interactions
559 will facilitate the design of studies aimed at elucidating the role of the microbiota in modulating
560 host resistance to infections and the efficacy of vaccines. Personalized medicine approaches using
561 microbiota-based therapies tailored to individual microbiome profiles hold promise for more
562 effective treatments.

563 **Table 1.** Cutaneous Leishmaniasis and microbiota correlation consensus. Showing different
564 studies and their different findings relating CL disease with prokaryote microbiota associations.

565 **Reference annotations**

566 ***Hossain E, Khanam S, Dean DA, et al. Mapping of host-parasite-microbiome interactions**
567 **reveals metabolic determinants of tropism and tolerance in Chagas disease. Sci Adv**
568 **[Internet]. 2020 [cited 2021 Jun 15];6(30):eaaz2015.**

569 *This study highlights the changes in parasite burden and microbiota across different sections of the*
570 *gastrointestinal (GI) tract in mice, providing important insights into the interactions between*
571 *Trypanosoma cruzi and the gut microbiota. By examining these dynamics, the research sheds light*
572 *on how T. cruzi influences and is influenced by the gut microbial communities, potentially affecting*
573 *disease progression and immune responses. This information could be valuable for developing*
574 *microbiota-targeted therapies to improve the management and treatment of Chagas disease.*

575 ***Castañeda S, Muñoz M, Hotez PJ, et al. Microbiome Alterations Driven by Trypanosoma**
576 **cruzi Infection in Two Disjunctive Murine Models . Microbiol Spectr [Internet]. 2023 [cited**
577 **2024 Aug 9];11(3).**

578 *This study is the first to employ metagenomics to analyze the acute phase of Chagas disease,*
579 *revealing how specific metabolic pathways contribute to microbiota dysbiosis and exacerbate*
580 *disease severity.*

581 ***Jaimes J, Patiño LH, Herrera G, et al. Prokaryotic and eukaryotic skin microbiota**
582 **modifications triggered by Leishmania infection in localized Cutaneous**
583 **Leishmaniasis. PLoS Negl Trop Dis [Internet]. 2024 [cited 2024 Aug 9];18(3):1–25.**

584

585 *This study utilizes next-generation sequencing to evaluate the impact of Leishmania parasite*
586 *diversity on the skin microbiota, providing insights into how variations in the parasite*
587 *may influence microbial communities and affect disease outcomes.*

588 ***Amorim CF, Lovins VM, Singh TP, et al. Multiomic profiling of cutaneous leishmaniasis**
589 **infections reveals microbiota-driven mechanisms underlying disease severity. Sci Transl**
590 **Med [Internet]. 2023 [cited 2024 Aug 9];15(718).**

591 *This study employs a state-of-the-art multiomics approach to unravel the complex interactions*
592 *between Leishmania and the host microbiota in cutaneous leishmaniasis. By integrating*
593 *metagenomics, transcriptomics, and metabolomics, the research provides a comprehensive view of*
594 *how microbial communities influence disease progression, immune responses, and tissue damage.*
595 *This advanced methodology not only deepens our understanding of the host-microbiota-parasite*
596 *interplay but also paves the way for novel microbiota-targeted therapeutic strategies to mitigate*
597 *disease severity and improve treatment outcomes.*

598 **References**

599 [1] Hotez PJ, Brindley PJ, Bethony JM, et al. Helminth infections: The great neglected
600 tropical diseases. J. Clin. Invest. 2008. p. 1311–1321.

601 [2] Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet [Internet]. 2010 [cited 2024
602 Aug 9];375(9723):1388–1402.

603 [3] Alvar J, Vélez ID, Bern C, et al. Leishmaniasis Worldwide and Global Estimates of Its
604 Incidence. PLoS One [Internet]. 2012 [cited 2024 Aug 9];7(5):e35671.

605 [4] Pérez-Molina JA, Molina I. Chagas disease. Lancet (London, England) [Internet]. 2018
606 [cited 2024 Aug 9];391(10115):82–94.

- 607 [5] Bern C. Chagas' Disease. Longo DL, editor. *N Engl J Med* [Internet]. 2015 [cited 2024
608 Aug 9];373(5):456–466.
- 609 [6] Ready PD. Epidemiology of visceral leishmaniasis. *Clin Epidemiol* [Internet]. 2014 [cited
610 2024 Aug 9];6(1):147–154.
- 611 [7] Bethony J, Brooker S, Albonico M, et al. Soil-transmitted helminth infections: ascariasis,
612 trichuriasis, and hookworm. *Lancet (London, England)* [Internet]. 2006 [cited 2024 Aug
613 9];367(9521):1521–1532.
- 614 [8] Belkaid Y, Hand TW. Role of the Microbiota in Immunity and inflammation. *Cell*
615 [Internet]. 2014 [cited 2024 Aug 9];157(1):121.
- 616 [9] Kamada N, Seo SU, Chen GY, et al. Role of the gut microbiota in immunity and
617 inflammatory disease. *Nat Rev Immunol* [Internet]. 2013 [cited 2022 Mar 14];13(5):321–
618 335.
- 619 [10] de Souza-Basqueira M, Ribeiro RM, de Oliveira LC, et al. Gut Dysbiosis in Chagas
620 Disease. A Possible Link to the Pathogenesis. *Front Cell Infect Microbiol* [Internet]. 2020
621 [cited 2021 May 6];10:402.
- 622 [11] IMSN T, N D, L H-B, et al. Intestinal microbiota – A modulator of the *Trypanosoma*
623 *cruzi*-vector-host triad. *Microb Pathog* [Internet]. 2019 [cited 2021 Mar
624 22];137(July):103711.
- 625 [12] Lappan R, Classon C, Kumar S, et al. Meta-taxonomic analysis of prokaryotic and
626 eukaryotic gut flora in stool samples from visceral leishmaniasis cases and endemic
627 controls in Bihar State India. *PLoS Negl Trop Dis*. 2019;13(9):e0007444.
- 628 [13] Gallo-Francisco PH, Brocchi M, Giorgio S. *Leishmania* and its relationships with bacteria.
629 <https://doi.org/102217/fmb-2021-0133> [Internet]. 2022 [cited 2022 Jan 26];17(3):199–
630 218.
- 631 [14] Cooper P, Walker AW, Reyes J, et al. Patent Human Infections with the Whipworm,
632 *Trichuris trichiura*, Are Not Associated with Alterations in the Faecal Microbiota. *PLoS*
633 *One* [Internet]. 2013 [cited 2022 May 16];8(10):e76573.
- 634 [15] Giacomini P, Croese J, Krause L, et al. Suppression of inflammation by helminths: A role
635 for the gut microbiota? *Philos Trans R Soc B Biol Sci*. 2015;370(1675).
- 636 [16] Gorvitovskaia A, Holmes SP, Huse SM. Interpreting *Prevotella* and *Bacteroides* as
637 biomarkers of diet and lifestyle. *Microbiome* [Internet]. 2016 [cited 2024 Aug 9];4.
- 638 [17] Wang C, Zhao J, Zhang H, et al. Roles of intestinal bacteroides in human health and
639 diseases. <https://doi.org/101080/1040839820201802695> [Internet]. 2020 [cited 2022 Jul
640 18];61(21):3518–3536.
- 641 [18] Castañeda S, Muñoz M, Hotez PJ, et al. Microbiome Alterations Driven by *Trypanosoma*
642 *cruzi* Infection in Two Disjunctive Murine Models . *Microbiol Spectr* [Internet]. 2023
643 [cited 2024 Aug 9];11(3).
- 644 [19] Springer A, Wagner L, Koehler S, et al. Modulation of the porcine intestinal microbiota in
645 the course of *Ascaris suum* infection. *Parasites and Vectors* [Internet]. 2022 [cited 2023
646 May 27];15(1):1–21.
- 647 [20] Wang Y, Liu F, Urban JF, et al. *Ascaris suum* infection was associated with a worm-

- 648 independent reduction in microbial diversity and altered metabolic potential in the porcine
649 gut microbiome. *Int J Parasitol* [Internet]. 2019 [cited 2021 Mar 23];49(3–4):247–256.
- 650 [21] Ereqat S, Al-Jawabreh A, Abdeen Z, et al. Characterization of Leishmania Ulcers
651 Microbiota Using Next Generation Sequencing. *Al-Quds J Nat Sci* [Internet]. 2021 [cited
652 2024 Aug 9];1(1):1–1.
- 653 [22] Jayasena Kaluarachchi TD, Campbell PM, Wickremasinghe RR, et al. Distinct
654 microbiome profiles and biofilms in Leishmania donovani-driven cutaneous leishmaniasis
655 wounds. *Sci Reports* 2021 111 [Internet]. 2021 [cited 2024 Aug 9];11(1):1–14.
- 656 [23] Vazquez BP, Vazquez TP, Miguel CB, et al. Inflammatory responses and intestinal injury
657 development during acute Trypanosoma cruzi infection are associated with the parasite
658 load. *Parasites and Vectors* [Internet]. 2015 [cited 2024 Aug 9];8(1):1–12.
- 659 [24] Khan AA, Langston HC, Costa FC, et al. Local association of Trypanosoma cruzi chronic
660 infection foci and enteric neuropathic lesions at the tissue micro-domain scale. *PLOS*
661 *Pathog* [Internet]. 2021 [cited 2022 Mar 14];17(8):e1009864.
- 662 [25] McCall L-II, Tripathi A, Vargas F, et al. Experimental Chagas disease-induced
663 perturbations of the fecal microbiome and metabolome. *PLoS Negl Trop Dis* [Internet].
664 2018 [cited 2021 May 6];12(3):1–15.
- 665 [26] C R, DP M, A H, et al. The fecal, oral, and skin microbiota of children with Chagas
666 disease treated with benznidazole. *PLoS One* [Internet]. 2019 [cited 2021 Oct 20];14(2).
- 667 [27] Lewis MD, Francisco AF, Taylor MC, et al. Host and parasite genetics shape a link
668 between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy. *Cell*
669 *Microbiol* [Internet]. 2016 [cited 2024 Aug 13];18(10):1429.
- 670 [28] Poveda C, Bottazzi ME, Jones KM. Mining the Metabolome for New and Innovative
671 Chagas Disease Treatments. *Trends Pharmacol Sci* [Internet]. 2021 [cited 2021 Oct
672 20];42(1):1–3.
- 673 [29] de Souza-Basqueira M, Ribeiro RM, de Oliveira LC, et al. Gut Dysbiosis in Chagas
674 Disease. A Possible Link to the Pathogenesis. *Front Cell Infect Microbiol*. 2020;10.
- 675 [30] Hossain E, Khanam S, Dean DA, et al. Mapping of host-parasite-microbiome interactions
676 reveals metabolic determinants of tropism and tolerance in Chagas disease. *Sci Adv*
677 [Internet]. 2020 [cited 2021 Jun 15];6(30):eaaz2015.
- 678 [31] Pérez-Molinar JA, Crespillo-Andujar C, Trigo E, et al. Chagas disease is related to
679 structural changes of the gut microbiota in adults with chronic infection (TRIPOBIOME
680 Study). *PLoS Negl Trop Dis* [Internet]. 2023 [cited 2024 Aug 9];17(7).
- 681 [32] Beatty NL, Forsyth CJ, Burkett-Cadena N, et al. Our Current Understanding of Chagas
682 Disease and Trypanosoma cruzi Infection in the State of Florida — an Update on
683 Research in this Region of the USA. *Curr Trop Med Reports* [Internet]. 2022 [cited 2024
684 Aug 9];9(4):150–159.
- 685 [33] Chu H, Mazmanian SK. Innate immune recognition of the microbiota promotes host-
686 microbial symbiosis. *Nat Immunol* [Internet]. 2013 [cited 2024 Oct 22];14(7):668–675.
- 687 [34] Carvalho FA, Koren O, Goodrich JK, et al. Transient inability to manage proteobacteria
688 promotes chronic gut inflammation in TLR5-deficient mice. *Cell Host Microbe* [Internet].

- 689 2012 [cited 2024 Oct 22];12(2):139–152.
- 690 [35] Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health
691 and disease. *Cell Res* 2020 306 [Internet]. 2020 [cited 2024 Oct 22];30(6):492–506.
- 692 [36] Pérez-Mazliah D, Ward AI, Lewis MD. Host-parasite dynamics in Chagas disease from
693 systemic to hyper-local scales. 2021 [cited 2024 Aug 9];43(2):e12786.
- 694 [37] Vellozo NS, Matos-Silva TC, Lopes MF. Immunopathogenesis in *Trypanosoma cruzi*
695 infection: a role for suppressed macrophages and apoptotic cells. *Front Immunol*.
696 2023;14:1244071.
- 697 [38] Meng EX, Verne GN, Zhou Q. Macrophages and Gut Barrier Function: Guardians of
698 Gastrointestinal Health in Post-Inflammatory and Post-Infection Responses. *Int J Mol Sci*
699 2024, Vol 25, Page 9422 [Internet]. 2024 [cited 2024 Oct 22];25(17):9422.
- 700 [39] Graham DB, Xavier RJ. Conditioning of the immune system by the microbiome. *Trends*
701 *Immunol* [Internet]. 2023 [cited 2024 Oct 22];44(7):499–511.
- 702 [40] Watanabe Costa R, da Silveira JF, Bahia D. Interactions between *Trypanosoma cruzi*
703 secreted proteins and host cell signaling pathways. *Front Microbiol* [Internet]. 2016 [cited
704 2024 Oct 21];7(MAR):185375.
- 705 [41] Pech-Canul ÁDLC, Monteón V, Solís-Oviedo RL. A Brief View of the Surface
706 Membrane Proteins from *Trypanosoma cruzi*. *J Parasitol Res* [Internet]. 2017 [cited 2024
707 Oct 21];2017:3751403.
- 708 [42] Di Noia JM, Buscaglia CA, De Marchi CR, et al. A *Trypanosoma cruzi* Small Surface
709 Molecule Provides the First Immunological Evidence that Chagas' Disease Is Due to a
710 Single Parasite Lineage. *J Exp Med* [Internet]. 2002 [cited 2024 Oct 21];195(4):401.
- 711 [43] Atyame Nten CM, Sommerer N, Rofidal V, et al. Excreted/Secreted Proteins from
712 Trypanosome Procyclic Strains. *J Biomed Biotechnol* [Internet]. 2009 [cited 2024 Oct
713 21];2010:212817.
- 714 [44] Jaimes J, Patiño LH, Herrera G, et al. Prokaryotic and eukaryotic skin microbiota
715 modifications triggered by *Leishmania* infection in localized Cutaneous Leishmaniasis.
716 *PLoS Negl Trop Dis* [Internet]. 2024 [cited 2024 Aug 9];18(3):1–25.
- 717 [45] Gimblet C, Meisel JS, Loesche MA, et al. Cutaneous leishmaniasis induces a
718 transmissible dysbiotic skin microbiota that promotes skin inflammation. *Cell Host*
719 *Microbe* [Internet]. 2017 [cited 2024 Aug 9];22(1):13.
- 720 [46] Naz S, Ali Z, Minhas A, et al. Generation of dysbiotic microbiota in cutaneous
721 leishmaniasis and enhancement of skin inflammation. *Microb Pathog*. 2023;181:106202.
- 722 [47] Mrázek J, Mrázková L, Mekadim C, et al. Effects of *Leishmania major* infection on the
723 gut microbiome of resistant and susceptible mice. *Appl Microbiol Biotechnol* [Internet].
724 2024 [cited 2024 Aug 9];108(1):145.
- 725 [48] Amorim CF, Lovins VM, Singh TP, et al. Multiomic profiling of cutaneous leishmaniasis
726 infections reveals microbiota-driven mechanisms underlying disease severity. 2023 [cited
727 2024 Aug 9];15(718).
- 728 [49] Passos FC, Gois MB, Sousa AD, et al. Investigating associations between intestinal
729 alterations and parasite load according to *Bifidobacterium* spp. and *Lactobacillus* spp.

- 730 abundance in the gut microbiota of hamsters infected by *Leishmania infantum*. *Mem Inst*
731 *Oswaldo Cruz* [Internet]. 2020 [cited 2024 Aug 9];115(11).
- 732 [50] Meazzi S, Lauzi S, Martini V, et al. Gut Microbiota and Lymphocyte Subsets in Canine
733 *Leishmaniasis*. *Front Vet Sci* [Internet]. 2022 [cited 2024 Aug 9];9:868967.
- 734 [51] Misra P, Singh S. Site specific microbiome of *Leishmania* parasite and its cross-talk with
735 immune milieu. *Immunol Lett*. 2019;216:79–88.
- 736 [52] Olias-Molero AI, Botías P, Cuquerella M, et al. *Leishmania infantum* infection does not
737 affect the main composition of the intestinal microbiome of the Syrian hamster. *Parasites*
738 *and Vectors* [Internet]. 2022 [cited 2024 Aug 9];15(1):1–10.
- 739 [53] Karimian F, Vatandoost H, Rassi Y, et al. Aerobic midgut microbiota of sand fly vectors
740 of zoonotic visceral leishmaniasis from northern Iran, a step toward finding potential
741 paratransgenic candidates 06 Biological Sciences 0605 Microbiology. *Parasites and*
742 *Vectors* [Internet]. 2019 [cited 2024 Aug 9];12(1):1–12.
- 743 [54] Sherafati J, Dayer MS, Ghaffarifard F. Therapeutic effects of *Lucilia sericata* larval
744 excretion/secretion products on *Leishmania major* under in vitro and in vivo conditions.
745 *Parasit Vectors* [Internet]. 2022 [cited 2024 Oct 21];15(1):212.
- 746 [55] Telleria EL, Martins-Da-Silva A, Tempone AJ, et al. *Leishmania*, microbiota and sand fly
747 immunity. *Parasitology* [Internet]. 2018 [cited 2024 Oct 21];145(10):1336.
- 748 [56] Campolina TB, Villegas LEM, Monteiro CC, et al. Tripartite interactions: *Leishmania*,
749 microbiota and *Lutzomyia longipalpis*. *PLoS Negl Trop Dis* [Internet]. 2020 [cited 2024
750 Oct 21];14(10):e0008666.
- 751 [57] Tabbabi A, Mizushima D, Yamamoto DS, et al. Effects of host species on microbiota
752 composition in *Phlebotomus* and *Lutzomyia* sand flies. *Parasites and Vectors* [Internet].
753 2023 [cited 2024 Oct 21];16(1):1–10.
- 754 [58] Martin I, Djuardi Y, Sartono E, et al. Dynamic changes in human-gut microbiome in
755 relation to a placebo-controlled anthelmintic trial in Indonesia. *PLoS Negl Trop Dis*
756 [Internet]. 2018;12(8):1–19.
- 757 [59] Klomkiew P, Sawaswong V, Chanchaem P, et al. Gut bacteriome and metabolome of
758 *Ascaris lumbricoides* in patients. *Sci Reports* 2022 121 [Internet]. 2022 [cited 2023 May
759 27];12(1):1–13.
- 760 [60] Jang S, Lakshman S, Beshah E, et al. Flavanol-Rich Cocoa Powder Interacts with
761 *Lactobacillus rhamnosus* LGG to Alter the Antibody Response to Infection with the
762 Parasitic Nematode *Ascaris suum*. *Nutrients*. 2017;9(10).
- 763 [61] McSorley HJ, Maizels RM. Helminth infections and host immune regulation. *Clin*
764 *Microbiol Rev*. 2012;25(4):585–608.
- 765 [62] Maizels RM, Smits HH, McSorley HJ. Modulation of Host Immunity by Helminths: The
766 Expanding Repertoire of Parasite Effector Molecules. *Immunity* [Internet].
767 2018;49(5):801–818.
- 768 [63] Weatherhead JE, Porter P, Coffey A, et al. *Ascaris* larval infection and lung invasion
769 directly induce severe allergic airway disease in mice. *Infect Immun* [Internet]. 2018
770 [cited 2021 Mar 5];86(12):533–551.

- 771 [64] Wang T, Van Steendam K, Dhaenens M, et al. Proteomic Analysis of the Excretory-
772 Secretory Products from Larval Stages of *Ascaris suum* Reveals High Abundance of
773 Glycosyl Hydrolases. *PLoS Negl Trop Dis* [Internet]. 2013 [cited 2024 Feb
774 29];7(10):e2467.
- 775 [65] Hansen EP, Fromm B, Andersen SD, et al. Exploration of extracellular vesicles from
776 *Ascaris suum* provides evidence of parasite–host cross talk. *J Extracell Vesicles*.
777 2019;8(1).
- 778 [66] Berrilli F, Di Cave D, Cavallero S, et al. Interactions between parasites and microbial
779 communities in the human gut. *Front Cell Infect Microbiol*. 2012;2(November):141.
- 780 [67] Li RW, Wu S, Li W, et al. Alterations in the porcine colon microbiota induced by the
781 gastrointestinal nematode *Trichuris suis*. *Infect Immun*. 2012;80(6):2150–2157.
- 782 [68] Cantacessi C, Giacomini P, Croese J, et al. Impact of experimental hookworm infection on
783 the human gut microbiota. *J Infect Dis*. 2014;210(9):1431–1434.
- 784 [69] Glendinning L, Nausch N, Free A, et al. The microbiota and helminths: Sharing the same
785 niche in the human host. *Parasitology*. 2014;141(10):1255–1271.
- 786 [70] Kay GL, Millard A, Sergeant MJ, et al. Differences in the faecal microbiome in
787 schistosoma haematobium infected children vs. uninfected children. *PLoS Negl Trop Dis*.
788 2015;9(6):e0003861.
- 789 [71] Zaiss MM, Rapin A, Lebon L, et al. The Intestinal Microbiota Contributes to the Ability
790 of Helminths to Modulate Allergic Inflammation. *Immunity* [Internet]. 2015 [cited 2021
791 Jul 14];43(5):998–1010.
- 792 [72] Midha A, Schlosser J, Hartmann S. Reciprocal interactions between nematodes and their
793 microbial environments. *Front Cell Infect Microbiol* [Internet]. 2017 [cited 2021 Apr
794 5];7(APR):144.
- 795 [73] Rosa BA, Supali T, Gankpala L, et al. Differential human gut microbiome assemblages
796 during soil-transmitted helminth infections in Indonesia and Liberia. *Microbiome*
797 [Internet]. 2018 [cited 2021 Mar 23];6(1):1–19.
- 798 [74] Nogueira DS, Gazzinelli-Guimarães PH, Barbosa FS, et al. Multiple Exposures to *Ascaris*
799 *suum* Induce Tissue Injury and Mixed Th2/Th17 Immune Response in Mice. *PLoS Negl*
800 *Trop Dis* [Internet]. 2016 [cited 2021 Jul 14];10(1):e0004382.
- 801 [75] Castañeda S, Paniz-Mondolfi A, Ramírez JD. Detangling the Crosstalk Between *Ascaris*,
802 *Trichuris* and Gut Microbiota: What’s Next? *Front Cell Infect Microbiol* [Internet]. 2022
803 [cited 2022 May 29];0:615.
- 804 [76] Midha A, Jarquín-Díaz VH, Ebner F, et al. Guts within guts: the microbiome of the
805 intestinal helminth parasite *Ascaris suum* is derived but distinct from its host. *Microbiome*
806 [Internet]. 2022 [cited 2023 May 27];10(1):1–21.
- 807 [77] Bennuru S, Semnani R, Meng Z, et al. *Brugia malayi* Excreted/Secreted Proteins at the
808 Host/Parasite Interface: Stage- and Gender-Specific Proteomic Profiling. *PLoS Negl Trop*
809 *Dis* [Internet]. 2009 [cited 2024 May 27];3(4).
- 810 [78] Salloum PMM, Jorge F, Dheilly NMM, et al. Eco-evolutionary implications of helminth
811 microbiomes. *J Helminthol* [Internet]. 2023 [cited 2023 Feb 16];97:e22.

- 812 [79] Cortés A, Peachey L, Scotti R, et al. Helminth-microbiota cross-talk – A journey through
813 the vertebrate digestive system. *Mol Biochem Parasitol* [Internet]. 2019 [cited 2021 Mar
814 17];233(September):111222.
- 815 [80] Yasuda K, Nakanishi K. Host responses to intestinal nematodes. *Int Immunol*.
816 2018;30(3):93–102.
- 817 [81] Pillai A, Ueno S, Zhang H, et al. Cecropin P1 and novel nematode cecropins: a bacteria-
818 inducible antimicrobial peptide family in the nematode *Ascaris suum*. *Biochem J*
819 [Internet]. 2005 [cited 2021 Jul 15];390(1):207–214.
- 820 [82] Pillai A, Ueno S, Zhang H, et al. Induction of ASABF (*Ascaris suum* antibacterial factor)-
821 type antimicrobial peptides by bacterial injection: novel members of ASABF in the
822 nematode *Ascaris suum*. *Biochem J* [Internet]. 2003 [cited 2021 Jul 14];371(3):663–668.
- 823 [83] Midha A, Ebner F, Schlosser-Brandenburg J, et al. Trilateral Relationship: *Ascaris*,
824 Microbiota, and Host Cells. *Trends Parasitol* [Internet]. 2021 [cited 2021 Mar
825 5];37(3):251–262.
- 826 [84] Whitman JD, Sakanari JA, Mitreva M. Areas of Metabolomic Exploration for Helminth
827 Infections. 2021 [cited 2021 Mar 5];7:206–214.
- 828 [85] Formenti F, Cortés A, Brindley PJ, et al. A bug’s life: Delving into the challenges of
829 helminth microbiome studies. *PLoS Negl Trop Dis* [Internet]. 2020 [cited 2021 Jul
830 28];14(9):1–7.
- 831 [86] Myhill LJ, Stolzenbach S, Mejer H, et al. Parasite-Probiotic Interactions in the Gut:
832 *Bacillus* sp. and *Enterococcus faecium* Regulate Type-2 Inflammatory Responses and
833 Modify the Gut Microbiota of Pigs During Helminth Infection. *Front Immunol* [Internet].
834 2022 [cited 2022 Jan 11];
- 835 [87] Darwesh OM, El-Sayed HS, Darwesh OM, et al. Perspective Chapter: Application
836 of Probiotics to Inactivate Helminth Parasitic Zoonosis. *Parasit Helminths Zoonoses -*
837 *From Basic to Appl Res* [Internet]. 2022 [cited 2022 Oct 26]; doi:
838 10.5772/INTECHOPEN.103744.
- 839 [88] Reynolds LA, Finlay BB, Maizels RM. Cohabitation in the Intestine: Interactions among
840 Helminth Parasites, Bacterial Microbiota, and Host Immunity. *J Immunol*.
841 2015;195(9):4059–4066.
- 842 [89] Williams AR, Krych L, Ahmad HF, et al. A polyphenol-enriched diet and *Ascaris suum*
843 infection modulate mucosal immune responses and gut microbiota composition in pigs.
844 *PLoS One* [Internet]. 2017 [cited 2021 Mar 23];12(10):1–21.
- 845 [90] Mejia R, Damania A, Jeun R, et al. Impact of intestinal parasites on microbiota and
846 cobalamin gene sequences: A pilot study. *Parasit Vectors* [Internet]. 2020 [cited 2021 Apr
847 5];13(1):1–9.
- 848 [91] Mitreva M. Parasite OMICS, the grand challenges ahead. *Front Parasitol*. 2022;1:995302.
- 849 [92] Moysidou C, Withers AM, Nisbet AJ, et al. Investigation of Host–Microbe–Parasite
850 Interactions in an In Vitro 3D Model of the Vertebrate Gut. *Adv Biol* [Internet]. 2022
851 [cited 2022 Jun 6];2200015.
- 852 [93] Duarte-Silva E, Morais LH, Clarke G, et al. Targeting the Gut Microbiota in Chagas

853 Disease: What Do We Know so Far? [Internet]. *Front. Microbiol.* Frontiers Media S.A.;
854 Dec 10, 2020 p. 3083. Available from: www.frontiersin.org.

855 [94] Wang Y, Li J V, Saric J, et al. Advances in metabolic profiling of experimental nematode
856 and trematode infections. *Adv Parasitol.* 2010;73:373–404.

857 [95] Mu Q, Tavella VJ, Luo XM. Role of *Lactobacillus reuteri* in human health and diseases.
858 *Front Microbiol.* 2018;9(APR):757.

859 [96] Gourbeyre P, Denery S, Bodinier M. Probiotics, prebiotics, and synbiotics: impact on the
860 gut immune system and allergic reactions. *J Leukoc Biol.* 2011;89(5):685–695.

861 [97] Pinazo MJ, Forsyth C, Losada I, et al. Efficacy and safety of fexinidazole for treatment of
862 chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-
863 blind, phase 2 trial. *Lancet Infect Dis* [Internet]. 2024 [cited 2024 Oct 21];24(4):395–403.

864 [98] Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and Treatment of Leishmaniasis:
865 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and
866 the American Society of Tropical Medicine and Hygiene (ASTMH). *Am J Trop Med Hyg*
867 [Internet]. 2017 [cited 2024 Oct 21];96(1):24.

868 [99] Conterno LO, Turchi MD, Corrêa I, et al. Anthelmintic drugs for treating ascariasis.
869 *Cochrane Database Syst Rev* [Internet]. 2020 [cited 2024 Oct 21];2020(4):CD010599.

870 [100] Mukherjee S, Joardar N, Sengupta S, et al. Gut microbes as future therapeutics in treating
871 inflammatory and infectious diseases: Lessons from recent findings. *J Nutr Biochem*
872 [Internet]. 2018 [cited 2024 Aug 9];61:111.

873 [101] Khan I, Bai Y, Zha L, et al. Mechanism of the Gut Microbiota Colonization Resistance
874 and Enteric Pathogen Infection. *Front Cell Infect Microbiol* [Internet]. 2021 [cited 2024
875 Aug 9];11.

876 [102] Mandal S, Mondal C, Lyndem LM. Probiotics: an alternative anti-parasite therapy. *J*
877 *Parasit Dis* 2024 [Internet]. 2024 [cited 2024 Aug 9];1–15.

878 [103] Travers MA, Florent I, Kohl L, et al. Probiotics for the Control of Parasites: An Overview.
879 *J Parasitol Res* [Internet]. 2011 [cited 2024 Aug 9];2011:11.

880 [104] Saracino MP, Vila CC, Baldi PC, et al. Searching for the one(s): Using Probiotics as
881 Anthelmintic Treatments. *Front Pharmacol* [Internet]. 2021 [cited 2024 Aug
882 9];12:714198.

883 [105] Sharpton TJ, Combrink L, Arnold HK, et al. Harnessing the Gut Microbiome in the Fight
884 against Anthelmintic Drug Resistance. *Curr Opin Microbiol* [Internet]. 2020 [cited 2024
885 Aug 9];53:26.

886 [106] Zhao Q, Chen Y, Huang W, et al. Drug-microbiota interactions: an emerging priority for
887 precision medicine. *Signal Transduct Target Ther* 2023 81 [Internet]. 2023 [cited 2024
888 Aug 9];8(1):1–27.

889 [107] Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome.
890 *Gut* [Internet]. 2020 [cited 2024 Aug 9];69(8):1510–1519.

891 [108] Wan Y, Zuo T. Interplays between drugs and the gut microbiome. *Gastroenterol Rep*
892 [Internet]. 2022 [cited 2024 Aug 9];10.

893 [109] Hong SH. Influence of Microbiota on Vaccine Effectiveness: “Is the Microbiota the Key

894 to Vaccine-induced Responses?" J Microbiol [Internet]. 2023 [cited 2024 Aug
895 9];61(5):483.

896 [110] Ponziani FR, Coppola G, Rio P, et al. Factors Influencing Microbiota in Modulating
897 Vaccine Immune Response: A Long Way to Go. *Vaccines* 2023, Vol 11, Page 1609
898 [Internet]. 2023 [cited 2024 Aug 9];11(10):1609.

899 [111] Huang B, Wang J, Li L. Recent five-year progress in the impact of gut microbiota on
900 vaccination and possible mechanisms. *Gut Pathog* [Internet]. 2023 [cited 2024 Aug
901 9];15(1).

902 [112] Lynn DJ, Benson SC, Lynn MA, et al. Modulation of immune responses to vaccination by
903 the microbiota: implications and potential mechanisms. *Nat Rev Immunol* 2021 221
904 [Internet]. 2021 [cited 2024 Aug 9];22(1):33–46.


905 [113] Cheng YW, Phelps E, Ganapini V, et al. Fecal microbiota transplantation for the treatment
906 of recurrent and severe *Clostridium difficile* infection in solid organ transplant recipients:
907 A multicenter experience. *Am J Transplant* [Internet]. 2019 [cited 2024 Aug 9];19(2):501.


908 [114] Gardner TB, Hill DR. Treatment of Giardiasis. *Clin Microbiol Rev* [Internet]. 2001 [cited
909 2024 Aug 9];14(1):114.


910 [115] Littmann ER, Lee JJ, Denny JE, et al. Host immunity modulates the efficacy of microbiota
911 transplantation for treatment of *Clostridioides difficile* infection. *Nat Commun* 2021 121
912 [Internet]. 2021 [cited 2024 Aug 9];12(1):1–15.

913

914







Genomics

Sequencing platforms include DNA sequencing and microarrays.

Assembly, annotation, comparative genomics

Transcriptomics

RNA-seq technologies and pipelines involve sequencing RNA and analyzing differential expression.

Differential expression analysis, non-coding RNAs

Proteomics and Metabolomics


Techniques and pipelines include protein separation, MS1/MS2 analysis, and identifying protein-protein interactions.

Identifying, protein-protein interactions, functional proteomics

Helminths-Host-Microbiome Interactions

Metabarcoding and metagenomics approaches identify differentially abundant taxa and metabolic genes and pathways.

Identification of differentially abundant taxa and metabolic genes and pathways



Vaccine, probiotic and prebiotic development. Personalized medicine approaches using microbiota-based therapies

7. CONCLUSIONES

Capítulo 1.

- La presencia generalizada de parásitos intestinales en la población rural de Las Guacas, especialmente la alta frecuencia de *Blastocystis*, subraya la necesidad de implementar estrategias direccionadas al mejoramiento en el suministro y calidad del agua y en las prácticas de saneamiento. Las condiciones socioeconómicas desfavorables, junto con la ausencia de tratamiento adecuado del agua y la eliminación inadecuada de excretas, aumentan el riesgo de infecciones transmitidas por el agua y facilitan la transmisión zoonótica, ya que las mascotas en la comunidad también albergan parásitos que afectan tanto a humanos como a animales.
- La coinfección y el poliparasitismo observados en la comunidad sugieren interacciones complejas entre los parásitos y el huésped, que pueden influir en la presentación clínica y en la dinámica de transmisión. Los resultados de este estudio refuerzan la importancia de una aproximación integrada de "Una Sola Salud" para abordar la prevención y el control de estas infecciones, considerando no solo a los humanos, sino también a los animales y al ambiente como actores clave en los ciclos de transmisión de los parásitos.
- La colonización por *Blastocystis* está asociada con un aumento en la diversidad bacteriana del intestino, un factor que generalmente se relaciona con mejores resultados de salud. Un microbioma intestinal diverso mejora la resiliencia frente a alteraciones como infecciones y cambios en la dieta.
- En individuos positivos para *Blastocystis*, se observan ciertos taxones bacterianos, como *Bacteroides uniformis*, *Oscillibacter sp.* y *Prevotella copri*, en mayor abundancia. Estos taxones son conocidos por su papel en la absorción de nutrientes, el metabolismo energético y los efectos antiinflamatorios.
- El impacto de *Blastocystis* en el microbioma intestinal varía según la región geográfica y el estilo de vida, con efectos más marcados en poblaciones rurales no occidentalizadas donde el consumo de dietas ricas en vegetales y alimentos fermentados es característica.
- Estos hallazgos resaltan la importancia de la dieta en la composición del microbioma, sugiriendo que *Blastocystis* podría contribuir a los beneficios para la salud, siendo más evidente en individuos con dietas ricas en fibra y vegetales, comunes en entornos rurales.

- Diferentes niveles de carga de *Blastocystis* (alta, media, baja) se asocian con variaciones en la abundancia de ciertos taxones microbianos. Las cargas más altas están relacionadas con taxones como *Alistipes* y *Lachnospira*, conocidos por sus propiedades antiinflamatorias. Una relación dependiente de la dosis sugiere que la abundancia de *Blastocystis* puede influir en el grado en que modula el microbiota intestinal.
- Los individuos positivos para *Blastocystis* presentan perfiles distintos de microbiota eucariota, con mayor abundancia de *Entamoeba coli*, mientras que los grupos negativos muestran más *Saccharomyces cerevisiae* y *Candida albicans*.
- Las posibles interacciones entre *Blastocystis* y otros eucariotas, incluidos los hongos, requieren más investigación para comprender sus efectos en el ecosistema intestinal.
- Un clasificador de *machine learning*, específicamente un *random forest*, distingue efectivamente entre individuos positivos y negativos para *Blastocystis* basándose en la composición de la microbiota, identificando taxones clave como *Faecalibacterium prausnitzii* y *Bacteroides ovatus*. Estos taxones están asociados con propiedades antiinflamatorias y el metabolismo de carbohidratos, lo que sugiere que *Blastocystis* puede fomentar un entorno intestinal favorable para funciones microbianas beneficiosas.
- El estudio contribuye a la hipótesis de que *Blastocystis* podría actuar como un organismo comensal que apoya un microbioma diverso y funcionalmente rico.
- Las investigaciones futuras deberían centrarse en dilucidar los mecanismos por los cuales *Blastocystis* influye en la salud intestinal, con énfasis en estudios longitudinales y métodos avanzados como la metagenómica y la metabolómica.
- Entre las limitaciones se incluyen un tamaño de muestra relativamente pequeño y la falta de datos dietéticos detallados. Es necesario realizar estudios longitudinales con conjuntos de datos complementarios para llegar a conclusiones que permitan determinar direccionalidad y causalidad.
- En resumen, los hallazgos sugieren que la colonización por *Blastocystis* podría desempeñar un papel beneficioso en la configuración de la microbiota intestinal, especialmente en poblaciones rurales no occidentalizadas. Su presencia se asocia con una mayor diversidad microbiana y con taxones vinculados a funciones metabólicas e inmunológicas mejoradas, lo que apoya la noción de *Blastocystis* como un comensal más que como un patógeno.

Capítulo 2.

- En este estudio se propuso evaluar el impacto de la infección por *T. cruzi* en la composición y función de la microbioma intestinal en un modelo murino. Se observó que ambos modelos de ratón presentaron parasitemia detectable a partir del segundo día post-infección (dpi), siendo más elevados los niveles en ratones BALB/c en comparación con C57BL/6.
- Los ratones infectados desarrollaron esplenomegalia, un hallazgo consistente con estudios previos que utilizan cepas quimioluminiscentes.
- Análisis de citoquinas en sueros mostraron una respuesta inmune proinflamatoria predominante en C57BL/6, con incremento de IFN- γ , TNF- α e IL-6. En contraste, los ratones BALB/c mostraron niveles más altos de citoquinas antiinflamatorias como IL-10 e IL-4.
- A través de análisis metagenómicos, se identificaron los mismos taxones con mayores abundancias relativas en ambos modelos: *Lactobacillus johnsonii*, *Akkermansia muciniphila*, *Bacteroides thetaiotaomicron*, *Bacteroides pseudolongum*, *Anaerostipes finegoldii*, *Fusobacterium rodentium* y *Staphylococcus xylosum*.
- Se identificó una correlación negativa entre la reducción de *L. johnsonii* e IL-10 en BALB/c y entre *A. muciniphila* con IL-22 e IFN- γ en C57BL/6.
- Se evidenció que, con el transcurso de la infección por *T. cruzi*, se presentó una reducción de bacterias como *L. johnsonii* y *B. thetaiotaomicron*, las cuales son esenciales para mantener la barrera intestinal y regular la respuesta inmune, así como para procesos metabólicos cruciales como la biosíntesis de ácidos grasos de cadena corta (AGCC).
- La predicción funcional a partir de datos metagenómicos reveló que las alteraciones en las abundancias relativas de los taxones bacterianos descritos se asociaron con una disminución en varios procesos metabólicos, incluyendo la biosíntesis de AGCC en ratones BALB/c. La reducción de AGCC podría afectar la regeneración de tejidos en un entorno proinflamatorio, facilitando así la colonización por patógenos.
- *B. thetaiotaomicron* desempeña un papel crucial en procesos metabólicos esenciales para la fisiología del huésped. La disminución en la abundancia relativa de este taxón podría estar directamente implicada en la disminución de las capacidades metabólicas del microbioma durante la infección por *T. cruzi*.
- Se sugiere que la interacción de *T. cruzi* con el microbioma intestinal podría estar relacionada con la generación de perfiles inmunológicos que favorecen un ambiente proinflamatorio.
- Los cambios en el microbioma intestinal identificados en este estudio sugieren alteraciones en los perfiles inmunológicos y en varias vías metabólicas esenciales que favorecen los

procesos asociados con la infección. Los hallazgos destacan la necesidad de investigar nuevas alternativas terapéuticas para la enfermedad de Chagas, incluyendo el uso de probióticos que podrían ayudar a resolver infecciones y reducir cargas parasitarias.

- Es fundamental realizar estudios transcriptómicos y metabolómicos para corroborar los resultados funcionales predichos.
- Se necesita investigar los efectos en la fase crónica de la infección y establecer la causalidad y direccionalidad de los cambios en el microbioma y la respuesta inmune.
- Este estudio es el primero en reportar MAGs en huéspedes durante un proceso infeccioso por *T. cruzi*, abriendo nuevas oportunidades de investigación sobre las interacciones parásito-microbioma.

Capítulo 3.

- Este estudio ha caracterizado de manera detallada la microbiota asociada a las larvas de *Ascaris* en diversas etapas de desarrollo, evidenciando la complejidad de las interacciones entre el parásito y el hospedero durante el ciclo migratorio larval.
- Se encontraron diferencias significativas en la composición y diversidad de la microbiota entre los grupos analizados, destacando la predominancia de *Proteobacteria* en la microbiota de *Ascaris*, lo que sugiere su papel fundamental en la biología del parásito.
- Los perfiles de microbiota observados en los tejidos del hospedero resaltan la intrincada interacción entre las comunidades microbianas del hospedero y del parásito, sugiriendo un impacto potencial en la salud del hospedero y en el éxito del parásito.
- La evaluación de la microbiota de las larvas de *Ascaris* y sus cambios a lo largo del ciclo larval proporciona información valiosa sobre cómo el parásito se adapta y se beneficia de su entorno, específicamente, de la microbiota del hospedero.
- Se observaron cambios significativos en la abundancia de géneros específicos durante el ciclo migratorio larval. Por ejemplo, los géneros *Lactobacillus*, y *Lachnospiraceae NK4A136* mostraron un aumento en su abundancia en las larvas aisladas del hígado y pulmón en comparación con las larvas en etapas iniciales. Esto sugiere que la adquisición horizontal de estas bacterias del hospedero durante la migración es probable.
- Los hallazgos de este estudio abren nuevas posibilidades para investigar estrategias de control de helmintos, al resaltar la importancia de las interacciones entre microbiota y parásitos en la persistencia y patogenicidad de *Ascaris*.

- Es esencial que futuras investigaciones se centren en comprender los roles funcionales de las comunidades bacterianas dentro de *Ascaris* y los mecanismos de adquisición de estas bacterias, tanto vertical como horizontalmente, para obtener una comprensión más completa de estas interacciones.
- A pesar de los avances logrados, es importante reconocer las limitaciones del estudio, incluyendo el uso de un modelo animal no nativo para *Ascaris*. Se recomienda considerar modelos porcinos en futuros estudios para validar los hallazgos y su aplicabilidad a la infección en humanos.
- En relación con el análisis proteómico, este estudio llevó a cabo una evaluación completa de los proteomas de productos de ES en las diferentes etapas larvales de *Ascaris*, utilizando LC-MS/MS para identificar 58 proteínas únicas en los productos ES de las larvas L3-egg, L3-lung y L3-trachea. Las diferencias en la composición proteica entre estas etapas sugieren funciones biológicas específicas durante el desarrollo, reflejando la complejidad del proceso migratorio del parásito a través del hospedero. Se identificaron 5 proteínas exclusivas de L3-egg, 20 de L3-lung y 3 de L3-trachea, mientras que 14 proteínas fueron conservadas en todas las etapas.
- La identificación de proteínas específicas por etapa proporciona hallazgos valiosos. Por ejemplo, la presencia de factores nucleares asociados a la replicación y transcripción, como Ell-associated factor Eaf (UniProt ID F1LBV5) y Protein SDA1 (UniProt ID F1KVQ9) en L3-egg, sugiere un papel crítico en la división celular y diferenciación, fundamentales para el desarrollo inicial de larvas. En contraste, las proteínas en L3-lung y L3-trachea reflejan una mayor necesidad de proteínas relacionadas con el metabolismo energético, como fructosa-bisfosfato aldolasa (UniProt ID F1L5H2) y malato deshidrogenasa (UniProt ID F1L8Z9), evidenciando la adaptación a entornos anaeróbicos durante la migración a través del pulmón.
- La identificación de proteínas como peptidil-prolilo isomerasa (UniProt ID F1LGZ3) y las proteínas ERM (UniProt ID F1KY69) en las etapas L3-lung y L3-trachea sugiere que estas podrían jugar roles en la modulación inmune y la migración larval. Dada la función de las proteínas de choque térmico (HSPs) en la adaptación del parásito al hospedero, estas características podrían ser objetivos potenciales para intervenciones terapéuticas. Las variaciones en la expresión proteica podrían contribuir a la capacidad del parásito para evadir respuestas inmunitarias y establecer infecciones persistentes.
- Aunque no se detectaron diferencias estadísticamente significativas en la abundancia de proteínas entre las etapas, se observaron diferencias cualitativas evidentes en los perfiles

proteómicos, como lo indica el análisis de componentes principales (PCA). La heterogeneidad de los productos ES y su variabilidad inherente podrían haber enmascarado sutiles diferencias en la abundancia, lo que sugiere la necesidad de enfoques más amplios en futuras investigaciones. El uso de modelos porcinos, que son hospederos naturales de *Ascaris*, también se recomienda para validar estos hallazgos.

- Las diferencias en la composición proteica y los roles funcionales identificados en las distintas etapas larvales sugieren que estos productos ES podrían ser valiosos para el desarrollo de nuevos diagnósticos y objetivos de vacunas. La caracterización de las interacciones entre las proteínas ES, las células del hospedero y la microbiota del hospedero, podría abrir vías para nuevas estrategias terapéuticas, al identificar dianas moleculares y novedosas estrategias relevantes para la intervención en la ascariasis.
- Este estudio proporciona una visión integral sobre la dinámica proteómica de las larvas de *Ascaris*, destacando la importancia de las proteínas ES en su ciclo de vida y su interacción con el hospedero. Los hallazgos pueden guiar investigaciones futuras dirigidas a desentrañar los mecanismos de patogenicidad de *Ascaris*, así como a desarrollar herramientas efectivas para el control de ascariasis.
- Las interacciones entre helmintos y la microbiota del hospedero son complejas y multidimensionales, influidas por una variedad de factores, incluidos los componentes eucariotas y virales. Estas interacciones no solo afectan la patogénesis de las infecciones por helmintos, sino que también tienen implicaciones significativas para la salud del hospedero.
- La microbiota intestinal desempeña un papel crucial en la susceptibilidad y la respuesta a las infecciones por helmintos. Los cambios en la composición y la diversidad de la microbiota pueden facilitar la colonización y persistencia de estos parásitos, lo que subraya la necesidad de investigar estrategias que modulen la microbiota como posibles enfoques terapéuticos.
- Es esencial adoptar enfoques de investigación integrados que combinen diferentes estrategias ómicas para comprender los mecanismos involucrados, la causalidad y direccionalidad de estas interacciones.

8. PERSPECTIVAS

La comprensión de las interacciones entre los parásitos intestinales, sus hospederos y el microbioma es un campo de creciente interés, con múltiples áreas en las que se requieren avances para mejorar el conocimiento sobre las dinámicas y consecuencias de estas interacciones. Los estudios futuros deben enfocarse en explorar tanto las bases mecánicas de la relación parásito-microbioma como en el desarrollo de aplicaciones prácticas para el control de infecciones y el manejo de la salud pública.

- **Estudios longitudinales en parásitos intestinales**

La necesidad de estudios longitudinales es fundamental para caracterizar la evolución temporal de la interacción entre los parásitos, el microbioma y el hospedero. Estos estudios permitirían evaluar cómo las infecciones intestinales crónicas, las intervenciones terapéuticas o los cambios ambientales afectan la composición y función del microbioma a lo largo del tiempo. Además, permitirían elucidar la direccionalidad y causalidad de los cambios observados, lo cual es crucial para determinar si las alteraciones en el microbioma contribuyen a la patogénesis de las infecciones parasitarias o si, en cambio, son una consecuencia de estas. La implementación de cohortes con seguimiento prolongado en poblaciones vulnerables y el uso de técnicas multiómicas podría arrojar luz sobre los factores subyacentes que modulan la resistencia o susceptibilidad a las infecciones.

- **Investigaciones transcriptómicas y metabolómicas**

El empleo de la transcriptómica y la metabolómica ofrece un enfoque integral para el estudio de las interacciones entre parásitos y microbioma. Los análisis transcriptómicos permiten identificar cambios en la expresión génica en respuesta a la infección, proporcionando información sobre las vías moleculares implicadas en la adaptación del parásito y del hospedero. De manera complementaria, la metabolómica ofrece una visión directa de los metabolitos producidos y consumidos en estas interacciones, lo que es fundamental para identificar rutas metabólicas alteradas. En modelos de infección crónica con parásitos como *Trypanosoma cruzi*, estas tecnologías pueden ayudar a caracterizar las adaptaciones funcionales del microbioma y la respuesta inmune del hospedero, así como a identificar biomarcadores potenciales para la detección y el monitoreo de la enfermedad.

- **Desarrollo de modelos crónicos de infección**

La creación de modelos experimentales que simulen infecciones crónicas es esencial para entender la relación a largo plazo entre parásitos y microbiota. Los modelos de infección por *Trypanosoma cruzi*, entre otros parásitos, ofrecen la posibilidad de estudiar cómo las infecciones persistentes modifican la ecología microbiana y cómo los cambios en el microbioma influyen en la progresión de la enfermedad y la respuesta inmune. Además, estos modelos pueden proporcionar información

valiosa sobre la plasticidad del microbioma en respuesta a diferentes etapas de la infección y ayudar a evaluar el impacto de intervenciones terapéuticas dirigidas a restaurar el equilibrio microbiano.

- **Exploración de comunidades bacterianas en *Ascaris* y otros helmintos**

Los parásitos intestinales como *Ascaris* albergan diversas comunidades bacterianas asociadas, cuya composición y función son poco comprendidas. Futuras investigaciones deben centrarse en el análisis de estos microbiomas para elucidar cómo se establecen las interacciones simbióticas entre el parásito y las bacterias, incluyendo los mecanismos de transmisión vertical y horizontal. Un conocimiento detallado de estas asociaciones podría revelar nuevas dianas para el desarrollo de estrategias de control basadas en la manipulación del microbioma asociado a los parásitos, favoreciendo así un enfoque terapéutico complementario.

- **Interacciones eucariotas y virales**

Es esencial ampliar el foco de la investigación para considerar las interacciones de eucariotas y virus con helmintos y el microbioma. La microbiota intestinal no se limita solo a bacterias, sino que también incluye hongos, protistas y virus, todos los cuales juegan un papel en la dinámica de las infecciones parasitarias. La integración de estudios de viomas y micobiomas junto con la caracterización de la microbiota bacteriana podría proporcionar una comprensión más completa de cómo los diferentes componentes del microbioma interactúan entre sí y con el parásito para influir en la salud del hospedero.

- **Avances en bioinformática y análisis de datos**

El desarrollo continuo de herramientas bioinformáticas es esencial para manejar la complejidad de los datos generados en los estudios multiómicos. La integración de datos de secuenciación metagenómica, transcriptómica y metabolómica mediante enfoques de análisis avanzados, como la inteligencia artificial y el aprendizaje automático, facilitará la identificación de patrones emergentes y la inferencia de redes funcionales de interacciones. Además, es fundamental estandarizar los métodos de análisis para mejorar la reproducibilidad entre estudios, lo que permitirá la comparación de datos obtenidos en diferentes contextos y regiones geográficas.

- **Implicaciones clínicas y de salud pública**

Los hallazgos sobre las interacciones parásito-microbioma tienen implicaciones directas en la práctica clínica y en las políticas de salud pública. La identificación de marcadores microbianos específicos asociados a la susceptibilidad a infecciones puede facilitar el desarrollo de pruebas de diagnóstico más precisas. Además, el enfoque de modulación del microbioma como intervención terapéutica podría ser una estrategia prometedora para prevenir o tratar infecciones helmínticas,

especialmente en poblaciones con acceso limitado a medicamentos. La implementación de programas de control basados en la microbiota podría reducir la prevalencia de infecciones intestinales y mejorar la salud intestinal en comunidades endémicas.

9. PRODUCTOS DE LA TESIS

Todos los productos derivados de la formación doctoral y la tesis correspondiente se indican a continuación. Los soportes respectivos se adjuntan con el documento.

9.1. Artículos científicos:

- **Artículo 1:** Castañeda, S., Acosta, Claudia Patricia, Vasquez-A, Luis Reinel, Patiño, Luz H, Mejía, Rojelio, Ramírez JD. Molecular detection of intestinal parasites in a rural community of Colombia: A one health approach to explore potential environmental–zoonotic transmission. *Zoonoses Public Health* [Internet]. 2024 [cited 2024 Oct 23];71(6):723–735. <https://doi.org/10.1111/zph.13138>.
- **Artículo 2:** Castañeda S., Stensvold CR, Andersen LOBB, Acosta, Claudia Patricia, Vasquez-A, Luis Reinel, Ramírez JD. Impact of *Blastocystis* Colonization and Burden on Gut Microbiota Composition in a Non-Westernized Rural Population from Colombia. *Sometido a PLOS Neglected Tropical Diseases (Q1)*.
- **Artículo 3:** Castañeda S., Muñoz M, Hotez PJ, Bottazzi ME, Paniz-Mondolfi AE, Jones KM, Mejia R, Poveda C, Ramírez JD. Microbiome Alterations Driven by *Trypanosoma cruzi* Infection in Two Disjunctive Murine Models. *Microbiology Spectrum* [Internet]. 2023 [cited 2023 Jun 16];11(3). <https://doi.org/10.1128/spectrum.00199-23>.
- **Artículo 4:** Castañeda S., R,Poveda Charlie Suarez-Reyes, Yifan Wu, Noah Haugen, Patiño, Luz H, Weatherhead JE, Ramírez JD. Microbiota Dynamics During *Ascaris* Larval Migration: Implications for Host Microbial Communities. *Sometido a Microbial Pathogenesis (Q1)*.
- **Artículo 5:** Castañeda S., Adeniyi-Ipadeola G, Wu Y, Suarez-Reyes C, Jain A, Ramírez JD, Weatherhead JE. Characterizing Excretory-Secretory Products Proteome Across Larval Development Stages in *Ascaris suum*. *Sometido a Microbes and Infection (Q1)* <https://doi.org/10.1101/2024.07.03.601870>.
- **Artículo 6:** Castañeda S., Paniz-Mondolfi A, Ramírez JD. 2024. Detangling the Crosstalk Between *Ascaris*, *Trichuris*, and Gut Microbiota: What’s Next? *Frontiers in Cellular and Infection Microbiology* [Internet]. 2022. <https://doi.org/10.3389/fcimb.2022.852900>.
- **Artículo 7:** Ramírez JD, Castañeda S., Weatherhead JE, R,Poveda. 2024. Parasite-Microbiota Interactions: A Pathway to Innovative Interventions for Chagas Disease, Leishmaniasis, and Ascariasis. *Sometido a Future Microbiology (Q1)*.

9.2. Capítulo de libro:

- **Castañeda S**, Ramírez JD. 2024 Libro: Recent Advances in Parasitomics. Capítulo: From Genes to Worms: A Deep Dive into Helminth Omics. Springer; 2024th edition (2024).

9.3. Presentaciones En Eventos Científicos:

- Poster: ***In silico* prediction of gut microbial genes as potential targets for *Fasciola hepatica* EV-associated miRNAs.** 7th GEIVEX symposium, Palma, Mallorca, España, Octubre 23-25, 2024.
- Poster: **Nanovesicles from frozen homogenized *Fasciola hepatica* adults exhibit similar properties to extracellular vesicles from parasitic cultures.** 2nd MOVE Symposium. Serbia, October 2024.
- Ponente Mesa Redonda de **Análisis bioinformáticos en Parasitología** con la presentación: "***Estudio de las interacciones parásito-hospedero-microbioma en infecciones causadas por protozoos y helmintos***". XXIII Congreso de la Sociedad Española de Parasitología, Sevilla, España, 2 al 5 de septiembre de 2024.
- Presentación Oral: **Molecular Detection of Intestinal Parasites in a Rural Community of Colombia: A One Health Approach to Explore Potential Environmental-Zoonotic Transmission.** XXIII Congreso de la Sociedad Española de Parasitología, Sevilla, España, 2 al 5 de septiembre de 2024.
- Presentación Oral: **Microbiome Alterations Driven By *Trypanosoma cruzi* Infection In Two Disjunctive Mouse Models.** XVIII Congreso Colombiano de Parasitología y Medicina Tropical. Diciembre 2022.
- Presentación Oral: **Microbiome Alterations Driven By *Trypanosoma cruzi* Infection In Two Disjunctive Mouse Models.** 15th International Congress of Parasitology. Copenhagen, Dinamarca. Agosto 21 - 26, 2022.

9.4. Cursos:

- COST Action. *Blastocystis* Under One Health. ***Blastocystis* and the Gut Microbiome - a bioinformatics training school.** Barcelona. Abril 2024

- Universidad EAN. **Curso Python**. Mar 2023.
- Universidad Javeriana – Universidad Peruana Cayetano Heredia. **International Course on Outbreak Analysis, Modeling and Response in Public Health**. Jul 2021.
- Universidad del Rosario. **Structuring of public investment projects in science, technology and innovation and innovation**. Jun 2021.
- Universidad del Valle. **Fundamentals of Genomics for Health Research**. Mayo 2021
- Winter Genomics. **Metagenome**. Mayo 2021
- RSG/iGEM Ecuador. **UNIX Boot Camp: Linux and Bash Scripting (Basic - Advanced modules)**. Mayo 2021
- Biofreelancer. **Bioinformatics Course: Linux**. Enero 2021.
- Pontificia Universidad Javeriana. **Course: R as a Geographical Information System (GIS) Tool**. Diciembre 2020
- Biofreelancer. **R for beginners**. Diciembre 2020
- The School of Biomedical Informatics UTHealth. **Population Health**. Diciembre 2020.
- The School of Biomedical Informatics UTHealth. **Care Coordination & Interoperable Health IT Systems**. Diciembre 2020.
- Welcome Genome Campus Advanced Course. Sanger Institute. **Bacterial genomes II: Accessing and analyzing microbial genome data using ARTEMIS**. Noviembre 2020. Certificado: <https://www.futurelearn.com/certificates/2i4dj6n>
- Welcome Genome Campus Advanced Course. Sanger Institute. **Bacterial genomes I: from DNA to proteinfunction using bioinformatics**. Octubre 2020. Certificado: <https://www.futurelearn.com/certificates/34jw3ei>
- Welcome Genome Campus Advanced Course. Sanger Institute. **Working with Protozoan Parasite Database Resources (Virtual)** 5-9 Octubre 2020.

9.5. Pasantía Internacional

2024. Laboratory of Parasitology, Department of Bacteria, Parasites & Fungi of Statens Serum Institut, Copenhagen, Denmark

Inicialmente se desarrolló una colaboración en Laboratory of Parasitology, Department of Bacteria, Parasites & Fungi of Statens Serum Institut (SSI), Copenhagen, Dinamarca, bajo la tutoría del Prof. Rune Stensvold. Durante esta estancia, el trabajo se centró en la identificación

molecular y tipificación de parásitos intestinales en humanos y animales, principalmente *Blastocystis*, así como en la evaluación de los cambios en los perfiles del microbioma asociados con estos parásitos, mediante la secuenciación del ADN ribosomal 16S y 18S en muestras de humanos y mascotas de una población rural del departamento del Cauca (suroeste de Colombia), y sus posibles implicaciones en las interacciones parásito-hospedero-microbioma del hospedero. Durante la estancia en el SSI, se participó activamente en actividades tales como:

- Análisis de laboratorio seco de las secuencias de ADN ya obtenidas.
- Perfilado del microbioma en laboratorio húmedo (secuenciación de genes 16S + 18S) a partir del ADN genómico de heces, utilizando el protocolo y la línea de análisis interna (BION).
- Análisis de laboratorio seco de los datos de salida de la secuenciación del microbioma, incluyendo la evaluación de la calidad de las secuencias y el análisis de la diversidad del microbioma mediante R.

Como producto de este trabajo se ha generado el artículo:

- **Castañeda S**, Stensvold CR, Andersen LOBB, Acosta, Claudia Patricia, Vasquez-A, Luis Reinel, Ramírez JD. Impact of *Blastocystis* Colonization and Burden on Gut Microbiota Composition in a Non-Westernized Rural Population from Colombia. *Submitted*.

Así mismo, gracias al trabajo realizado durante esta pasantía, tuve la oportunidad de ser elegido como **Early Career Researcher Lead**. *Blastocystis* under One Health. COST (European Cooperation in Science and Technology), específicamente como líder de los grupos de trabajo WG2: *Blastocystis* collection and databases (<https://blastocystis-cost.com/working-groups/wg2-blastocystis-collection-and-databases/>) y del grupo WG3: Omics' generation and analysis (<https://blastocystis-cost.com/working-groups/wg3-omics-generation-and-analysis/>).

2024. Laboratorio de Bioquímica y Biología Molecular de Parásitos del Grupo Parásitos y Salud, Universitat de València, España.

Así mismo, tuve la oportunidad de realizar una pasantía en el Laboratorio de Bioquímica y Biología Molecular de Parásitos del Grupo Parásitos y Salud, Universitat de València, España, bajo la tutoría del Prof. Antonio Marcilla. Durante esta estancia, el trabajo se centró en el estudio de la acción de las vesículas extracelulares (VEs) en las interacciones parásito-hospedero-microbioma en las infecciones por helmintos, usando como modelo biológico *Fasciola hepatica*. Usando enfoques bioinformáticos y experimentales el estudio se centró en evaluar cómo ciertos

componentes de las VEs, particularmente miRNAs generados por el parásito, pueden tener un efecto en la microbiota del hospedero.

Durante la estancia se participó activamente en actividades tales como:

- Análisis experimental: aislamiento de VEs de *Fasciola hepatica*, microscopía electrónica y confocal, cultivos celulares, entre otros.
- Desarrollo de pipelines bioinformáticos para la predicción de targets de miRNA en bacterias componentes de la microbiota del hospedero.
- Análisis proteómicos de VEs aisladas de *Fasciola hepatica*.

Como resultado de este trabajo se han generado los siguiente productos:

Poster: ***In silico prediction of gut microbial genes as potential targets for Fasciola hepatica EV-associated miRNAs.*** 7th GEIVEX symposium, Palma, Mallorca, España, Octubre 23-25, 2024.

Poster: ***Nanovesicles from frozen homogenized Fasciola hepatica adults exhibit similar properties to extracellular vesicles from parasitic cultures.*** 2nd MOVE Symposium. Serbia, October 2024.

9.6. Beca

Becas de Excelencia Doctoral del Bicentenario. Sistema General de Regalías (Departamento del Cauca)

10. REFERENCIAS

- 1 Ministerio de Salud y Protección Social U de A. *Encuesta nacional de parasitismo intestinal en población escolar 2012 – 2014*. (2014).
- 2 Ahmed M. Intestinal Parasitic Infections in 2023. *Gastroenterol. Res.* 16(3), 127 (2023).
- 3 Ortiz C, López MC, Rivas FA. Prevalencia de helmintos en la planta de aguas residuales del municipio El Rosal, Cundinamarca. *Rev. Salud Pública* 14(2), 296–304 (2012).
- 4 Sayasone S, Mak TK, Vanmany M *et al.* Helminth and Intestinal Protozoa Infections, Multiparasitism and Risk Factors in Champasack Province, Lao People’s Democratic Republic. *PLoS Negl. Trop. Dis.* 5(4), e1037 (2011).
- 5 Cacciò SM, Thompson RCAA, McLauchlin J, Smith H V. Unravelling Cryptosporidium and Giardia epidemiology. *Trends Parasitol.* 21(9), 430–437 (2005).
- 6 Sponseller JK, Griffiths JK, Tzipori S. The evolution of respiratory cryptosporidiosis: Evidence for transmission by inhalation. *Clin. Microbiol. Rev.* 27(3), 575–586 (2014).
- 7 Wawrzyniak I, Poirier P, Texier C *et al.* Blastocystis, an unrecognized parasite: An overview of pathogenesis and diagnosis. *Ther. Adv. Infect. Dis.* 1(5), 167–178 (2013).
- 8 Higuera A, Villamizar X, Herrera G *et al.* Molecular detection and genotyping of intestinal protozoa from different biogeographical regions of Colombia. *PeerJ* (3), e8554 (2020).
- 9 Stensvold CR, Clark CG. Current status of Blastocystis: A personal view. *Parasitol. Int.* 65(6), 763–771 (2016).
- 10 Jeremiah SS, Parija S. Blastocystis: Taxonomy, biology and virulence. *Trop. Parasitol.* 3(1), 17 (2013).
- 11 Verma R, Delfanian K. Blastocystis hominis associated acute urticaria. *Am. J. Med. Sci.* 346(1), 80–81 (2013).
- 12 Jimenez-Gonzalez DE, Martinez-Flores WA, Reyes-Gordillo J *et al.* Blastocystis infection is associated with irritable bowel syndrome in a Mexican patient population. *Parasitol. Res.* 110(3), 1269–1275 (2012).
- 13 Tito RY, Chaffron S, Caenepeel C *et al.* Population-level analysis of Blastocystis subtype prevalence and variation in the human gut microbiota. *Gut* 68(7), 1180–1189 (2019).
- 14 Nourrisson C, Scanzi J, Pereira B *et al.* Blastocystis is associated with decrease of fecal microbiota protective bacteria: Comparative analysis between patients with irritable bowel syndrome and control subjects. *PLoS One* 9(11) (2014).

- 15 Cimino RO, Jeun R, Juarez M *et al.* Identification of human intestinal parasites affecting an asymptomatic peri-urban Argentinian population using multi-parallel quantitative real-time polymerase chain reaction. *Parasites and Vectors* 8(1), 1–7 (2015).
- 16 Piperni E, Nguyen LH, Manghi P *et al.* Intestinal Blastocystis is linked to healthier diets and more favorable cardiometabolic outcomes in 56,989 individuals from 32 countries. *Cell* 187(17), 4554-4570.e18 (2024).
- 17 Stensvold CR, van der Giezen M. Associations between Gut Microbiota and Common Luminal Intestinal Parasites. *Trends Parasitol.* 34(5), 369–377 (2018).
- 18 Stensvold CR, Suresh GK, Tan KSW *et al.* Terminology for Blastocystis subtypes - a consensus. *Trends Parasitol.* 23(3), 93–96 (2007).
- 19 Alfellani MA, Stensvold CR, Vidal-Lapiedra A, Onuoha ESU, Fagbenro-Beyioku AF, Clark CG. Variable geographic distribution of Blastocystis subtypes and its potential implications. *Acta Trop.* 126(1), 11–18 (2013).
- 20 Darwish B, Aboualchamat G, Nahhas S Al. Molecular characterization of Blastocystis subtypes in symptomatic patients from the southern region of Syria. *PLoS One* 18(3), e0283291 (2023).
- 21 Maloney JG, Molokin A, Seguí R *et al.* Identification and Molecular Characterization of Four New Blastocystis Subtypes Designated ST35-ST38. *Microorg.* 2023, Vol. 11, Page 46 11(1), 46 (2022).
- 22 Jiménez P, Muñoz M, Ramírez JD. An update on the distribution of Blastocystis subtypes in the Americas. *Heliyon* 8(12), e12592 (2022).
- 23 Noël C, Dufernez F, Gerbod D *et al.* Molecular phylogenies of Blastocystis isolates from different hosts: Implications for genetic diversity, identification of species, and zoonosis. *J. Clin. Microbiol.* 43(1), 348–355 (2005).
- 24 Parkar U, Traub RJ, Kumar S *et al.* Direct characterization of Blastocystis from faeces by PCR and evidence of zoonotic potential. *Parasitology* 134(3), 359–367 (2007).
- 25 Stensvold CR, Alfellani MA, Nørskov-Lauritsen S *et al.* Subtype distribution of Blastocystis isolates from synanthropic and zoo animals and identification of a new subtype. *Int. J. Parasitol.* 39(4), 473–479 (2009).
- 26 Ryan U, Cacciò SM. Zoonotic potential of Giardia. *Int. J. Parasitol.* 43(12–13), 943–956 (2013).
- 27 Wielinga C, Williams A, Monis P, Thompson RCA. Proposed taxonomic revision of Giardia duodenalis. *Infect. Genet. Evol.* 111, 105430 (2023).
- 28 Giraldo-Gómez JM, Lora F, Henao LH, Mejía S, Gómez-Marín JE. Prevalence of giardiasis

- and intestinal parasites in pre-school children from homes being attended as part of a state programme in Armenia, Colombia. *Rev. Salud Publica (Bogota)*. 7(3), 327–338 (2005).
- 29 Ravid Z, Duque S, Arévalo A, Nicholls RS, Wasserman M. Genetic diversity of *Giardia intestinalis* populations in Colombia. *Biomedica* 27(1), 34–41 (2007).
 - 30 Arroyo-Salgado B, Buelvas-Montes Y, Villalba-Vizcaíno V, Salomón-Arzuza O. Caracterización genética por reacción en cadena de la polimerasa de *Giardia intestinalis* en muestras de humanos y perros del Caribe colombiano. *Enferm. Infecc. Microbiol. Clin.* 32(7), 424–427 (2014).
 - 31 Sánchez A, Muñoz M, Gómez N *et al.* Molecular epidemiology of *Giardia*, *Blastocystis* and *Cryptosporidium* among Indigenous children from the Colombian Amazon basin. *Front. Microbiol.* 8(FEB), 1–14 (2017).
 - 32 Monis PT, Andrews RH, Mayrhofer G, Ey PL. Molecular systematics of the parasitic protozoan *Giardia intestinalis*. *Mol. Biol. Evol.* 16(9), 1135–1144 (1999).
 - 33 Cacciò SM, Beck R, Lalle M, Marinculic A, Pozio E. Multilocus genotyping of *Giardia duodenalis* reveals striking differences between assemblages A and B. *Int. J. Parasitol.* 38(13), 1523–1531 (2008).
 - 34 Wielinga C, Williams A, Monis P, Thompson RCACA. Proposed taxonomic revision of *Giardia duodenalis*. *Infect. Genet. Evol.* 111, 105430 (2023).
 - 35 Kotloff KL, Nataro JP, Blackwelder WC *et al.* Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): A prospective, case-control study. *Lancet* 382(9888), 209–222 (2013).
 - 36 Savioli L, Smith H, Thompson A. *Giardia* and *Cryptosporidium* join the ‘Neglected Diseases Initiative’. *Trends Parasitol.* 22(5), 203–208 (2006).
 - 37 Velasco CA, Méndez F, López P. Cryptosporidiosis in Colombian children with HIV/AIDS infection. *Colomb. Med.* 42(4), 418–429 (2011).
 - 38 Villamizar X, Higuera A, Herrera G *et al.* Molecular and descriptive epidemiology of intestinal protozoan parasites of children and their pets in Cauca, Colombia: A cross-sectional study. *BMC Infect. Dis.* 19(1), 1–11 (2019).
 - 39 Ryan U, Fayer R, Xiao L. *Cryptosporidium* species in humans and animals: Current understanding and research needs. *Parasitology* 141(13), 1667–1685 (2014).
 - 40 Garcia-R JC, French N, Pita A, Velathanthiri N, Shrestha R, Hayman D. Local and global genetic diversity of protozoan parasites: Spatial distribution of *Cryptosporidium* and *Giardia* genotypes. *PLoS Negl. Trop. Dis.* 11(7), 1–20 (2017).
 - 41 Galván-Díaz AL. Cryptosporidiosis in Colombia: a Systematic Review. *Curr. Trop. Med.*

- Reports* 5(3), 144–153 (2018).
- 42 Gaviria LM, Soscua D, Campo-Polanco LF, Cardona-Arias J, Galván-Díaz AL. Prevalencia de parasitosis intestinal, anemia y desnutrición en niños de un resguardo indígena Nasa, Cauca, Colombia, 2015. *Rev. Fac. Nac. Salud Pública* 35(3), 390–399 (2017).
- 43 Abal-Fabeiro JL, Maside X, Bello X, Llovo J, Bartolomé C. Multilocus patterns of genetic variation across *Cryptosporidium* species suggest balancing selection at the gp60 locus. *Mol. Ecol.* 22(18), 4723–4732 (2013).
- 44 Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. PCR detection of *Entamoeba histolytica*, *Entamoeba dispar*, and *Entamoeba moshkovskii* in stool samples from Sydney, Australia. *J. Clin. Microbiol.* 45(3), 1035–1037 (2007).
- 45 WHO. Amoebiasis. WHO Weekly Epidemiological Record. (14), 97–99 (1997).
- 46 López MC, León CM, Fonseca J *et al.* Molecular epidemiology of entamoeba: First description of *Entamoeba moshkovskii* in a rural area from central Colombia. *PLoS One* 10(10) (2015).
- 47 Fonseca JA, Heredia RD, Ortiz C, Mazo M, Clavijo-Ramírez CA, Lopez MC. Identification of *Entamoeba moshkovskii* in treated waste water used for agriculture. *Ecohealth* 13(1), 156–160 (2016).
- 48 López OY, López MC, Corredor V, Clara Echeverri M, Pinilla Roa AE. Diferenciación del complejo *Entamoeba histolytica/Entamoeba dispar* mediante Gal/GalNAc-lectina y PCR en aislamientos colombianos. *Rev. Med. Chil.* 140(4), 476–483 (2012).
- 49 Mejia R, Vicuña Y, Broncano N *et al.* A novel, multi-parallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. *Am. J. Trop. Med. Hyg.* 88(6), 1041–1047 (2013).
- 50 Saboyá MI, Catalá L, Nicholls RS, Ault SK. Update on the Mapping of Prevalence and Intensity of Infection for Soil-Transmitted Helminth Infections in Latin America and the Caribbean: A Call for Action. *PLoS Negl. Trop. Dis.* 7(9) (2013).
- 51 Fuentes C. Parasitismo intestinal infantil: factores epidemiológicos en Orange Walk, Belice
Intestinal parasitism in children: epidemiological factors in Orange Walk, Belize. *Rev. Ciencias Médicas Pinar del Río* 15(4), 163–178 (2011).
- 52 Cuadro Mogollon OF, Florez RP, Duran AR, Gonzalez Lopez JS. *Ascaris* spp antigens. *Contemp. Eng. Sci.* 11(7), 333–355 (2018).
- 53 Villafaña-Ferrer LM, Pinilla-Pérez M. Parásitos intestinales en niños y suelo de Turbaco, Colombia y factores de riesgo asociados. *Rev. Salud Publica* 18(1), 117–128 (2016).

- 54 Dacombe RJ, Crampin AC, Floyd S *et al.* Time delays between patient and laboratory selectively affect accuracy of helminth diagnosis. *Trans. R. Soc. Trop. Med. Hyg.* 101(2), 140–145 (2007).
- 55 Pullan RL, Smith JL, Jasrasaria R, Brooker SJ. Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. *Parasites and Vectors* 7(1) (2014).
- 56 Hotez PJ, Alvarado M, Basáñez M-G *et al.* The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases. *PLoS Negl. Trop. Dis.* 8(7), e2865 (2014).
- 57 Knopp S, Steinmann P, Keiser J, Utzinger J. Nematode Infections. Soil-Transmitted Helminths and Trichinella. *Infect. Dis. Clin. North Am.* 26(2), 341–358 (2012).
- 58 Stoltzfus RJ, Chwaya HM, Tielsch JM, Schulze KJ, Albonico M, Savioli L. Epidemiology of iron deficiency anemia in Zanzibari schoolchildren: The importance of hookworms. *Am. J. Clin. Nutr.* 65(1), 153–159 (1997).
- 59 Periago M V., Bethony JM. Hookworm virulence factors: Making the most of the host. *Microbes Infect.* 14(15), 1451–1464 (2012).
- 60 World Health Organization. ‘Soil-transmitted helminth infections’. <https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections>.
- 61 Jourdan PM, Lamberton PHL, Fenwick A, Addiss DG. Soil-transmitted helminth infections, Lancet Publishing Group, (2018).
- 62 Harhay MO, Horton J, Olliaro PL. Epidemiology and control of human gastrointestinal parasites in children, Expert Reviews Ltd., (2010).
- 63 Schüle SA, Clowes P, Kroidl I *et al.* *Ascaris lumbricoides* Infection and Its Relation to Environmental Factors in the Mbeya Region of Tanzania, a Cross-Sectional, Population-Based Study. *PLoS One* 9(3), 1–10 (2014).
- 64 Easton A V., Quiñones M, Vujkovic-Cvijin I *et al.* The Impact of Anthelmintic Treatment on Human Gut Microbiota Based on Cross-Sectional and Pre- and Postdeworming Comparisons in Western Kenya. *MBio* 10(2), 1–14 (2019).
- 65 Cools P, Vlaminck J, Verweij JJ, Levecke B. Quantitative PCR in soil-transmitted helminth epidemiology and control programs: Toward a universal standard. *PLoS Negl. Trop. Dis.* 15(3), e0009134 (2021).
- 66 Midha A, Janek K, Niewienda A *et al.* The Intestinal Roundworm *Ascaris suum* Releases Antimicrobial Factors Which Interfere With Bacterial Growth and Biofilm Formation. *Front. Cell. Infect. Microbiol.* 8(AUG), 271 (2018).
- 67 Cooper PJ, Figueredo CA. Immunology of *Ascaris* and Immunomodulation. In: *Ascaris*:

- The Neglected Parasite*. Elsevier Inc., 3–19 (2013).
- 68 Arora P, Moll JM, Andersen D *et al*. Body fluid from the parasitic worm *Ascaris suum* inhibits broad-acting pro-inflammatory programs in dendritic cells. *Immunology* 159(3), 322–334 (2020).
- 69 Easton A, Gao S, Lawton S *et al*. Extensive hybridization between pig and human *Ascaris* identifies a highly interbred species complex infecting humans. 1–26 (2020).
- 70 Williams AR, Krych L, Ahmad HF *et al*. A polyphenol-enriched diet and *Ascaris suum* infection modulate mucosal immune responses and gut microbiota composition in pigs. *PLoS One* 12(10), 1–21 (2017).
- 71 Hansen EP, Fromm B, Andersen SD *et al*. Exploration of extracellular vesicles from *Ascaris suum* provides evidence of parasite–host cross talk. *J. Extracell. Vesicles* 8(1) (2019).
- 72 Monteiro KJL, Calegar DA, Santos JP *et al*. Genetic diversity of *Ascaris* spp. infecting humans and pigs in distinct Brazilian regions, as revealed by mitochondrial DNA. *PLoS One* 14(6), e0218867 (2019).
- 73 Zhou C, Guo T, Deng Y, He J, Ouyang S, Wu X. Mitochondrial phylogenomics of human-type *Ascaris*, pig-type *Ascaris*, and hybrid *Ascaris* populations. *Vet. Parasitol.* 287, 109256 (2020).
- 74 Rassi A, Rassi A, Marin-Neto JA. Chagas disease. *Lancet* 375(9723), 1388–1402 (2010).
- 75 Sandri TL, Lidani KCF, Andrade FA *et al*. *Trypanosoma cruzi*. Elsevier Inc. (2021).
- 76 Rassi A, Rassi A, Marcondes de Rezende J. American trypanosomiasis (Chagas disease). *Infect. Dis. Clin. North Am.* 26(2), 275–291 (2012).
- 77 Cucunubá ZM, Gutiérrez-Romero SA, Ramírez J-D *et al*. The epidemiology of Chagas disease in the Americas. *Lancet Reg. Heal. - Am.* 37, 100881 (2024).
- 78 Cucunubá ZM, Okuwoga O, Basáñez MG, Nouvellet P. Increased mortality attributed to Chagas disease: a systematic review and meta-analysis. *Parasit. Vectors* 9(1) (2016).
- 79 Guhl F, Auderheide A, Ramírez JD. From ancient to contemporary molecular eco-epidemiology of Chagas disease in the Americas. *Int. J. Parasitol.* 44(9), 605–612 (2014).
- 80 Jansen AM, Xavier SC das C, Roque ALR. Landmarks of the Knowledge and *Trypanosoma cruzi* Biology in the Wild Environment. *Front. Cell. Infect. Microbiol.* 0, 10 (2020).
- 81 Nouvellet P, Cucunubá ZM, Gourbière S. Ecology, Evolution and Control of Chagas Disease: A Century of Neglected Modelling and a Promising Future. *Adv. Parasitol.* 87, 135–191 (2015).
- 82 Maeda FY, Cortez C, Yoshida N. Cell signaling during *Trypanosoma cruzi* invasion. *Front.*

- Immunol.* 3(NOV) (2012).
- 83 Herreros-Cabello A, Callejas-Hernández F, Gironès N, Fresno M. Trypanosoma Cruzi Genome: Organization, Multi-Gene Families, Transcription, and Biological Implications. *Genes* 2020, Vol. 11, Page 1196 11(10), 1196 (2020).
- 84 Barko PC, McMichael MA, Swanson KS, Williams DA. The Gastrointestinal Microbiome: A Review. *J. Vet. Intern. Med.* 32(1), 9–25 (2018).
- 85 Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. *Nature* 489(7415), 220–230 (2012).
- 86 Tropini C, Earle KA, Huang KC, Sonnenburg JL. The Gut Microbiome: Connecting Spatial Organization to Function. *Cell Host Microbe* 21(4), 433–442 (2017).
- 87 Shashkova T, Popenko A, Tyakht A *et al.* Agent based modeling of human gut microbiome interactions and perturbations. *PLoS One* 11(2), 1–26 (2016).
- 88 Heintz-Buschart A, Wilmes P. Human Gut Microbiome: Function Matters. *Trends Microbiol.* 26(7), 563–574 (2018).
- 89 Shreiner A. The gut microbiome in health and in disease. *Curr Opin Gastroenterol.* 31(1), 69–75 (2016).
- 90 Wang Z, Klipfell E, Bennett BJ *et al.* Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 472(7341), 57–65 (2011).
- 91 Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by *Clostridium difficile*. *Gastroenterology* 146(6), 1547–1553 (2014).
- 92 Van Hul M, Cani PD, Petifils C, De Vos WM, Tilg H, El Omar EM. What defines a healthy gut microbiome? *Gut* (figure 2), 1–16 (2024).
- 93 Rinninella E, Raoul P, Cintoni M *et al.* What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms* 7(1), 14 (2019).
- 94 Arumugam M, Raes J, Pelletier E *et al.* Enterotypes in the landscape of gut microbial community composition. *Nature* 3(1), 1–12 (2013).
- 95 Schmidt TSB, Raes J, Bork P. The Human Gut Microbiome: From Association to Modulation. *Cell* 172(6), 1198–1215 (2018).
- 96 Daniel R. The metagenomics of soil, (2005).
- 97 Huttenhower C, Morgan XC. Meta’omic Analytic Techniques for Studying the Intestinal Microbiome. *Gastroenterology* 146 (2014).

- 98 Sadowsky MJ, Staley C, Heiner C *et al.* Analysis of gut microbiota - An ever changing landscape. *Gut Microbes* 8(3), 268–275 (2017).
- 99 Simon C, Daniel R. Metagenomic analyses: Past and future trends, (2011).
- 100 D’Argenio V, D’Argenio V. Human microbiome acquisition and bioinformatic challenges in metagenomic studies. *Int. J. Mol. Sci.* 19(2), 1–12 (2018).
- 101 Yang C, Chowdhury D, Zhang Z *et al.* A review of computational tools for generating metagenome-assembled genomes from metagenomic sequencing data. *Comput. Struct. Biotechnol. J.* 19, 6301–6314 (2021).
- 102 Wylezich C, Höper D. Meta-Ribosomalomics: RNA Sequencing Is an Unbiased Method for Parasite Detection of Different Sample Types. *Front. Microbiol.* 12, 1616 (2021).
- 103 Paul B. Concatenated 16S rRNA sequence analysis improves bacterial taxonomy. *F1000Research* 11 (2022).
- 104 Ammer-Herrmenau C, Pfisterer N, van den Berg T *et al.* Comprehensive Wet-Bench and Bioinformatics Workflow for Complex Microbiota Using Oxford Nanopore Technologies. *mSystems* 6(4) (2021).
- 105 Wajid B, Anwar F, Wajid I *et al.* Music of metagenomics—a review of its applications, analysis pipeline, and associated tools. *Funct. Integr. Genomics* 22(1), 3–26 (2022).
- 106 Parfrey LW, Walters WA, Knight R. Microbial eukaryotes in the human microbiome: Ecology, evolution, and future directions, Frontiers Research Foundation, (2011).
- 107 Castañeda S, Muñoz M, Villamizar X *et al.* Microbiota characterization in Blastocystis-colonized and Blastocystis-free school-age children from Colombia. *Parasit. Vectors* 13(1), 521 (2020).
- 108 Audebert C, Even G, Cian A *et al.* Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota. *Sci. Rep.* 6(February), 1–11 (2016).
- 109 Yason JA, Liang YR, Png CW, Zhang Y, Tan KSW. Interactions between a pathogenic Blastocystis subtype and gut microbiota: In vitro and in vivo studies. *Microbiome* 7(1), 1–13 (2019).
- 110 Chen TL, Chen S, Wu HW *et al.* Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice. *Gut Pathog.* 5(1), 1–12 (2013).
- 111 Toro-Londono MA, Bedoya-Urrego K, Garcia-Montoya GM, Galvan-Diaz AL, Alzate JF. Intestinal parasitic infection alters bacterial gut microbiota in children. *PeerJ* 2019(1), 1–24 (2019).

- 112 Mejia R, Damania A, Jeun R *et al.* Impact of intestinal parasites on microbiota and cobalamin gene sequences: A pilot study. *Parasit. Vectors* 13(1), 1–9 (2020).
- 113 Humen MA, De Antoni GL, Benyacoub J *et al.* Lactobacillus johnsonii La1 antagonizes Giardia intestinalis in vivo. *Infect. Immun.* 73(2), 1265–1269 (2005).
- 114 Morton ER, Lynch J, Froment A *et al.* Variation in Rural African Gut Microbiota Is Strongly Correlated with Colonization by Entamoeba and Subsistence. *PLOS Genet.* 11(11), e1005658 (2015).
- 115 Gilchrist CA, Petri SE, Schneider BN *et al.* Role of the Gut Microbiota of Children in Diarrhea Due to the Protozoan Parasite Entamoeba histolytica. *J. Infect. Dis.* 213(10), 1579–1585 (2016).
- 116 Chappell CL, Darkoh C, Shimmin L *et al.* Fecal indole as a biomarker of susceptibility to cryptosporidium infection. *Infect. Immun.* 84(8), 2299–2306 (2016).
- 117 Chalmers RM, Katzer F. Looking for Cryptosporidium: The application of advances in detection and diagnosis. *Trends Parasitol.* 29(5), 237–251 (2013).
- 118 Burgess SL, Gilchrist CA, Lynn TC, Petri WA. Parasitic protozoa and interactions with the host intestinal microbiota. *Infect. Immun.* 85(8) (2017).
- 119 Ramírez-Carrillo E, Gaona O, Nieto J *et al.* Disturbance in human gut microbiota networks by parasites and its implications in the incidence of depression. *Sci. Rep.* 10(1), 1–12 (2020).
- 120 Partida-Rodriguez O, Nieves-Ramirez M, Laforest-Lapointe I *et al.* Exposure to parasitic protists and helminths changes the intestinal community structure of bacterial microbiota but not of eukaryotes in a cohort of mother-child binomial from a semi-rural setting in Mexico. *bioRxiv* 717165 (2019).
- 121 Cho I, Blaser MJ. The human microbiome: At the interface of health and disease. *Nat. Rev. Genet.* 13(4), 260–270 (2012).
- 122 de Souza-Basqueira M, Ribeiro RM, de Oliveira LC *et al.* Gut Dysbiosis in Chagas Disease. A Possible Link to the Pathogenesis. *Front. Cell. Infect. Microbiol.* 10, 402 (2020).
- 123 Hossain E, Khanam S, Dean DA *et al.* Mapping of host-parasite-microbiome interactions reveals metabolic determinants of tropism and tolerance in Chagas disease. *Sci. Adv.* 6(30), eaaz2015 (2020).
- 124 Ferreira BL, Ferreira ÉR, de Brito M V. *et al.* BALB/c and C57BL/6 mice cytokine responses to Trypanosoma cruzi infection are independent of parasite strain infectivity. *Front. Microbiol.* 9(MAR), 553 (2018).
- 125 Park JC, Im SH. Of men in mice: the development and application of a humanized gnotobiotic mouse model for microbiome therapeutics. *Exp. Mol. Med.* 2020 529 52(9),

- 1383–1396 (2020).
- 126 Nguyen TLA, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? *DMM Dis. Model. Mech.* 8(1), 1–16 (2015).
- 127 Hugenholtz F, de Vos WM. Mouse models for human intestinal microbiota research: a critical evaluation. *Cell. Mol. Life Sci.* 75(1), 149 (2018).
- 128 Hoffman K, Liu Z, Hossain E *et al.* Alterations to the Cardiac Metabolome Induced by Chronic *T. cruzi* Infection Relate to the Degree of Cardiac Pathology. *ACS Infect. Dis.* 7(6), 1638–1649 (2021).
- 129 Lewis R, Behnke JM, Stafford P, Holland C V. The development of a mouse model to explore resistance and susceptibility to early *Ascaris suum* infection. *Parasitology* 132(2), 289–300 (2006).
- 130 C R, DP M, A H *et al.* The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole. *PLoS One* 14(2) (2019).
- 131 McCall L-II, Tripathi A, Vargas F, Knight R, Dorrestein PC, Siqueira-Neto JL. Experimental Chagas disease-induced perturbations of the fecal microbiome and metabolome. *PLoS Negl. Trop. Dis.* 12(3), 1–15 (2018).
- 132 de Souza-Basqueira M, Ribeiro RM, de Oliveira LC *et al.* Gut Dysbiosis in Chagas Disease. A Possible Link to the Pathogenesis. *Front. Cell. Infect. Microbiol.* 10 (2020).
- 133 Giacomini P, Croese J, Krause L, Loukas A, Cantacessi C. Suppression of inflammation by helminths: A role for the gut microbiota? *Philos. Trans. R. Soc. B Biol. Sci.* 370(1675) (2015).
- 134 Yasuda K, Nakanishi K. Host responses to intestinal nematodes. *Int. Immunol.* 30(3), 93–102 (2018).
- 135 Briggs N, Weatherhead J, Sastry KJ, Hotez PJ. The Hygiene Hypothesis and Its Inconvenient Truths about Helminth Infections. *PLoS Negl. Trop. Dis.* 10(9), e0004944 (2016).
- 136 White MPJJ, McManus CM, Maizels RM. Regulatory T-cells in helminth infection: induction, function and therapeutic potential, Blackwell Publishing Ltd, (2020).
- 137 McSorley HJ, Maizels RM. Helminth infections and host immune regulation. *Clin. Microbiol. Rev.* 25(4), 585–608 (2012).
- 138 Maizels RM, Smits HH, McSorley HJ. Modulation of Host Immunity by Helminths: The Expanding Repertoire of Parasite Effector Molecules. *Immunity* 49(5), 801–818 (2018).
- 139 Manuel Corral-Ruiz G, Enid Sánchez-Torres L. Relevance of Helminth-Microbiota

- Interplay in the Host Immune Response. *Cell. Immunol.* 104499 (2022).
- 140 Jenkins TP, Rathnayaka Y, Perera PK *et al.* Infections by human gastrointestinal helminths are associated with changes in faecal microbiota diversity and composition. *PLoS One* 12(9), 1–18 (2017).
- 141 Barelli C, Donati C, Albanese D *et al.* Interactions between parasitic helminths and gut microbiota in wild tropical primates from intact and fragmented habitats. *Sci. Reports 2021* 11(1), 1–10 (2021).
- 142 Rapin A, Harris NL. Helminth–Bacterial Interactions: Cause and Consequence. *Trends Immunol.* 39(9), 724–733 (2018).
- 143 Midha A, Ebner F, Schlosser-Brandenburg J, Rausch S, Hartmann S. Trilateral Relationship: Ascaris, Microbiota, and Host Cells. *Trends Parasitol.* 37(3), 251–262 (2021).
- 144 Rosa BA, Supali T, Gankpala L *et al.* Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia. *Microbiome* 6(1), 1–19 (2018).
- 145 Giacomini P, Zakrzewski M, Croese J *et al.* Experimental hookworm infection and escalating gluten challenges are associated with increased microbial richness in celiac subjects. *Sci. Rep.* 5(September), 4–11 (2015).
- 146 Li RW, Wu S, Li W *et al.* Alterations in the porcine colon microbiota induced by the gastrointestinal nematode *Trichuris suis*. *Infect. Immun.* 80(6), 2150–2157 (2012).
- 147 Kay GL, Millard A, Sergeant MJ *et al.* Differences in the faecal microbiome in schistosoma haematobium infected children vs. uninfected children. *PLoS Negl. Trop. Dis.* 9(6), e0003861 (2015).
- 148 Berrilli F, Di Cave D, Cavallero S, D’Amelio S. Interactions between parasites and microbial communities in the human gut. *Front. Cell. Infect. Microbiol.* 2(November), 141 (2012).
- 149 Ajibola O, Rowan AD, Ogedengbe CO *et al.* Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents. *Sci. Rep.* 9(1), 1–15 (2019).
- 150 Midha A, Schlosser J, Hartmann S. Reciprocal interactions between nematodes and their microbial environments. *Front. Cell. Infect. Microbiol.* 7(APR), 144 (2017).
- 151 Lee SC, Tang MS, Lim YALYALYAL *et al.* Helminth Colonization Is Associated with Increased Diversity of the Gut Microbiota. *PLoS Negl. Trop. Dis.* 8(5), e2880–e2880 (2014).
- 152 Rosa BA, Snowden C, Martin J *et al.* Whipworm-Associated Intestinal Microbiome

- Members Consistent Across Both Human and Mouse Hosts. *Front. Cell. Infect. Microbiol.* 11, 1 (2021).
- 153 Cantacessi C, Giacomini P, Croese J *et al.* Impact of experimental hookworm infection on the human gut microbiota. *J. Infect. Dis.* 210(9), 1431–1434 (2014).
- 154 Glendinning L, Nausch N, Free A, Taylor DW, Mutapi F. The microbiota and helminths: Sharing the same niche in the human host. *Parasitology* 141(10), 1255–1271 (2014).
- 155 Cooper P, Walker AW, Reyes J *et al.* Patent Human Infections with the Whipworm, *Trichuris trichiura*, Are Not Associated with Alterations in the Faecal Microbiota. *PLoS One* 8(10), e76573 (2013).
- 156 Zaiss MM, Rapin A, Lebon L *et al.* The Intestinal Microbiota Contributes to the Ability of Helminths to Modulate Allergic Inflammation. *Immunity* 43(5), 998–1010 (2015).
- 157 Midha A, Jarquín-Díaz VH, Ebner F *et al.* Guts within guts: the microbiome of the intestinal helminth parasite *Ascaris suum* is derived but distinct from its host. *Microbiome* 10(1), 1–21 (2022).
- 158 Su C, Su L, Li Y *et al.* Helminth-induced alterations of the gut microbiota exacerbate bacterial colitis. *Mucosal Immunol.* 11(1), 144–157 (2018).
- 159 Stecher B, Hardt WD. The role of microbiota in infectious disease. *Trends Microbiol.* 16(3), 107–114 (2008).
- 160 Loke P, Lim YAL. Helminths and the microbiota: Parts of the hygiene hypothesis. *Parasite Immunol.* 37(6), 314–323 (2015).
- 161 Houlden A, Hayes KS, Bancroft AJ *et al.* Chronic *Trichuris muris* infection in C57BL/6 mice causes significant changes in host microbiota and metabolome: Effects reversed by pathogen clearance. *PLoS One* 10(5) (2015).
- 162 Martín R, Bermúdez-Humarán LG, Langella P. Gnotobiotic rodents: An in vivo model for the study of microbe-microbe interactions. *Front. Microbiol.* 7(MAR), 1–7 (2016).
- 163 Douglas AE. Simple animal models for microbiome research. *Nat. Rev. Microbiol.* 17(12), 764–775 (2019).
- 164 Montañó KJ, Cuéllar C, Sotillo J. Rodent Models for the Study of Soil-Transmitted Helminths: A Proteomics Approach. *Front. Cell. Infect. Microbiol.* 11, 639573 (2021).
- 165 Nogueira DS, Gazzinelli-Guimarães PH, Barbosa FS *et al.* Multiple Exposures to *Ascaris suum* Induce Tissue Injury and Mixed Th2/Th17 Immune Response in Mice. *PLoS Negl. Trop. Dis.* 10(1), e0004382 (2016).
- 166 Weatherhead JE, Porter P, Coffey A *et al.* *Ascaris* larval infection and lung invasion directly

- induce severe allergic airway disease in mice. *Infect. Immun.* 86(12), 533–551 (2018).
- 167 Wu Y, Li E, Knight M *et al.* Transient *Ascaris suum* larval migration induces intractable chronic pulmonary disease and anemia in mice. *PLoS Negl. Trop. Dis.* 15(12), e0010050 (2021).
- 168 Wang Y, Liu F, Urban JF, Paerewijck O, Geldhof P, Li RW. *Ascaris suum* infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome. *Int. J. Parasitol.* 49(3–4), 247–256 (2019).
- 169 Springer A, Wagner L, Koehler S *et al.* Modulation of the porcine intestinal microbiota in the course of *Ascaris suum* infection. *Parasites and Vectors* 15(1), 1–21 (2022).
- 170 Whitman JD, Sakanari JA, Mitreva M. Areas of Metabolomic Exploration for Helminth Infections. 7, 206–214 (2021).
- 171 Manuel Corral-Ruiz G, Enid Sánchez-Torres L, Corral-ruiz GM, Sánchez-torres LE, Manuel Corral-Ruiz G, Enid Sánchez-Torres L. Relevance of Helminth-Microbiota Interplay in the Host Immune Response. *Cell. Immunol.* 374, 104499 (2022).
- 172 Pillai A, Ueno S, Zhang H, Kato Y. Induction of ASABF (*Ascaris suum* antibacterial factor)-type antimicrobial peptides by bacterial injection: novel members of ASABF in the nematode *Ascaris suum*. *Biochem. J.* 371(3), 663–668 (2003).
- 173 Pillai A, Ueno S, Zhang H, Lee JM, Kato Y. Cecropin P1 and novel nematode cecropins: a bacteria-inducible antimicrobial peptide family in the nematode *Ascaris suum*. *Biochem. J.* 390(1), 207–214 (2005).
- 174 Stensvold C. Blastocystis: Genetic diversity and molecular methods for diagnosis and epidemiology. *Trop. Parasitol.* 3(1), 26 (2013).
- 175 Chabé M, Lokmer A, Ségurel L. Gut Protozoa: Friends or Foes of the Human Gut Microbiota? *Trends Parasitol.* 33(12), 925–934 (2017).
- 176 Stensvold CR, Sørland BA, Berg RPKD *et al.* Stool Microbiota Diversity Analysis of Blastocystis-Positive and Blastocystis-Negative Individuals. *Microorg.* 2022, Vol. 10, Page 326 10(2), 326 (2022).
- 177 Poveda C, Bottazzi ME, Jones KM. Mining the Metabolome for New and Innovative Chagas Disease Treatments. *Trends Pharmacol. Sci.* 42(1), 1–3 (2021).
- 178 Hotez PJ, Bundy DAP, Beegle K *et al.* Helminth Infections: Soil-transmitted Helminth Infections and Schistosomiasis. *Dis. Control Priorities Dev. Ctries.* (2006).
- 179 Muslim A, Aazmi S, Er YX, Shahrizal S, Lim YAL. *Ascaris lumbricoides* harbors a distinct gut microbiota profile from its human host: Preliminary insights. *Food Waterborne Parasitol.* 34, e00223 (2024).

- 180 McVeigh P. Post-genomic progress in helminth parasitology. *Parasitology* 147(8), 835–840 (2020).
- 181 Mitreva M. Parasite OMICS, the grand challenges ahead. *Front. Parasitol.* 1, 995302 (2022).
- 182 Marzano V, Mancinelli L, Bracaglia G *et al.* “Omic” investigations of protozoa and worms for a deeper understanding of the human gut “parasitome”. *PLoS Negl. Trop. Dis.* 11(11), 1–19 (2017).
- 183 Salloum PMM, Jorge F, Dheilily NMM, Poulin R. Eco-evolutionary implications of helminth microbiomes. *J. Helminthol.* 97, e22 (2023).

ANEXOS

Se adjunta carpeta con artículos, certificados y demás documentos.